

RW L Roulvain M

Cochrane Database of Systematic Reviews

Mechanical methods for induction of labour (Review)

2116, 20attain In
de Vaan MDT ten Fikelder MLG - Jozwiak M. Palmer KR. Davies-Tuck M. Bloemenkamp KWM, Mol RWT Boulvain M.

de Vaan MDT, ten Eikelder MLG, Jozwiak M, Palmer KR, Davies-Tuck M, Bloemenkamp KWM, Mol

www.cochranelibrary.com

Mechanical methods for induction of labour.

DOI: 10.1002/14651858.CD001233.pub3.

Cochrane Database of Systematic Reviews 2019, Issue 10. Art. No.: CD001233.



TABLE OF CONTENTS

I AIN I ANGU	
LANGU	AGE SUMMARY
SUMMARY OF	FINDINGS
BACKGROUND	
BJECTIVES	
IETHODS	
ESULTS	
Figure 1.	
Figure 2.	
Figure 3.	
Figure 4.	
Figure 5.	
Figure 6.	
Figure 7.	
Figure 8.	
Figure 9.	
Figure 10.	
Figure 11.	
Figure 12.	
ISCUSSION	
UTHORS' CO	NCLUSIONS
CKNOWLEDG	EMENTS
EFERENCES	
HARACTERIS	TICS OF STUDIES
ATA AND AN	ALYSES
	1. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 1 Vaginal delivery red in 24 hours.
Analysis 1	.2. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 2 Uterine
hyperstim	ulation with FHR changes.
	ulation with FHR changes3. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 3 Caesarean section.
Analysis 1. Analysis 1	3. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 3 Caesarean section. 4. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 4 Serious neonatal
Analysis 1. Analysis 1 morbidity Analysis 1	3. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 3 Caesarean section. 4. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 4 Serious neonatal /perinatal death. 5. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 5 Serious maternal
Analysis 1 Analysis 1 morbidity Analysis 1 morbidity Analysis 1	3. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 3 Caesarean section. 4. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 4 Serious neonatal /perinatal death. 5. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 5 Serious maternal or death. 6. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 6 Oxytocin
Analysis 1. Analysis 1 morbidity Analysis 1 morbidity Analysis 1 augmenta Analysis 1	3. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 3 Caesarean section. 4. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 4 Serious neonatal /perinatal death. 5. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 5 Serious maternal or death.
Analysis 1. Analysis 1 morbidity Analysis 1 morbidity Analysis 1 augmenta Analysis 1 hyperstim	3. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 3 Caesarean section. 4. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 4 Serious neonatal /perinatal death. 5. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 5 Serious maternal or death. 6. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 6 Oxytocin tion. 7. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 7 Uterine ulation without fetal heart rate changes.
Analysis 1. Analysis 1 morbidity Analysis 1 morbidity Analysis 1 augmenta Analysis 1 hyperstim Analysis 1	3. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 3 Caesarean section. 4. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 4 Serious neonatal /perinatal death. 5. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 5 Serious maternal or death. 6. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 6 Oxytocin tion. 7. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 7 Uterine ulation without fetal heart rate changes. 8. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 8 Uterine rupture.
Analysis 1. Analysis 1 morbidity Analysis 1 augmenta Analysis 1 hyperstim Analysis 1 Analysis 1 Analysis 1	3. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 3 Caesarean section. 4. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 4 Serious neonatal /perinatal death. 5. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 5 Serious maternal or death. 6. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 6 Oxytocin tion. 7. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 7 Uterine ulation without fetal heart rate changes. 8. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 8 Uterine rupture. 9. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 9 Epidural analgesia. 10. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 10 Instrumental
Analysis 1. Analysis 1 morbidity Analysis 1 augmenta Analysis 1 hyperstim Analysis 1 Analysis 1 vaginal de Analysis 1	3. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 3 Caesarean section. 4. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 4 Serious neonatal /perinatal death. 5. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 5 Serious maternal or death. 6. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 6 Oxytocin tion. 7. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 7 Uterine ulation without fetal heart rate changes. 8. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 8 Uterine rupture. 9. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 9 Epidural analgesia. 10. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 10 Instrumental livery. 11. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 10 Instrumental livery.
Analysis 1. Analysis 1 morbidity Analysis 1 morbidity Analysis 1 augmenta Analysis 1 Analysis 1 Analysis 1 vaginal de Analysis 1 stained lic Analysis 1	3. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 3 Caesarean section. 4. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 4 Serious neonatal /perinatal death. 5. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 5 Serious maternal or death. 6. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 6 Oxytocin tion. 7. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 7 Uterine ulation without fetal heart rate changes. 8. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 8 Uterine rupture. 9. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 9 Epidural analgesia. 10. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 10 Instrumental livery. 11. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 11 Meconium- uor. 12. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 12 Apgar score <
Analysis 1. Analysis 1 morbidity Analysis 1 morbidity Analysis 1 augmenta Analysis 1 Analysis 1 Analysis 1 vaginal de Analysis 1 stained lic Analysis 1 7 at 5 min Analysis 1	3. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 3 Caesarean section. 4. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 4 Serious neonatal /perinatal death. 5. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 5 Serious maternal or death. 6. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 6 Oxytocin tion. 7. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 7 Uterine ulation without fetal heart rate changes. 8. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 8 Uterine rupture. 9. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 9 Epidural analgesia. 10. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 10 Instrumental livery. 11. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 11 Meconium- 12. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 12 Apgar score < utes. 13. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 13 Neonatal
Analysis 1. Analysis 1 morbidity Analysis 1 morbidity Analysis 1 augmenta Analysis 1 Analysis 1 Analysis 1 vaginal de Analysis 1 stained lic Analysis 1 7 at 5 min Analysis 1 intensive	3. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 3 Caesarean section. 4. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 4 Serious neonatal /perinatal death. 5. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 5 Serious maternal or death. 6. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 6 Oxytocin tion. 7. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 7 Uterine ulation without fetal heart rate changes. 8. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 8 Uterine rupture. 9. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 9 Epidural analgesia. 10. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 10 Instrumental livery. 11. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 11 Meconium-luor. 12. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 12 Apgar score < utes.



Analysis 1.16. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 16 Women not satisfied.	
Analysis 1.17. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 17 Maternal fever during labour.	
Analysis 1.18. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 18 Antibiotics during labour.	
Analysis 1.19. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 19 Chorioamnionitis.	
Analysis 1.20. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 20 Endometritis Analysis 1.21. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 21 Fetal distress Analysis 1.22. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 22 Umbilical artery pH < 7.10.	
Analysis 2.1. Comparison 2 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.	
Analysis 2.2. Comparison 2 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all primiparae, Outcome 2 Uterine hyperstimulation with FHR changes.	
Analysis 2.3. Comparison 2 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all primiparae, Outcome 3 Caesarean section.	
Analysis 2.4. Comparison 2 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all primiparae, Outcome 4 Serious neonatal morbidity/perinatal death.	
Analysis 2.5. Comparison 2 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all primiparae, Outcome 5 Serious maternal morbidity or death.	
Analysis 3.1. Comparison 3 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.	
Analysis 3.2. Comparison 3 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all multiparae, Outcome 2 Caesarean section.	
Analysis 4.1. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.	
Analysis 4.2. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 2 Uterine hyperstimulation with FHR changes.	
Analysis 4.3. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 3 Caesarean section.	
Analysis 4.4. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 4 Serious neonatal morbidity/perinatal death.	
Analysis 4.5. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 5 Cervix unfavourable/unchanged after 24 hours.	
Analysis 4.6. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 6 Oxytocin	
Analysis 4.7. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 7 Uterine hyperstimulation without FHR changes.	
Analysis 4.8. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 8 Epidural analgesia.	
Analysis 4.9. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 9 Instrumental vaginal delivery.	
Analysis 4.10. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 10 Meconium- stained liquor.	
Analysis 4.11. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 11 Apgar score	
Analysis 4.12. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 12 Neonatal ntensive care unit admission.	
Analysis 4.13. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 13 Perinatal	
deathAnalysis 4.14. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 14 Maternal side effects	
Analysis 4.15. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 15 Postpartum haemorrhage.	



Analysis 4.16. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 16 Chorioamnionitis.	244
Analysis 4.17. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 17 Endometritis.	244
Analysis 4.18. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 18 Fetal distress.	245
Analysis 5.1. Comparison 5 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all primiparae, Outcome 1 Uterine	245
hyperstimulation with FHR changes. Analysis 5.2. Comparison 5 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all primiparae, Outcome 2 Caesarean section.	246
Analysis 6.1. Comparison 6 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all multiparae, Outcome 1 Uterine hyperstimulation with FHR changes.	246
Analysis 6.2. Comparison 6 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all multiparae, Outcome 2 Caesarean section.	246
Analysis 7.1. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.	248
Analysis 7.2. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 2 Uterine hyperstimulation with FHR changes.	249
Analysis 7.3. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 3 Caesarean section.	249
Analysis 7.4. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 4 Serious neonatal morbidity/perinatal death.	250
Analysis 7.5. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 5 Serious maternal morbidity or death.	250
Analysis 7.6. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 6 Cervix unfavourable/unchanged after 12 hours.	25
Analysis 7.7. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 7 Oxytocin augmentation.	25
Analysis 7.8. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 8 Uterine hyperstimulation without FHR changes.	25
Analysis 7.9. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 9 Uterine rupture.	25
Analysis 7.10. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 10 Epidural analgesia.	25
Analysis 7.11. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 11 Instrumental vaginal delivery.	25
Analysis 7.12. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 12 Meconium-stained liquor.	25
Analysis 7.13. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 13 Apgar score < 7 at 5 minutes.	25
Analysis 7.14. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 14 Neonatal intensive care unit admission.	25
Analysis 7.15. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 15 Perinatal death.	25
Analysis 7.16. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 16 Maternal vomiting.	25
Analysis 7.17. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 17 Postpartum	25
haemorrhage. Analysis 7.18. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 18 Maternal fover during Jahour.	25
fever during labour. Analysis 7.19. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 19	25
Chorioamnionitis	250
Endometritis. Analysis 7.21. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 21 Fetal	256



Analysis 7.22. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 22 Umbilical artery pH <7.10.	256
Analysis 8.1. Comparison 8 Balloon (Foley or ATAD versus low dose vaginal misoprostol: all primiparae, Outcome 1 Caesarean section.	257
Analysis 9.1. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 1 Vaginal delivery not achieved within 24 hours.	259
Analysis 9.2. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 2 Uterine hyperstimulation with FHR changes.	259
Analysis 9.3. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 3 Caesarean section.	259
Analysis 9.4. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 4 Serious perinatal morbidity/perinatal death.	260
Analysis 9.5. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 5 Serious maternal morbidity or death.	260
Analysis 9.6. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 6 Cervix unfavourable after 24 hours.	261
Analysis 9.7. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 7 Oxytocin augmentation.	261
Analysis 9.8. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 8 Uterine hyperstimulation without FHR changes.	261
Analysis 9.9. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 9 Uterine rupture	262
Analysis 9.10. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 10 Epidural	262
Analysis 9.11. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 11 Instrumental vaginal delivery.	262
Analysis 9.12. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 12 Meconium-stained liquor.	263
Analysis 9.13. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 13 Apgar score < 7 after 5 minutes.	263
Analysis 9.14. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 14 Neonatal intensive care unit admission.	264
Analysis 9.15. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 15 Neonatal encephalopathy.	264
Analysis 9.16. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 16 Perinatal death.	264
Analysis 9.17. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 17 Maternal side effects (all).	265
Analysis 9.18. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 18 Maternal vomiting.	265
Analysis 9.19. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 19 Maternal diarrhoea.	265
Analysis 9.20. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 20 Postpartum haemorrhage.	266
Analysis 9.21. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 21 Maternal death.	266
Analysis 9.22. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 22 Women not satisfied.	266
Analysis 9.23. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 23 Maternal fever during labour.	267
Analysis 9.24. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 24 Antibiotics during labour.	267
Analysis 9.25. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 25 Endometritis	267
Analysis 9.26. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 26 Fetal distress	268
Analysis 9.27. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 27 Umbilical artery pH < 7.10.	268
Analysis 10.1. Comparison 10 Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.	269



hyperstimulation with FIR changes. Analysis 10.4. Comparison 10 Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae, Outcome 3 Caesarean section. Analysis 10.4. Comparison 10 Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae, Outcome 4 Serious 270 neneratal morbidity/perinatal death. Analysis 10.5. Comparison 10 Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae, Outcome 5 Serious 270 maternal morbidity or death. Analysis 11.1. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 1 Vaginal 271 delivery not achieved in 24 hours. Analysis 11.2. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 2 Uterine 172 hyperstimulation with FIR changes. Analysis 11.3. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 3 Caesarean 271 section. Analysis 11.4. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 4 Serious 272 neneratal morbidity/perinatal death. Analysis 11.2. Comparison 12 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 5 Serious 272 maternal morbidity or death. Analysis 12.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 1 Uterine hyperstimulation with 174 FIR changes. Analysis 12.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 2 Caesarean section. 273 Analysis 12.4. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 3 Serious neonatal morbidity or death. Analysis 12.4. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Cervix unfavourable after 24 perinatal death or 14 peri	Analysis 10.2. Comparison 10 Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae, Outcome 2 Uterine	269
Analysis 1.0.4. Comparison 10 Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae, Outcome 4 Serious 270 neonatal morbidity/perinatal death. Analysis 11.0.5. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 1 Vaginal 271 delivery not achieved in 24 hours. Analysis 11.1. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 2 Uterine Propertination with FIRC changes. Analysis 11.2. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 2 Uterine Propertination with FIRC changes. Analysis 11.3. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 4 Serious 272 neonatal morbidity perinatal death. Analysis 11.3. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 4 Serious 272 material morbidity perinatal death. Analysis 11.3. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 4 Serious 272 material morbidity perinatal death. Analysis 11.3. Comparison 12 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 5 Serious 272 material morbidity or death. Analysis 11.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 1 Uterine hyperstimulation with 273 Analysis 12.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 2 Caesarean section. 273 Analysis 12.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 4 Serious maternal morbidity or 274 death. Analysis 12.4. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 4 Serious maternal morbidity or 274 hours. Analysis 12.4. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without 275 Analysis 12.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 8 Instrumental vaginal delivery. 275 Analysis		
neonatal morbidity (prinatal death. Analysis 11.5. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 5 Serious 270 maternal morbidity or death. Analysis 11.1. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 2 Uterine Phyperstimulation with FIRC changes. Analysis 11.2. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 2 Uterine Phyperstimulation with FIRC changes. Analysis 11.3. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 3 Caesarean 271 section. Analysis 11.3. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 4 Serious 272 maternal morbidity or death. Analysis 11.3. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 5 Serious 272 maternal morbidity or death. Analysis 11.3. Comparison 12 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 5 Serious 272 maternal morbidity or death. Analysis 12.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 1 Uterine hyperstimulation with 273 Analysis 12.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 2 Caesarean section. Analysis 12.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 3 Serious meenatal morbidity or 274 death. Analysis 12.4. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 4 Serious maternal morbidity or 274 death. Analysis 12.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Cervix unfavourable after 24 place 274 death. Analysis 12.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without 275 Analysis 12.8. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 9 Meconium-stained lidevery. Analysis 12.9. Comparison 12 Balloon (Foley or ATAD) versu		269
Analysis 1.1. Comparison 10 Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae, Outcome 5 Serious maternal morbidity or death. Analysis 1.1. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 1.1. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 2 Uterine 17 hyperstimulation with FHR changes. Analysis 1.1. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 3 Caesarean 271 section. Analysis 1.1. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 4 Serious 272 neonatal morbidity/perinatal death. Analysis 1.1. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 5 Serious 272 neonatal morbidity/perinatal death. Analysis 1.1. Comparison 12 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 5 Serious 272 neonatal morbidity or death. Analysis 1.2. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 1 Uterine hyperstimulation with 273 HRR changes. Analysis 1.2. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 2 Caesarean section. 273 Analysis 1.2. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 3 Serious maternal morbidity or death. Analysis 1.2. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without 275 HRR changes. Analysis 1.2. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without 276 Analysis 1.2. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without 276 Analysis 1.2. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without 276 Analysis 1.2. Comparison 12 Balloon (Foley or ATAD) versus oxytocin		270
Analysis 1.1.1. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 11.2. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 2 Uterine hyperstimulation with FHR changes. Analysis 11.3. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 3 Caesarean error section. Analysis 11.3. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 4 Serious 272 neonatal morbidity/perinatal death. Analysis 11.3. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 4 Serious 272 neonatal morbidity/perinatal death. Analysis 11.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 1 Uterine hyperstimulation with 273 FHR changes. Analysis 12.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 3 Serious neonatal morbidity/ 274 perinatal death. Analysis 12.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 4 Serious maternal morbidity or death. Analysis 12.4. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Cervix unfavourable after 24 plouts. Analysis 12.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Uterine hyperstimulation without 275 place 275 pl	Analysis 10.5. Comparison 10 Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae, Outcome 5 Serious	270
delivery not achieved in 24 hours. Analysis 11.2. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 2 Uterine hyperstimulation with FHR changes. Analysis 11.3. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 3 Caesarean 271 section. Analysis 11.4. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 4 Serious 272 neonatal morbidity/perinatal death. Analysis 11.5. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 5 Serious 272 maternal morbidity or death. Analysis 11.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 1 Uterine hyperstimulation with 273 FHR changes. Analysis 12.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 2 Caesarean section. 273 Analysis 12.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 3 Serious neonatal morbidity 274 perinatal death. Analysis 12.4. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 4 Serious maternal morbidity 274 death. Analysis 12.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Cervix unfavourable after 24 death. Analysis 12.6. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without 275 HR changes. Analysis 12.7. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without 275 Analysis 12.7. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without 275 Analysis 12.9. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 10 Repara score 7 at 5 minutes. 275 Analysis 12.9. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 10 Apgar score 7 at 5 minutes. 276 Analysis 12.1. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 11 Perinat		271
Analysis 1.1.2. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 2 Uterine pretrimulation with FHR changes. Analysis 11.3. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 3 Caesarean section. Analysis 11.4. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 4 Serious 727 neonatal morbidity/perinatal death. Analysis 11.5. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 4 Serious 727 neonatal morbidity or death. Analysis 11.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 1 Uterine hyperstimulation with 7273 FHR changes. Analysis 12.2. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 2 Caesarean section. 723 Analysis 12.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 3 Serious neonatal morbidity 7274 perinatal death. Analysis 12.4. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 4 Serious maternal morbidity 7274 perinatal death. Analysis 12.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Cervix unfavourable after 24 7274 hours. Analysis 12.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without 7275 Analysis 12.6. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without 7276 Analysis 12.7. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without 7276 Analysis 12.9. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 8 Instrumental vaginal delivery. 725 Analysis 12.9. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 9 Meconium-stained liquor. 726 Analysis 12.1. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 10 Appar score 7 at 5 minutes. 727 Analysis 1		
Analysis 1.1.3. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 3 Caesarean Section. Analysis 1.1.4. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 4 Serious 272 neonatal morbidity/perinatal death. Analysis 1.1.5. Comparison 11 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 1 Uterine hyperstimulation with 273 FHIR changes. Analysis 1.2.1. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 2 Caesarean section. 273 Analysis 1.2.2. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 3 Serious maternal morbidity or 274 perinatal death. Analysis 1.2.4. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 4 Serious maternal morbidity or 274 perinatal death. Analysis 1.2.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Serious maternal morbidity or 274 death. Analysis 1.2.6. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Cervix unfavourable after 24 death. Analysis 1.2.6. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without 275 FHIR changes. Analysis 1.2.6. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without 275 Analysis 1.2.9. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 8 Instrumental vaginal delivery. 275 Analysis 1.2.9. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 10 Apgar score <7 at 5 minutes. 276 Analysis 1.2.1. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 10 Apgar score <7 at 5 minutes. 277 Analysis 1.2.1. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 10 Apgar score <7 at 5 minutes. 278 Analysis 1.2.1. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 13 Hemorrhagia poxtpartum. 279 Analysis 1.2.1. Comparison 12 Balloon	Analysis 11.2. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 2 Uterine	271
Analysis 1.1.4. Comparison 1.1 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 4 Serious neonatal morbidity or death. Analysis 11.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 2 Caesarean section. Analysis 12.1. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 2 Caesarean section. Analysis 12.2. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 2 Caesarean section. Analysis 12.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 3 Serious neonatal morbidity perinatal death. Analysis 12.4. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 4 Serious maternal morbidity or 274 death. Analysis 12.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Cervix unfavourable after 24 douts. Analysis 12.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without 7 EHR changes. Analysis 12.7. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without 7 EHR changes. Analysis 12.8. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 8 Instrumental vaginal delivery. Analysis 12.9. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 9 Meconium-stained liquor. Analysis 12.10. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 10 Apgar score <7 at 5 minutes. Analysis 12.11. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 11 Neonatal intensive care unit 276 admission. Analysis 12.12. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 11 Reonatal intensive care unit 276 admission. Analysis 12.14. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 11 Reonatal intensive care unit 276 admission. Analysis 12.15. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 15 Fetal distres	Analysis 11.3. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 3 Caesarean	271
Analysis 1.1.5. Comparison 1.1 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 1 Uterine hyperstimulation with Analysis 12.1. Comparison 1.2 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 2 Caesarean section. Analysis 12.2. Comparison 1.2 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 3 Serious neonatal morbidity 274 perinatal death. Analysis 12.4. Comparison 1.2 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 4 Serious maternal morbidity 274 perinatal death. Analysis 12.4. Comparison 1.2 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 4 Serious maternal morbidity 274 death. Analysis 12.5. Comparison 1.2 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Cervix unfavourable after 24 274 hours. Analysis 12.5. Comparison 1.2 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Cervix unfavourable after 24 275 hours. Analysis 12.6. Comparison 1.2 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without 5 PHR changes. Analysis 12.7. Comparison 1.2 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 7 Uterine rupture. 275 Analysis 12.8. Comparison 1.2 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 9 Meconium-stained idjuor. 276 Analysis 12.9. Comparison 1.2 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 9 Meconium-stained idjuor. 276 Analysis 12.11. Comparison 1.2 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 1.0 Hours 1.0 Featal death. 277 Analysis 12.12. Comparison 1.2 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 1.1 Neonatal intensive care unit admission. Analysis 12.12. Comparison 1.2 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 1.2 Perinatal death. 277 Analysis 12.13. Comparison 1.2 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 1.5 Hander death. 278 Analysis 12.14. Comparison 1.2 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 1.2 Caesarean section. 278	Analysis 11.4. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 4 Serious	272
Analysis 12.1. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 1 Uterine hyperstimulation with Analysis 12.2. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 2 Caesarean section. 273 Analysis 12.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 3 Serious neonatal morbidity or death. Analysis 12.4. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 4 Serious maternal morbidity or death. Analysis 12.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Cervix unfavourable after 24 or Analysis 12.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Uterine hyperstimulation without FHR changes. Analysis 12.7. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without FHR changes. Analysis 12.8. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 7 Uterine rupture. 275 Analysis 12.9. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 9 Meconium-stained liquor. 276 Analysis 12.10. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 10 Apgar score 7 at 5 minutes. 277 Analysis 12.11. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 10 Apgar score 7 at 5 minutes. 278 Analysis 12.12. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 11 Neonatal intensive care unit admission. 279 Analysis 12.13. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 12 Perinatal death. 270 Analysis 12.14. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 14 Maternal fever during labour. 271 Analysis 12.15. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 15 Fetal distress. 272 Analysis 12.15. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 2 Serious maternal morbidity or death. 273 Analysis 12.15. Compa	Analysis 11.5. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 5 Serious	272
Analysis 12.2. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 2 Caesarean section	Analysis 12.1. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 1 Uterine hyperstimulation with	273
Analysis 12.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 3 Serious neonatal morbidity, perinatal death. Analysis 12.4. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 4 Serious maternal morbidity or death. Analysis 12.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Cervix unfavourable after 24 274 hours. Analysis 12.6. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without 5 FHR changes. Analysis 12.7. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 7 Uterine rupture. Analysis 12.8. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 8 Instrumental vaginal delivery. 275 Analysis 12.9. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 9 Meconium-stained liquor. 276 Analysis 12.10. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 10 Apgar score <7 at 5 minutes. 276 Analysis 12.11. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 11 Neonatal intensive care unit 276 admission. Analysis 12.12. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 12 Perinatal death. 277 Analysis 12.13. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 14 Haternal fever during labour. 278 Analysis 12.14. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 15 Fetal distress. 279 Analysis 12.15. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 1 Caesarean 278 section. Analysis 13.1. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 2 Serious maternal morbidity or death. Analysis 13.2. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 2 Serious maternal morbidity or death. Analysis 14.2. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 1 Caesarea		273
Analysis 12.4. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 4 Serious maternal morbidity or death. Analysis 12.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Cervix unfavourable after 24 hours. Analysis 12.6. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without FHR changes. Analysis 12.7. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without FHR changes. Analysis 12.7. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 7 Uterine rupture. 275 Analysis 12.8. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 8 Instrumental vaginal delivery. 276 Analysis 12.9. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 9 Meconium-stained liquor. 276 Analysis 12.1. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 10 Apgar score 7 at 5 minutes. 276 Analysis 12.1. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 11 Neonatal intensive care unit admission. 277 Analysis 12.1. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 13 Hemorrhagia postpartum. 277 Analysis 12.1. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 14 Maternal fever during labour. 277 Analysis 12.1. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 1 Caesarean section. 278 Analysis 13.2. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 2 Serious maternal morbidity perinatal death. Analysis 13.3. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 2 Serious maternal morbidity or death. Analysis 14.1. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 2 Serious maternal morbidity or death. Analysis 15.1. Comparison 16 Single balloon (Foley) versus double bal	Analysis 12.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 3 Serious neonatal morbidity/	
Analysis 12.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Cervix unfavourable after 24 hours. Analysis 12.6. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without FIRR changes. Analysis 12.7. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 7 Uterine rupture. Analysis 12.8. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 8 Instrumental vaginal delivery. 275 Analysis 12.9. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 9 Meconium-stained liquor. 276 Analysis 12.10. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 10 Apgar score <7 at 5 minutes. 276 Analysis 12.11. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 10 Apgar score <7 at 5 minutes. 276 Analysis 12.12. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 11 Neonatal intensive care unit 277 Analysis 12.13. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 13 Hemorrhagia postpartum. 277 Analysis 12.14. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 14 Maternal fever during labour. 277 Analysis 12.15. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 15 Fetal distress. 278 Analysis 13.1. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 1 Caesarean section. Analysis 13.2. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 2 Serious maternal morbidity or death. Analysis 14.1. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 1 Caesarean section. 279 Analysis 14.2. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 2 Serious maternal morbidity or death. Analysis 15.1. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 2 Verine 280 Analysis 16.2. Comparison 16	Analysis 12.4. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 4 Serious maternal morbidity or	274
Analysis 12.6. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without FHR changes. Analysis 12.7. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 7 Uterine rupture. 275 Analysis 12.8. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 8 Instrumental vaginal delivery. 276 Analysis 12.9. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 9 Meconium-stained liquor. 276 Analysis 12.10. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 10 Apgar score < 7 at 5 minutes. 276 Analysis 12.11. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 11 Neonatal intensive care unit admission. Analysis 12.12. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 12 Perinatal death. 277 Analysis 12.13. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 14 Maternal fever during labour. 277 Analysis 12.14. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 15 Fetal distress. 277 Analysis 12.15. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 15 Fetal distress. 278 Analysis 13.1. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 1 Caesarean arection. Analysis 13.3. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 2 Serious meonatal morbidity/perinatal death. Analysis 13.3. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 2 Serious maternal morbidity or death. Analysis 14.1. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 1 Caesarean section. 279 Analysis 14.2. Comparison 15 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 2 Serious maternal morbidity or death. Analysis 15.1. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 1 Vaginal delivery not ach	Analysis 12.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Cervix unfavourable after 24	274
Analysis 12.7. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 7 Uterine rupture	Analysis 12.6. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without	275
Analysis 12.8. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 8 Instrumental vaginal delivery	•	275
Analysis 12.9. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 9 Meconium-stained liquor		
Analysis 12.10. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 10 Apgar score < 7 at 5 minutes		
Analysis 12.11. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 11 Neonatal intensive care unit admission. Analysis 12.12. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 12 Perinatal death. 277 Analysis 12.13. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 13 Hemorrhagia postpartum. 277 Analysis 12.14. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 14 Maternal fever during labour. 277 Analysis 12.15. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 15 Fetal distress. 277 Analysis 13.1. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 1 Caesarean section. Analysis 13.2. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 2 Serious neonatal morbidity/perinatal death. Analysis 13.3. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 3 Serious maternal morbidity or death. Analysis 14.1. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 1 Caesarean section. 279 Analysis 14.2. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 2 Serious maternal morbidity or death. Analysis 15.1. Comparison 16 Balloon (Foley or ATAD) versus amniotomy: all women, Outcome 1 Caesarean section. 280 Analysis 16.1. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 2 Uterine hyperstimulation with FHR changes. Analysis 16.2. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 3 Caesarean 282		
Analysis 12.12. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 12 Perinatal death	Analysis 12.11. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 11 Neonatal intensive care unit	
Analysis 12.13. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 13 Hemorrhagia postpartum 277 Analysis 12.14. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 14 Maternal fever during labour. 277 Analysis 12.15. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 15 Fetal distress. 277 Analysis 13.1. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 1 Caesarean 278 section. 278 Analysis 13.2. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 2 Serious neonatal 278 morbidity/perinatal death. 279 Analysis 13.3. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 3 Serious maternal 279 morbidity or death. 279 Analysis 14.1. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 1 Caesarean section. 279 Analysis 14.2. Comparison 15 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 2 Serious maternal morbidity or death. 280 Analysis 15.1. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 1 Vaginal delivery 282 Analysis 16.2. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 2 Uterine 282 hyperstimulation with FHR changes. 282 Analysis 16.3. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 3 Caesarean 282		277
Analysis 12.15. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 15 Fetal distress		277
Analysis 13.1. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 1 Caesarean section. Analysis 13.2. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 2 Serious neonatal morbidity/perinatal death. Analysis 13.3. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 3 Serious maternal morbidity or death. Analysis 14.1. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 1 Caesarean section. Analysis 14.2. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 2 Serious maternal morbidity or death. Analysis 15.1. Comparison 15 Balloon (foley or ATAD) versus amniotomy: all women, Outcome 1 Caesarean section. Analysis 16.1. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 16.2. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 2 Uterine hyperstimulation with FHR changes. Analysis 16.3. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 3 Caesarean 282	Analysis 12.14. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 14 Maternal fever during labour.	277
Analysis 13.2. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 2 Serious neonatal morbidity/perinatal death. Analysis 13.3. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 3 Serious maternal morbidity or death. Analysis 14.1. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 1 Caesarean section. Analysis 14.2. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 2 Serious maternal morbidity or death. Analysis 15.1. Comparison 15 Balloon (foley or ATAD) versus amniotomy: all women, Outcome 1 Caesarean section. 280 Analysis 16.1. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 16.2. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 2 Uterine hyperstimulation with FHR changes. Analysis 16.3. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 3 Caesarean 282	Analysis 12.15. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 15 Fetal distress	277
morbidity/perinatal death. Analysis 13.3. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 3 Serious maternal morbidity or death. Analysis 14.1. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 1 Caesarean section. Analysis 14.2. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 2 Serious maternal morbidity or death. Analysis 15.1. Comparison 15 Balloon (foley or ATAD) versus amniotomy: all women, Outcome 1 Caesarean section. Analysis 16.1. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 16.2. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 2 Uterine hyperstimulation with FHR changes. Analysis 16.3. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 3 Caesarean 282		278
morbidity or death		278
Analysis 14.1. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 1 Caesarean section. 279 Analysis 14.2. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 2 Serious maternal morbidity or death. 280 Analysis 15.1. Comparison 15 Balloon (foley or ATAD) versus amniotomy: all women, Outcome 1 Caesarean section. 280 Analysis 16.1. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 1 Vaginal delivery not achieved in 24 hours. 282 Analysis 16.2. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 2 Uterine hyperstimulation with FHR changes. 282 Analysis 16.3. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 3 Caesarean 282		279
or death. Analysis 15.1. Comparison 15 Balloon (foley or ATAD) versus amniotomy: all women, Outcome 1 Caesarean section. Analysis 16.1. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 16.2. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 2 Uterine hyperstimulation with FHR changes. Analysis 16.3. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 3 Caesarean 282	•	279
Analysis 16.1. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 16.2. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 2 Uterine hyperstimulation with FHR changes. Analysis 16.3. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 3 Caesarean 282	Analysis 14.2. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 2 Serious maternal morbidity	280
Analysis 16.1. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 16.2. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 2 Uterine hyperstimulation with FHR changes. Analysis 16.3. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 3 Caesarean 282		280
Analysis 16.2. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 2 Uterine hyperstimulation with FHR changes. Analysis 16.3. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 3 Caesarean 282	Analysis 16.1. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 1 Vaginal delivery	
Analysis 16.3. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 3 Caesarean 282	Analysis 16.2. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 2 Uterine	282
	Analysis 16.3. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 3 Caesarean	282



Analysis 16.5. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 6 Uterine plays 16.6. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 6 Uterine plays in the property of	Analysis 16.4. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 4 Serious maternal morbidity or death.	283
hyperstimulation without FHR changes. Analysis 16.7. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 7 Uterine rupture. Analysis 16.8. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 8 Epidural 284 analysis 16.9. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 9 Instrumental 284 vaginal delivery. Analysis 16.10. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 10 Meconium- 284 stained (iquor. Analysis 16.11. Comparison 15 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 10 Meconium- 285 rates of the care unit admission 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 11 Apgar score 27 at 5 minutes. Analysis 16.12. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 12 Neonatal 285 intensive care unit admission. Analysis 16.13. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 13 Other naternal side-effects pain after insertion. Analysis 16.14. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 15 Maternal 286 haemorrhage. Analysis 16.15. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 15 Maternal 286 deuring labour. Analysis 16.18. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 16 Antibiotics 286 during labour. Analysis 16.19. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 17 287 Chorioaminonitis. Analysis 16.19. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal 287 distress. Analysis 16.19. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal 287 distress. Analysis 16.19. Comparison 19 Single balloon (Foley) versus double balloon (Analysis 16.5. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 5 Oxytcocin	283
Analysis 16.8. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 8 Epidural 284 analgesia. Analysis 16.9. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 9 instrumental 284 vaginal delivery. Analysis 16.10. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 10 Meconium-284 stained (liquor. Analysis 16.11. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 11 Apgar score 285 < 7 at 5 minutes. Analysis 16.12. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 12 Neonatal 285 intensive care unit admission. Analysis 16.13. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 13 Other 285 maternal side-effects: pain after insertion. Analysis 16.14. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 14 Postpartum 286 haemorrhage. Analysis 16.15. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 15 Maternal 286 fever during labour. Analysis 16.15. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 15 Maternal 286 fever during labour. Analysis 16.17. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 16 Antibiotics 286 during labour. Analysis 16.17. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 17 287 Choricoamnionitis. Analysis 16.19. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal 287 distress. Analysis 16.19. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 20 Umbilical 288 artery pH < 7.10. Analysis 17.1. Comparison 17 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 2 Caesarean 288 section. Analysis 18.1. Comparison 18 Single balloon (Foley)		283
analgesia. Analysis 16.9. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 9 Instrumental vaginal delivery. Analysis 16.10. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 10 Meconium-stained (lquor. Analysis 16.11. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 11 Apgar score 7 at 5 minutes. Analysis 16.12. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 12 Neonatal 285 intensive care unit admission. Analysis 16.13. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 13 Other 285 maternal side-effects: pain after insertion. Analysis 16.14. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 14 Postpartum 286 haemorrhage. Analysis 16.15. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 15 Maternal 286 fever during labour. Analysis 16.16. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 16 Antibiotics 286 during labour. Analysis 16.17. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 16 Antibiotics 286 during labour. Analysis 16.18. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 17 287 Chorioamnionitis. Analysis 16.19. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal 287 distress. Analysis 16.19. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal 287 distress. Analysis 17.2. Comparison 17 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 20 Umbilical 288 artery pH < 7.10. Analysis 18.1. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 1 Vaginal delivery 289 not achieved in 24 hours. Analysis 18.2. Comparison 18 Single balloon		283
Naginal delivery. Analysis 16.10. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 10 Meconium-to-to-to-to-to-to-to-to-to-to-to-to-to-		284
Analysis 16.10. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 11 Apgar score 285 < 7 at 5 minutes. Analysis 16.11. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 11 Apgar score 285 intensive care unit admission. Analysis 16.12. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 12 Neonatal 285 intensive care unit admission. Analysis 16.13. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 13 Other 285 maternal side-effects: pain after insertion. Analysis 16.14. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 14 Postpartum 286 heamorrhage. Analysis 16.15. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 15 Maternal 286 fever during labour. Analysis 16.15. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 16 Antibiotics 286 during labour. Analysis 16.17. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 17 287 Choricamnionitis. Analysis 16.18. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal 287 distress. Analysis 16.19. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal 287 distress. Analysis 16.20. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 20 Umbilical 288 artery pH < 7.10. Analysis 16.20. Comparison 17 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 20 Umbilical 288 artery pH < 7.10. Analysis 18.1. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 1 Vaginal delivery 288 not achieved in 24 hours. Analysis 18.1. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 2 Caesarean 288 section. Analysis 19.1. Comparison 1		284
Analysis 16.12. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 12 Neonatal intensive care unit admission. Analysis 16.13. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 13 Other maternal side-effects: pain after insertion. Analysis 16.14. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 14 Postpartum 286 haemorrhage. Analysis 16.15. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 15 Maternal 286 fever during labour. Analysis 16.15. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 16 Antibiotics 286 during labour. Analysis 16.17. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 17 287 Chorioamnionitis. Analysis 16.18. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 18 287 Endometritis. Analysis 16.19. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal 287 distress. Analysis 16.20. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal 287 distress. Analysis 16.20. Comparison 17 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 20 Umbilical 288 artery pH < 7.10. Analysis 17.1. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 1 Vaginal delivery 289 not achieved in 24 hours. Analysis 18.1. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 2 Caesarean 288 section. Analysis 19.2. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 3 Serious perinatal orbitality or death. Analysis 19.3. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 3 Serious perinatal 291 morbidity or death. Analysis 19.4. Comparison 19 Laminaria tent versus vaginal prostaglandin	Analysis 16.10. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 10 Meconium-	284
Analysis 16.12. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 12 Neonatal intensive care unit admission. Analysis 16.13. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 13 Other also described and the properties of the properties	Analysis 16.11. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 11 Apgar score	285
Analysis 16.13. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 13 Other maternal side-effects: pain after insertion. Analysis 16.14. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 14 Postpartum paints on 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 15 Maternal path of the ver during labour. Analysis 16.15. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 16 Antibiotics during labour. Analysis 16.17. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 17 287 Chorioamnionitis. Analysis 16.18. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 18 287 Endometritis. Analysis 16.19. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal distress. Analysis 16.20. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 20 Umbilical 288 artery pH < 7.10. Analysis 17.1. Comparison 17 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 20 Umbilical 288 artery pH < 7.10. Analysis 17.2. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 1 Vaginal delivery 289 not achieved in 24 hours. Analysis 18.1. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 2 Caesarean 289 section. Analysis 19.2. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 2 Caesarean section. Analysis 19.4. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 2 Caesarean section. 291 Analysis 19.3. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 5 Uterine hyperstimulation without fetal heart rate changes. Analysis 19.5. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia. 292 Analysis	Analysis 16.12. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 12 Neonatal	285
Analysis 16.14. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 14 Postpartum Analysis 16.15. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 15 Maternal fever during labour. Analysis 16.16. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 16 Antibiotics Analysis 16.17. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 17 Chorioamnionitis. Analysis 16.18. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 18 Endometritis. Analysis 16.19. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal Gistress. Analysis 16.20. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal Analysis 16.20. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 20 Umbilical artery pH < 7.10. Analysis 17.1. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 2 Umbilical artery pH < 7.10. Analysis 17.1. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 18.1. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 2 Caesarean section. Analysis 19.2. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 1 Uterine hyperstimulation with FHR changes. Analysis 19.2. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 3 Serious perinatal morbidity or death. Analysis 19.3. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 4 Serious maternal morbidity or death. Analysis 19.4. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 5 Uterine hyperstimulation with FHR changes. Analysis 19.5. Comparison 19 Laminaria tent versus vaginal prost	Analysis 16.13. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 13 Other	285
Analysis 16.15. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 15 Maternal fever during labour. Analysis 16.16. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 17 287 Chorioamnionitis. Analysis 16.17. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 17 287 Chorioamnionitis. Analysis 16.18. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 18 287 Endometritis. Analysis 16.19. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal stress. Analysis 16.20. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 20 Umbilical artery pH < 7.10. Analysis 17.1. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 2 Umbilical artery pH < 7.10. Analysis 17.2. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 2 Caesarean esection. Analysis 18.1. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 18.2. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 2 Caesarean section. Analysis 19.1. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 1 Uterine hyperstimulation with FHR changes. Analysis 19.2. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 3 Serious perinatal morbidity/perinatal death. Analysis 19.4. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 5 Uterine hyperstimulation without fetal heart rate changes. Analysis 19.5. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia. 292 Analysis 19.6. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia. 293 Analysis 1	Analysis 16.14. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 14 Postpartum	286
Analysis 16.16. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 16 Antibiotics during labour. Analysis 16.17. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 17 287 Chorioamnionitis. Analysis 16.18. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 18 287 Endometritis. Analysis 16.19. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal distress. Analysis 16.20. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 20 Umbilical artery pH < 7.10. Analysis 16.20. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 17.2 Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 2 Caesarean esection. Analysis 18.1. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 18.2. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 19.1. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 2 Caesarean esection. Analysis 19.1. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 2 Caesarean section. Analysis 19.3. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 4 Serious maternal morbidity/perinatal death. Analysis 19.4. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 4 Serious maternal morbidity or death. Analysis 19.5. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia. 292 Analysis 19.6. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 7 Instrumental vaginal politivery. Analysis 19.8. Compariso	Analysis 16.15. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 15 Maternal	286
Analysis 16.17. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 17 Chorioamnionitis. Analysis 16.18. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 18 287 Endometritis. Analysis 16.19. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal distress. Analysis 16.20. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 20 Umbilical artery pH < 7.10. Analysis 17.1. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 17.2. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 2 Caesarean section. Analysis 18.1. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 2 Caesarean section. Analysis 18.2. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 2 Caesarean section. Analysis 19.2. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 1 Uterine hyperstimulation with FHR changes. Analysis 19.3. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 2 Caesarean section. Analysis 19.3. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 3 Serious perinatal morbidity/perinatal death. Analysis 19.4. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 4 Serious maternal morbidity or death. Analysis 19.5. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia. 291 Analysis 19.6. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 7 Instrumental vaginal delivery. Analysis 19.8. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 7 Instrumental vaginal delivery.	Analysis 16.16. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 16 Antibiotics	286
Analysis 16.18. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 18 287 Endometritis. Analysis 16.19. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal distress. Analysis 16.20. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 20 Umbilical 288 artery pH < 7.10. Analysis 17.1. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 17.2. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 2 Caesarean 288 section. Analysis 18.1. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 18.2. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 2 Caesarean 289 section. Analysis 19.1. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 1 Uterine hyperstimulation with FHR changes. Analysis 19.2. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 2 Caesarean section. 291 Analysis 19.3. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 3 Serious perinatal morbidity/perinatal death. Analysis 19.4. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 5 Uterine hyperstimulation without fetal heart rate changes. Analysis 19.5. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia. Analysis 19.5. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 7 Instrumental vaginal politive or death. Analysis 19.5. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 8 Meconium-stained 292 Analysis 19.5. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 8 Meconium-stained 292 Analysis 19.8. Co	Analysis 16.17. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 17	287
Analysis 16.19. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal distress. Analysis 16.20. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 20 Umbilical artery pH < 7.10. Analysis 17.1. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 17.2. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 2 Caesarean section. Analysis 18.1. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 18.2. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 2 Caesarean section. Analysis 19.1. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 1 Uterine hyperstimulation with FHR changes. Analysis 19.2. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 2 Caesarean section. Analysis 19.3. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 3 Serious perinatal morbidity/perinatal death. Analysis 19.4. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 4 Serious maternal morbidity or death. Analysis 19.5. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 5 Uterine hyperstimulation without fetal heart rate changes. Analysis 19.6. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia. 292 Analysis 19.6. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 7 Instrumental vaginal delivery. Analysis 19.8. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 8 Meconium-stained 292	Analysis 16.18. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 18	287
Analysis 16.20. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 20 Umbilical artery pH < 7.10. Analysis 17.1. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 17.2. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 2 Caesarean section. Analysis 18.1. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 18.2. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 2 Caesarean section. Analysis 19.1. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 1 Uterine hyperstimulation with FHR changes. Analysis 19.2. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 2 Caesarean section. Analysis 19.3. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 3 Serious perinatal morbidity/perinatal death. Analysis 19.4. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 4 Serious maternal morbidity or death. Analysis 19.5. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 5 Uterine hyperstimulation without fetal heart rate changes. Analysis 19.6. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia. 292 Analysis 19.6. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia. 292 Analysis 19.7. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 8 Meconium-stained 292 Analysis 19.8. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 8 Meconium-stained 292	Analysis 16.19. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal	287
Analysis 17.1. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 17.2. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 2 Caesarean section. Analysis 18.1. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 18.2. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 2 Caesarean section. Analysis 19.1. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 1 Uterine hyperstimulation with FHR changes. Analysis 19.2. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 2 Caesarean section. Analysis 19.3. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 3 Serious perinatal morbidity/perinatal death. Analysis 19.4. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 4 Serious maternal morbidity or death. Analysis 19.5. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 5 Uterine hyperstimulation without fetal heart rate changes. Analysis 19.6. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia. 292 Analysis 19.7. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 7 Instrumental vaginal delivery. Analysis 19.8. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 8 Meconium-stained 292	Analysis 16.20. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 20 Umbilical	288
Analysis 17.2. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 2 Caesarean section. Analysis 18.1. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 18.2. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 2 Caesarean section. Analysis 19.1. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 1 Uterine hyperstimulation with FHR changes. Analysis 19.2. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 2 Caesarean section. Analysis 19.3. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 3 Serious perinatal morbidity/perinatal death. Analysis 19.4. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 4 Serious maternal morbidity or death. Analysis 19.5. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 5 Uterine hyperstimulation without fetal heart rate changes. Analysis 19.6. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia. 292 Analysis 19.7. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 7 Instrumental vaginal delivery. Analysis 19.8. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 8 Meconium-stained 292	Analysis 17.1. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 1 Vaginal delivery	288
Analysis 18.1. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 18.2. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 2 Caesarean section. Analysis 19.1. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 1 Uterine hyperstimulation with FHR changes. Analysis 19.2. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 2 Caesarean section. Analysis 19.3. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 3 Serious perinatal morbidity/perinatal death. Analysis 19.4. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 4 Serious maternal morbidity or death. Analysis 19.5. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 5 Uterine hyperstimulation without fetal heart rate changes. Analysis 19.6. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia. 292 Analysis 19.7. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 7 Instrumental vaginal delivery. Analysis 19.8. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 8 Meconium-stained 292	Analysis 17.2. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 2 Caesarean	288
Analysis 18.2. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 2 Caesarean section. Analysis 19.1. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 1 Uterine hyperstimulation with FHR changes. Analysis 19.2. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 2 Caesarean section	Analysis 18.1. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 1 Vaginal delivery	289
Analysis 19.1. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 1 Uterine hyperstimulation with FHR changes. Analysis 19.2. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 2 Caesarean section	Analysis 18.2. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 2 Caesarean	289
Analysis 19.2. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 2 Caesarean section 291 Analysis 19.3. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 3 Serious perinatal 291 morbidity/perinatal death	Analysis 19.1. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 1 Uterine hyperstimulation	290
morbidity/perinatal death. Analysis 19.4. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 4 Serious maternal morbidity or death. Analysis 19.5. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 5 Uterine hyperstimulation without fetal heart rate changes. Analysis 19.6. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia	Analysis 19.2. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 2 Caesarean section	
morbidity or death. Analysis 19.5. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 5 Uterine hyperstimulation without fetal heart rate changes. Analysis 19.6. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia	morbidity/perinatal death	
without fetal heart rate changes. Analysis 19.6. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia	morbidity or death.	
Analysis 19.7. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 7 Instrumental vaginal delivery. Analysis 19.8. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 8 Meconium-stained 292	without fetal heart rate changes.	
Analysis 19.8. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 8 Meconium-stained 292	Analysis 19.7. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 7 Instrumental vaginal	
liquor.		292



Analysis 19.9. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 9 Apgar score < 7 at 5
minutes
Analysis 19.11. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 11 Maternal side effects: 29: all.
Analysis 19.12. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 12 Maternal nausea 294
Analysis 19.13. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 13 Fetal distress
Analysis 20.1. Comparison 20 Laminaria tent versus vaginal prostaglandin E2: all primiparae, Outcome 1 Uterine 29:
hyperstimulation with FHR changes.
Analysis 20.2. Comparison 20 Laminaria tent versus vaginal prostaglandin E2: all primiparae, Outcome 2 Caesarean section 295
Analysis 21.1. Comparison 21 Laminaria tent versus vaginal prostaglandin E2: all multiparae, Outcome 1 Caesarean section 295
Analysis 22.1. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 1 Uterine 29' hyperstimulation with FHR changes.
Analysis 22.2. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 2 Caesarean section.
Analysis 22.3. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 3 Serious neonatal 29' morbidity/perinatal death.
Analysis 22.4. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 4 Serious maternal morbidity or death
Analysis 22.5. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 5 Cervix unfavourable/ unchanged after 12-24 hours.
Analysis 22.6. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 6 Oxytocin augmentation.
Analysis 22.7. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 7 Uterine 298 hyperstimulation without FHR changes.
Analysis 22.8. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 8 Uterine rupture 299
Analysis 22.9. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 9 Instrumental vaginal delivery.
Analysis 22.10. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 10 Apgar score < 7 at 5 minutes.
Analysis 22.11. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 11 Neonatal intensive care unit admission.
Analysis 22.12. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 12 Perinatal death 300
Analysis 22.13. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 13 Maternal side effects.
Analysis 22.14. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 14 Postpartum 30. haemorrhage.
Analysis 22.15. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 15 30: Chorioamnionitis.
Analysis 22.16. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 16 Endometritis 30:
Analysis 22.17. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 17 Fetal distress 30.2
Analysis 23.1. Comparison 23 Laminaria tent versus intracervical prostaglandin E2: all primiparae, Outcome 1 Caesarean section.
Analysis 24.1. Comparison 24 Laminaria tent versus intracervical: prostaglandin E2 all multiparae, Outcome 1 Caesarean section.
Analysis 25.1. Comparison 25 Laminaria tent versus oxytocin: all women, Outcome 1 Caesarean section
Analysis 25.2. Comparison 25 Laminaria tent versus oxytocin: all women, Outcome 2 Fetal distress
Analysis 26.1. Comparison 26 Laminaria tent versus amniotomy: all women, Outcome 1 Caesarean section
Analysis 27.1. Comparison 27 Laminaria tent versus other hygroscopic dilator: all women, Outcome 1 Caesarean section 304
Analysis 28.1. Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 1 Vaginal delivery not achieved in 24 30!
hours.
Analysis 28.2. Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 2 Uterine hyperstimulation with FHR changes.
Analysis 28.3. Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 3 Caesarean section
Analysis 28.4. Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 4 Oxytocin augmentation





Analysis 32.5. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 5 Oxytocin augmentation.	319
Analysis 32.6. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women,	320
Outcome 6 Uterine hyperstimulation without FHR changes.	
Analysis 32.7. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 7 Instrumental vaginal delivery.	320
Analysis 32.8. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 8 Meconium-stained liquor.	320
Analysis 32.9. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 9 Apgar score < 7 at 5 minutes.	321
Analysis 32.10. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 10 Neonatal intensive care unit admission.	321
Analysis 32.11. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 11 Perinatal death.	321
Analysis 32.12. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 12 Chorioamnionitis.	322
Analysis 32.13. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 13 Endometritis.	322
Analysis 33.1. Comparison 33 Any mechanical method and prostaglandin E2 versus oxytocin alone: all women, Outcome 1 Caesarean section.	322
Analysis 33.2. Comparison 33 Any mechanical method and prostaglandin E2 versus oxytocin alone: all women, Outcome 2 Instrumental vaginal delivery.	323
Analysis 33.3. Comparison 33 Any mechanical method and prostaglandin E2 versus oxytocin alone: all women, Outcome 3 Endometritis.	323
Analysis 34.1. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.	324
Analysis 34.2. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 2 Uterine hyperstimulation with FHR changes.	325
Analysis 34.3. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 3 Caesarean section.	325
Analysis 34.4. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 4 Serious neonatal morbidity/perinatal death.	325
Analysis 34.5. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 5 Serious maternal morbidity or death.	326
Analysis 34.6. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 6 Oxytocin augmentation.	326
Analysis 34.7. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 7 Uterine hyperstimulation without fetal heart rate changes.	326
Analysis 34.8. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 8 Uterine rupture.	327
Analysis 34.9. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 9 Instrumental vaginal delivery.	327
Analysis 34.10. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 10 Meconium-stained liquor.	327
Analysis 34.11. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 11 Apgar score < 7 at 5 minutes.	328
Analysis 34.12. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 12 Neonatal intensive care unit admission.	328
Analysis 34.13. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 13 Perinatal death.	328
Analysis 34.14. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 14 Maternal side effects.	329
Analysis 34.15. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 15 Maternal nausea.	329
Analysis 34.16. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 16 Maternal diarrhoea.	329



Analysis 34.13. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 19 Maternal fewer during labour. Analysis 34.15. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 19 Maternal fewer during labour. Analysis 35.1. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 35.2. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 2 Uterine hyperstimulation with FHR changes. Analysis 35.2. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 3 Caesarean section. Analysis 35.5. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 4 Serious meteral morbidity/perinatal death. Analysis 35.6. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 6 Serious maternal morbidity or death. Analysis 35.6. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 6 Serious maternal morbidity or death. Analysis 35.6. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 7 Ou	Analysis 34.17. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 17 Postpartum haemorrhage.	330
Analysis 34.19. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 10 Mathernal fever during labour. Analysis 35.1. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 10 Vaginal delivery not achieved in 24 hours. Analysis 35.2. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 2 Uterine hyperstimulation with FHR changes. Analysis 35.3. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 3 Caesarean section. Analysis 35.4. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 4 Serious neonatal morbidity perinatal death. Analysis 35.6. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Analysis 35.6. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Analysis 35.6. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Analysis 35.6. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 70 Evrick unfavourable/unchanged after 12 hours. Analysis 35.8. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 80 Uterine hyperstimulation without FHR changes. Analysis 35.10. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 90 Uterine rupture. Analysis 35.10. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 10 Epidural analgesia. Analysis 35.11. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 10 Epidural analgesia. Analysis 35.11	Analysis 34.18. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women,	330
Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 35.2 Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, outcome 2 Uterine hyperstimulation with FHR changes. Analysis 35.2 Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, analysis 35.4 Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, analysis 35.5 Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, analysis 35.5 Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, analysis 35.5 Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, analysis 35.7 Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, analysis 35.7 Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, analysis 35.7 Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, analysis 35.6 Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, analysis 35.6 Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, analysis 35.6 Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, analysis 35.1 Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, analysis 35.1 Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all analysis 35.1 Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, outcome 10 Epidural analgesia. Analysis 35.1 Comparison 35 Any mechanical method and low dose misoprostol versus low dose misopro	Analysis 34.19. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women,	330
Analysis 35.2. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 2 Uterine hyperstimulation with FHR changes. Analysis 35.3. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Analysis 35.4. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 4 Serious neonatal morbidity/perinatal death. Analysis 35.6. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Analysis 35.6. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 5 Serious maternal morbidity or death. Analysis 35.6. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Analysis 35.7. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 6 Uterine hyperstimulation without FHR changes. Analysis 35.8. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 9 Uterine hyperstimulation without FHR changes. Analysis 35.10. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 10 Epidural analgesia. Analysis 35.11. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 10 Epidural analgesia. Analysis 35.12. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 10 Epidural analgesia. Analysis 35.12. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 10 Reprimation and provide method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 10 Maternal versus and provide method and low dose misoprostol versus low dose misoprostol		332
Analysis 35.3. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 4 Serious neonatal morbidity) perinatal death. Analysis 35.4. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 5 Serious maternal morbidity) perinatal death. Analysis 35.6. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 6 Serious maternal morbidity or death. Analysis 35.6. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 6 Serious unfavourable/unchanged after 12 hours. Analysis 35.6. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 70 Ovtocin augmentation. Analysis 35.8. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 80 Uterine rupture. Analysis 35.9. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 90 Uterine rupture. Analysis 35.10. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 10 Epidural analgesia. Analysis 35.11. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 10 Epidural analgesia. Analysis 35.12. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 11 Instrumental vaginal delivery. Analysis 35.13. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 14 Meconium-stained liquor. Analysis 35.15. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 14 Meconium-stained liquor. Analysis 35.15. Comparison 35 Any mechanical method and low dose misoprostol versus lo	Analysis 35.2. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women,	332
Outcome 4 Serious neonatal morbidity/perinatal death. Analysis 35.5. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 5 Serious maternal morbidity or death. Analysis 35.6. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 6 Cervix unfavourable/unchanged after 12 hours. Analysis 35.7. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 7 Oxytocin augmentation. Analysis 35.8. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 8 Uterine hyperstimulation without FHR changes. Analysis 35.9. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 9 Uterine rupture. Analysis 35.10. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 10 Epidural analgesia. Analysis 35.11. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 10 Epidural analgesia. Analysis 35.12. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 12 Meconium-stained liquor. Analysis 35.12. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 12 Meconium-stained liquor. Analysis 35.15. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 14 Neonatal intensive care unit admission. Analysis 35.15. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 14 Neonatal death. Analysis 35.15. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 14 Neonatal death. Analysis 35.16. Comparison 35 Any mechanical method a	Analysis 35.3. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women,	332
Outcome 5 Serious maternal morbidity or death. Analysis 35.6. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Oytcome 7 Oytcome 10 Septian and 10 without FHR changes. Analysis 35.7. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 7 Oytcome a Uterine hyperstimulation without FHR changes. Analysis 35.8. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 8 Uterine hyperstimulation without FHR changes. Analysis 35.9. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 9 Uterine rupture. Analysis 35.10. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 10 Epidural analgesia. Analysis 35.11. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 11 Instrumental vaginal delivery. Analysis 35.12. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 11 Meconium-stained liquor. Analysis 35.13. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 14 Neonatal intensive care unit admission. Analysis 35.15. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 14 Neonatal intensive care unit admission. Analysis 35.15. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 15 Perinatal death. Analysis 35.16. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 337 women, Outcome 16 Maternal diaerthoca. Analysis 35.17. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 338 women, Outcome 19 Postpartum haemorrhage. Analysi		333
Analysis 35.1. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 7 Daystocin augmentation. Analysis 35.8. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 8 Uterine hyperstimulation without FHR changes. Analysis 35.9. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 9 Uterine rupture. Analysis 35.10. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 10 Epidural analgesia. Analysis 35.11. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 11 Instrumental vaginal delivery. Analysis 35.12. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 12 Meconium-stained liquor. Analysis 35.13. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 12 Meconium-stained liquor. Analysis 35.14. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 14 Neonatal intensive care unit admission. Analysis 35.15. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 15 Perinatal death. Analysis 35.16. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 16 Maternal side effects. Analysis 35.17. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 18 Maternal nausea. Analysis 35.18. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 19 Postpartum haemorrhage. Analysis 35.19. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women,		333
Analysis 35.8. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 10 Epidural analysis 35.9. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, outcome 9 Uterine rupture. Analysis 35.9. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 335 women, Outcome 10 Epidural analgesia. Analysis 35.10. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 336 women, Outcome 11 Instrumental vaginal delivery. Analysis 35.12. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 36 women, Outcome 12 Meconium-stained liquor. Analysis 35.13. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 36 women, Outcome 13 Apgar score < 7 at 5 minutes. Analysis 35.14. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 37 women, Outcome 14 Neonatal intensive care unit admission. Analysis 35.15. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 37 women, Outcome 15 Perinatal death. Analysis 35.16. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 37 women, Outcome 16 Maternal side effects. Analysis 35.17. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 38 women, Outcome 17 Maternal diarrhoea. Analysis 35.19. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 38 women, Outcome 18 Maternal diarrhoea. Analysis 35.19. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 38 women, Outcome 20 Serious maternal complications. Analysis 35.20. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all		334
Analysis 35.10. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 10 Epidural analgesia. Analysis 35.10. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 335 women, Outcome 10 Epidural analgesia. Analysis 35.11. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 336 women, Outcome 11 Instrumental vaginal delivery. Analysis 35.12. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 336 women, Outcome 12 Meconium-stained liquor. Analysis 35.13. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 336 women, Outcome 13 Apgar score < 7 at 5 minutes. Analysis 35.14. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 336 women, Outcome 14 Neonatal intensive care unit admission. Analysis 35.15. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 337 women, Outcome 15 Perinatal death. Analysis 35.16. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 337 women, Outcome 16 Maternal side effects. Analysis 35.17. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 338 women, Outcome 17 Maternal nausea. Analysis 35.18. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 338 women, Outcome 18 Maternal diarrhoea. Analysis 35.19. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 338 women, Outcome 19 Postpartum haemorrhage. Analysis 35.20. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 338 women, Outcome 21 Chorioamnionitis. Analysis 35.21. Comparison 35 Any mechanical method and low dose misoprostol versus low dose miso	Analysis 35.7. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 7 Oxytocin augmentation.	334
Analysis 35.10. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 335 women, Outcome 10 Epidural analgesia. Analysis 35.11. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 336 women, Outcome 11 Instrumental vaginal delivery. Analysis 35.12. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 336 women, Outcome 12 Meconium-stained liquor. Analysis 35.13. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 36 women, Outcome 13 Apgar score < 7 at 5 minutes. Analysis 35.14. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 36 women, Outcome 14 Neonatal intensive care unit admission. Analysis 35.15. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 37 women, Outcome 15 Perinatal death. Analysis 35.16. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 37 women, Outcome 16 Maternal side effects. Analysis 35.17. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 38 women, Outcome 18 Maternal mausea. Analysis 35.18. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 38 women, Outcome 18 Maternal diarrhoea. Analysis 35.19. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 38 women, Outcome 19 Postpartum haemorrhage. Analysis 35.20. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 39 women, Outcome 20 Serious maternal complications. Analysis 35.21. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 39 women, Outcome 21 Endometrits. Analysis 35.22. Comparison 35 Any mechanical method and low dose misoprostol versus low dose mi		334
women, Outcome 10 Epidural analgesia. Analysis 35.11. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 336 women, Outcome 11 Instrumental vaginal delivery. Analysis 35.12. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 336 women, Outcome 12 Meconium-stained liquor. Analysis 35.13. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 336 women, Outcome 13 Apgar score <7 at 5 minutes. Analysis 35.14. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 337 women, Outcome 14 Neonatal intensive care unit admission. Analysis 35.15. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 337 women, Outcome 15 Perinatal death. Analysis 35.16. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 337 women, Outcome 16 Maternal side effects. Analysis 35.18. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 338 women, Outcome 17 Maternal nausea. Analysis 35.19. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 338 women, Outcome 19 Postpartum haemorrhage. Analysis 35.20. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 338 women, Outcome 20 Serious maternal complications. Analysis 35.21. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 339 women, Outcome 21 Chorioamnionitis. Analysis 35.22. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 340 women, Outcome 22 Endometrits. Analysis 35.22. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 340 women, Outcome 23 Fetal distress. Analysis 36.2. Comparison 36 Any mechanical method and	Analysis 35.9. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 9 Uterine rupture.	335
women, Outcome 11 Instrumental vaginal delivery. Analysis 35.12. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 12 Meconium-stained liquor. Analysis 35.13. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 13 Apgar score < 7 at 5 minutes. Analysis 35.14. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 14 Neonatal intensive care unit admission. Analysis 35.15. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 15 Perinatal death. Analysis 35.16. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 16 Maternal side effects. Analysis 35.17. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 18 Maternal nausea. Analysis 35.18. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 18 Maternal diarrhoea. Analysis 35.19. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 19 Postpartum haemorrhage. Analysis 35.20. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 20 Serious maternal complications. Analysis 35.21. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 21 Chorioammionitis. Analysis 35.22. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 22 Endometrits. Analysis 35.23. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 23 Fetal distress. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprost		335
women, Outcome 12 Meconium-stained liquor. Analysis 35.13. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 13 Apgar score < 7 at 5 minutes. Analysis 35.14. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 14 Neonatal intensive care unit admission. Analysis 35.15. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 15 Perinatal death. Analysis 35.16. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 16 Maternal side effects. Analysis 35.17. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 17 Maternal nausea. Analysis 35.18. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 18 Maternal diarrhoea. Analysis 35.19. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 19 Postpartum haemorrhage. Analysis 35.20. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 20 Serious maternal complications. Analysis 35.21. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 21 Chorioamnionitis. Analysis 35.22. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 22 Endometrits. Analysis 35.23. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 23 Fetal distress. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 24 Fetal distress. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all pr	Analysis 35.11. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 11 Instrumental vaginal delivery.	335
women, Outcome 13 Apgar score < 7 at 5 minutes. Analysis 35.14. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 14 Neonatal intensive care unit admission. Analysis 35.15. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 15 Perinatal death. Analysis 35.16. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 16 Maternal side effects. Analysis 35.17. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 17 Maternal nausea. Analysis 35.18. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 18 Maternal diarrhoea. Analysis 35.19. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 19 Postpartum haemorrhage. Analysis 35.20. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 20 Serious maternal complications. Analysis 35.21. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 21 Chorioamnionitis. Analysis 35.22. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 22 Endometrits. Analysis 35.23. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 23 Fetal distress. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 36.2. Comparison 36 Any mechanical method and low dose m		336
women, Outcome 14 Neonatal intensive care unit admission. Analysis 35.15. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 15 Perinatal death. Analysis 35.16. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 16 Maternal side effects. Analysis 35.17. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 17 Maternal nausea. Analysis 35.18. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 18 Maternal diarrhoea. Analysis 35.19. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 19 Postpartum haemorrhage. Analysis 35.20. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 20 Serious maternal complications. Analysis 35.21. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 21 Chorioamnionitis. Analysis 35.22. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 22 Endometrits. Analysis 35.23. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 23 Fetal distress. Analysis 36.1. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.		336
women, Outcome 15 Perinatal death. Analysis 35.16. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 16 Maternal side effects. Analysis 35.17. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 17 Maternal nausea. Analysis 35.18. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 18 Maternal diarrhoea. Analysis 35.19. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 19 Postpartum haemorrhage. Analysis 35.20. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 20 Serious maternal complications. Analysis 35.21. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 21 Chorioamnionitis. Analysis 35.22. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 22 Endometrits. Analysis 35.23. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 23 Fetal distress. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all ado primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.	women, Outcome 14 Neonatal intensive care unit admission.	336
women, Outcome 16 Maternal side effects. Analysis 35.17. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 17 Maternal nausea. Analysis 35.18. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 18 Maternal diarrhoea. Analysis 35.19. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 19 Postpartum haemorrhage. Analysis 35.20. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 20 Serious maternal complications. Analysis 35.21. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 21 Chorioamnionitis. Analysis 35.22. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 22 Endometrits. Analysis 35.23. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 23 Fetal distress. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 340 primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 340		337
women, Outcome 17 Maternal nausea. Analysis 35.18. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 18 Maternal diarrhoea. Analysis 35.19. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 19 Postpartum haemorrhage. Analysis 35.20. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 20 Serious maternal complications. Analysis 35.21. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 21 Chorioamnionitis. Analysis 35.22. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 22 Endometrits. Analysis 35.23. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 23 Fetal distress. Analysis 36.1. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 340 primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 340		337
women, Outcome 18 Maternal diarrhoea. Analysis 35.19. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 19 Postpartum haemorrhage. Analysis 35.20. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 20 Serious maternal complications. Analysis 35.21. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 21 Chorioamnionitis. Analysis 35.22. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 22 Endometrits. Analysis 35.23. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 23 Fetal distress. Analysis 36.1. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 340 primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 340		337
women, Outcome 19 Postpartum haemorrhage. Analysis 35.20. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 20 Serious maternal complications. Analysis 35.21. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 21 Chorioamnionitis. Analysis 35.22. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 22 Endometrits. Analysis 35.23. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 23 Fetal distress. Analysis 36.1. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 340		338
women, Outcome 20 Serious maternal complications. Analysis 35.21. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 21 Chorioamnionitis. Analysis 35.22. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 22 Endometrits. Analysis 35.23. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 23 Fetal distress. Analysis 36.1. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 340		338
women, Outcome 21 Chorioamnionitis. Analysis 35.22. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 22 Endometrits. Analysis 35.23. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 23 Fetal distress. Analysis 36.1. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 340		338
women, Outcome 22 Endometrits. Analysis 35.23. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 23 Fetal distress. Analysis 36.1. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 340		339
women, Outcome 23 Fetal distress. Analysis 36.1. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 340		339
primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 340		339
Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all 340		340
	Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all	340



Analysis 37.1. Comparison 37 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all	341
multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours. Analysis 37.2. Comparison 37 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all multiparae, Outcome 2 Caesarean section.	341
Analysis 38.1. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre-	342
specified), Outcome 1 Uterine hyperstimulation with FHR changes. Analysis 38.2. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre-	343
specified), Outcome 2 Caesarean section.	343
Analysis 38.3. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not prespecified), Outcome 3 Serious maternal morbidity or death.	343
Analysis 38.4. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not prespecified), Outcome 4 Oxytocin augmentation.	343
Analysis 38.5. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not prespecified), Outcome 5 Uterine hyperstimulation without FHR changes.	344
Analysis 38.6. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not prespecified), Outcome 6 Instrumental vaginal delivery.	344
Analysis 38.7. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not prespecified), Outcome 7 Meconium-stained liquor.	344
Analysis 38.8. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not prespecified), Outcome 8 Apgar score < 7 at 5 minutes.	345
Analysis 38.9. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not prespecified), Outcome 9 Neonatal intensive care unit admission.	345
Analysis 38.10. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not prespecified), Outcome 10 Postpartum haemorrhage.	345
Analysis 38.11. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not prespecified), Outcome 11 Endometritis.	346
Analysis 38.12. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not prespecified), Outcome 12 Fetal distress.	346
Analysis 39.1. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not prespecified), Outcome 1 Vaginal delivery not achieved in 24 hours.	347
Analysis 39.2. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not prespecified), Outcome 2 Uterine hyperstimulation with FHR changes.	348
Analysis 39.3. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not prespecified), Outcome 3 Caesarean section.	348
Analysis 39.4. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not prespecified), Outcome 4 Serious neonatal morbidity/perinatal death.	348
Analysis 39.5. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not prespecified), Outcome 5 Oxytocin augmentation.	349
Analysis 39.6. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not prespecified), Outcome 6 Uterine hyperstimulation without FHR changes.	349
Analysis 39.7. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not prespecified), Outcome 7 Epidural analgesia.	349
Analysis 39.8. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not prespecified), Outcome 8 Meconium-stained liquor.	350
Analysis 39.9. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not prespecified), Outcome 9 Apgar score < 7 at 5 minutes.	350
Analysis 39.10. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not prespecified), Outcome 10 Neonatal intensive care unit admission.	350
Analysis 39.11. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not prespecified), Outcome 11 Perinatal death.	351
Analysis 39.12. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not prespecified), Outcome 12 Women not satisfied.	351
	351
	352



Analysis 40.1. Comparison 40 Any mechanical method and oxytocin versus low dose misoprostol alone: all multipara Outcome 1 Caesarean section.	
Analysis 41.1. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified Outcome 1 Vaginal delivery not achieved in 24 hours.	
Analysis 41.2. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified Outcome 2 Caesarean section.	
Analysis 41.3. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified Outcome 3 Serious neonatal morbidity/perinatal death.	
Analysis 41.4. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified Outcome 4 Serious maternal morbidity or death.	
Analysis 41.5. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified Outcome 5 Uterine hyperstimulation without FHR changes.	
Analysis 41.6. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified Outcome 6 Uterine rupture.	
Analysis 41.7. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified Outcome 7 Epidural analgesia.	
Analysis 41.8. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified Outcome 8 Instrumental vaginal delivery.	
Analysis 41.9. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified Outcome 9 Meconium-stained liquor.	
Analysis 41.10. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified Outcome 10 Neonatal intensive care unit admission.	
Analysis 41.11. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified Outcome 11 Postpartum haemorrhage.	
Analysis 41.12. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified Outcome 12 Serious maternal complications.	d),
Analysis 41.13. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified Outcome 13 Antibiotics during labour.	
Analysis 41.14. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified Outcome 14 Chorionamnionitis.	
Analysis 41.15. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified Outcome 15 Endometritis.	
Analysis 41.16. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified Outcome 16 Fetal distress.	
PPENDICES	
/HAT'S NEW	
ISTORY	
ONTRIBUTIONS OF AUTHORS	
ECLARATIONS OF INTEREST	
OURCES OF SUPPORT	
IFFERENCES BETWEEN PROTOCOL AND REVIEW	



[Intervention Review]

Mechanical methods for induction of labour

Marieke DT de Vaan^{1,2}, Mieke LG ten Eikelder³, Marta Jozwiak⁴, Kirsten R Palmer⁵, Miranda Davies-Tuck⁶, Kitty WM Bloemenkamp⁷, Ben Willem J Mol⁸, Michel Boulvain⁹

¹Department of Obstetrics, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands. ²Department of Health Care Studies, Rotterdam University of Applied Sciences, Rotterdam, Netherlands. ³Department of Obstetrics and Gynaecology, Royal Cornwall Hospital NHS Trust, Truro, UK. ⁴Erasmus Medical Center, Rotterdam, Netherlands. ⁵Department of Obstetrics and Gynaecology, Monash Health and Monash University, Clayton, Australia. ⁶Monash University, Clayton, Australia. ⁷Department of Obstetrics, Division Women and Baby, Birth Centre Wilhelmina's Children Hospital, University Medical Center Utrecht, Utrecht, Netherlands. ⁸Department of Obstetrics and Gynaecology, Monash University, Clayton, Australia. ⁹Department of Gynecology and Obstetrics, University of Geneva/GHOL-Nyon Hospital, NYON, Switzerland

Contact address: Michel Boulvain, Department of Gynecology and Obstetrics, University of Geneva/GHOL-Nyon Hospital, NYON, Switzerland. michel.boulvain@ghol.ch.

Editorial group: Cochrane Pregnancy and Childbirth Group

Publication status and date: New search for studies and content updated (conclusions changed), published in Issue 10, 2019.

Citation: de Vaan MDT, ten Eikelder MLG, Jozwiak M, Palmer KR, Davies-Tuck M, Bloemenkamp KWM, Mol BWJ, Boulvain M. Mechanical methods for induction of labour. *Cochrane Database of Systematic Reviews* 2019, Issue 10. Art. No.: CD001233. DOI: 10.1002/14651858.CD001233.pub3.

Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

ABSTRACT

Background

Mechanical methods were the first methods developed to ripen the cervix and induce labour. During recent decades they have been substituted by pharmacological methods. Potential advantages of mechanical methods, compared with pharmacological methods may include reduction in side effects that could improve neonatal outcomes. This is an update of a review first published in 2001, last updated in 2012.

Objectives

To determine the effectiveness and safety of mechanical methods for third trimester (> 24 weeks' gestation) induction of labour in comparison with prostaglandin E2 (PGE2) (vaginal and intracervical), low-dose misoprostol (oral and vaginal), amniotomy or oxytocin.

Search methods

For this update, we searched Cochrane Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP), and reference lists of retrieved studies (9 January 2018). We updated the search in March 2019 and added the search results to the awaiting classification section of the review.

Selection criteria

 $Clinical\ trials\ comparing\ mechanical\ methods\ used\ for\ third\ trimester\ cervical\ ripening\ or\ labour\ induction\ with\ pharmacological\ methods.$

Mechanical methods include: (1) the introduction of a catheter through the cervix into the extra-amniotic space with balloon insufflation; (2) introduction of laminaria tents, or their synthetic equivalent (Dilapan), into the cervical canal; (3) use of a catheter to inject fluid into the extra-amniotic space (EASI).



This review includes the following comparisons: (1) specific mechanical methods (balloon catheter, laminaria tents or EASI) compared with prostaglandins (different types, different routes) or with oxytocin; (2) single balloon compared to a double balloon; (3) addition of prostaglandins or oxytocin to mechanical methods compared with prostaglandins or oxytocin alone.

Data collection and analysis

Two review authors independently assessed trials for inclusion and assessed risk of bias. Two review authors independently extracted data and assessed the quality of the evidence using the GRADE approach.

Main results

This review update includes a total of 113 trials (22,373 women) contributing data to 21 comparisons. Risk of bias of trials varied. Overall, the evidence was graded from very-low to moderate quality. All evidence was downgraded for lack of blinding and, for many comparisons, the effect estimates were too imprecise to make a valid judgement.

Balloon versus vaginal PGE2: there may be little or no difference in **vaginal deliveries not achieved within 24 hours** (average risk ratio (RR) 1.01, 95% confidence interval (CI) 0.82 to 1.26; 7 studies; 1685 women; I² = 79%; low-quality evidence) and there probably is little or no difference in **caesarean sections** (RR 1.00, 95% CI 0.92 to 1.09; 28 studies; 6619 women; moderate-quality evidence) between induction of labour with a balloon catheter and vaginal PGE2. A balloon catheter probably reduces the risk of uterine **hyperstimulation with fetal heart rate** (**FHR**) **changes** (RR 0.35, 95% CI 0.18 to 0.67; 6 studies; 1966 women; moderate-quality evidence), **serious neonatal morbidity or perinatal death** (RR 0.48, 95% CI 0.25 to 0.93; 8 studies; 2757 women; moderate-quality evidence) and may slightly reduce the risk of aneonatal intensive care unit (**NICU**) **admission** (RR 0.82, 95% CI 0.65 to 1.04; 3647 women; 12 studies; low-quality evidence). It is uncertain whether there is a difference in **serious maternal morbidity or death** (RR 0.20, 95% CI 0.01 to 4.12; 4 studies; 1481 women) or **five-minute Apgar score < 7** (RR 0.74, 95% CI 0.49 to 1.14; 4271 women; 14 studies) because the quality of the evidence was found to be very low and low, respectively.

Balloon versus low-dose vaginal misoprostol: it is uncertain whether there is a difference in **vaginal deliveries not achieved within 24 hours** between induction of labour with a balloon catheter and vaginal misoprostol (RR 1.09, 95% CI 0.85 to 1.39; 340 women; 2 studies; low-quality evidence). A balloon catheter probably reduces the risk of **uterine hyperstimulation with FHR changes** (RR 0.39, 95% CI 0.18 to 0.85; 1322 women; 8 studies; moderate-quality evidence) but may increase the risk of a **caesarean section** (average RR 1.28, 95% CI 1.02 to 1.60; 1756 women; 12 studies; I² = 45%; low-quality evidence). It is uncertain whether there is a difference in **serious neonatal morbidity or perinatal death** (RR 0.58, 95% CI 0.12 to 2.66; 381 women; 3 studies), **serious maternal morbidity or death** (no events; 4 studies, 464 women), both very low-quality evidence, and **five-minute Apgar score < 7** (RR 1.00, 95% CI 0.50 to 1.97; 941 women; 7 studies) and **NICU admissions** (RR 1.00, 95% CI 0.61 to 1.63; 1302 women; 9 studies) both low-quality evidence.

Balloon versus low-dose oral misoprostol: a balloon catheter probably increases the risk of a **vaginal delivery not achieved within 24 hours** (RR 1.28, 95% CI 1.13 to 1.46; 782 women, 2 studies, and probably slightly increases the risk of a **caesarean section** (RR 1.17, 95% CI 1.04 to 1.32; 3178 women; 7 studies; both moderate-quality evidence) when compared to oral misoprostol. It is uncertain whether there is a difference in **uterine hyperstimulation with FHR changes** (RR 0.81, 95% CI 0.48 to 1.38; 2033 women; 2 studies), **serious neonatal morbidity or perinatal death** (RR 1.11, 95% CI 0.60 to 2.06; 2627 women; 3 studies), both low-quality evidence, **serious maternal morbidity or death** (RR 0.50, 95% CI 0.05 to 5.52; 2627 women; 3 studies), very low-quality evidence, **five-minute Apgar scores** < **7** (RR 0.71, 95% CI 0.38 to 1.32; 2693 women; 4 studies) and **NICU admissions** (RR 0.82, 95% CI 0.58 to 1.17; 2873 women; 5 studies) both low-quality evidence.

Authors' conclusions

Low- to moderate-quality evidence shows mechanical induction with a balloon is probably as effective as induction of labour with vaginal PGE2. However, a balloon seems to have a more favourable safety profile. More research on this comparison does not seem warranted.

Moderate-quality evidence shows a balloon catheter may be slightly less effective as oral misoprostol, but it remains unclear if there is a difference in safety outcomes for the neonate. When compared to low-dose vaginal misoprostol, low-quality evidence shows a balloon may be less effective, but probably has a better safety profile.

Future research could be focused more on safety aspects for the neonate and maternal satisfaction.

PLAIN LANGUAGE SUMMARY

Mechanical methods for induction of labour

We set out to determine from randomised controlled trials the effectiveness and safety of mechanical methods to bring on labour in the third trimester of pregnancy (> 24 weeks' gestation). Use of a balloon to stretch the cervix (the lower end of the uterus) was compared with prostaglandin E2 (PGE2), low-dose misoprostol or oxytocin.

What is the issue?

Induction is carried out generally when the risk of continuing pregnancy outweighs the benefits, or at the request of pregnant women.



Mechanical methods for induction promote cervical ripening and onset of labour by stretching the cervix. They are amongst the oldest methods used to initiate labour. During the last decades, medication such as PGE2, misoprostol and oxytocin have partly replaced mechanical methods.

Why is this important?

More and more women have labour induced and indications are often not urgent. This means that the safety aspects of induction methods become more important, although this could be at the expense of effectiveness. Mechanical methods could have advantages over pharmacological methods as they are widely available, low in cost and may have fewer side effects, such as excessive contractions of the uterus (uterine hyperstimulation). This could potentially be safer for the baby because if contractions are too long or very close together, the baby may not receive sufficient oxygen.

What evidence did we find?

For this review we included a total of 113 randomised controlled trials involving 22,373 women who were scheduled for induction of labour for different indications. The data contributed to 21 different comparisons and 20 subgroup comparisons. Overall, the evidence was graded from very low to moderate quality. For many comparisons there were too few women in the trials to determine any clear differences in serious illness for mothers and babies.

Twenty-eight trials (6619 women) showed mechanical induction with a balloon is as effective as vaginal PGE2 as there may be little or no difference in vaginal deliveries within 24 hours and there probably is little or no difference in caesarean sections between groups. However, a balloon appears to be safer for the neonate as it probably reduces the risk of uterine hyperstimulation with an abnormal heart rate of the baby, serious illness or death of the baby and may slightly reduce the risk for a neonatal intensive care unit admission. It was unclear if there was a difference in serious illness or death of the mother or in the five-minute Apgar score less than seven.

Thirteen trials (1818 women) compared induction of labour with a balloon with vaginal misoprostol and showed a balloon probably reduces the risk of uterine hyperstimulation with an abnormal heart rate of the baby, but may increase the risk of a caesarean section. It was unclear if there was a difference in vaginal deliveries within 24 hours, serious illness or death of the baby, serious illness or death of the mother, five-minute Apgar score less than seven or neonatal intensive care unit admissions.

Seven trials (3178 women) showed a balloon may be less effective than oral misoprostol as a balloon probably increases the risk of a vaginal delivery not achieved within 24 hours and probably slightly increases the risk of a caesarean section. Data on safety are still unclear as it is uncertain whether there is a difference in uterine hyperstimulation with an abnormal heart rate of the baby, serious illness or death of the baby, serious illness or death of the mother, five-minute Apgar score less than seven or neonatal intensive care unit admissions.

What does this mean?

Mechanical induction with a balloon is probably as effective as induction of labour with vaginal PGE2. However, a balloon seems to have a more favourable safety profile for the baby. More research on this comparison does not seem warranted.

A balloon catheter may be slightly less effective as oral misoprostol, but It remains unclear if there is a difference in safety outcomes for the baby. When compared to low-dose vaginal misoprostol, a balloon catheter may be less effective, but probably has a better safety profile for the baby.

Future research could focus more on safety aspects for the baby and maternal satisfaction.



Summary of findings for the main comparison. Balloon (Foley or ATAD) compared to vaginal prostaglandin E2 for third trimester labour induction in women with a viable fetus

Balloon (Foley or ATAD) compared to vaginal prostaglandin E2 for third trimester labour induction in women with a viable fetus

Patient or population: third trimester labour induction in women with a viable fetus

Setting: Australia, China, Denmark, Iran, Jordan, India, Italy, Israel, Nigeria, Pakistan, Singapore, Sweden, the Netherlands, USA, UK

Intervention: balloon (Foley or ATAD) **Comparison:** vaginal prostaglandin E2

Outcomes	Anticipated absolute e	effects* (95% CI)	Relative effect (95% CI)	№ of partici- pants	Certainty of the evidence	Comments
	Risk with vaginal prostaglandin E2	Risk with balloon (Foley or ATAD)	(30% 01)	(studies)	(GRADE)	
Vaginal delivery not achieved in 24 hours	Study population		RR 1.01 - (0.82 to 1.26)	1685 (7 RCTs)	⊕⊕⊙⊝ LOW 12	
Tiours	528 per 1000	533 per 1000 (433 to 665)	(0.02 to 1.20)	(Tite13)	LOW	
Uterine hyperstimulation with FHR changes	Study population		RR 0.35 - (0.18 to 0.67)	1966 (6 RCTs)	⊕⊕⊕⊝ MODERATE ¹	
changes	31 per 1000	11 per 1000 (6 to 21)	(cile to dioi)	(o ners)	MODERATE -	
Caesarean section	Study population		RR 1.00 - (0.92 to 1.09)	6619 (28 RCTs)	⊕⊕⊕⊝ MODERATE ¹	
	238 per 1000	238 per 1000 (219 to 260)	(0.52 to 1.05)	(20 11015)	MODERATE	
Serious neonatal morbidity or perinatal death	Study population		RR 0.48 - (0.25 to 0.93)	2757 (8 RCTs)	⊕⊕⊕⊚ MODERATE ¹	
Tidat death	20 per 1000	9 per 1000 (5 to 18)	(0.25 to 0.55)	(o ners)	MODERATE -	
Serious maternal morbidity or death	Study population		RR 0.20 - (0.01 to 4.12)	1481 (4 RCTs)	⊕⊝⊝⊝ VERY LOW ¹³	
	3 per 1000	1 per 1000 (0 to 11)	(5.52.65 1.12)	(11013)	VEIXI LOVV	
Apgar score < 7 at 5 minutes	Study population		RR 0.74 (0.49 to 1.14)	4271 (14 RCTs)	⊕⊕⊝⊝ LOW ^{1 4}	

	22 per 1000	16 per 1000 (11 to 25)			
Neonatal intensive care unit ad- mission	Study population		RR 0.82 - (0.65 to 1.04)	3647 (12 RCTs)	⊕⊕⊝⊝ LOW ¹ ⁴
	74 per 1000	60 per 1000 (48 to 77)	(0.00 to 1.0 !)	(12 1.0.3)	LOW

^{*}The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio

GRADE Working Group grades of evidence

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

¹We downgraded (1) level for serious limitation in study design due to lack of blinding (although not feasible due to nature of event)

 2 We downgraded (1) level for serious inconsistency due to evidence of statistical heterogeneity (12 = >30%)

³We downgraded (2) levels for very serious imprecision due to wide CI crossing the line of no effect and small number of events

⁴We downgraded (1) level for serious imprecision due to wide CI crossing the line of no effect

Summary of findings 2. Balloon (Foley or ATAD) compared to low-dose vaginal misoprostol for third trimester induction of labour in women with a viable fetus

Balloon (Foley or ATAD) compared to low-dose vaginal misoprostol for third trimester induction of labour in women with a viable fetus

Patient or population: third trimester induction of labour in women with a viable fetus

Setting: Brazil, Egypt, India, Iran, Nigeria, the Netherlands, Sweden

Intervention: balloon (Foley or ATAD) **Comparison:** low-dose vaginal misoprostol

Outcomes	Risk with low-dose Risk with balloon (Fo-		Relative effect (95% CI)	№ of partici-	Certainty of the evidence	Comments
	Risk with low-dose vaginal misoprostol	Risk with balloon (Foley or ATAD)	,	(studies)	(GRADE)	
Vaginal delivery not achieved in 24 hours	Study population		RR 1.09 (0.85 to 1.39)	340 (2 RCTs)	⊕⊕⊝⊝ LOW ¹ ²	

	412 per 1000	449 per 1000				
		(350 to 573)				
Uterine hyperstimulation with FHR changes	Study population		RR 0.39 - (0.18 to 0.85)	1322 (8 RCTs)	⊕⊕⊕⊝ MODERATE ¹	
	33 per 1000	13 per 1000 (6 to 28)	(0.00 0.00)	(5 112 12)	MODERATIE	
Caesarean section	Study population		RR 1.28 - (1.02 to 1.60)	1756 (12 RCTs)	⊕⊕⊝⊝ LOW ¹³	
	243 per 1000	311 per 1000 (247 to 388)	(2.02.10.2)	(== 1.01.0)	LOW	
Serious neonatal morbidity or perinatal death	Study population		RR 0.58 - (0.12 to 2.66)	381 (3 RCTs)	⊕⊝⊝⊝ VERY LOW ¹⁴	
notal death	21 per 1000	12 per 1000 (2 to 55)	(0.12 to 2.00)	(o No Is)	VERT LOW	
Serious maternal morbidity or death	Study population		not estimable	464 (4 RCTs)	⊕⊝⊝⊝ VERY LOW 15	no events oc- curred in in-
death	0 per 1000	0 per 1000 (0 to 0)		(TROIS)	VERT LOW - 3	cluded stud- ies
Apgar score < 7 at 5 minutes	Study population		RR 1.00 - (0.50 to 1.97)	941 (7 RCTs)	⊕⊕⊙⊝ LOW 1 2	,
	30 per 1000	30 per 1000 (15 to 59)	(0.30 to 1.31)	(FRC13)	LOW	
Neonatal intensive care unit ad- mission	Study population		RR 1.00 - (0.61 to 1.63)	1302 (9 RCTs)	⊕⊕⊝⊝ LOW 1 2 6	
	47 per 1000	47 per 1000 (29 to 77)	(5.51 to 1.55)	(3 ((3))	LOW 0	

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio

GRADE Working Group grades of evidence

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

²We downgraded (1) level for serious imprecision due to wide CI crossing the line of no effect

³We downgraded (1) level for serious inconsistency due to evidence of statistical heterogeneity (I² = >30%)

⁴We downgraded (2) levels for very serious imprecision due to wide CI crossing the line of no effect and small number of events

⁵ We downgraded (2) levels for very serious imprecision due to wide CI crossing the line of no effect and no events reported in included studies

⁶ Although there was some evidence suggesting small-study effect we did not downgrade for publication bias because individual studies did not reach statistical significance and there was low heterogeneity across all studies for this outcome. Also, no difference was found between fixed-effect or random-effect analyses

Summary of findings 3. Balloon (Foley or ATAD) compared to low-dose oral misoprostol for third trimester induction of labour in women with a viable fetus

Balloon (Foley or ATAD) compared to low-dose oral misoprostol for third trimester induction of labour in women with a viable fetus

Patient or population: third trimester induction of labour in women with a viable fetus

Setting: Finland, India, Pakistan, Sri Lanka, the Netherlands

Intervention: balloon (Foley or ATAD)
Comparison: low-dose oral misoprostol

Outcomes	Anticipated absolute effe	ects* (95% CI)	Relative effect (95% CI)	№ of partici- pants	Certainty of the evidence	Comments
	Risk with low-dose oral misoprostol	Risk with balloon (Foley or ATAD)	- (55% 6.1)	(studies)	(GRADE)	
Vaginal delivery not achieved within 24 hours	Study population		RR 1.28 - (1.13 to 1.46)	782 (2 RCTs)	⊕⊕⊕⊝ MODERATE ¹	
deficeed within 2 mounts	476 per 1000		(21(013)	MODERATE -		
Uterine hyperstimulation with FHR changes	Study population		RR 0.81 2033 ⊕⊕⊙⊝ - (0.48 to 1.38) (2 RCTs) LOW ¹²		⊕⊕⊝⊝ LOW ¹ ²	
with the changes	29 per 1000	24 per 1000 (14 to 40)	(0.40 to 1.50)	(2 1013)	LOW	
Caesarean section	Study population		RR 1.17 - (1.04 to 1.32)	3178 ⊕⊕⊕⊚ (7 RCTs) MODERA	⊕⊕⊕⊚ MODERATE ¹³	
	222 per 1000	259 per 1000 (230 to 293)	- (1.04 to 1.32)	(Fice1s)	MODERATE 19	
Serious neonatal morbidity or perinatal death	Study population				⊕⊕⊝⊝ LOW 124	
or permatar death	14 per 1000	16 per 1000 (9 to 30)	- (0.00 to 2.00)	(Siters)	LOWY	

Serious maternal morbidity or death	Study population		RR 0.50 - (0.05 to 5.52)	2627 (3 RCTs)	⊕⊝⊝⊝ VERY LOW ¹⁵
or death	2 per 1000	1 per 1000 (0 to 8)	(0.03 to 3.32)	(5 NC13)	VERT LOW - 5
Apgar score < 7 after 5 min- utes	Study population		RR 0.71 2693 (0.38 to 1.32) (4 RCTs)		⊕⊕⊝⊝ LOW 124
utes	18 per 1000	13 per 1000 (6 to 28)	(0.30 to 1.32)	(411013)	LOW 12
Neonatal intensive care unit admission	Study population	RR 0.82 (0.58 to 1.17)		2873 (5 RCTs)	⊕⊕⊝⊝ LOW 124
	46 per 1000	37 per 1000 (26 to 53)	(0.00 to 1.1.)	(5.1.5.3)	LOW

^{*}The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio

GRADE Working Group grades of evidence

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

¹We downgraded (1) level for serious limitation in study design due to lack of blinding (although not feasible due to nature of event)

²We downgraded (1) level for serious imprecision due to wide CI crossing the line of no effect

³ Trial of Mundle 2017 did not meet the pre-specified population as pregnancies with a non viable fetus were included. Sensitivity analyses did not alter the estimated effect size. Therefore we did not downgrade

⁴ Trial of Mundle 2017 did not meet the pre-specified population as pregnancies with a non viable fetus were included. Sensitivity analysis did not change the direction of the effect size and numbers of events were not higher compared to other trials. Therefore we did not downgrade.

⁵ We downgraded (2) levels for very serious imprecision due to wide CI crossing the line of no effect and small number of events



BACKGROUND

The previous version of this review formed one of a series of reviews of methods for induction of labour that followed a standardised published 'generic' protocol (Hofmeyr 2009). These reviews were initially developed to help inform the recommendations of the National Institute for Health and Care Excellence (NICE) clinical practice guidelines on induction of labour (NICE 2008). This review no longer strictly follows the original protocol and has been updated with the intention of being a stand-alone review. This is an update of a review first published in 2001 (Boulvain 2001), and last updated in 2012 (Jozwiak 2012).

Description of the condition

Labour induction is a common obstetric procedure, which is generally carried out when the risk of continuing pregnancy outweighs the benefits. Also, induction of labour is being used more and more at the request of pregnant women to shorten the duration of pregnancy or to time the birth of the baby according to the convenience of the mother and/or healthcare workers (WHO 2011). In the USA, approximately one in four women are induced and in the last decade, the induction rate in the UK has risen up to almost 30% (NICE 2008; NHS 2017). Although rates are generally lower in developing countries, in some settings they can be as high as those observed in developed countries (WHO 2011). To maximise the success of induction of labour in women with an unfavourable cervix, various ripening methods are available.

Description of the intervention

Mechanical methods were the first methods developed to ripen the cervix and induce labour (Thiery 1989). Devices that were used in this context include various type of catheters and laminaria tents, introduced into the cervical canal or through the cervix into the extra-amniotic space. During recent decades they were partly substituted by pharmacological methods, including various prostaglandin E2 (PGE2) preparations (vaginal gel, tablets, inserts, intracervical gel), prostaglandin E1 (PGE1; misoprostol tablets, applied either orally or vaginally) and oxytocin. Pharmacological methods however, have a variety of effects at different sites and receptors in the body that can lead to unwanted side effects when used, such as uterine hyperstimulation (excessive contractions of the uterus) and as result, fetal distress. Therefore, mechanical induction methods are gaining in popularity as it has the potential to have a better safety profile compared to pharmacological methods, however possibly at the cost of a longer duration of labour. These factors need to be considered to determine the most appropriate methods depending on the clinical situation, with impact on labour duration possibly being of secondary importance as more women have labour induced for less urgent indications.

How the intervention might work

The goal of mechanical induction methods is to ripen the cervix, which can be achieved directly through dilatation of the canal, indirectly by increasing prostaglandin or oxytocin secretion, or both (Keirse 1983). In addition to the local effect, mechanisms which involve neuro-endocrine reflexes (the Ferguson reflex) may promote the onset of contractions, leading to labour onset (Krammer 1995b).

The standard Foley urinary catheter can be used, as well as a specially developed 'Atad' double-balloon catheter (Atad 1996) or Cook

balloon. The catheter is introduced through the cervical canal to reach the extra-amniotic space. The balloon is then inflated to keep the catheter in place. Traction is applied to the catheter in some cases. Another method involving catheters consists of infusing saline solution or prostaglandins through a catheter inserted, via the cervical canal, in the extra-amniotic space (EASI).

Laminaria tents, made from sterile sea-weed or synthetic hydrophilic materials (e.g. Lamicel), are introduced into the cervical canal. These devices increase in diameter because of their hydrophilic properties. This achieves a gradual stretching of the cervix.

Digital stripping or sweeping of the membranes is evaluated in a different review (Boulvain 2005).

Why it is important to do this review

Mechanical methods were never completely abandoned, but were substituted by pharmacological methods in recent decades. However, as induction rates rise and indications are often less urgent, the safety aspects of induction methods become more important, although this could be at the expense of effectiveness. Apart for being widely available and low in cost, potential advantages of mechanical methods over pharmacological ones may include a reduction in side effects, such as uterine hyperstimulation, thereby having the potential to improve neonatal outcomes.

OBJECTIVES

To determine the effectiveness and safety of mechanical methods for third trimester (> 24 weeks' gestation) induction of labour in comparison with prostaglandin E2 (PGE2) (vaginal and intracervical), low-dose misoprostol (oral and vaginal), amniotomy or oxytocin.

METHODS

Criteria for considering studies for this review

Types of studies

Clinical trials, comparing mechanical methods for cervical ripening or labour induction with other induction methods. Quasi-randomised controlled trials and trials only reported as abstract were eligible for inclusion. Cluster-randomised trials are unlikely to be conducted in this area, however, if identified by a future search, they will be handled with appropriate methods.

Types of participants

Pregnant women due for third trimester induction of labour, carrying a viable fetus.

Predefined subgroup comparisons were: previous caesarean section or not, nulliparity or multiparity. Only those outcomes with data appear in the analyses tables.

Types of interventions

Different types of intervention have been considered as mechanical methods: (1) the introduction of a catheter (Foley single balloon, Atad/Cook double balloon or other type), through the cervix into the extra-amniotic space, either with or without traction; (2) introduction of laminaria tents, or their synthetic equivalent (Dilapan),



into the cervical canal; (3) use of a catheter to inject fluids, usually saline water, in the extra-amniotic space (EASI).

Mechanical methods were compared with other induction methods (i.e. vaginal PGE2, intracervical PGE2, intravenous oxytocin, amniotomy, vaginal and oral misoprostol). For this update, the comparison with placebo/no treatment was left out. When the protocol for reviews of induction methods was designed, it was relevant to know if cervical ripening before actual induction of labour (rupturing the membranes, and if needed, administer of oxytocin) was beneficial. Since we already know the advantages of cervical ripening in case of an unfavourable cervix, no future trials will be done to study the effect of cervical ripening with a mechanical method versus no ripening. Also, in the case of pharmacological methods, it is possible to perform a placebo-controlled study, but with mechanical methods of labour, this is not possible. Studies which do make this comparison between mechanical induction and no treatment, explore other objectives rather than the ones relevant for his review (induction of labour versus expectant management to improve birth outcome). Therefore, the choice was made to depart from the original research protocol and leave out this prespecified comparison. For this update, we also chose only to include low-dose misoprostol (defined as \leq 50 mcg every \geq 4 hours) as evidence suggests low-dose misoprostol is superior to high-dose misoprostol regarding safety outcomes and being equally effective (Alfirevic 2014; Hofmeyr 2010).

In addition, other comparisons were made: (1) a single balloon compared to a double balloon; (2) laminaria tent compared to other hygroscopic dilatators; (3) addition of prostaglandins or oxytocin to mechanical methods compared with prostaglandins or oxytocin alone. These comparisons were not pre-specified in the generic protocol of induction of labour reviews (Hofmeyr 2009).

Types of outcome measures

We included all clinically relevant outcomes for trials of methods of cervical ripening/labour induction as had been pre-specified by two authors of the generic protocol for labour induction reviews (Justus Hofmeyr and Zarko Alfirevic). We added six more outcomes to the list of the original protocol. Differences were settled by discussion.

Primary outcomes

Five primary outcomes were chosen as being most representative of the clinically important measures of effectiveness and complications. Subgroup comparisons were limited to the primary outcomes:

- vaginal delivery not achieved within 24 hours (from start cervical ripening);
- 2. uterine hyperstimulation with fetal heart rate (FHR) changes;
- 3. caesarean section;
- 4. serious neonatal morbidity or perinatal death (e.g. seizures, birth asphyxia defined by trialists, neonatal encephalopathy, disability in childhood);
- 5. serious maternal morbidity or death (e.g. uterine rupture, admission to intensive care unit, septicaemia).

Perinatal and maternal morbidity and mortality are composite outcomes. This is not an ideal solution because some components are clearly less severe than others. It is possible for one intervention to cause more deaths but less severe morbidity. However, in the context of labour induction in mainly term pregnancies, this is unlikely. All these events are rare, and a modest change in their incidence will be easier to detect if composite outcomes are presented. The incidence of individual components were explored as secondary outcomes (see below).

Secondary outcomes relate to measures of effectiveness, complications and satisfaction.

Measures of effectiveness:

- 1. cervix unfavourable/unchanged after 12 to 24 hours;
- 2. oxytocin augmentation.

Complications:

- 1. uterine hyperstimulation without FHR changes;
- 2. uterine rupture;
- 3. epidural analgesia;
- 4. instrumental vaginal delivery;
- 5. meconium-stained liquor;
- 6. Apgar score less than seven at five minutes;
- 7. neonatal intensive care unit (NICU) admission;
- 8. neonatal encephalopathy;
- 9. perinatal death;
- 10.disability in childhood;
- 11.maternal side effects (all);
- 12.maternal nausea;
- 13.maternal vomiting;
- 14.maternal diarrhoea;
- 15.other maternal side effects;

16.postpartum haemorrhage (as defined by the trial authors);

17. serious maternal complications (e.g. intensive care unit admission, septicaemia but excluding uterine rupture);

18.maternal death.

Measures of satisfaction:

- 1. woman not satisfied;
- 2. caregiver not satisfied.

The terminology of uterine hyperstimulation is problematic (Curtis 1987). In the review, we use the term 'uterine hyperstimulation without FHR changes' to include uterine tachysystole (more than five contractions per 10 minutes for at least 20 minutes) and uterine hypersystole/hypertonus (a contraction lasting at least two minutes) and 'uterine hyperstimulation with FHR changes' to denote uterine hyperstimulation syndrome (tachysystole or hypersystole with FHR changes such as persistent decelerations, tachycardia or decreased short-term variability).

Search methods for identification of studies

The following methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth.

Electronic searches

For this update, we searched Cochrane Pregnancy and Childbirth's Trials Register by contacting their Information Specialist (9 January 2018). We updated this search on 19 March 2019 and added the re-



sults to Studies awaiting classification for consideration in the next update.

The Register is a database containing over 25,000 reports of controlled trials in the field of pregnancy and childbirth. It represents over 30 years of searching. For full current search methods used to populate Pregnancy and Childbirth's Trials Register including the detailed search strategies for CENTRAL, MEDLINE, Embase and CINAHL; the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service, please follow this link.

Briefly, Cochrane Pregnancy and Childbirth's Trials Register is maintained by their Information Specialist and contains trials identified from:

- monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);
- 2. weekly searches of MEDLINE (Ovid);
- 3. weekly searches of Embase (Ovid);
- 4. monthly searches of CINAHL (EBSCO);
- handsearches of 30 journals and the proceedings of major conferences;
- weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.

Search results are screened by two people and the full text of all relevant trial reports identified through the searching activities described above is reviewed. Based on the intervention described, each trial report is assigned a number that corresponds to a specific Pregnancy and Childbirth review topic (or topics) and is then added to the Register. The Information Specialist searches the Register for each review using this topic number rather than keywords. This results in a more specific search set that has been fully accounted for in the relevant review sections (Included, Excluded, Awaiting Classification or Ongoing).

In addition, we searched ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) for unpublished, planned and ongoing trial reports (19 March 2019) using the search methods detailed in Appendix 1.

Searching other resources

We searched the reference lists of retrieved studies.

We did not apply any language or date restrictions.

Data collection and analysis

For methods used in the previous version of this review, see Jozwiak 2012.

For this update, the following methods were used for assessing the 247 reports that were identified as a result of the updated search. The following methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth.

Selection of studies

Two review authors (Marieke de Vaan and Mieke ten Eikelder) independently assessed all potential studies identified as a result of the search strategy for inclusion. Any disagreement was resolved through discussion, or if required, by involving a third review author (Marta Jozwiak).

Data extraction and management

We designed a form to extract data. For eligible studies, two groups of two review authors (Marieke de Vaan, Marta Jozwiak, Ben Willem Mol and Kirsten Palmer) extracted the data using the agreed form. We resolved discrepancies through discussion or, if required, we consulted a third review author. Data were entered into Review Manager software (RevMan 2014) and checked by a second review author for accuracy.

When information regarding any of the above was unclear, we contacted authors of the original reports to provide further details.

Assessment of risk of bias in included studies

Two review authors (Marieke de Vaan and Mieke ten Eikelder) independently assessed risk of bias for each study using the criteria outlined in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). Any disagreement was resolved by discussion or by involving a third assessor (Marta Jozwiak).

(1) Random sequence generation (checking for possible selection bias)

We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.

We assessed the method as:

- low risk of bias (any truly random process, e.g. random number table; computer random number generator);
- high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);
- unclear risk of bias.

(2) Allocation concealment (checking for possible selection bias)

We described for each included study the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.

We assessed the methods as:

- low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);
- high risk of bias (open random allocation; unsealed or nonopaque envelopes, alternation; date of birth);
- unclear risk of bias.

(3.1) Blinding of participants and personnel (checking for possible performance bias)

We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes.

We assessed the methods as:



- low, high or unclear risk of bias for participants;
- low, high or unclear risk of bias for personnel.

(3.2) Blinding of outcome assessment (checking for possible detection bias)

We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes.

We assessed methods used to blind outcome assessment as:

• low, high or unclear risk of bias.

(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data)

We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we planned to re-include missing data in the analyses which we undertook.

We assessed methods as:

- low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups);
- high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; 'as treated' analysis done with substantial departure of intervention received from that assigned at randomisation);
- unclear risk of bias.

(5) Selective reporting (checking for reporting bias)

We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found.

We assessed the methods as:

- low risk of bias (where it is clear that all of the study's pre-specified outcomes and all expected outcomes of interest to the review have been reported);
- high risk of bias (where not all the study's pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);
- unclear risk of bias.

(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)

We described for each included study any important concerns we had about other possible sources of bias.

Assessment of the quality of the evidence using the GRADE approach

For this update, the quality of the evidence was assessed for the comparisons relating to the most frequently used methods of cervical ripening (i.e. vaginal prostaglandin E2 (PGE2), vaginal misoprostol, and oral misoprostol) using the GRADE approach as outlined in the GRADE handbook in order to assess the quality of the body of evidence relating to the following outcomes.

- 1. Vaginal delivery not achieved within 24 hours
- 2. Uterine hyperstimulation with FHR changes
- 3. Caesarean section
- Serious neonatal morbidity or perinatal death (e.g. seizures, birth asphyxia defined by trialists, neonatal encephalopathy, disability in childhood)
- 5. Serious maternal morbidity or death (e.g. uterine rupture, admission to intensive care unit, septicaemia)
- 6. Neonatal intensive care unit admission
- 7. Apgar score less than seven at five minutes

For the main comparisons we used GRADEpro Guideline Development Tool to import data from Review Manager 5.3 (RevMan 2014) in order to create 'Summary of findings' tables. A summary of the intervention effect and a measure of quality for each of the above outcomes was produced using the GRADE approach. The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for each outcome. The evidence can be downgraded from 'high quality' by one level for serious (or by two levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias.

Measures of treatment effect

Dichotomous data

For dichotomous data, we presented results as summary risk ratio with 95% confidence intervals.

Continuous data

No continuous data were analysed in this update. If outcomes using continuous data are included in future versions of this review, we will use the mean difference if outcomes are measured in the same way between trials. We will use the standardised mean difference to combine trials that measure the same outcome but use different methods.

Unit of analysis issues

Cluster-randomised trials

Cluster-randomised trials are eligible for inclusion in the analyses along with individually-randomised trials. None have currently been identified. If in the future such trials are identified, we will adjust their standard errors using the methods described in the Handbook (Higgins 2011) using an estimate of the intracluster correlation co-efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we use ICCs from other sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster-randomised trials and individually-randomised trials, we plan to synthesise the relevant information. We will consider it



reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit is considered to be unlikely.

We will also acknowledge heterogeneity in the randomisation unit and perform a sensitivity analysis to investigate the effects of the randomisation unit.

Cross-over trials

Cross-over trials were not eligible for inclusion.

Other unit of analysis issues

Trials in pregnancy and childbirth may include outcomes for multiple pregnancies, but the trials identified to date have included singleton pregnancies only. Trials with multiple pregnancy will be included, but the outcomes relating to the babies will have to take account of clustering of events, as outlined in the Pregnancy and Childbirth Group Methodological Guidelines and the *Handbook* (Higgins 2011).

Some trials are multi-arm studies, where this occurs only the intervention arms relevant to this review were included and this is noted in the Characteristics of included studies table.

Dealing with missing data

For included studies, levels of attrition were noted. In future updates, if more eligible studies are included, we will explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis.

For all outcomes, analyses were carried out, as far as possible, on an intention-to-treat basis, i.e. we attempted to include all participants randomised to each group in the analyses. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing.

Assessment of heterogeneity

We assessed statistical heterogeneity in each meta-analysis using the Tau², I² and Chi² statistics. We regarded heterogeneity as substantial if an I² was greater than 30% and either a Tau² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity. In the case of substantial heterogeneity (above 30%), if possible, we explored it by subgroup analyses.

Assessment of reporting biases

When there were 10 or more studies in the meta-analysis, we investigated reporting biases (such as publication bias) using funnel plots. We assessed funnel plot asymmetry visually. If asymmetry was suggested by a visual assessment, we performed exploratory analyses to investigate it.

Data synthesis

We carried out statistical analysis using the Review Manager software (RevMan 2014). We used fixed-effect meta-analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials were examining the same intervention, and the trials' populations and methods were judged sufficiently similar.

If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity was detected, we used random-effects meta-analysis to produce an overall summary, if an average treatment effect across trials was considered clinically meaningful. The random-effects summary was treated as the average range of possible treatment effects and the clinical implications of treatment effects differing between trials is discussed. If the average treatment effect was not clinically meaningful, we did not combine trials. When random-effects analyses were used, the results were presented as the average treatment effect with 95% confidence intervals, and the estimates of Tau² and I².

Subgroup analysis and investigation of heterogeneity

We did not carry out formal subgroup analysis to investigate heterogeneity, but carried out additional analyses of subgroups of trials based on the following.

- 1. Previous caesarean section or not
- 2. Nulliparity or multiparity

The following outcomes were used in the subgroups.

- 1. Vaginal delivery not achieved within 24 hours
- 2. Uterine hyperstimulation with FHR changes
- 3. Caesarean section
- Serious neonatal morbidity or perinatal death (e.g. seizures, birth asphyxia defined by trialists, neonatal encephalopathy, disability in childhood)
- Serious maternal morbidity or death (e.g. uterine rupture, admission to intensive care unit, septicaemia)

Sensitivity analysis

We carried out sensitivity analyses to explore the effect of trial quality assessed by concealment of allocation, high attrition rates, or both, with poor quality studies being excluded from the analyses in order to assess whether this made any difference to the overall result.

RESULTS


Description of studies

Results of the search

See: Figure 1.



Figure 1. Study flow diagram.





For this update, we identified 418 trial reports to assess in the search of 9 January 2018. One study (Pineda Rivas 2016) was retrieved through other sources. When exploring the included trial registration of this study, we found out that an abstract of this study was published.

We also reassessed the 17 reports awaiting classification and the four ongoing studies in the previous version of the review (Jozwiak 2012). One hundred and seventy-one reports were screened out because they did not meet the scope for this review or were not randomised controlled trials. We then assessed trial reports which related to 166 new trials (247 reports). We included 60 new trials (120 reports), added two trial reports to already included studies and excluded 74 trials (102 reports). Two trials from the January 2018 search are awaiting classification (Agboghoroma 2015; Mallah 2011), and 21 are ongoing (Argilagos 2016; Beckmann 2013; Bekele 2017; Berndl 2016; Bhide 2017; Eser 2016; Goli 2017; Goonewardene 2016; Gupta 2016; Hassanzadeh 2017; Igwe 2017; Lacarin 2017; Lauterbach 2017; Levy 2016; Osoti 2016; Park 2012; Perrotin 2016; Tagore 2015; Viteri 2015; Wise 2016; Yildirim 2017).

Of the 71 previous included studies, we excluded 18 trials because they were no longer within the scope of this review. Four studies were excluded because they compared a mechanical method with a placebo or no cervical ripening (De Oliveira 2003; Gilson 1996; Gower 1982; Lackritz 1979), 11 studies because of the use of high-dose misoprostol (Adeniji 2005b; Barrilleaux 2002a; Buccellato 2000; Chung 2003; Greybush 2001; Hill 2009; Kashanian 2006; Owolabi 2005; Rust 2001; Sciscione 2001; Vengalil 1998), two studies compared extra-amniotic space infusion (EASI) versus induction with a balloon or laminaria (El-Torkey 1995; Lin 1995), and one study compared a balloon versus prostaglandin F2alpha (Mawire 1999).

In the updated search of 19 March 2019, we identified an additional 38 trial reports which were added to Studies awaiting classification for consideration in the next update. The references have been assessed but not incorporated into the review. Only seven of these trials are likely to contribute data for this review and are mainly small trials (Khatib 2019; Lim 2018; Osoti 2018; Souizi 2018; ten Eikelder 2017; Tulek 2018; Viteri 2019). We imputed the data for these trials and this resulted in no changes in terms of the direction or strength of the evidence. We will incorporate these studies fully at the next update.

Included studies

Altogether, this review now comprises 113 included studies, 105 of which contributed data. The studies that contributed data involved 22,373 women (see Characteristics of included studies). Trials with more than two arms may be included in more than one comparison. No cluster-randomised trials were identified by the search.

Eight studies did not contribute any data to this review because the outcomes of interest were not reported, or reported in a format that could not be included in this review (Biron-Shental 2004; Deo 2013; Hughes 2002; Jalilian 2011; Peedicayil 1998; Qamar 2012; Thiery 1981; Zahoor 2014). These studies are therefore not included in the descriptions of study details and 'Risk of bias' assessment below.

Design

All included studies were randomised controlled trials although the randomisation method was not always well described and in three studies the allocation process was not truly random (Jagani 1982; Kandil 2012; Roztocil 1998). All studies involved two trial arms except for Aduloju 2016, Allouche 1993, Atad 1996, Browne 2011, Cromi 2011, Deo 2012, Dionne 2011, El Khouly 2017, Guinn 2000, Matonhodze 2003, Lewis 1983, Orhue 1995, Pennell 2009, Prager 2008, Saleem 2006, Sheikher 2009 and Yuen 1996, which had three arms. Gelisen 2005, Lyndrup 1989 and Roberts 1986 had four arms, and Jagani 1982 had five arms. Not all comparisons in these studies were relevant for this review and therefore one or more arms in the studies of Gelisen 2005, Jagani 1982, Lewis 1983 and Roberts 1986 were excluded.

Setting

Nine studies were multicentre studies (Edwards 2014c; Guinn 2000; Jozwiak 2012; Jozwiak 2013; Jozwiak 2014; Lokkegaard 2015; Mundle 2017; Sarreau 2016; ten Eikelder 2016), the remaining studies were single-centre studies.

All studies took place in a hospital setting, except for Henry 2013, in which the period of cervical ripening took place in an outpatient setting.

The included studies were conducted in the following countries: Australia (Henry 2013; Pennell 2009), Brazil (Filho 2002; Oliveira 2010, Canada (Lemyre 2006; Pineda Rivas 2016; St Onge 1995), Czech Republic (Roztocil 1998), China (Wang 2012; Wang 2014; Wu 2017; Yuen 1996), Denmark (Lokkegaard 2015; Lyndrup 1989; Lyndrup 1994), Egypt (Ahmed 2016; El Khouly 2017; Kandil 2012), Finland (Kruit 2016), France (Allouche 1993; Sarreau 2016;), India (Chavakula 2015; Dalui 2005; Deo 2012; Deshmukh 2011; Goonewardene 2014; Gunawardena 2012; Joshi 2016; Kuppulakshmi 2016; Laddad 2013; Lanka 2014; Meetei 2015; Mundle 2017; Sheikher 2009), Iran (Moini 2003; Niromanesh 2003; Roudsari 2011; Sharami 2005) Italy (Cromi 2011; Cromi 2012), Israel (Atad 1996; Barda 2018; Ophir 1992; Shechter-Maor 2015; Salim 2011; Solt 2009), Jordan (Al-Taani 2004; Khamaiseh 2012), the Netherlands (Jozwiak 2012; Jozwiak 2013; Jozwiak 2014; ten Eikelder 2016), Nigeria (Aduloju 2016; Garba 2016; Orhue 1995; Tabowei 2003), Norway (Haugland 2012), Pakistan (Husain 2017; Matonhodze 2003; Mazhar 2003; Saleem 2006), Russia (Glagoleva 1999), Rwanda (Gilson 2017), South Africa (Bagratee 1990; Jeeva 1982; Ntsaluba 1997), Singapore (Chua 1997), Sri Lanka (Rudra 2012; Somirathne 2017; Tan 2015), Sweden (Hemlin 1998; Prager 2008), Tunis (Benzineb 1996), Turkey (Gelisen 2005), the UK (Dionne 2011; Guinn 2000; Hay 1995; Johnson 1985; Lewis 1983), the USA (Al-Ibraheemi 2018; Amorosa 2017; Blumenthal 1990; Browne 2011; Carbone 2013; Casey 1995; Culver 2004; Edwards 2014c; Hibbard 1998; Hoppe 2016; Hudon 1999; Jagani 1982; Krammer 1995a; Mackeen 2018; Mullin 2002; Perry 1998; Ridgway 1991; Roberts 1986; Rouben 1993; Sanchez-Ramos 1992; Sciscione 1999; Suffecool 2014; Sullivan 1996; Tita 2006; Turnquest 1997).

Dates

The study of Blumenthal 1990 and Sanchez-Ramos 1992 took place between 1980 and 1989; the studies of Allouche 1993, Guinn 2000, Hemlin 1998, Hibbard 1998, Khamaiseh 2012, Lyndrup 1994, Orhue 1995, Perry 1998, Roudsari 2011, Roztocil 1998, Sciscione 1999,



St Onge 1995, Sullivan 1996 and Turnquest 1997 between 1990 and 1999; the studies of Tabowei 2003, Culver 2004 and Mullin 2002 between 1998 and 2001; the studies of Al-Taani 2004, Cromi 2011, Deshmukh 2011, Dionne 2011, Filho 2002, Joshi 2016, Jozwiak 2012, Jozwiak 2013, Krammer 1995a, Lokkegaard 2015, Matonhodze 2003, Mazhar 2003, Moini 2003, Niromanesh 2003, Oliveira 2010, Pennell 2009, Prager 2008, Roudsari 2011, Rudra 2012, Saleem 2006, Sharami 2005 and Tita 2006 between 2000 and 2009; the studies of Jozwiak 2014 and Salim 2011 between 2008 and 2011; and the studies of Aduloju 2016, Ahmed 2016, Al-Ibraheemi 2018, Amorosa 2017, Barda 2018, Browne 2011, Carbone 2013, Chavakula 2015, Cromi 2012, Edwards 2014c, El Khouly 2017, Garba 2016, Goonewardene 2014, Haugland 2012, Henry 2013, Hoppe 2016, Husain 2017, Kandil 2012, Kruit 2016, Kuppulakshmi 2016, Laddad 2013, Mundle 2017, Noor 2015, Sarreau 2016, Somirathne 2017, Suffecool 2014, ten Eikelder 2016, Wang 2014 and Wu 2017 between 2010 and the present day.

For the remaining studies, no study period was reported (Atad 1996; Bagratee 1990; Benzineb 1996; Casey 1995; Chua 1997; Dalui 2005; Deo 2012; Gelisen 2005; Gilson 2017; Glagoleva 1999; Gunawardena 2012; Hay 1995; Hudon 1999; Jagani 1982; Jeeva 1982; Johnson 1985; Lanka 2014; Lanka 2014; Lewis 1983; Lyndrup 1989; Ntsaluba 1997; Ophir 1992; Pineda Rivas 2016; Ridgway 1991; Roberts 1986; Rouben 1993; Solt 2009; Shechter-Maor 2015; Sheikher 2009; Tan 2015; Wang 2012; Yuen 1996).

Participants

Most studies included both nulliparous and multiparous women. Nine studies included only nulliparous women (Culver 2004; Deshmukh 2011; Gunawardena 2012; Johnson 1985; Kandil 2012; Pennell 2009; Sharami 2005; Suffecool 2014; Wang 2012) and two studies included only multiparous women (Al-Taani 2004; Garba 2016).

Thirteen studies included women with a specific indication for labour induction or specific patient groups, i.e. women with a hypertensive disease (Mundle 2017), women with a body mass index (BMI) greater than 30 (Pineda Rivas 2016), post-date pregnancies (Gelisen 2005; Goonewardene 2014; Gunawardena 2012; Kandil 2012; Somirathne 2017), oligohydramnios (Shechter-Maor 2015; Wang 2014) or pre labour rupture of membranes (PROM; Amorosa 2017; Kruit 2016; Mackeen 2018; Tita 2006). Most authors specified that only women with intact membranes were included, except for Prager 2008, in which this was not an exclusion criteria. Orhue 1995, Roudsari 2011 and Roztocil 1998 reported nothing on membrane status, so it was not clear if women with ruptured membranes could be included.

Most studies excluded women with a past history of caesarean section, although four studies only included women with a past history of caesarean section (Joshi 2016; Meetei 2015; Sarreau 2016; Tabowei 2003). Three studies did not exclude women with a past history of caesarean section, but did not specify the outcomes for this subgroup of women separately (Mackeen 2018; Tabowei 2003; Tita 2006). Benzineb 1996, Cromi 2011, Deo 2012, Guinn 2000, Haugland 2012, Lyndrup 1994, Pineda Rivas 2016, Rouben 1993, and Wu 2017 reported nothing on previous caesarean section in their inclusion and exclusion criteria.

The majority of studies included women with a gestational age beyond 37 weeks, except for Edwards 2014c and Hemlin 1998 who reported a minimal gestational age of 36 weeks, Amorosa 2017,

Chavakula 2015, Cromi 2011, Cromi 2012, Mackeen 2018 Matonhodze 2003, Pennell 2009; Roudsari 2011 and Sharami 2005 of 34 weeks, Dalui 2005 of 33 weeks, Lokkegaard 2015 of 32 weeks, Culver 2004, Lanka 2014 and El Khouly 2017 of 28 weeks, Browne 2011 of 26 weeks, Carbone 2013 of 24 weeks and Mundle 2017 of 20 weeks, although in this last study, no women with a gestational age below 28 weeks were included.

Twenty-four studies were not clear on their inclusion and exclusion criteria: Gilson 2017, Jeeva 1982 and Kuppulakshmi 2016 reported no inclusion or exclusion criteria. Jagani 1982, Rudra 2012 and Turnquest 1997 only reported that women with intact membranes were included. Glagoleva 1999 only reported that women with a previous caesarean section were excluded. Bagratee 1990, Dionne 2011, Johnson 1985, Lyndrup 1989, Ridgway 1991, Solt 2009; Sullivan 1996 reported that only women with an indication for labour induction with an unfavourable cervix were included. Hemlin 1998 reported nothing on membrane status or previous caesarean section. Casey 1995, Garba 2016, Hudon 1999, Krammer 1995a, Lemyre 2006, Lewis 1983 and Saleem 2006 reported nothing on fetal presentation, membrane status or previous caesarean section. Chua 1997 and Ophir 1992 reported nothing on gestational age, fetal presentation, membrane status or previous caesarean section.

Interventions and comparisons

The protocol of administration in the intervention and in the control groups varied between studies. Different mechanical devices were evaluated (i.e. balloon catheter, laminaria tents, and extra-amniotic infusion). Prostaglandins (intracervical or intravaginal PGE2, and oral or vaginal misoprostol) were used with different protocols of administration. We regrouped these protocols as follows: (1) balloon catheter versus other interventions; (2) laminaria tent versus other interventions: (3) extra-amniotic infusion versus other interventions; (4) any mechanical method combined with other (non-mechanical) intervention versus other interventions. For this last group of comparisons, we considered both PGE2 (intracervical or intravaginal PGE2) and misoprostol (oral or vaginal misoprostol) as a single intervention. The information on comparisons made in each trial, used device and balloon size is summarised below.

Studies evaluating laminaria or Dilapan were considered together, irrespective of the number of devices inserted. Similarly, evaluations of a Foley catheter (regardless of sizes and amount of liquid used to inflate the balloon and traction applied on the catheter) and a specially designed double-balloon catheter (ATAD or Cook catheter), we considered as similar interventions. However, when a catheter was used to perform extra-amniotic saline infusion (EASI), we considered these studies separately. Despite having regrouped similar interventions, this review still includes a large number of comparisons.

Most of the studies included in the review examined a balloon and compared it with either vaginal PGE2 or with vaginal or oral misoprostol. A smaller number of studies examined a balloon versus either intracervical PGE2 or oxytocin. Since the last update, no more studies have been published about induction of labour with a Laminaria tent or with EASI. None of the included studies examined the combination of a mechanical method with amniotomy.

The following comparisons were made in this review.



1. Balloon comparisons

Balloon (Foley or ATAD) versus vaginal prostaglandin E2

PGE2 tablets: Al-Taani 2004 (50 cc); Atad 1996 (double balloon); Barda 2018 (80 cc); Khamaiseh 2012 (50 cc to 60 cc); Lokkegaard 2015 (double balloon); Niromanesh 2003 (30 cc); Ophir 1992 (40 cc); Pennell 2009 (30 cc and double balloon); Tan 2015 (double balloon).

PGE2 gel: Browne 2011 (40 cc); Deo 2012 (30 cc); Deshmukh 2011 (balloon size unknown); Henry 2013 (30 cc); Jozwiak 2012 (30 cc); Orhue 1995 (30 cc); Prager 2008 (30 cc); Rouben 1993 (30 cc); Rudra 2012 (40 cc).

PGE2 vaginal insert: Cromi 2011 (50 cc; for this comparison the two groups of Foley catheter (12 hours and 24 hours) were combined); Cromi 2012 (double balloon); Edwards 2014c (30 cc); Jozwiak 2013 (30 cc); Lewis 1983 (30 cc); Lyndrup 1994 (30 cc); Pineda Rivas 2016 (balloon size unknown); Saleem 2006 (40 cc to 50cc); Shechter-Maor 2015 (double balloon); Suffecool 2014 (double balloon); Wang 2012 (80 cc); Wang 2014 (double balloon); Yuen 1996 (double balloon).

Balloon (Foley or ATAD) versus intracervical prostaglandin E2

PGE2 intracervical gel: Allouche 1993 (50 cc); gel: Benzineb 1996 (40 cc); Dalui 2005 (30 cc); Gunawardena 2012 (balloon size unknown); Hudon 1999 (40 cc); Kuppulakshmi 2016 (30 cc); Laddad 2013: (balloon size unknown); Moini 2003 (30 cc); Ntsaluba 1997 (30 cc); Sciscione 1999 (30 cc); St Onge 1995 (30 cc); Yuen 1996 (double balloon).

Balloon (Foley or ATAD) versus low-dose vaginal misoprostol

Misoprostol tablets: Aduloju 2016 (30 cc); Chavakula 2015 (30 cc); Filho 2002 (30 cc); Jozwiak 2014 (30 cc); Kandil 2012 (30 cc); Lemyre 2006 (balloon size unknown); Noor 2015 (50 cc); Oliveira 2010 (30 cc); Prager 2008 (30 cc); Roudsari 2011 (50 cc); Sheikher 2009 (30 cc); Tabowei 2003 (50 cc).

Balloon (Foley or ATAD) versus low-dose oral misoprostol

Misoprostol tablets: Goonewardene 2014 (balloon size unknown); Kruit 2016 (50 cc to 60 cc); Mundle 2017 (30 cc); Saleem 2006 (40 cc to 50 cc); Sheikher 2009 (30 cc); Somirathne 2017 (60 cc); ten Eikelder 2016 (30 cc). misoprostol solution: Matonhodze 2003 (50 cc).

Balloon (Foley or ATAD) versus oxytocin

Amorosa 2017 (60 cc); Atad 1996 (double balloon); El Khouly 2017 (30 cc); Gelisen 2005 (50 cc); Jagani 1982 (70 to 80 cc); Joshi 2016; (30 cc); Meetei 2015 (30 cc); Orhue 1995 (30 cc); Sarreau 2016 (50 cc).

Balloon (Foley or ATAD) versus amniotomy

Jagani 1982 (70 cc to 80 cc).

Single balloon (Foley versus double balloon (ATAD)

Ahmed 2016 (50 cc); Haugland 2012 (size unknown); Hoppe 2016 (30 cc); Pennell 2009 (30 cc); Salim 2011 (60 cc); Solt 2009 (balloon size unknown).

No studies were found for the comparison of a balloon versus oxytocin with amniotomy.

2. Laminaria comparisons

Laminaria tent versus vaginal prostaglandin E2

PGE2 tablets: Bagratee 1990 (Lamicel); Hay 1995 (Dilapan); Jeeva 1982; (laminaria).

PGE2 gel: Johnson 1985 (Lamicel); Roudsari 2011 (Dilapan); Sanchez-Ramos 1992 (Dilapan).

Laminaria tent versus intracervical prostaglandin E2

PGE2 intracervical gel: Chua 1997 (Dilapan); Glagoleva 1999 (Dilapan); Krammer 1995a; (Dilapan); Roztocil 1998 (Dilapan).

Laminaria tent versus oxytocin

Jagani 1982 (70 to 80 cc); Roberts 1986 (Lamicel).

Laminaria tent versus amniotomy

Jagani 1982 (70 to 80 cc).

Laminaria tent versus other hygroscopic dilator

Blumenthal 1990 (Dilapan versus laminaria tent).

No studies were found for the comparison of laminaria tent versus oxytocin with amniotomy or laminaria tent versus vaginal or oral misoprostol.

3. EASI comparisons

The only studies which were found compared EASI with PGE2.

EASI versus vaginal prostaglandin E2

Vaginal insert: Mazhar 2003.

EASI versus intracervical prostaglandin E2

Intracervical gel: Hemlin 1998.

4. Any mechanical combined with prostaglandin E2 comparisons

Any mechanical method combined with prostaglandin E2 versus prostaglandin E2 alone

PGE2 intracervical gel: Allouche 1993 (50 cc); Casey 1995 (50 cc); Ridgway 1991 (Lamicel); Sullivan 1996 (50 cc).

PGE2 vaginal gel: Browne 2011 (40 cc); Hibbard 1998 (Dilapan); Lyndrup 1989; (Lamicel); Turnquest 1997 (Laminaria)

Any mechanical method combined with prostaglandin E2 versus low-dose misoprostol alone

Vaginal misoprostol: Perry 1998.

Any mechanical method combined with prostaglandin E2 versus oxytocin alone

Lyndrup 1989 (Lamicel).

No studies were found which compared a mechanical method combined with PGE2 with amniotomy or oxytocin with amniotomy



5. Any mechanical combined with low-dose misoprostol comparisons

Any mechanical method combined with low-dose misoprostol versus prostaglandin E2 alone

Oral misoprostol: Matonhodze 2003.

Any mechanical method combined with low-dose misoprostol versus low-dose misoprostol alone

Vaginal misoprostol: Aduloju 2016 (30 cc); Al-Ibraheemi 2018 (60 cc); Carbone 2013 (60 cc); Dionne 2011 (balloon size and dosage of misoprostol unknown); Lanka 2014 (30 cc).

Oral misoprostol: Husain 2017 (30 cc); Matonhodze 2003 (50 cc).

No studies were found which compared a mechanical method combined with low-dose misoprostol with amniotomy, oxytocin or oxytocin with amniotomy.

6. Any mechanical method combined with oxytocin comparisons

Any mechanical method combined with oxytocin versus prostaglandin E2 alone

PGE2 intracervical gel: Guinn 2000 (laminaria + oxytocin and EASI + oxytocin); Lyndrup 1989 (Lamicel); Sharami 2005 (EASI).

Any mechanical method combined with oxytocin versus low-dose misoprostol alone

Vaginal misoprostol: Culver 2004 (30 cc); Dionne 2011 (balloon size unknown); Gilson 2017 (30 cc); Garba 2016 (balloon size and dosage of misoprostol unknown); Mullin 2002.

Any mechanical method combined with oxytocin versus oxytocin alone

El Khouly 2017 (30 cc); Lyndrup 1989 (Lamicel); Mackeen 2018 (30 cc); Tita 2006 (balloon size unknown); Wu 2017 (double balloon).

No studies were found which compared a mechanical method combined with oxytocin to amniotomy or oxytocin with amniotomy.

Outcomes

The study authors frequently reported on continuous outcome measures such as change in the cervical status or time to onset of labour, but also mean Apgar score after five minutes and mean pH in the umbilical artery. As these were not pre-specified in our protocol, we have not included these results in the review. In several studies, the only pre-specified result available was the number of women delivered by caesarean section. Maternal or neonatal death were infrequently pre-specified by the authors and therefore not specifically reported. Therefore, these outcomes could not be included in this review.

Maternal satisfaction was reported in seven studies (Ahmed 2016; Chavakula 2015; Gilson 2017; Henry 2013; Lyndrup 1994; Mundle 2017; Shechter-Maor 2015). Of these seven studies, only three studies contributed data for the meta-analysis (Gilson 2017; Lyndrup 1994; Mundle 2017). The other four studies reported on maternal satisfaction with continuous data. Because of the importance of this outcome, we decided to report these results in narrative form.

Source of trial funding

Only 14 trials provided details for their funding sources: Filho 2002 received financial support from CAPES. Guinn 2000 reported that UpJohn Pharmaceuticals provided funds to purchase study drugs. Kruit 2016 received a grand from the Finnish medical society Duodecim and Helsinky university central hospital. Lokkegaard 2015 reported the randomisation procedure was funded by Snedkermester Sophus Jacobsen & Astrid Jacobsens fond and the Danish Toyota Foundation. Mackeen 2018 received a small internal grant to assist with the conduct and statistical analyses for the entire study. Mundle 2017 received funding from the Department for International Development, Medical Research Council, and Wellcome Trust Joint Global Health Trials Scheme. The study of Pennell 2009 was supported by a grant from the Women and Infants Research Foundation and Adeza Biomedical Corporation contributed support for the fetal fibronectin test kits. Roberts 1986 and Sullivan 1996 stated they were supported by the Vicksburg hospital medical foundation. Salim 2011 received funding from the Emek medical centre. Tan 2015 reported that the double balloons were provided by Cook medical. ten Eikelder 2016 received funding from Fonds Nuts Ohra. Wang 2014 received financial support of The People's Liberation Army. Wu 2017 received a grant from the Nature Science Foundation of China.

Thirteen studies reported they received no funding (Aduloju 2016; El Khouly 2017; Garba 2016; Hoppe 2016; Husain 2017; Jozwiak 2012; Jozwiak 2013; Jozwiak 2014; Laddad 2013; Lanka 2014; Meetei 2015; Shechter-Maor 2015; Somirathne 2017). All other studies did not provide information on received funding.

Declarations of interest

Thirty-five studies declared no conflict of interest (Aduloju 2016; Ahmed 2016; Al-Ibraheemi 2018; Amorosa 2017; Barda 2018; Chavakula 2015; Cromi 2012; Edwards 2014c; El Khouly 2017; Filho 2002; Garba 2016; Goonewardene 2014; Henry 2013; Hoppe 2016; Husain 2017; Jozwiak 2012; Jozwiak 2013; Jozwiak 2014; Kandil 2012; Kruit 2016; Laddad 2013; Lanka 2014; Lewis 1983; Lokkegaard 2015; Mackeen 2018; Meetei 2015; Noor 2015; Pennell 2009; Salim 2011; Shechter-Maor 2015; Somirathne 2017; Tan 2015; ten Eikelder 2016; Wang 2014; Wu 2017).

Two studies reported they had conflicts of interest. Atad 1996 stated that the first author has a patent licensing arrangement for Atad ripening device and thus has the potential gain from its sales. Mundle 2017 reported that one of the authors was a scientific adviser to Azanta, a Danish pharmaceutical company.

The remaining studies did not report whether any conflicts of interest were present.

Excluded studies

In total, 138 studies were excluded (see Characteristics of excluded studies), 74 studies (102 reports) in this update. In this update, most of the excluded trials (54 studies) made comparisons not within the scope of this review (Ahmad 2015; Arsenijevic 2012; Arshad 2016; Caughey 2007; Connolly 2016; Connolly 2017; Demirel 2015; Edwards 2017; El-Khayat 2016; El Sharkwy 2017; Forgie 2016; Forooshani 2011; Fruhman 2017; Gadel 2015; Ghanaei 2009; Ghanaie 2013; Gibson 2013; Gu 2015; Haghighi 2015; Hallak 2008; He 2000; Hill 2013; Hussein 2012; Ifnan 2006; Jonsson 2011; Kehl 2012; Kehl 2015; Lam 2006; Leong 2017; Levine 2016;



Lutgendorf 2012; Manish 2016; Mattingly 2015; McGee 2016; Mei-Dan 2012a; Mei-Dan 2014; Movahed 2016; Mullin 2014; Neethurani 2013; Rameez 2007; Rezk 2014; Saad 2016; Salmeen 2012; Sandberg 2017; Schoen 2017; Sharma 2015a; Sharma 2017; Siddiqui 2013; Torbenson 2015; Walfisch 2015; Wickramasinghe 2014; Wilkinson 2015; Yaddehige 2015; Zakaria 2017). Four studies were not randomised trials (Du 2015; Miller 2015; Naseem 2007; Nasir 2012) and one study did a cross-over after 24 hours (Ugwu 2013). Thirteen trial registration were excluded because they exceeded the participated end date by more than two years and it was presumed

the trial was terminated before enrolment (Anabosy 2014; Baacke 2006; Behrashi 2013; Cullimore 2009; Dias 2008 EUCTR 2012; Kamilya 2011; Mei-Dan 2012; Park 2011 Pathiraja 2014; Reif 2012; Yazdani 2011; Zhang 2014). For more information, see Characteristics of excluded studies.

Risk of bias in included studies

The quality assessments are graphically summarised in Figure 2 and Figure 3.

Figure 2. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.






Figure 3. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.

Sure of Man Summary	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	
	Random	Allocatio	Blinding	Blinding	Incomple	Selective	Other bias
Aduloju 2016	•	•	?	?	•	•	•
Ahmed 2016	•	•	?	?			•
Al-Ibraheemi 2018	•	•	?	?	•	•	•
Allouche 1993	?	?	?	?	?	?	•
Al-Taani 2004	•	?	?	?	•	•	•
Amorosa 2017	•	•	?	?	•	•	•
Atad 1996	•	?	?	?	•	•	•
Bagratee 1990	•	?	?	?	•	•	•
Barda 2018	?	?	?	?	?	•	?
Benzineb 1996	?	?	?	?	?	?	•
Biron-Shental 2004	•	?	?	?	?	?	?



Figure 3. (Continued)

e 3. (Continued)							
Benzineb 1996	U	U	U	U	v	U	•
Biron-Shental 2004	•	?	?	?	?	?	?
Blumenthal 1990	•	•	?	?		•	•
Browne 2011	•	•	?	?		•	?
Carbone 2013	•	•	?	?	•	•	•
Casey 1995	?	?	?	?	?	?	?
Chavakula 2015	•	•	?	?	•	•	•
Chua 1997	•	?	?	?	•	•	•
Cromi 2011	•	?	?	?	•	•	•
Cromi 2012	•	•	?	?		•	•
Culver 2004	•	•	?	?	•	•	•
Dalui 2005	?	?	?	?	•	•	•
Deo 2012	•	•	?	?		•	•
Deo 2013	?	?	?	?	?	?	?
Deshmukh 2011	?	?	?	?	•	•	•
Dionne 2011	?	?	?	?	?	?	?
Edwards 2014c	•	•	?	?	•	•	•
El Khouly 2017	•	•	?	?	•	•	•
Filho 2002	•	•	?	?	•	•	•
Garba 2016	•	?	?	?	?	•	?
Gelisen 2005	•	•	?	•	?	•	•
Gilson 2017	?	?	?	?	?	?	?
Olemeleus 4000	2	2	_	2	2	2	2



Figure 3. (Continued)

,							
Gilson 2017	?	?	?	?	?	?	?
Glagoleva 1999	?	?	?	?	?	?	?
Goonewardene 2014	•	•	?	?		•	•
Guinn 2000	•	•	?	?	•	?	?
Gunawardena 2012	?	?	?	?	?	?	•
Haugland 2012	?	?	?	•	?	?	?
Hay 1995	?	?	?	?	?	?	?
Hemlin 1998	?	•	?	?	?	•	•
Henry 2013	•	•	?	?	•	•	•
Hibbard 1998	•	•	?	?	?	•	•
Hoppe 2016	?	•	?	?	?	•	•
Hudon 1999	?	?	?	?	?	?	?
Hughes 2002	?	?	?	?	?	?	?
Husain 2017	•	•	?	?		•	•
Jagani 1982			?	?	?	•	•
Jalilian 2011	?	?	?	?	?	?	?
Jeeva 1982	?	?	?	?	•	?	•
Johnson 1985	•	?	?	?	?	•	•
Joshi 2016	?	?	?	?	?	•	•
Jozwiak 2012	•	•	?	?	•	•	•
Jozwiak 2013	•	•	?	?	•	•	•
Jozwiak 2014	•	•	?	?	•	•	•



Figure 3. (Continued)

ire 3. (Continued)							
Jozwiak 2013	•	•	?	?	•	•	•
Jozwiak 2014	•	•	?	?	•	•	•
Kandil 2012			?	?		•	•
Khamaiseh 2012	•	?	?	?	?	•	•
Krammer 1995a	•	?	?	?		•	•
Kruit 2016	?	•	?	?		•	•
Kuppulakshmi 2016	?	?	?	?	?	•	•
Laddad 2013	?	?	?	?	?	?	•
Lanka 2014	•	•	?	?	•	•	•
Lemyre 2006	?	?	?	?	?	?	?
Lewis 1983	?	?	?	?	?	?	•
Lokkegaard 2015	•	•	?	?	•	•	•
Lyndrup 1989	?	•	?	?		?	•
Lyndrup 1994	?	•	?	?		•	•
Mackeen 2018	•		?	?	•	•	•
Matonhodze 2003	•	•	?	?	?	•	•
Mazhar 2003	•	?	?	?	?	•	•
Meetei 2015	•	?	?	?	?	•	•
Moini 2003	?	?	?	?	?	?	•
Mullin 2002	•	•	?	?	•	•	?
Mundle 2017	•	•	?	?	•	•	•
Niromanesh 2003	•	•	?	?	?	?	•
	_	_	_	_			



Figure 3. (Continued)

,	_						
Niromanesh 2003	•	•	?	?	?	?	•
Noor 2015	?	?	?	?	•	•	•
Ntsaluba 1997	?	•	?	?	•	•	•
Oliveira 2010	•	•	?	?	•	•	?
Ophir 1992	•	•	?	?	$\color{red} \bullet$	•	•
Orhue 1995	•	•	?	?	$\color{red} \bullet$	•	•
Peedicayil 1998	?	•	?	?	?	?	•
Pennell 2009	?	•	?	•	•	•	•
Perry 1998	•	•	?	?	•	•	•
Pineda Rivas 2016	?	?	?	?	?	?	?
Prager 2008	•	•	?	?	•	•	?
Qamar 2012	•	•	?	?	?		•
Ridgway 1991	?	?	?	?	?	?	?
Roberts 1986	?	•	?	?	•	?	•
Rouben 1993	•	•	?	?	$\color{red} \bullet$	•	•
Roudsari 2011	?	?	?	?	?	?	•
Roztocil 1998			?	?	•	•	•
Rudra 2012	?	?	•	•	?	?	?
Saleem 2006	?	?	?	?	?	?	?
Salim 2011	•	•	?	?	?	•	•
Sanchez-Ramos 1992	•	?	?	?	?	?	•
Sarreau 2016	?	?	?	?	?	?	?




Figure 3. (Continued)

ure 3. (Continueu)	_	-	-		-	-	
Sanchez-Ramos 1992	•	•	•	•	•	•	•
Sarreau 2016	?	?	?	?	?	?	?
Sciscione 1999	•	•	?	?		•	•
Sharami 2005	•	•	?	?	?	•	•
Shechter-Maor 2015	•	?	?	?	?	•	?
Sheikher 2009	?	?	?	?	•	•	•
Solt 2009	•	?	?	?	?	•	?
Somirathne 2017	•	•	?	?	?	•	•
St Onge 1995	•	•	?	?	?	•	•
Suffecool 2014	•	•	?	?	•	•	•
Sullivan 1996	?	•	?	?	•	•	•
Tabowei 2003	•	•	?	?	?	•	?
Tan 2015	•	•	?	?	•	?	•
ten Eikelder 2016	•	•	?	?	•	•	•
Thiery 1981	?	•	?	?	•	•	•
Tita 2006	?	?	?	?	•	•	?
Turnquest 1997	•	•	?	?	•	•	•
Wang 2012	•	?	?	?	•	•	?
Wang 2014	?	•	?	?		?	•
Wu 2017	?	?	?	?	•	•	•
Yuen 1996	•	•	?	?	•	•	•
Zahoor 2014	?	?	?	?	?	?	?



Figure 3. (Continued)





This review update includes nine comparisons with more than 10 studies, of which we constructed funnel plots (Figure 4; Figure 5; Figure 6; Figure 7; Figure 8; Figure 9; Figure 10; Figure 11; Figure 12). Visual inspection of one funnel plot (Figure 5) was somewhat asymmetrical suggesting some form of publication bias for this out-

come (oxytocin augmentation) for the comparison of a balloon versus vaginal PGE2. Visual assessment of the other funnel plots did not show asymmetry, suggesting there is no publication bias for these comparisons.

Figure 4. Funnel plot of comparison: 1 Balloon (Foley or ATAD) versus vaginal Prostaglandin E2: all women, outcome: 1.3 Caesarean section.






Figure 5. Funnel plot of comparison: 1 Balloon (Foley or ATAD) versus vaginal Prostaglandin E2: all women, outcome: 1.6 Oxytocin augmentation.






Figure 6. Funnel plot of comparison: 1 Balloon (Foley or ATAD) versus vaginal Prostaglandin E2: all women, outcome: 1.7 Uterine hyperstimulation without fetal heart rate changes.






Figure 7. Funnel plot of comparison: 1 Balloon (Foley or ATAD) versus vaginal Prostaglandin E2: all women, outcome: 1.10 Instrumental vaginal delivery.






Figure 8. Funnel plot of comparison: 1 Balloon (Foley or ATAD) versus vaginal Prostaglandin E2: all women, outcome: 1.12 Apgar score < 7 at 5 minutes.






Figure 9. Funnel plot of comparison: 1 Balloon (Foley or ATAD) versus vaginal Prostaglandin E2: all women, outcome: 1.13 Neonatal intensive care unit admission.






Figure 10. Funnel plot of comparison: 1 Balloon (Foley or ATAD) versus vaginal Prostaglandin E2: all women, outcome: 1.21 Fetal distress.






Figure 11. Funnel plot of comparison: 4 Balloon (Foley or ATAD) versus intracervical Prostaglandin E2: all women, outcome: 4.3 Caesarean section.







Figure 12. Funnel plot of comparison: 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, outcome: 7.3 Caesarean section.



Allocation

Sequence generation

We judged 62 trials to be at low risk of selection bias, reporting some form of adequate random sequencing such as a computer-generated sequence or a list of random numbers (Aduloju 2016; Ahmed 2016; Al-Ibraheemi 2018; Al-Taani 2004; Amorosa 2017; Atad 1996; Bagratee 1990; Blumenthal 1990; Browne 2011; Carbone 2013; Chavakula 2015; Chua 1997; Cromi 2011; Cromi 2012; Culver 2004; Deo 2012; Edwards 2014c; El Khouly 2017; Filho 2002; Garba 2016; Gelisen 2005; Goonewardene 2014; Guinn 2000; Henry 2013; Hibbard 1998; Husain 2017; Johnson 1985; Jozwiak 2012; Jozwiak 2013; Jozwiak 2014; Khamaiseh 2012; Krammer 1995a; Lanka 2014; Lokkegaard 2015; Mackeen 2018; Matonhodze 2003; Mazhar 2003; Meetei 2015; Mullin 2002; Mundle 2017; Niromanesh 2003; Oliveira 2010; Ophir 1992; Orhue 1995; Perry 1998; Prager 2008; Rouben 1993; Salim 2011; Sanchez-Ramos 1992; Sciscione 1999; Sharami 2005; Shechter-Maor 2015; Solt 2009; Somirathne 2017; St Onge 1995; Suffecool 2014; Tabowei 2003; Tan 2015; ten Eikelder 2016; Turnquest 1997; Wang 2012; Yuen 1996).

Three trials were classified as high risk because they were quasi-randomised trials. Jagani 1982 randomised by last digit of the chart number, Kandil 2012 randomised by odd or even admission date and Roztocil 1998 randomised by week of admission.

We judged the remaining 40 trials to be at unclear risk of selection bias, as they did not report on how a random sequence was generated (Allouche 1993; Barda 2018; Benzineb 1996; Casey 1995; Dalui 2005; Deshmukh 2011; Dionne 2011; Gilson 2017; Glagoleva 1999; Gunawardena 2012; Haugland 2012; Hay 1995; Hemlin 1998; Hoppe 2016; Hudon 1999; Jeeva 1982; Joshi 2016; Kruit 2016; Kuppulakshmi 2016; Laddad 2013; Lemyre 2006; Lewis 1983; Lyndrup 1989; Lyndrup 1994; Moini 2003; Noor 2015; Ntsaluba 1997; Pennell 2009; Pineda Rivas 2016; Ridgway 1991; Roberts 1986; Roudsari 2011; Rudra 2012; Saleem 2006; Sarreau 2016; Sheikher 2009; Sullivan 1996; Tita 2006; Wang 2014; Wu 2017).

Allocation concealment

Fifty-five studies reported a method of allocation concealment likely to have a low risk of bias, either by central randomisation or sequentially numbered, sealed, opaque envelopes (Aduloju 2016; Ahmed 2016; Al-Ibraheemi 2018; Amorosa 2017; Blumenthal 1990; Browne 2011; Carbone 2013; Chavakula 2015; Cromi 2012; Culver 2004; Deo 2012; Edwards 2014c; El Khouly 2017; Filho 2002; Gelisen 2005; Goonewardene 2014; Guinn 2000; Hemlin 1998; Henry 2013; Hibbard 1998; Hoppe 2016; Husain 2017; Jozwiak 2012; Jozwiak 2013; Jozwiak 2014; Kruit 2016; Lanka 2014; Lokkegaard 2015; Lyndrup 1989; Lyndrup 1994; Matonhodze 2003; Mullin 2002; Mundle 2017; Niromanesh 2003; Ntsaluba 1997; Oliveira 2010; Orhue 1995; Pennell 2009; Perry 1998; Prager 2008; Roberts 1986; Rouben 1993; Salim 2011; Sciscione 1999; Sharami 2005; Somirathne 2017; St



Onge 1995; Suffecool 2014; Sullivan 1996; Tabowei 2003; Tan 2015; ten Eikelder 2016; Turnquest 1997; Wang 2014; Yuen 1996).

Five studies were judged to be high risk. In the quasi-randomised trials of Jagani 1982, Kandil 2012 and Roztocil 1998 no measures were taken to conceal the allocation; Mackeen 2018 stated that the allocation was not concealed and Ophir 1992 allocated women by odd or even randomisation number.

The remaining 45 studies did not report a method for concealing allocation and were judged as being at unclear risk of bias (Allouche 1993; Al-Taani 2004; Atad 1996; Bagratee 1990; Barda 2018; Benzineb 1996; Casey 1995; Chua 1997; Cromi 2011; Dalui 2005; Deshmukh 2011; Dionne 2011; Garba 2016; Gilson 2017; Glagoleva 1999; Gunawardena 2012; Haugland 2012; Hay 1995; Hudon 1999; Jeeva 1982; Johnson 1985; Joshi 2016; Khamaiseh 2012; Krammer 1995a; Kuppulakshmi 2016; Laddad 2013; Lemyre 2006; Lewis 1983; Mazhar 2003; Meetei 2015; Moini 2003; Noor 2015; Pineda Rivas 2016; Ridgway 1991; Roudsari 2011; Rudra 2012; Saleem 2006; Sanchez-Ramos 1992; Sarreau 2016; Shechter-Maor 2015; Sheikher 2009; Solt 2009; Tita 2006; Wang 2012; Wu 2017).

Blinding

Performance bias

Given the nature of the intervention (mechanical methods for induction of labour) and comparison (pharmacological methods for induction of labour), it was not possible for women or clinicians to be blinded to the treatment group in any of the trials. For the more objective outcomes such as perinatal death, the lack of blinding is unlikely to be a major source of bias. Therefore, risk of performance bias was judged as unclear in all studies, but was a reason to downgrade the quality of evidence from high to moderate.

Detection bias

It would have been possible for outcome assessment to have been undertaken by someone blinded to allocation groups. However, only four trials reported blinded outcome assessment (rated as low risk of bias). Gelisen 2005 blinded only for the outcome of hyperstimulation. In the studies of Pennell 2009 and Gelisen 2005, data were collected by research midwives who were blinded to the intervention. Rudra 2012 and Haugland 2012 both stated they performed a double blind-trial but provided too little information to assess how this was done. The remaining 101 trials did not detail whether outcome assessment was blinded, and thus we judged risk of detection bias to be unclear. Measurement of outcomes such as perinatal death are unlikely to be biased by lack of blinding.

Incomplete outcome data

We considered 38 studies to be at low risk of attrition bias with data analyses according to intention- to-treat and minimal/no loss to follow-up or exclusion of women (Aduloju 2016; Al-Ibraheemi 2018; Al-Taani 2004; Amorosa 2017; Atad 1996; Carbone 2013; Chavakula 2015; Chua 1997; Cromi 2011; Culver 2004; Dalui 2005; Deshmukh 2011; Edwards 2014c; El Khouly 2017; Filho 2002; Guinn 2000; Henry 2013; Jeeva 1982; Jozwiak 2012; Jozwiak 2013; Jozwiak 2014; Lanka 2014; Lokkegaard 2015; Mackeen 2018; Mullin 2002; Mundle 2017; Noor 2015; Ntsaluba 1997; Oliveira 2010; Pennell 2009; Perry 1998; Prager 2008; Roberts 1986; Roztocil 1998; Suffecool 2014; Sullivan 1996; ten Eikelder 2016; Wu 2017).

Forty-three studies were judged to be at unclear risk of attrition bias, mainly because it was not clear if intention-to-treat analyses was used (Allouche 1993; Benzineb 1996; Garba 2016; Gelisen 2005; Hemlin 1998; Hibbard 1998; Hoppe 2016; Jagani 1982; Johnson 1985; Joshi 2016; Khamaiseh 2012; Laddad 2013; Lewis 1983; Matonhodze 2003; Meetei 2015; Niromanesh 2003; Roudsari 2011; Salim 2011; Sanchez-Ramos 1992; Sharami 2005; Shechter-Maor 2015; Somirathne 2017; St Onge 1995), or there was too little information to judge attrition bias (Barda 2018; Casey 1995; Dionne 2011; Gilson 2017; Glagoleva 1999; Gunawardena 2012; Haugland 2012; Hay 1995; Hudon 1999; Kuppulakshmi 2016; Lemyre 2006; Mazhar 2003; Moini 2003; Pineda Rivas 2016; Ridgway 1991; Rudra 2012; Saleem 2006; Sarreau 2016; Solt 2009; Tabowei 2003).

Twenty-four studies were classified as high risk for attrition bias. In the studies of Ahmed 2016, Cromi 2012 and Wang 2014, women were excluded because of failed placement of the balloon. Kandil 2012 also excluded nine patients because of failed placement of the Foley catheter, but replaced them with women who did receive a Foley catheter. Deo 2012 analysed data as treated and also four cases went missing without a given explanation. Husain 2017, Kruit 2016, Lyndrup 1989, Sciscione 1999, Tan 2015, Turnquest 1997, Wang 2012 and Yuen 1996 excluded cases because of protocol violation and Krammer 1995a reported they analysed intention-to-treat, but eventually excluded women because of protocol violation or if they delivered within six hours after induction had started. Goonewardene 2014 also excluded women if they went into spontaneous labour after the intervention. Lyndrup 1994 excluded women if they delivered after 48 hours of induction had started. Orhue 1995 excluded women if they had an unfavourable cervix after 12 hours of induction. Rouben 1993 excluded women after failed induction. The studies of Bagratee 1990, Blumenthal 1990, Browne 2011, Ophir 1992, Sheikher 2009, Tita 2006 were judged to be of high risk for attrition bias because cases were missing without a given explanation.

Selective reporting

Seventy-two studies were judged to be at low risk of reporting bias as all pre-specified outcomes were reported (Aduloju 2016; Al-Ibraheemi 2018; Al-Taani 2004; Amorosa 2017; Atad 1996; Bagratee 1990; Barda 2018; Blumenthal 1990; Carbone 2013; Chavakula 2015; Chua 1997; Cromi 2011; Cromi 2012; Culver 2004; Dalui 2005; Deo 2012; Deshmukh 2011; Edwards 2014c; El Khouly 2017; Filho 2002; Garba 2016; Gelisen 2005; Goonewardene 2014; Guinn 2000; Hemlin 1998; Henry 2013; Hibbard 1998; Hoppe 2016; Husain 2017; Jagani 1982; Johnson 1985; Joshi 2016; Jozwiak 2012; Jozwiak 2013; Jozwiak 2014; Kandil 2012; Khamaiseh 2012; Krammer 1995a; Kruit 2016; Kuppulakshmi 2016; Lanka 2014; Lokkegaard 2015; Lyndrup 1994; Mackeen 2018; Matonhodze 2003; Mazhar 2003; Meetei 2015; Mullin 2002; Mundle 2017; Noor 2015; Ntsaluba 1997; Oliveira 2010; Ophir 1992; Orhue 1995; Pennell 2009; Perry 1998; Prager 2008; Rouben 1993; Roztocil 1998; Salim 2011; Sciscione 1999; Sharami 2005; Solt 2009; Somirathne 2017; St Onge 1995; Suffecool 2014; Sullivan 1996; Tabowei 2003; ten Eikelder 2016; Turnquest 1997; Wang 2012; Wu 2017; Yuen 1996). It is important to note that not all studies had a trial protocol available and therefore it was not possible to check if there were other pre-specified outcomes not reported in the method section of the article.

Twenty-eight studies were judged to be of unclear risk of reporting bias. In 10 studies no outcomes were pre-specified in the methods section (Allouche 1993; Benzineb 1996; Jeeva 1982; Laddad 2013;



Lewis 1983; Lyndrup 1989; Roberts 1986; Sanchez-Ramos 1992; Tan 2015; Wang 2014 and in 18 studies there was too little information to judge reporting bias (Casey 1995; Dionne 2011; Gilson 2017; Glagoleva 1999; Guinn 2000; Gunawardena 2012; Haugland 2012; Hay 1995; Hudon 1999; Lemyre 2006; Moini 2003; Niromanesh 2003; Pineda Rivas 2016; Ridgway 1991; Roudsari 2011; Rudra 2012; Saleem 2006; Sarreau 2016).

The studies of Ahmed 2016, Browne 2011, Shechter-Maor 2015, Sheikher 2009 and Tita 2006 were judged as high risk as not all prespecified outcomes were reported in the results section.

Other potential sources of bias

For 24 studies it was not clear if there was another source of bias and these were therefore judged as unclear. For one study (Barda 2018), only a manuscript with no tables was available. Two trials (Browne 2011; Tita 2006) were not published, but the results of the primary outcome and adverse events were reported in the trial registration. Guinn 2000 stopped recruiting women for one arm of the study without an explanation. Mullin 2002 calculated a sample size of 140 women but included 200 women without explanation. Prager 2008 included patients who did not meet inclusion criteria. Eighteen studies were only published as abstracts, or there was too little information provided and so it was not possible to judge the risk of bias (Casey 1995; Dionne 2011; Garba 2016; Gilson 2017; Glagoleva 1999; Haugland 2012; Hay 1995; Hudon 1999; Lemyre 2006; Oliveira 2010; Pineda Rivas 2016; Ridgway 1991; Rudra 2012; Sarreau 2016; Shechter-Maor 2015; Solt 2009; Tabowei 2003; Wang 2012).

The studies of Culver 2004, Hibbard 1998, and Kruit 2016 were judged as high risk for other potential sources of bias as they were terminated early before the required sample size was recruited.

Effects of interventions

See: Summary of findings for the main comparison Balloon (Foley or ATAD) compared to vaginal prostaglandin E2 for third trimester labour induction in women with a viable fetus; Summary of findings 2 Balloon (Foley or ATAD) compared to low-dose vaginal misoprostol for third trimester induction of labour in women with a viable fetus; Summary of findings 3 Balloon (Foley or ATAD) compared to low-dose oral misoprostol for third trimester induction of labour in women with a viable fetus

Balloon (single or double) versus vaginal prostaglandin E2 (28 trials involving 6619 women)

Primary outcomes

Vaginal delivery not achieved within 24 hours

There may be little or no difference in vaginal deliveries not achieved within 24 hours between induction of labour with a balloon catheter and vaginal PGE2 (average risk ratio (RR) 1.01, 95% confidence interval (CI) 0.82 to 1.26; 7 studies; 1685 women; low-quality evidence; Analysis 1.1), although there was substantial heterogeneity for this outcome (Tau² = 0.06; Chi² = 29.06, df = 6 (P =< 0.0001); $I^2 = 79\%$).

A sensitivity analysis, after eliminating the two trials assessed as having a potentially higher risk of concealment or attrition bias (Cromi 2012; Wang 2014), did not change the effect observed, de-

spite the result becoming less precise (average RR 1.10, 95% CI 0.86 to 1.41; 1351 women; 5 studies; $I^2 = 82\%$).

The same result was seen on a subgroup comparison for primiparous women (RR 1.01, 95% CI 0.83 to 1.23; 330 women; 1 study; Analysis 2.1). While for multiparous women, a balloon catheter may increase the risk of a vaginal delivery not being achieved within 24 hours (RR 4.38, 95% CI 1.74 to 10.98; 147 women; 1 study; Analysis 3.1).

Uterine hyperstimulation with fetal heart rate (FHR) changes

A balloon catheter probably reduces the risk of uterine hyperstimulation with FHR changes when compared to vaginal PGE2 (RR 0.35, 95% CI 0.18 to 0.67; 6 studies; 1966 women; moderate-quality evidence; Analysis 1.2), the absolute effect being 21 less per 1000 deliveries.

The same result was seen on a subgroup comparison for primiparous women (RR 0.05, 95% CI 0.00 to 0.85; 330 women; 1 study; Analysis 2.2). For multiparous women, no outcomes were reported.

Caesarean section

There probably is little or no difference in caesarean sections between both induction methods (RR 1.00, 95% CI 0.92 to 1.09; 28 studies; 6619 women; moderate-quality evidence; Analysis 1.3). Visual inspection of the funnel plot associated with this outcome does not suggest any evidence of publication bias (Figure 4).

It is uncertain whether there is a difference in caesarean sections between both induction methods on subgroups for both primiparous women (average RR 0.89, 95% CI 0.59 to 1.33; 828 women; 5 studies; Analysis 2.3) and multiparous women (RR 1.31, 95% CI 0.65 to 2.63; 180 women; 2 studies; Analysis 3.2) as the results of these outcomes were imprecise. Furthermore, for the primiparous group, there was also substantial heterogeneity (Tau² = 0.11; Chi² = 10.01, df = 4 (P = 0.04); $I^2 = 60\%$).

Serious neonatal morbidity or perinatal death

A balloon catheter probably reduces the risk of serious neonatal morbidity or perinatal death when compared to vaginal PGE2 (RR 0.48, 95% CI 0.25 to 0.93; 8 studies; 2757 women; moderate-quality evidence; Analysis 1.4). However, numbers are low (12/1483 versus 25/1274, respectively) and almost all of these numbers were cases of birth asphyxia. Only two perinatal deaths were reported, both in the PGE2 group (Edwards 2014c). No heterogeneity was seen for this outcome.

For primiparous women, it is uncertain whether there is a difference in effect as the result for this outcome was imprecise (RR 0.17, 95% CI 0.01 to 4.24; 330 women; 1 study; Analysis 2.4). For multiparous women, no outcomes were reported.

Serious maternal morbidity or death

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods (RR 0.20, 95% CI 0.01 to 4.12; 4 studies; 1481 women; very low-quality evidence; Analysis 1.5). Of all the 28 studies included for this comparison, only four studies reported on this composite outcome. No events were reported in the balloon group. One author (Jozwiak 2012) reported two events in the PGE2 group, both events being uterine rupture.



Only one study (60 women) reported on this outcome in primiparous women, in which no events were seen (Analysis 2.5). For multiparous women, no outcomes were reported.

Secondary outcomes

Cervix unfavourable/unchanged after 24 hours

Not reported.

Oxytocin augmentation

Induction of labour with a balloon catheter may increase the risk of oxytocin augmentation when compared to vaginal PGE2 (average RR 1.54, 95% CI 1.35 to 1.76; 4828 women; 16 studies; Analysis 1.6), although there was substantial heterogeneity for this outcome ($Tau^2 = 0.05$; $Chi^2 = 141.47$, df = 15 (P = < 0.0001); $I^2 = 89\%$). Visual inspection of the funnel plot was somewhat asymmetrical, suggesting some form of publication bias (Figure 5).

A sensitivity analysis, after eliminating the five trials assessed as having a potentially higher risk of allocation or attrition bias (Cromi 2012; Deo 2012; Tan 2015; Wang 2012; Wang 2014), did not alter the result, nor did it lower heterogeneity (average RR 1.37, 95% CI 1.21 to 1.54; 4005 women; 11 studies; $I^2 = 87\%$).

Uterine hyperstimulation without FHR changes

A balloon catheter may reduce the risk of uterine hyperstimulation without FHR changes when compared to vaginal PGE2 (average RR 0.27, 95% CI 0.11 to 0.66; 2444 women; 15 studies; Analysis 1.7), although there was moderate heterogeneity for this outcome (Tau² = 1.13; Chi² = 22.28, df = 12 (P = 0.03); I² = 46%). Visual inspection of the funnel plot associated with this outcome does not suggest any evidence of publication bias (Figure 6).

A sensitivity analysis, after eliminating the seven trials assessed as having a potentially higher risk of allocation or attrition bias (Deo 2012; Orhue 1995; Shechter-Maor 2015; Tan 2015; Wang 2012; Wang 2014; Zahoor 2014), made this result less precise and therefore raises uncertainty as to whether there is a difference in uterine hyperstimulation without FHR changes (average RR 0.26, 95% CI 0.06 to 1.05; 1694 women; 8 studies; I² = 62%).

Uterine rupture

It is uncertain whether there is a difference in uterine rupture between both induction methods (RR 0.20, 95% CI 0.01 to 4.12; 1045 women; 2 studies; Analysis 1.8). Only two cases of uterine rupture were reported, both in the PGE2 group in the study of Jozwiak 2012. Uterine rupture was defined by the authors as a separation of the uterine wall, and in one case this was caused by inserting an intrauterine pressure catheter.

Epidural analgesia

A balloon catheter may slightly increase the use of epidural analgesia during labour when compared to vaginal PGE2 (average RR 1.14, 95% CI 1.00 to 1.29; 2828 women; 8 studies; Analysis 1.9). However, there was substantial heterogeneity for this outcome ($Tau^2 = 0.02$; $Chi^2 = 32.09$, df = 7 (P = < 0.0001); $I^2 = 78\%$).

A sensitivity analysis, after eliminating the two trials assessed as having a potentially higher risk of allocation or attrition bias (Cromi 2012; Tan 2015), did not alter the result, nor did it lower heterogeneity (average RR 1.11, 95% CI 0.97 to 1.28; 2537 women; 6 studies; $I^2 = 80\%$).

Instrumental vaginal delivery

There probably is little or no difference in instrumental vaginal deliveries between both induction methods (RR 0.93, 95% CI 0.79 to 1.09; 4514 women; 16 studies; Analysis 1.10). Visual inspection of the funnel plot associated with this outcome does not suggest any evidence of publication bias (Figure 7).

Meconium-stained liquor

It is uncertain whether there is a difference in meconium-stained liquor between both induction methods (RR 0.89, 95% CI 0.67 to 1.19; 964 women; 4 studies; Analysis 1.11).

Apgar score less than seven at five minutes

It is uncertain whether there is a difference in Apgar score less than seven at five minutes between both induction methods (RR 0.74, 95% CI 0.49 to 1.14; 4271 women; 14 studies; low-quality evidence; Analysis 1.12). Visual inspection of the funnel plot associated with this outcome does not suggest any evidence of publication bias (Figure 8).

Neonatal intensive care unit (NICU) admission

A balloon catheter may reduce the risk of a NICU admission when compared to vaginal PGE2 (RR 0.82, 95% CI 0.65 to 1.04; 3647 women; 12 studies; low-quality evidence; Analysis 1.13), the absolute effect being 15 fewer NICU admission per 1000 deliveries. Although it should be noted that there is a wide range of treatment effects that are compatible with the data, from a very small increase in risk to very large decrease. Visual inspection of the funnel plot associated with this outcome does not suggest any evidence of publication bias (Figure 9).

Neonatal encephalopathy

Not reported.

Perinatal death

It is uncertain whether there is a difference in perinatal death between both induction methods (RR 0.21, 95% CI 0.01 to 4.27; 1036 women; 5 studies; Analysis 1.14). Only two cases of perinatal death were reported by Edwards 2014c, both being cases of neonatal death and born to women randomised to vaginal PGE2. The authors describe that in both cases the neonates died as a result of complications related to a congenital diaphragmatic hernia and were unrelated to the induction method.

Disability in childhood

Not reported.

Maternal side effects (all)

Not reported.

Maternal nausea

Not reported.

Maternal vomiting

Not reported.

Maternal diarrhoea



Other maternal side effects

Not reported.

Postpartum haemorrhage

It is uncertain whether there is a difference in postpartum haemorrhage between both induction methods (RR 0.82, 95% CI 0.63 to 1.06; 2215 women; 8 studies; Analysis 1.15).

Serious maternal complications

Not reported.

Maternal death

Not reported.

Woman not satisfied

A balloon catheter may reduce the amount of women not being satisfied with the induction method when compared to prostaglandin E2 (RR 0.61, 95% CI 0.39 to 0.97; 93 women; 1 study; Analysis 1.16), the absolute effect being 224 fewer women not satisfied per 1000 deliveries. This outcome was reported by Henry 2013 by asking the women if they would choose the randomised induction method again. Patient satisfaction was also reported by Shechter-Maor 2015, but could not be included in the meta-analysis. In this study women were asked to score their satisfaction with the induction process on a five-point Likert scale. No difference in satisfaction was seen between both induction methods (3.41 (\pm 1.3) versus 3.33 (\pm 1.2), respectively; P = 0.860).

Caregiver not satisfied

Not reported.

Other outcomes (not pre-specified)

Maternal fever during labour

It is uncertain whether there is a difference in maternal fever during labour between both methods (RR 0.87, 95% CI 0.65 to 1.17; 2362 women; 7 studies; Analysis 1.17).

Antibiotics during labour

It is uncertain whether there is a difference in antibiotics during labour between both methods (RR 1.43, 95% CI 0.89 to 2.29; 330 women; 1 study; Analysis 1.18).

Chorioamnionitis

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (RR 0.69, 95% CI 0.32 to 1.49; 376 women; 1 study; Analysis 1.19).

Endometritis

It is uncertain whether there is a difference in endometritis between both induction methods (RR 0.49, 95% CI 0.19 to 1.27; 706 women; 2 studies; Analysis 1.20).

Fetal distress

A balloon catheter probably reduces the risk of fetal distress for which a caesarean section is indicated when compared to vaginal PGE2 (RR 0.71, 95% CI 0.60 to 0.83; 4753 women; 20 studies; Analysis 1.21). Visual inspection of the funnel plot associated with this outcome does not suggest any evidence of publication bias (Figure 10).

Umbilical artery pH < 7.10

A balloon catheter probably reduces the risk of an umbilical artery pH less than 7.10 directly postpartum when compared to vaginal PGE2 (RR 0.65, 95% CI 0.44 to 0.94; 2675 women, 8 studies; Analysis 1.22). However, numbers occurred infrequently in both groups (35 per 1000 versus 56 per 1000, respectively).

Balloon (single or double) versus cervical prostaglandin E2 (10 trials involving 1428 women)

Primary outcomes

Vaginal delivery not achieved within 24 hours

It is uncertain whether there is a difference in vaginal deliveries achieved within 24 hours between induction of labour with a balloon catheter and cervical PGE2 (average RR 1.01, 95% CI 0.35 to 2.91; 200 women; 2 studies; Analysis 4.1). There also was substantial heterogeneity for this outcome (Tau² = 0.53; Chi² = 10.35, df = 1 (P = 0.001); I² = 90%). Even though data were pooled, both studies may be incompatible as no overlap of CIs is present. No sensitivity analysis was conducted as no potential high-risk studies were included for this outcome.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Uterine hyperstimulation with FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between both induction methods (RR 0.37, 95% CI 0.02 to 8.90; 447 women; 4 studies; Analysis 4.2).

Only one small study (53 women) reported this outcome for the subgroups of primiparous and multiparous women. No events were reported in primiparous women (Analysis 5.1). For multiparous women, it is uncertain whether there is a difference for this outcome between both induction methods (RR 0.30, 95% CI 0.01 to 7.02; 53 women; 1 study; Analysis 6.1).

Caesarean section

There probably is little or no difference in caesarean sections between both induction methods (RR 0.97, 95% CI 0.81 to 1.15; 1309 women; 9 studies; Analysis 4.3). Visual inspection of the funnel plot associated with this outcome does not suggest any evidence of publication bias (Figure 11).

It is uncertain whether there is a difference in caesarean sections between both induction methods on subgroup comparisons for both primiparous women (RR 1.30, 95% CI 0.86 to 1.95; 245 women; 3 studies; Analysis 5.2) and multiparous women (average RR 0.66, 95% CI 0.16 to 2.78; 136 women; 3 studies; Analysis 6.2) as the results for both comparisons were imprecise. For the multiparous group, there also was substantial heterogeneity (Tau² = 0.90; Chi² = 4.78, df = 2 (P = 0.09); $I^2 = 58\%$).

Serious neonatal morbidity or perinatal death

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (RR 0.78, 95% CI 0.29 to 2.05; 500 women; 2 studies; Analysis 4.4). Of the 10 studies included for this comparison, two studies (Benzineb 1996; Laddad 2013) reported on this composite outcome. All reported events in these studies were cases of perinatal death.



For the subgroups of primiparous and multiparous women, no outcomes were reported.

Serious maternal morbidity or death

Not reported.

Secondary outcomes

Cervix unfavourable/unchanged after 24 hours

It is uncertain whether there is a difference in an unfavourable cervix after 24 hours between both induction methods (RR 0.96, 95% CI 0.70 to 1.34; 219 women; 2 studies; Analysis 4.5).

Oxytocin augmentation

There may be little or no difference in oxytocin augmentation between both induction methods (RR 1.08, 95% CI 0.93 to 1.26; 400 women; 1 study; Analysis 4.6).

Uterine hyperstimulation without FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation without FHR changes between both induction methods (average RR 0.99, 95% CI 0.09 to 10.38; 654 women; 5 studies; Analysis 4.7). Also, there was substantial heterogeneity for this outcome ($Tau^2 = 2.92$; $Chi^2 = 6.33$, df = 2 (P = 0.04); $I^2 = 68\%$).

A sensitivity analysis, after eliminating the two trials assessed as having a potentially higher risk of allocation or attrition bias (Sciscione 1999; Yuen 1996) did not alter the result, nor did it lower heterogeneity (average RR 0.56, 95% CI 0.01 to 39.31; 430 women; 3 studies; $I^2 = 76\%$).

Uterine rupture

Not reported.

Epidural analgesia

There may be little or no difference in epidural analysis during labour between both induction methods (RR 0.91, 95% CI 0.81 to 1.02; 149 women; 1 study; Analysis 4.8).

Instrumental vaginal delivery

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 1.18, 95% CI 0.68 to 2.05; 337 women; 3 studies; Analysis 4.9).

Meconium-stained liquor

It is uncertain whether there is a difference in meconium-stained liquor between both induction methods (RR 1.17, 95% CI 0.42 to 3.26; 118 women; 1 study; Analysis 4.10).

Apgar score less than seven at five minutes

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes (RR 0.79, 95% CI 0.41 to 1.53; 475 women; 2 studies; Analysis 4.11).

Neonatal intensive care unit admission

It is uncertain whether there is a difference in NICU admissions between both methods (RR 0.88, 95% CI 0.60 to 1.31; 400 women; 1 study; Analysis 4.12).

Neonatal encephalopathy

Not reported.

Perinatal death

It is uncertain whether there is difference in perinatal death between both induction methods (RR 0.78, 95% CI 0.29 to 2.05; 500 women; 2 studies. Analysis 4.13). Noteworthy, there was a relatively high number of neonatal deaths reported in the study of Laddad 2013 for the balloon group (6/200), as well as in the cervical PGE2 group (8/200), for which no explanation was given by the authors.

Disability in childhood

Not reported.

Maternal side effects

It is uncertain whether there is a difference in maternal side effects (RR 0.15, 95% CI 0.02 to 1.24; 211 women; 2 studies; Analysis 4.14). The nature of the side effects was not specified in both included studies.

Maternal nausea

Not reported.

Maternal vomiting

Not reported.

Maternal diarrhoea

Not reported.

Other maternal side effects

Not reported.

Postpartum haemorrhage

It is uncertain whether there is a difference in postpartum haemorrhage between both induction methods (RR 0.20, 95% CI 0.01 to 4.06; 100 women; 1 study; Analysis 4.15).

Serious maternal complications

Not reported.

Maternal death

Not reported.

Woman not satisfied

Not reported.

Caregiver not satisfied

Not reported.

Other outcomes (not pre-specified)

Maternal fever during labour

Not reported.

Antibiotics during labour



Chorioamnionitis

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (RR 1.00, 95% CI 0.21 to 4.75; 118 women; 1 study; Analysis 4.16).

Endometritis

It is uncertain whether there is a difference in endometritis between both induction methods (RR 1.00, 95% CI 0.06 to 15.61; 118 women; 1 study; Analysis 4.17).

Fetal distress

A balloon catheter probably reduces the risk of fetal distress for which a caesarean section is indicated when compared to cervical PGE2 (RR 0.61, 95% CI 0.42 to 0.89; 1023 women; 6 studies; Analysis 4.18).

Umbilical artery pH < 7.10

Not reported.

Balloon (single or double) versus low-dose vaginal misoprostol (13 trials involving 1818 women)

Primary outcomes

Vaginal delivery not achieved within 24 hours

It is uncertain whether there is a difference in vaginal deliveries not achieved within 24 hours between induction of labour with a balloon catheter and vaginal misoprostol (RR 1.09, 95% CI 0.85 to 1.39; 340 women; 2 studies; low-quality evidence; Analysis 7.1).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Uterine hyperstimulation with FHR changes

A balloon catheter probably reduces the risk of uterine hyperstimulation with FHR changes when compared to vaginal misoprostol (RR 0.39, 95% CI 0.18 to 0.85; 1322 women; moderate-quality evidence; 8 studies; Analysis 7.2), the absolute effect being 22 fewer cases per 1000 deliveries.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Caesarean section

A balloon catheter may increase the risk of a caesarean section when compared to vaginal misoprostol (average RR 1.28, 95% CI 1.02 to 1.60; 1756 women; 12 studies; low-quality evidence; Analysis 7.3), the absolute effect being 53 more caesarean sections per 1000 deliveries. However, there was moderate heterogeneity for this outcome ($Tau^2 = 0.06$; $Chi^2 = 19.86$, $Chi^2 = 19.86$).

A sensitivity analysis, after eliminating the three trials assessed as having a potentially higher risk of allocation or attrition bias (Deo 2012; Kandil 2012; Sheikher 2009), did not alter the result, nor did it lower heterogeneity (average RR 1.34, 95% CI 1.05 to 1.71; 1492 women; 10 studies; I² = 48%). Visual inspection of the funnel plot associated with this outcome does not suggest any evidence of publication bias (Figure 12).

For the subgroup of primiparous women, it is uncertain whether there is a difference in caesarean sections between both induction

methods (RR 0.82, 95% CI 0.59 to 1.13; 255 women; 1 study; Analysis 8.1). For multiparous women, no outcomes were reported.

Serious neonatal morbidity or perinatal death

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (RR 0.58, 95% CI 0.12 to 2.66; 381 women; 3 studies; very low-quality evidence; Analysis 7.4). All of the cases included for this composite outcome were cases of perinatal asphyxia (2/187 versus 4/194, respectively).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Serious maternal morbidity or death

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods (very low-quality evidence; Analysis 7.5). Of the 13 studies included for this comparison, four studies (464 women) reported on this composite outcome. No events of maternal morbidity or death occurred in one of these studies.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Secondary outcomes

Cervix unfavourable/unchanged after 12 hours

It is uncertain whether there is a difference in an unfavourable cervix after 12 hours between both induction methods (average RR 2.66, 95% CI 0.60 to 11.89; 200 women; 2 studies; Analysis 7.6). Also, there was moderate heterogeneity for this outcome ($Tau^2 = 0.63$; $Chi^2 = 1.56$, df = 1 (P = 0.21); $I^2 = 36\%$). No studies reported on a time period of 24 hours.

A sensitivity analysis, after eliminating one trial assessed as having a potentially higher risk of allocation or attrition bias (Sheikher 2009), did not change the result, but did narrow the CI (RR 1.82, 95% CI 0.94 to 3.51; 1 study).

Oxytocin augmentation

A balloon catheter probably increases the risk of oxytocin augmentation when compared to vaginal misoprostol (average RR 1.62, 95% CI 1.38 to 1.90; 911 women; 9 studies; Analysis 7.7), although there was substantial heterogeneity for this outcome ($Tau^2 = 0.03$; $Chi^2 = 21.93$, df = 8 (P = 0.005); $I^2 = 64\%$).

In the sensitivity analysis, after eliminating two trial assessed as having a potentially higher risk of allocation or attrition bias (Kandil 2012 and Sheikher 2009), heterogeneity was lost without altering the effect observed (average RR 1.50, 95% CI 1.36 to 1.64; 751 women, 7 studies; $I^2 = 0\%$).

Uterine hyperstimulation without FHR changes

A balloon catheter probably reduces the risk of uterine hyperstimulation without FHR changes when compared to vaginal misoprostol (RR 0.25, 95% CI 0.14 to 0.44; 1139 women; 9 studies; Analysis 7.8).

Uterine rupture

It is uncertain whether there is a difference in uterine rupture between both induction methods (Analysis 7.9). Of the 13 studies included for this comparison, only three studies (364 women) report-



ed on this outcome. No events of uterine rupture occurred in one of these studies.

Epidural analgesia

A balloon catheter probably slightly increases the use of epidural analgesia during labour when compared to vaginal misoprostol (RR 1.22, 95% CI 1.06 to 1.41; 517 women; 2 studies; Analysis 7.10).

Instrumental vaginal delivery

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.72, 95% CI 0.50 to 1.05; 721 women; 4 studies; Analysis 7.11).

Meconium-stained liquor

A balloon catheter probably reduces the risk of meconium-stained liquor when compared to vaginal misoprostol (RR 0.64, 95% CI 0.48 to 0.87; 1268 women; 7 studies; Analysis 7.12).

Apgar score less than seven at five minutes

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 1.00, 95% CI 0.50 to 1.97; 941 women; 7 studies; low-quality evidence; Analysis 7.13).

Neonatal intensive care unit admission

It is uncertain whether there is a difference in NICU admissions between both induction methods (RR 1.00, 95% CI 0.61 to 1.63; 1302 women; 9 studies; low-quality evidence; Analysis 7.14).

Neonatal encephalopathy

Not reported.

Perinatal death

It is uncertain whether there is difference in perinatal death between both induction methods (Analysis 7.15). Of the 13 studies included for this comparison, only one study (121 women) pre-specified this outcome. No cases of perinatal death were reported in this study.

Disability in childhood

Not reported.

Maternal side effects (all)

Not reported.

Maternal nausea

Not reported.

Maternal vomiting

It is uncertain whether there is difference in maternal vomiting between both induction methods (Analysis 7.16). Of all the 13 studies included for this comparison, only one study (60 women) pre-specified this outcome. No cases of maternal vomiting were reported in this study.

Maternal diarrhoea

Not reported.

Other maternal side effects

Not reported.

Postpartum haemorrhage

It is uncertain whether there is difference in postpartum haemorrhage between both induction methods (RR 1.14, 95% CI 0.24 to 5.44; 120 women; 1 study; (Analysis 7.17).

Serious maternal complications

Not reported.

Maternal death

Not reported.

Woman not satisfied

One study (Chavakula 2015) reported on patient satisfaction, but could not be included in the meta-analysis. In this study, satisfaction was assessed by a visual analogue score ranging from zero to five (0 = very poor; 5 = very good), in which no difference between both induction methods was seen (100 women; 4.5 [4-5] versus 4.45 [3-5], respectively; P = 0.488).

Caregiver not satisfied

Not reported.

Not pre-specified outcomes

Maternal fever during labour

It is uncertain whether there is a difference in maternal fever during labour between both methods (average RR 1.84, 95% CI 0.22 to 15.62; 617 women; 3 studies; Analysis 7.18). Also, there was substantial heterogeneity for this outcome (Tau² = 1.86; Chi² = 3.95, df = 1 (P = 0.05); I^2 = 75%). No sensitivity analysis was performed as no potential high-risk studies were included for this outcome.

Antibiotics during labour

Not reported.

Chorioamnionitis

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (RR 1.24, 95% CI 0.31 to 4.88; 200 women; 2 studies; Analysis 7.19).

Endometritis

It is uncertain whether there is a difference in endometritis between both induction methods (RR 2.95, 95% CI 0.12 to 71.72; 240 women; 1 study; Analysis 7.20).

Fetal distress

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated (RR 0.84, 95% CI 0.67 to 1.05; 1127 women; 7 studies; Analysis 7.21).

Umbilical artery pH < 7.10

It is uncertain whether there is a difference in umbilical artery pH less than 7.10 directly postpartum between both induction methods (RR 1.14, 95% CI 0.35 to 3.74; 120 women; 1 study; Analysis 7.22).



Balloon (single or double) versus low-dose oral misoprostol (seven trials involving 3178 women)

Primary outcomes

Vaginal delivery not achieved within 24 hours

A balloon catheter probably increases the risk of a vaginal delivery not achieved within 24 hours when compared to oral misoprostol (RR 1.28, 95% CI 1.13 to 1.46; 782 women, 2 studies. moderate-quality evidence, Analysis 9.1), the absolute effect being 133 more per 1000 deliveries.

The same results were seen on parity subgroup comparisons for primiparous women (RR 1.19, 95% CI 1.04 to 1.37; 573 women; 2 studies; Analysis 10.1) and multiparous women (RR 1.55, 95% CI 1.17 to 2.06; 209 women; 2 studies; Analysis 11.1).

Uterine hyperstimulation with FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between both induction methods (RR 0.81, 95% CI 0.48 to 1.38; 2033 women; 2 studies; low-quality evidence; Analysis 9.2).

The same results were seen on parity subgroup comparisons for primiparous women (RR 0.81, 95% CI 0.45 to 1.46; 1206 women; 1 study; Analysis 10.2 and multiparous women (RR 1.45, 95% CI 0.24 to 8.61; 639 women; 1 study; Analysis 11.2).

Caesarean section

A balloon catheter probably slightly increases the risk of a caesarean section when compared to oral misoprostol (RR 1.17, 95% CI 1.04 to 1.32; 3178 women; 7 studies; moderate-quality evidence; Analysis 9.3), the absolute effect being 37 more caesarean sections per 1000 deliveries.

The same result was seen on the subgroup of primiparous women (RR 1.21, 95% CI 1.06 to 1.38; 1778 women; 3 studies; Analysis 10.3). For multiparous women, it is uncertain whether there is a difference in caesarean sections between both methods (RR 1.22, 95% CI 0.79 to 1.87; 848 women; 3 studies; Analysis 11.3).

Serious neonatal morbidity or perinatal death

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (RR 1.11, 95% CI 0.60 to 2.06; 2627 women; 3 studies; low-quality evidence; Analysis 9.4).

The same results were seen on parity subgroup comparisons for primiparous women (RR 4.49, 95% CI 0.77 to 26.14; 1296 women; 2 studies; Analysis 10.4) and multiparous women (RR 0.98, 95% CI 0.14 to 6.86; 729 women; 2 studies; Analysis 11.4).

Serious maternal morbidity or death

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods (RR 0.50, 95% CI 0.05 to 5.52; 2627 women; 3 studies; very low-quality evidence; Analysis 9.5).

The same results were seen on parity subgroup comparisons for primiparous women (RR 0.51, 95% CI 0.05 to 5.63; 1296 women; 2 studies; Analysis 10.5) and multiparous women (Analysis 11.5). In the latter group, no events of maternal morbidity or death were reported (2 studies; 729 women).

Secondary outcomes

Cervix unfavourable/unchanged after 24 hours

It is uncertain whether there is a difference in an unfavourable cervix after 24 hours between both induction methods (average RR 0.98, 95% CI 0.61 to 1.56; 994 women; 4 studies; Analysis 9.6). Also, there was moderate heterogeneity for this outcome ($Tau^2 = 0.06$; $Chi^2 = 2.96$, df = 2 (P = 0.23); $I^2 = 33\%$).

A sensitivity analysis, after eliminating the two trials assessed as having a potentially higher risk of allocation or attrition bias (Goonewardene 2014; Sheikher 2009), did not change the result, although heterogeneity was lost (RR 1.31, 95% CI 0.81 to 2.15; 782 women; 2 studies; I² = 0%).

Oxytocin augmentation

A balloon catheter may increase the risk of oxytocin augmentation when compared to oral misoprostol (average RR 1.28, 95% CI 1.09 to 1.49; 2847 women; 5 studies; Analysis 9.7) although there was substantial heterogeneity for this outcome (Tau² = 0.03; Chi² = 31.32, df = 4 (P < 0.000001); $I^2 = 87\%$).

A sensitivity analysis, after eliminating the three trials assessed as having a potentially higher risk of allocation or attrition bias (Goonewardene 2014; Kruit 2016; Sheikher 2009), did not change this result, nor did it lower heterogeneity (average RR 1.35, 95% CI 1.02 to 1.79; 2447 women; 2 studies; I² = 95%).

Uterine hyperstimulation without FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation without FHR changes between both induction methods (average RR 0.50, 95% CI 0.12 to 2.07; 2838 women; 5 studies; Analysis 9.8). Also, there was substantial heterogeneity for this outcome $(Tau^2 = 1.26$; $Chi^2 = 8.12$, df = 4 (P = 0.09); $I^2 = 51\%$).

A sensitivity analysis, after eliminating the one trial assessed as having a potentially higher risk of allocation or attrition bias (Sheikher 2009), did not change the effect observed, nor did it lower heterogeneity (average RR 0.49, 95% CI 0.09 to 2.64; 2778 women; 4 studies; I² = 60%).

Uterine rupture

It is uncertain whether there is a difference in uterine rupture between both induction methods (Analysis 9.9). Of the seven studies included for this comparison, three studies (2627 women) prespecified this outcome. No events of uterine rupture occurred in any of these studies.

Epidural analgesia

A balloon catheter may slightly increase the risk for epidural analgesia when compared to oral misoprostol (average RR 1.08, 95% CI 0.96 to 1.22; 2635 women; 3 studies; Analysis 9.10). However, the result is still too imprecise to make a valid judgement on this outcome. Also, there was substantial heterogeneity for this outcome (Chi² = 4.73, df = 2 (P = 0.09); I^2 = 58%).

A sensitivity analysis, after eliminating the one trial assessed as having a potentially higher risk of allocation or attrition bias (Kruit 2016), did not change this result, but did lower heterogeneity for this outcome (RR 1.13, 95% CI 1.03 to 1.24; 2447; 2 studies; I² = 5%).



Instrumental vaginal delivery

A balloon catheter probably reduces the risk of an instrumental vaginal delivery when compared to oral misoprostol (RR 0.71, 95% CI 0.55 to 0.92; 2627 women; 3 studies; Analysis 9.11).

Meconium-stained liquor

It is uncertain whether there is a difference in meconium-stained liquor between both induction methods (average RR 0.77, 95% CI 0.44 to 1.35; 2627 women; 3 studies; Analysis 9.12). Also, there was moderate heterogeneity for this outcome ($Tau^2 = 0.11$; $Chi^2 = 3.09$, df = 2 (P = 0.21); $I^2 = 35\%$). No sensitivity analysis was conducted as no potential high-risk studies were included for this outcome.

Apgar score less than seven at five minutes

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 0.71, 95% CI 0.38 to 1.32; 2693 women; 4 studies; low-quality evidence; Analysis 9.13).

Neonatal intensive care unit admission

It is uncertain whether there is a difference in NICU admissions between both induction methods (RR 0.82, 95% CI 0.58 to 1.17; 2873 women; 5 studies; low-quality evidence; Analysis 9.14).

Neonatal encephalopathy

It is uncertain whether there is a difference in neonatal encephalopathy between both induction methods (RR 0.81, 95% CI 0.32 to 2.03; 600 women; 1 study; Analysis 9.15).

Perinatal death

It is uncertain whether there is difference in perinatal death between both induction methods (RR 1.28, 95% CI 0.49 to 3.30; 2627 women; 3 studies; Analysis 9.16) as the result was imprecise and events occurred infrequently (9/1310 versus 7/1317, respectively). In the balloon group, two cases of perinatal death were related to asphyxia, compared to one case in the misoprostol group.

Disability in childhood

Not reported.

Maternal side effects (all)

It is uncertain whether there is a difference in maternal side effects between both induction methods (RR 0.61, 95% CI 0.33 to 1.13; 662 women; 2 studies; Analysis 9.17).

Maternal nausea

Not reported.

Maternal vomiting

It is uncertain whether there is a difference in maternal vomiting between both induction methods (RR 0.73, 95% CI 0.37 to 1.46; 662 women; 2 studies; Analysis 9.18).

Maternal diarrhoea

It is uncertain whether there is a difference in maternal diarrhoea between both induction methods (RR 0.29, 95% CI 0.06 to 1.37; 602 women; 1 study; Analysis 9.19).

Other maternal side effects

Not reported.

Postpartum haemorrhage

It is uncertain whether there is difference in postpartum haemorrhage between both induction methods (RR 1.03, 95% CI 0.79 to 1.34; 2966 women; 5 studies; Analysis 9.20).

Serious maternal complications

Not reported.

Maternal death

It is uncertain whether there is a difference in maternal death between both induction methods (Analysis 9.21). Of the 13 studies included for this comparison, three studies (2627 women) pre-specified this outcome. No events of maternal death occurred in one of these studies.

Woman not satisfied

A balloon catheter may increase the risk of women not being satisfied when compared to oral misoprostol (RR 1.70, 95% CI 1.15 to 2.50; 602 women; 1 study; Analysis 9.22), the absolute effect being 80 more women not satisfied per 1000 deliveries. In the one study included for this outcome, women were asked if they would choose the same induction method again in a future induction of labour.

Caregiver not satisfied

Not reported.

Not pre-specified outcomes

Maternal fever during labour

There probably is little or no difference in maternal fever during labour between both induction methods (RR 0.98, 95% CI 0.78 to 1.24; 2033 women; 2 studies; Analysis 9.23).

Antibiotics during labour

It is uncertain whether there is a difference in antibiotics during labour between both induction methods (RR 1.22, 95% CI 0.75 to 2.00; 2033 women; 2 studies; Analysis 9.24).

Chorioamnionitis

Not reported.

Endometritis

It is uncertain whether there is a difference in endometritis between both induction methods (RR 0.56, 95% CI 0.05 to 6.03; 188 women; 1 study; Analysis 9.25).

Fetal distress

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (RR 0.82, 95% CI 0.61 to 1.09; 2966 women; 5 studies; Analysis 9.26).

Umbilical artery pH < 7.10

It is uncertain whether there is a difference in umbilical artery pH less than 7.10 directly postpartum between both induction methods (RR 0.77, 95% CI 0.53 to 1.12; 1535 women; 2 studies; Analysis 9.27).



Balloon (single or double) versus oxytocin (eight trials involving 781 women)

Primary outcomes

Vaginal delivery not achieved within 24 hours

Not reported.

Uterine hyperstimulation with FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between induction of labour with a balloon and oxytocin (RR 0.20, 95% CI 0.01 to 4.11; 200 women; 1 study; Analysis 12.1).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Caesarean section

A balloon catheter probably reduces the risk of a caesarean section when compared to oxytocin (RR 0.68, 95% CI 0.56 to 0.83; 781 women; 8 studies; Analysis 12.2), the absolute effect being 126 fewer caesarean sections per 1000 deliveries.

For women with a previous caesarean section, a balloon catheter may slightly reduce the risk of a caesarean section when compared to oxytocin (RR 0.80, 95% CI 0.64 to 1.00; 364 women; 3 studies; Analysis 13.1). However, the result is still too imprecise to make a valid judgement on this outcome.

For primiparous women, it is uncertain whether there is a difference in effect as the result of this outcome was imprecise (RR 0.43, 95% CI 0.12 to 1.50; 60 women; 1 study; Analysis 14.1). For multiparous women, no outcomes were reported.

Serious neonatal morbidity or perinatal death

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (Analysis 12.3). Of the eight studies included for this comparison, one study (100 women) reported on this composite outcome. No events of neonatal morbidity or perinatal death occurred in this study.

The same result was seen on a subgroup of women with a previous caesarean section. One study (100 women) reported on this outcome, in which no events of serious neonatal morbidity of perinatal death occurred (Analysis 13.2).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Serious maternal morbidity or death

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods (Analysis 12.4). Of the eight studies included for this comparison, two studies (160 women) reported on this composite outcome. No events of serious maternal morbidity or death occurred in these studies.

The same result was seen on a subgroup of women with a previous caesarean section. One study (100 women) reported on this outcome, in which no events of serious maternal morbidity of death occurred (Analysis 13.3).

On parity subgroup comparisons, one study (60 women) reported on this outcome in primiparous women, in which no events were seen (Analysis 14.2). For multiparous women, no outcomes were reported.

Secondary outcomes

Cervix unfavourable/unchanged after 24 hours

It is uncertain whether there is a difference in an unfavourable cervix after 24 hours between both induction methods (RR 0.56, 95% CI 0.20 to 1.54; 100 women; 1 study; Analysis 12.5).

Oxytocin augmentation

Not a relevant outcome because all women in the comparison group received oxytocin.

Uterine hyperstimulation without FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation without FHR changes between both induction methods (RR 1.00, 95% CI 0.23 to 4.29; 192 women; 3 studies; Analysis 12.6).

Uterine rupture

It is uncertain whether there is a difference in uterine rupture between both induction methods (Analysis 12.7). Of the eight studies included for this comparison, one study (100 women) pre-specified this outcome. No events of uterine rupture occurred in this study.

Epidural analgesia

Not reported.

Instrumental vaginal delivery

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 1.19, 95% CI 0.55 to 2.57; 220 women; 3 studies; Analysis 12.8).

Meconium-stained liquor

It is uncertain whether there is a difference in meconium-stained liquor between both induction methods (RR 0.53, 95% CI 0.23 to 1.21; 272 women; 2 studies; Analysis 12.9).

Apgar score less than seven at five minutes

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 0.71, 95% CI 0.14 to 3.53; 300 women; 2 studies; Analysis 12.10).

Neonatal intensive care unit admission

It is uncertain whether there is difference in NICU admissions between both induction methods (RR 0.80, 95% CI 0.32 to 1.98; 372 women; 3 studies; Analysis 12.11).

Neonatal encephalopathy

Not reported.

Perinatal death

It is uncertain whether there is a difference in perinatal death between both induction methods (Analysis 12.12). Of the eight studies included for this comparison, one study (100 women) pre-specified this outcome. No cases of perinatal death occurred in this study.

Disability in childhood



Maternal side effects (all)

Not reported.

Maternal nausea

Not reported.

Maternal vomiting

Not reported.

Maternal diarrhoea

Not reported.

Other maternal side effects

Not reported.

Postpartum haemorrhage

It is uncertain whether there is difference in postpartum haemorrhage between both induction methods (RR 1.26, 95% CI 0.51 to 3.11; 396 women; 4 studies; Analysis 12.13).

Serious maternal complications

Not reported.

Maternal death

Not reported.

Woman not satisfied

Not reported.

Caregiver not satisfied

Not reported.

Other outcomes (not pre-specified)

Maternal fever during labour

It is uncertain whether there is difference in maternal fever during labour between both induction methods (RR 0.20, 95% CI 0.01 to 4.00; 60 women; 1 study; Analysis 12.14).

Antibiotics during labour

Not reported.

Chorioamnionitis

Not reported.

Endometritis

Not reported.

Fetal distress

A balloon catheter probably reduces the risk of fetal distress for which a caesarean section is indicated when compared to oxytocin (RR 0.43, 95% CI 0.19 to 0.98; 332 women; 3 studies; Analysis 12.15).

Umbilical artery pH < 7.10

Not reported.

Balloon (single or double) versus amniotomy (one trial involving 20 women)

The only outcome of interest reported for this comparison was caesarean section. Other outcomes were not reported.

Caesarean section

It is uncertain whether there is difference in caesarean sections between induction of labour with a balloon and amniotomy (RR 0.25, 95% CI 0.03 to 1.86; 20 women; 1 study; Analysis 15.1).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Singe balloon (Foley) versus double balloon (ATAD/Cook) (five trials involving 826 women)

Primary outcomes

Vaginal delivery not achieved within 24 hours

There may be little or no difference in vaginal deliveries not achieved within 24 hours between induction of labour with a single balloon and a double balloon (average RR 0.97, 95% CI 0.75 to 1.25; 608 women; 3 studies; Analysis 16.1), although there was substantial heterogeneity for this outcome (Chi² = 5.64, df = 2 (P = 0.06); I^2 = 65%). No sensitivity analysis was performed as no high-risk studies were included for this outcome.

It is uncertain whether there is a difference in vaginal deliveries not achieved within 24 hours between both induction methods on subgroups for both primiparous women (RR 1.14, 95% CI 0.95 to 1.38; 50 women; 1 study; Analysis 17.1) and multiparous women (RR 1.24, 95% CI 0.80 to 1.93; 48 women; 1 study; Analysis 18.1) as the results for these outcomes were imprecise.

Uterine hyperstimulation with FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes (Analysis 16.2), as events seem to occur infrequently after the use of both induction methods. Of the five studies included for this comparison, one study (217 women) reported on this outcome. No events of uterine hyperstimulation with FHR occurred in this study.

Caesarean section

It is uncertain whether there is a difference in caesarean sections between both induction methods (average RR 0.97, 95% CI 0.71 to 1.33; 862 women; 5 studies; Analysis 16.3). Also, there was moderate heterogeneity for this outcome (Chi² = 6.99, df = 4 (P = 0.14); $I^2 = 43\%$).

A sensitivity analysis, after eliminating the one trial assessed as having a potentially higher risk of concealment or attrition bias (Ahmed 2016), did not change the effect observed, nor did it lower heterogeneity (average RR 0.92, 95% CI 0.65 to 1.32; 788 women; 5 studies; $I^2 = 50\%$).

The same result was seen on parity subgroup comparisons for primiparous women (average RR 1.30, 95% CI 0.76 to 2.22; 374 women; 4 studies; Analysis 17.2) and multiparous women (RR 0.74, 95% CI 0.30 to 1.84; 186 women; 2 studies; Analysis 18.2). Furthermore, for the primiparous group, there was also substantial heterogeneity ($Tau^2 = 0.18$; $Chi^2 = 7.96$, df = 3 (P = 0.05); $I^2 = 62\%$).



Serious neonatal morbidity or perinatal death

Not reported.

Serious maternal morbidity or death

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods (Analysis 16.4). Of the five studies included for this comparison, one study (217 women) reported on this composite outcome. No events of serious maternal morbidity or death occurred in this study.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Secondary outcomes

Cervix unfavourable/unchanged after 24 hours

Not reported.

Oxytocin augmentation

There probably is little or no difference in oxytocin augmentation between both induction methods (RR 0.94, 95% CI 0.82 to 1.08; 278 women; 2 studies; Analysis 16.5).

Uterine hyperstimulation without FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation without FHR changes (Analysis 16.6), although events seem to occur infrequently after the use of both induction methods. Of the five studies included for this comparison, one study (217 women) reported on this outcome. No events of uterine hyperstimulation without FHR occurred in this study.

Uterine rupture

It is uncertain whether there is a difference in uterine rupture between both induction methods (Analysis 16.7). Of the five studies included for this comparison, one study (217 women) reported on this outcome. No events of uterine rupture occurred in this study.

Epidural analgesia

There probably is little or no difference in epidural analgesia between both induction methods (RR 0.93, 95% CI 0.83 to 1.03; 608 women; 3 studies; Analysis 16.8).

Instrumental vaginal delivery

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.86, 95% CI 0.61 to 1.20; 690 women; 3 studies; Analysis 16.9).

Meconium-stained liquor

A single balloon may reduce the risk of meconium-stained liquor when compared to a double balloon (RR 0.40, 95% CI 0.15 to 1.04; 98 women; 1 study; Analysis 16.10). However, the result is still too imprecise to make a valid judgement on this outcome.

Apgar score less than seven at five minutes

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 0.84, 95% CI 0.25 to 2.79; 608 women; 3 studies; Analysis 16.11).

Neonatal intensive care unit admission

It is uncertain whether there is a difference in NICU admissions between both induction methods (RR 1.67, 95% CI 0.71 to 3.93; 391 women; 2 studies; Analysis 16.12).

Neonatal encephalopathy

Not reported.

Perinatal death

Not reported.

Disability in childhood

Not reported.

Maternal side effects (all)

Not reported.

Maternal nausea

Not reported.

Maternal vomiting

Not reported.

Maternal diarrhoea

Not reported.

Other maternal side effects: pain after insertion

It is uncertain whether there is a difference in pain after insertion of the catheter between both induction methods (RR 0.67, 95% CI 0.20 to 2.17; 74 women; 1 study; Analysis 16.13).

Postpartum haemorrhage

It is uncertain whether there is a difference in postpartum haemorrhage between both induction methods (RR 0.83, 95% CI 0.27 to 2.52; 291 women; 2 studies; Analysis 16.14).

Serious maternal complications

Not reported.

Maternal death

Not reported.

Woman not satisfied

Not reported.

Caregiver not satisfied

Not reported.

Other outcomes (not pre-specified)

Maternal fever during labour

It is uncertain whether there is a difference in maternal fever during labour between both induction methods (average RR 0.61, 95% CI 0.16 to 2.34; 584 women; 3 studies; Analysis 16.15). Also, there was substantial heterogeneity for this outcome (Chi² = 2.85, df = 1 (P = 0.09); I^2 = 65%).

A sensitivity analysis, after eliminating the one trial assessed as having a potentially higher risk of allocation or attrition bias



(Ahmed 2016), did not alter the result, nor did it lower heterogeneity (average RR 0.61, 95% CI 0.16 to 2.34; 510 women; 2 studies; $I^2 = 65\%$).

Antibiotics during labour

It is uncertain whether there is a difference in antibiotics during labour between both induction methods (RR 0.97, 95% CI 0.61 to 1.56; 217 women; 1 study; Analysis 16.16).

Chorioamnionitis

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (RR 1.56, 95% CI 0.47 to 5.20; 98 women;1 study; Analysis 16.17).

Endometritis

It is uncertain whether there is a difference in endometritis between both induction methods (RR 1.95, 95% CI 0.18 to 21.14; 217 women; 1 study; Analysis 16.18).

Fetal distress

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated (RR 0.98, 95% CI 0.70 to 1.36; 682 women; 4 studies; Analysis 16.19).

Umbilical artery pH < 7.10

It is uncertain whether there is a difference in umbilical artery pH less than 7.10 directly postpartum between both induction methods (RR 0.42, 95% CI 0.11 to 1.57; 217 women; 1 study; Analysis 16.20).

Laminaria tent versus vaginal prostaglandin E2 (five trials involving 263 women)

Primary outcomes

Vaginal delivery not achieved within 24 hours

Not reported.

Uterine hyperstimulation with FHR changes

A laminaria tent probably reduces the risk of uterine hyperstimulation with FHR changes when compared to vaginal prostaglandin E2 (RR 0.11, 95% CI 0.02 to 0.60; 188 women; 3 studies; Analysis 19.1), the absolute effect being 118 fewer per 1000 deliveries.

For primiparous women, it is uncertain whether there is a difference in effect as the result of this outcome was imprecise (RR 0.33, 95% CI 0.01 to 7.95; 80 women; 1 study; Analysis 20.1). For multiparous women, this outcome was not reported.

Caesarean section

It is uncertain whether there is a difference in caesarean sections between both induction methods (RR 0.91, 95% CI 0.56 to 1.48; 263 women; 5 studies; Analysis 19.2).

The same result was seen on parity subgroup comparisons for primiparous women (average RR 1.07, 95% CI 0.24 to 4.89; 90 women; 2 studies; Analysis 20.2) and multiparous women (RR 0.50, 95% CI 0.06 to 3.91; 10 women; 1 study; Analysis 21.1). Furthermore, for the primiparous group, there was also substantial heterogeneity (Chi² = 2.25, df = 1 (P = 0.13); $I^2 = 56\%$).

Serious neonatal morbidity or perinatal death

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (Analysis 19.3). Of the five studies included for this comparison, one study (80 women) reported on this composite outcome. No events of neonatal morbidity or perinatal death occurred in this study.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Serious maternal morbidity or death

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods (Analysis 19.4). Of the five studies included for this comparison, one study (28 women) reported on this composite outcome. No events of serious maternal morbidity or death occurred in this study.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Secondary outcomes

Cervix unfavourable/unchanged after 24 hours

Not reported.

Oxytocin augmentation

Not reported.

Uterine hyperstimulation without FHR changes

A laminaria tent may reduce the risk of uterine hyperstimulation without FHR changes when compared to vaginal PGE2 (RR 0.22, 95% CI 0.09 to 0.49; 180 women; 3 studies; Analysis 19.5).

Uterine rupture

Not reported.

Epidural analgesia

It is uncertain whether there is a difference in epidural analgesia between both induction methods (RR 0.91, 95% CI 0.74 to 1.13; 80 women; 1 study; Analysis 19.6).

Instrumental vaginal delivery

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.71, 95% CI 0.43 to 1.17; 80 women; 1 study; Analysis 19.7).

Meconium-stained liquor

It is uncertain whether there is a difference in meconium-stained liquor between both induction methods (RR 0.14, 95% CI 0.01 to 2.68; 80 women; 1 study; Analysis 19.8).

Apgar score less than seven at five minutes

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (Analysis 19.9). Of the five studies included for this comparison, two studies (160 women) reported on this outcome. No events of Apgar scores less than seven at five minutes occurred in these studies.

Neonatal intensive care unit admission



Neonatal encephalopathy

Not reported.

Perinatal death

It is uncertain whether there is a difference in perinatal death between both induction methods (Analysis 19.10). Of the five studies included for this comparison, one study (80 women) reported on this outcome. No events of perinatal deaths occurred in this study.

Disability in childhood

Not reported.

Maternal side effects (all)

It is uncertain whether there is a difference in maternal side effects between both induction methods (RR 0.29, 95% CI 0.01 to 6.60; 28 women; 1 study; Analysis 19.11).

Maternal nausea

It is uncertain whether there is a difference in maternal nausea between both induction methods (RR 0.29, 95% CI 0.01 to 6.60; 28 women; 1 study; Analysis 19.12).

Maternal vomiting

Not reported.

Maternal diarrhoea

Not reported.

Other maternal side effects

Not reported.

Postpartum haemorrhage

Not reported.

Serious maternal complications

Not reported.

Maternal death

Not reported.

Woman not satisfied

Not reported.

Caregiver not satisfied

Not reported.

Other outcomes (not pre-specified)

Maternal fever during labour

Not reported.

Antibiotics during labour

Not reported.

Chorioamnionitis

Not reported.

Endometritis

Not reported.

Fetal distress

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (RR 0.62, 95% CI 0.34 to 1.15; 188 women; 3 studies; Analysis 19.13).

Umbilical artery pH < 7.10

Not reported.

Laminaria tent versus cervical prostaglandin E2 (five trials involving 920 women)

Primary outcomes

Vaginal delivery not achieved within 24 hours

Not reported.

Uterine hyperstimulation with FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between induction of labour with a laminaria tent and cervical PGE2 (RR 0.17, 95% CI 0.02 to 1.42; 350 women; 2 studies; Analysis 22.1).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Caesarean section

It is uncertain whether there is a difference in caesarean sections between both induction methods (RR 1.16, 95% CI 0.93 to 1.45; 920 women; 5 studies; Analysis 22.2).

The same results were seen on parity subgroup comparisons for primiparous women (RR 1.15, 95% CI 0.62 to 2.13; 116 women; 1 study; Analysis 23.1) and multiparous women (RR 1.28, 95% CI 0.45 to 3.65; 69 women; 1 study; Analysis 24.1).

Serious neonatal morbidity or perinatal death

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (RR 3.16, 95% Cl 0.13 to 76.70; 185 women; 1 study; Analysis 22.3). One event, a case of perinatal death, was reported in the laminaria group. No events occurred in the cervical PGE2 group.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Serious maternal morbidity or death

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods (RR 0.35, 95% CI 0.01 to 8.52; 185 women; 1 study; Analysis 22.4). No events occurred in the laminaria group. One event, a uterine rupture, was reported in the cervical PGE2 group.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Secondary outcomes

Cervix unfavourable/unchanged after 24 hours

It is uncertain whether there is a difference in an unfavourable cervix after 24 hours between both induction methods (average RR 0.46, 95% CI 0.11 to 1.96; 218 women; 2 studies; Analysis 22.5). Also,



there was substantial heterogeneity for this outcome ($Tau^2 = 0.62$; $Chi^2 = 1.98$, df = 1 (P = 0.16); $I^2 = 50\%$).

A sensitivity analysis, after eliminating the one trial assessed as having a potentially higher risk of allocation or attrition bias (Roztocil 1998), did not alter the result (RR 0.16, 95% CI 0.02 to 1.24; 53 women; 1 study; $I^2 = 0\%$).

Oxytocin augmentation

A laminaria tent probably increases the risk of oxytocin augmentation when compared to cervical PGE2 (RR 1.41, 95% CI 1.21 to 1.64; 185 women; 1 study; Analysis 22.6).

Uterine hyperstimulation without FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation without FHR changes between both induction methods (RR 0.17, 95% CI 0.02 to 1.36; 601 women; 2 studies; Analysis 22.7).

Uterine rupture

It is uncertain whether there is a difference in uterine rupture between both induction methods (RR 0.35, 95% CI 0.01 to 8.52; 185 women; 1 study; Analysis 22.8). One study reported on this outcome in which one uterine rupture occurred in the PGE2 group. No uterine ruptures were seen in the laminaria group.

Epidural analgesia

Not reported.

Instrumental vaginal delivery

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 1.05, 95% CI 0.65 to 1.69; 424 women; 3 studies; Analysis 22.9).

Meconium-stained liquor

Not reported.

Apgar score less than seven at five minutes

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 5.28, 95% CI 0.63 to 44.30; 185 women; 1 study; Analysis 22.10).

Neonatal intensive care unit admission

It is uncertain whether there is a difference in NICU admissions between both induction methods (RR 1.58, 95% CI 0.58 to 4.33; 259 women; 2 studies; Analysis 22.11).

Neonatal encephalopathy

Not reported.

Perinatal death

It is uncertain whether there is a difference in perinatal death between both induction methods (RR 3.16, 95% CI 0.13 to 76.70; 185 women; 1 study; Analysis 22.12). One study reported on this outcome, in which one perinatal death occurred in the laminaria group. No perinatal death were seen in the cervical PGE2 group.

Disability in childhood

Not reported.

Maternal side effects (all)

It is uncertain whether there is a difference in maternal side effects between both induction methods (RR 0.20, 95% CI 0.01 to 4.15; 165 women; 1 study; Analysis 22.13). The one study included for this outcome reported on gastro-intestinal symptoms without specifying what the symptoms were.

Maternal nausea

Not reported.

Maternal vomiting

Not reported.

Maternal diarrhoea

Not reported.

Other maternal side effects

Not reported.

Postpartum haemorrhage

It is uncertain whether there is a difference in postpartum haemorrhage between both induction methods (RR 1.14, 95% CI 0.46 to 2.81; 239 women; 2 studies; Analysis 22.14).

Serious maternal complications

Not reported.

Maternal death

Not reported.

Woman not satisfied

Not reported.

Caregiver not satisfied

Not reported.

Other outcomes (not pre-specified)

Maternal fever during labour

Not reported.

Antibiotics during labour

Not reported.

Chorioamnionitis

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (RR 3.17, 95% CI 0.35 to 29.06; 74 women; 1 study; Analysis 22.15).

Endometritis

It is uncertain whether there is a difference in endometritis between both induction methods (average RR 0.30, 95% CI 0.08 to 1.09; 490 women; 2 studies; Analysis 22.16). Also, there was substantial heterogeneity for this outcome ($Tau^2 = 0.54$; $Chi^2 = 2.54$, df = 1 (P = 0.11); $I^2 = 61\%$).

A sensitivity analysis, after eliminating the one trial assessed as having a potentially higher risk of allocation or attrition bias (Kram-



mer 1995a), did not alter the result (RR 0.63, 95% CI 0.16 to 2.46; 74 women; 1 study; $I^2 = 0\%$).

Fetal distress

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (RR 0.44, 95% CI 0.07 to 2.90; 128 women; 2 studies; Analysis 22.17).

Umbilical artery pH < 7.10

Not reported.

Laminaria tent versus oxytocin (two trials involving 73 women)

The only outcomes of interest reported for this comparison were caesarean section and fetal distress. Other outcomes were not reported.

Caesarean section

It is uncertain whether there is a difference in caesarean sections between induction of labour with a laminaria tent and oxytocin (RR 0.83, 95% CI 0.36 to 1.89; 73 women; 2 studies; Analysis 25.1).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Fetal distress

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (RR 2.69, 95% CI 0.11 to 63.18; 53 women; 1 study; Analysis 25.2).

Laminaria tent versus amniotomy (one trial involving 20 women)

The only outcome of interest reported for this comparison was caesarean section. Other outcomes were not reported.

Caesarean section

It is uncertain whether there is a difference in caesarean sections between induction of labour with a laminaria tent compared to amniotomy (RR 0.75, 95% CI 0.22 to 2.52; 20 women; 1 study; Analysis 26.1).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Laminaria tent versus other hygroscopic dilators (one trial involving 41 women)

The only outcome of interest reported for this comparison was caesarean section. Other outcomes were not reported.

Caesarean section

It is uncertain whether there is a difference in caesarean sections between induction of labour with a laminaria tent and other hygroscopic dilators (RR 1.70, 95% CI 0.44 to 6.66; 41 women; 1 study; Analysis 27.1).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Extra amniotic saline infusion (EASI) versus vaginal prostaglandin E2 (two trials involving 221 women)

Primary outcomes

Vaginal delivery not achieved within 24 hours

EASI probably increases the risk of a vaginal delivery not achieved within 24 hours when compared to vaginal PGE2 (RR 1.74, 95% CI 1.21 to 2.49; 109 women; 1 study; Analysis 28.1).

Uterine hyperstimulation with FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between both induction methods (RR 0.23, 95% CI 0.03 to 2.07; 221 women; 2 studies; Analysis 28.2).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Caesarean section

It is uncertain whether there is a difference in caesarean sections between both induction methods (average RR 1.35, 95% CI 0.94 to 1.96; 221 women; 2 studies; Analysis 28.3). Also, there was substantial heterogeneity for this outcome (Chi² = 5.24, df = 1 (P = 0.02); I² = 81%). No sensitivity analysis could be done as both included studies were assessed as having a potentially higher risk of allocation or attrition bias.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Serious neonatal morbidity or perinatal death

Not reported.

Serious maternal morbidity or death

Not reported.

Secondary outcomes

Cervix unfavourable/unchanged after 24 hours

Not reported.

Oxytocin augmentation

EASI may increase the risk of oxytocin augmentation when compared to vaginal PGE2 (RR 12.71, 95% CI 3.20 to 50.57; 109 women; 1 study; Analysis 28.4).

Uterine hyperstimulation without FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation without FHR changes between both induction methods (RR 0.23, 95% CI 0.03 to 2.07; 221 women; 2 studies; Analysis 28.5).

Uterine rupture

Not reported.

Epidural analgesia

There may be little or no difference in epidural analgesia between both induction methods (RR 1.00, 95% CI 0.97 to 1.04; 112 women; 1 study; Analysis 28.6).



Instrumental vaginal delivery

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.58, 95% CI 0.30 to 1.14; 109 women; 1 study; Analysis 28.7).

Meconium-stained liquor

It is uncertain whether there is a difference in meconium-stained liquor between both induction methods (RR 3.00, 95% CI 0.12 to 72.10; 112 women; 1 study; Analysis 28.8).

Apgar score less than seven at five minutes

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 4.25, 95% CI 0.21 to 86.51; 109 women; 1 study; Analysis 28.9).

Neonatal intensive care unit admission

It is uncertain whether there is a difference in NICU admissions between both induction methods (RR 1.50, 95% CI 0.45 to 5.03; 112 women; 1 study; Analysis 28.10).

Neonatal encephalopathy

Not reported.

Perinatal death

Not reported.

Disability in childhood

Not reported.

Maternal side effects (all)

Not reported.

Maternal nausea

Not reported.

Maternal vomiting

Not reported.

Maternal diarrhoea

Not reported.

Other maternal side effects

Not reported.

Postpartum haemorrhage

Not reported.

Serious maternal complications

Not reported.

Maternal death

Not reported.

Woman not satisfied

It is uncertain whether there is a difference in women not being satisfied between both induction methods (RR 0.56, 95% CI 0.10 to 3.25; 109 women; 1 study; Analysis 28.11). For this outcome, women in the included study were asked to comment on the induction

method, for which they could choose between recommendable, satisfactory and unsatisfactory.

Caregiver not satisfied

Not reported.

Other outcomes (not pre-specified)

Maternal fever during labour

Not reported.

Antibiotics during labour

Not reported.

Chorioamnionitis

Not reported.

Endometritis

Not reported.

Fetal distress

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (RR 1.20, 95% CI 0.39 to 3.71; 112 women; 1 study; Analysis 28.12).

Umbilical artery pH < 7.10

Not reported.

Extra amniotic saline infusion versus cervical prostaglandin E2 (two trials involving 155 women)

Primary outcomes

Vaginal delivery not achieved within 24 hours

Not reported.

Uterine hyperstimulation with FHR changes

Not reported.

Caesarean section

It is uncertain whether there is a difference in caesarean sections between both induction methods (average RR 0.73, 95% CI 0.10 to 5.12; 155 women; 2 studies; Analysis 29.1). Also, there was substantial heterogeneity for this outcome (Tau² = 1.60; Chi² = 5.11, df = 1 (P = 0.02); I² = 80%). As the results for both included studies show no overlap of CI, this makes the pooled result for this outcome less meaningful. No sensitivity analysis was performed as no potential high-risk studies were included for this outcome.

The same result was seen on a subgroup comparison for primiparous women (RR 0.25, 95% CI 0.06 to 1.09; 70 women; 1 study; Analysis 30.1). For multiparous women, no outcomes were reported.

Serious neonatal morbidity or perinatal death

Not reported.

Serious maternal morbidity or death



Secondary outcomes

Cervix unfavourable/unchanged after 24 hours

EASI may reduce the risk of an unfavourable cervix after 24 hours when compared to cervical PGE2 (RR 0.06, 95% CI 0.00 to 0.97; 85 women; 1 study; Analysis 29.2).

Oxytocin augmentation

It is uncertain whether there is a difference in oxytocin augmentation between both induction methods (RR 1.10, 95% CI 0.54 to 2.25; 70 women; 1 study; Analysis 29.3).

Uterine hyperstimulation without FHR changes

Not reported.

Uterine rupture

Not reported.

Epidural analgesia

Not reported.

Instrumental vaginal delivery

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.33, 95% CI 0.04 to 3.01; 85 women; 1 study; Analysis 29.4).

Meconium-stained liquor

Not reported.

Apgar score less than seven at five minutes

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (Analysis 29.5). One study (85 women) pre-specified this outcome in which no Apgar scores less than seven after five minutes were reported.

Neonatal intensive care unit admission

Not reported.

Neonatal encephalopathy

Not reported.

Perinatal death

Not reported.

Disability in childhood

Not reported.

Maternal side effects (all)

Not reported.

Maternal nausea

Not reported.

Maternal vomiting

Not reported.

Maternal diarrhoea

Not reported.

Other maternal side effects

Not reported.

Postpartum haemorrhage

Not reported.

Serious maternal complications

Not reported.

Maternal death

Not reported.

Woman not satisfied

Not reported.

Caregiver not satisfied

Not reported.

Other outcomes (not pre-specified)

Maternal fever during labour

Not reported.

Antibiotics during labour

Not reported.

Chorioamnionitis

Not reported.

Endometritis

It is uncertain whether there is a difference in endometritis between both induction methods (Analysis 29.6). One study (85 women) prespecified this outcome in which no cases of endometritis were reported.

Fetal distress

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (RR 0.29, 95% CI 0.06 to 1.28; 70 women; 1 study; Analysis 29.7).

Umbilical artery pH < 7.10

Not reported.

Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone (eight trials involving 639 women)

Primary outcomes

Vaginal delivery not achieved within 24 hours

It is uncertain whether there is a difference in vaginal deliveries not achieved within 24 hours between induction of labour with a mechanical method combined with PGE2 and PGE2 alone (RR 0.84, 95% CI 0.53 to 1.33; 39 women; 1 study; Analysis 31.1).

For the subgroups of primiparous and multiparous women, no outcomes were reported.



Uterine hyperstimulation with FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between both induction methods (RR 0.26, 95% CI 0.01 to 5.12; 122 women; 2 studies; Analysis 31.2).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Caesarean section

It is uncertain whether there is a difference in caesarean sections between both induction methods (average RR 0.96, 95% CI 0.66 to 1.40; 517 women; 7 studies; Analysis 31.3). Also, there was moderate heterogeneity for this outcome ($Tau^2 = 0.11$; $Chi^2 = 11.16$, df = 6 (P = 0.08); $I^2 = 46\%$).

A sensitivity analysis, after eliminating three trials assessed as having a potentially higher risk of allocation or attrition bias (Browne 2011; Lyndrup 1989; Turnquest 1997), did not alter the result nor did it lower heterogeneity (average RR 1.02, 95% CI 0.56 to 1.84; 364 women; 4 studies; I² = 70%).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Serious neonatal morbidity or perinatal death

Not reported.

Serious maternal morbidity or death

Not reported.

Secondary outcomes

Cervix unfavourable/unchanged after 24 hours

A mechanical method combined with PGE2 may reduce the risk of an unfavourable cervix after 24 hours when compared to PGE2 alone (RR 0.52, 95% CI 0.31 to 0.85; 122 women; 1 study; Analysis 31.4).

Oxytocin augmentation

It is uncertain whether there is a difference in oxytocin augmentation between both induction methods (RR 0.95, 95% CI 0.64 to 1.41; 44 women; 1 study; Analysis 31.5).

Uterine hyperstimulation without FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation without FHR changes between both induction methods (Analysis 31.6). Of the eight studies included for this comparison, three studies (239 women) pre-specified this outcome. No events of uterine hyperstimulation without FHR changes occurred in these studies.

Uterine rupture

Not reported.

Epidural analgesia

There may be little or no difference in epidural analysis during labour between both induction methods (RR 0.98, 95% CI 0.77 to 1.24; 39 women; 1 study; Analysis 31.7).

Instrumental vaginal delivery

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.56, 95% CI 0.22 to 1.45; 78 women; 2 studies; Analysis 31.8).

Meconium-stained liquor

It is uncertain whether there is a difference in meconium-stained liquor between both induction methods (RR 0.97, 95% CI 0.33 to 2.83; 120 women; 1 study; Analysis 31.9).

Apgar score less than seven at five minutes

Not reported.

Neonatal intensive care unit admission

It is uncertain whether there is a difference in NICU admissions between both methods (RR 0.26, 95% CI 0.01 to 5.12; 44 women; 1 study; Analysis 31.10).

Neonatal encephalopathy

Not reported.

Perinatal death

Not reported.

Disability in childhood

Not reported.

Maternal side effects

Not reported.

Maternal nausea

Not reported.

Maternal vomiting

Not reported.

Maternal diarrhoea

Not reported.

Other maternal side effects

Not reported.

Postpartum haemorrhage

It is uncertain whether there is a difference in postpartum haemorrhage between both induction methods (Analysis 31.11). Of the eight studies included for this comparison, one study (39 women) pre-specified this outcome. No events of postpartum haemorrhage occurred in this study.

Serious maternal complications

Not reported.

Maternal death

Not reported.

Woman not satisfied



Caregiver not satisfied

Not reported.

Other outcomes (not pre-specified)

Maternal fever during labour

Not reported.

Antibiotics during labour

Not reported.

Chorioamnionitis

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (RR 1.56, 95% CI 0.45 to 5.45; 122 women; 2 studies; Analysis 31.12).

Endometritis

It is uncertain whether there is a difference in endometritis between both induction methods (RR 1.07, 95% CI 0.41 to 2.78; 237 women; 3 studies; Analysis 31.13).

Fetal distress

It is uncertain whether there is a difference fetal distress for which a caesarean section is indicated between both induction methods (RR 2.28, 95% CI 0.54 to 9.69; 140 women; 2 studies; Analysis 31.14).

Umbilical artery pH < 7.10

Not reported.

Any mechanical method and prostaglandin E2 versus low-dose misoprostol alone (one trial involving 127 women)

Primary outcomes

Vaginal delivery not achieved within 24 hours

A mechanical method combined with PGE2 probably reduces the risk of a vaginal delivery not achieved within 24 hours when compared to misoprostol (RR 0.32, 95% CI 0.12 to 0.82; 127 women; 1 study; Analysis 32.1). the absolute effect being 165 less per 1000 deliveries.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Uterine hyperstimulation with FHR changes

Not reported.

Caesarean section

It is uncertain whether there is a difference in caesarean sections between both induction methods (RR 1.09, 95% CI 0.58 to 2.04; 127 women; 1 study; Analysis 32.2).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Serious neonatal morbidity or perinatal death

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (RR 0.19, 95% CI 0.01 to 3.90; 127 women; 1 study; Analysis 32.3). Two events occurred in the misoprostol group, both being cases of perinatal death.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Serious maternal morbidity or death

Not reported.

Secondary outcomes

Cervix unfavourable/unchanged after 24 hours

A mechanical method combined with PGE2 probably reduces the risk of an unfavourable cervix after 24 hours when compared to misoprostol (RR 0.41, 95% CI 0.25 to 0.67; 127 women; 1 study; Analysis 32.4).

Oxytocin augmentation

A mechanical method combined with PGE2 probably slightly increases the risk of oxytocin augmentation when compared to misoprostol (RR 1.21, 95% CI 1.01 to 1.46; 127; 1 study; Analysis 32.5).

Uterine hyperstimulation without FHR changes

A mechanical method combined with PGE2 probably increases the risk of uterine hyperstimulation without FHR changes when compared to misoprostol (RR 4.05, 95% CI 1.44 to 11.38; 127; 1 study; Analysis 32.6).

Uterine rupture

Not reported.

Epidural analgesia

Not reported.

Instrumental vaginal delivery

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 1.26, 95% CI 0.77 to 2.04; 127 women; 1 study; Analysis 32.7).

Meconium-stained liquor

It is uncertain whether there is a difference in meconium-stained liquor between both induction methods (RR 0.56, 95% CI 0.23 to 1.32; 127 women; 1 study; Analysis 32.8).

Apgar score less than seven at five minutes

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 1.91, 95% CI 0.18 to 20.51; 127 women; 1 study; Analysis 32.9).

Neonatal intensive care unit admission

It is uncertain whether there is a difference in NICU admissions between both methods (RR 0.64, 95% CI 0.31 to 1.31; 127 women; 1 study; Analysis 32.10).

Neonatal encephalopathy

Not reported.

Perinatal death

It is uncertain whether there is a difference in perinatal death between both methods (RR 0.19, 95% CI 0.01 to 3.90; 127 women; 1 study; Analysis 32.11). Two cases of neonatal death were reported by Perry 1998, both were born to women randomised to misoprostol. The authors describe that in both cases the neonates died as a



result of complications of congenital malformations and were unrelated to the induction method.

Disability in childhood

Not reported.

Maternal side effects

Not reported.

Maternal nausea

Not reported.

Maternal vomiting

Not reported.

Maternal diarrhoea

Not reported.

Other maternal side effects

Not reported.

Postpartum haemorrhage

Not reported.

Serious maternal complications

Not reported.

Maternal death

Not reported.

Woman not satisfied

Not reported.

Caregiver not satisfied

Not reported.

Other outcomes (not pre-specified)

Maternal fever during labour

Not reported.

Antibiotics during labour

Not reported.

Chorioamnionitis

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (RR 1.91, 95% CI 0.18 to 20.51; 127 women; 1 study; Analysis 32.12).

Endometritis

It is uncertain whether there is a difference in endometritis between both induction methods (RR 1.91, 95% CI 0.36 to 10.05; 127 women; 1 study; Analysis 32.13).

Fetal distress

Not reported.

Umbilical artery pH < 7.10

Not reported.

Any mechanical method and prostaglandin E2 versus oxytocin alone (one trial involving 44 women)

The only outcomes of interest reported for this comparison were caesarean section, instrumental vaginal delivery and endometritis. Other outcomes were not reported.

Caesarean section

It is uncertain whether there is a difference in caesarean sections between induction of labour with a mechanical method combined with PGE2 versus oxytocin (RR 0.30, 95% CI 0.04 to 2.47; 44 women; 1 study; Analysis 33.1).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Instrumental vaginal delivery

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.60, 95% CI 0.12 to 2.94; 44 women; 1 study; Analysis 33.2).

Endometritis

It is uncertain whether there is a difference in endometritis between both induction methods (RR 3.57, 95% CI 0.15 to 83.14; 44 women; 1 study; Analysis 33.3).

Any mechanical method and low-dose misoprostol versus prostaglandin E2 alone (one trial involving 350 women)

Primary outcomes

Vaginal delivery not achieved within 24 hours

It is uncertain whether there is a difference in vaginal deliveries not achieved within 24 hours between induction of labour with a mechanical method combined with misoprostol and prostaglandin E2 (RR 1.14, 95% CI 0.89 to 1.46; 350 women; 1 study; Analysis 34.1).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Uterine hyperstimulation with FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between both induction methods (RR 0.75, 95% CI 0.27 to 2.13; 327 women; 1 study; Analysis 34.2).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Caesarean section

It is uncertain whether there is a difference in caesarean sections between both induction methods (RR 0.85, 95% CI 0.57 to 1.25; 350 women; 1 study; Analysis 34.3).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Serious neonatal morbidity or perinatal death

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (RR 2.04, 95% CI 0.19 to 22.24; 345 women; 1 study; Analysis 34.4).



For the subgroups of primiparous and multiparous women, no outcomes were reported.

Serious maternal morbidity or death

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods (Analysis 34.5). No events of maternal morbidity or death occurred in the one included study (350 women).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Secondary outcomes

Cervix unfavourable/unchanged after 24 hours

Not reported.

Oxytocin augmentation

A mechanical method combined with misoprostol probably reduces the risk of oxytocin augmentation when compared to PGE2 (RR 0.54, 95% CI 0.34 to 0.86; 350 women; 1 study; Analysis 34.6).

Uterine hyperstimulation without FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation without FHR changes between both induction methods (RR 0.54, 95% CI 0.22 to 1.32; 327 women; 1 study; Analysis 34.7).

Uterine rupture

It is uncertain whether there is a difference in uterine rupture between both induction methods (Analysis 34.8). No events of uterine rupture occurred in the one included study (350 women).

Epidural analgesia

Not reported.

Instrumental vaginal delivery

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 1.01, 95% CI 0.26 to 3.98; 350 women; 1 study; Analysis 34.9).

Meconium-stained liquor

It is uncertain whether there is a difference in meconium-stained liquor between both induction methods (RR 1.15, 95% CI 0.60 to 2.23; 339 women; 1 study; Analysis 34.10).

Apgar score less than seven at five minutes

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 0.68, 95% CI 0.25 to 1.88; 346 women; 1 study; Analysis 34.11).

Neonatal intensive care unit admission

It is uncertain whether there is a difference in NICU admissions between both methods (RR 0.68, 95% CI 0.12 to 4.03; 346 women; 1 study; Analysis 34.12).

Neonatal encephalopathy

Not reported.

Perinatal death

It is uncertain whether there is a difference in perinatal death between both induction methods (RR 1.02, 95% CI 0.06 to 16.14; 345 women; 1 study; Analysis 34.13). Two cases of perinatal death were reported by Matonhodze 2003, one in each group. No further information was given on timing or cause of the demise.

Disability in childhood

Not reported.

Maternal side effects

It is uncertain whether there is a difference in maternal side effects between both induction methods (RR 1.16, 95% CI 0.95 to 1.43; 314 women; 1 study; Analysis 34.14).

Maternal nausea

A mechanical method combined with misoprostol may increase the risk of maternal nausea when compared to PGE2 (RR 1.65, 95% CI 0.98 to 2.79; 300 women; 1 study; Analysis 34.15). However, the result is still too imprecise to make a valid judgement on this outcome

Maternal vomiting

Not reported.

Maternal diarrhoea

A mechanical method combined with misoprostol probably increases the risk of maternal diarrhoea when compared to PGE2 (RR 3.72, 95% CI 1.53 to 9.00; 313 women; 1 study; Analysis 34.16).

Other maternal side effects

Not reported.

Postpartum haemorrhage

It is uncertain whether there is a difference in postpartum haemorrhage between both induction methods (RR 0.98, 95% CI 0.67 to 1.41; 348 women; 1 study; Analysis 34.17).

Serious maternal complications

It is uncertain whether there is a difference in serious maternal complications between both induction methods (Analysis 34.18). One study (350 women) was included for this outcome in which no cases of septicaemia or intensive care unit admission were reported

Maternal death

Not reported.

Woman not satisfied

Not reported.

Caregiver not satisfied



Other outcomes (not pre-specified)

Maternal fever during labour

It is uncertain whether there is a difference in maternal fever during labour between both induction methods (RR 1.53, 95% CI 0.26 to 9.02; 347 women; 1 study; Analysis 34.19).

Antibiotics during labour

Not reported.

Chorioamnionitis

Not reported.

Endometritis

Not reported.

Fetal distress

Not reported.

Umbilical artery pH < 7.10

Not reported.

Any mechanical method and low dose misoprostol versus misoprostol alone (seven trials involving 1422 women)

Primary outcomes

Vaginal delivery not achieved within 24 hours

It is uncertain whether there is a difference in vaginal deliveries not achieved within 24 hours between any mechanical method combined with misoprostol and misoprostol alone (average RR 0.70, 95% Cl 0.25 to 1.95; 668 women; 2 studies; Analysis 35.1). Also, there was substantial heterogeneity for this outcome (Tau² = 0.51; Chi² = 14.00, df = 1 (P = 0.0002); $I^2 = 93\%$).

A sensitivity analysis, after eliminating one trial assessed as having a potentially higher risk of allocation or attrition bias (Husain 2017), did not alter the result (average RR 1.14, 95% CI 0.89 to 1.46; 350 women; 1 study).

The same results were seen on a subgroup comparison for primiparous women (RR 0.83, 95% CI 0.23 to 2.96; 53 women; 1 study; Analysis 36.1). For multiparous women, a mechanical method combined with misoprostol may reduce the risk of a vaginal delivery not achieved within 24 hours (RR 0.37, 95% CI 0.21 to 0.63; 265 women; 1 study; Analysis 37.1).

Uterine hyperstimulation with FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between both induction methods (average RR 0.54, 95% CI 0.20 to 1.45; 707 women; 4 studies; Analysis 35.2). Also, there was substantial heterogeneity for this outcome (Tau² = 0.57; Chi² = 7.40, df = 2 (P = 0.02); I² = 73%). No sensitivity analysis was performed as no potential high-risk studies were included for this outcome.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Caesarean section

It is uncertain whether there is a difference in caesarean sections between both induction methods (average RR 0.87, 95% CI 0.66 to

1.15; 1422 women; 7 studies; Analysis 35.3). Also, there was substantial heterogeneity for this outcome ($Tau^2 = 0.07$; $Chi^2 = 13.33$, df = 6 (P = 0.04); $I^2 = 55\%$).

A sensitivity analysis, after eliminating one trial assessed as having a potentially higher risk of allocation or attrition bias (Husain 2017), showed there probably is little or no difference in caesarean sections between both induction methods (RR 0.96, 95% CI 0.79 to 1.17; 1104 women; 6 studies; $1^2 = 5\%$).

The same results were seen on a subgroup comparison for primiparous women (RR 0.62, 95% CI 0.15 to 2.51; 53 women; 1 study; Analysis 36.2). For multiparous women, a mechanical method combined with misoprostol may reduce the risk a caesarean section (RR 0.35, 95% CI 0.18 to 0.68; 265 women; 1 study; Analysis 37.2).

Serious neonatal morbidity or perinatal death

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (RR 1.25, 95% CI 0.34 to 4.55; 487 women; 2 studies; Analysis 35.4).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Serious maternal morbidity or death

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods (Analysis 35.5). Of the seven studies included for this comparison, two studies (490 women) reported on this composite outcome. No events of serious maternal morbidity or death occurred in these studies.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Secondary outcomes

Cervix unfavourable/unchanged after 24 hours

A mechanical method combined with misoprostol probably reduces the risk of an unfavourable cervix after 24 hours when compared to misoprostol alone (RR 0.27, 95% CI 0.08 to 0.94; 140 women; 1 study; Analysis 35.6).

Oxytocin augmentation

It is uncertain whether there is a difference in oxytocin augmentation between both induction methods (average RR 0.94, 95% CI 0.70 to 1.25; 1051 women; 5 studies; Analysis 35.7). Also, there was substantial heterogeneity for this outcome ($Tau^2 = 0.07$; $Chi^2 = 16.91$, df = 4 (P = 0.002); $I^2 = 76\%$).

A sensitivity analysis, after eliminating one trial assessed as having a potentially higher risk of allocation or attrition bias (Husain 2017), did not alter the result nor did it lower heterogeneity (average RR 0.98, 95% CI 0.66 to 1.48; 733 women; 4 studies; $I^2 = 82\%$).

Uterine hyperstimulation without FHR changes

A mechanical method combined with misoprostol probably reduces the risk of uterine hyperstimulation without FHR changes when compared to misoprostol alone (RR 0.53, 95% CI 0.32 to 0.90; 982 women; 4 studies; Analysis 35.8).



Uterine rupture

It is uncertain whether there is a difference in uterine rupture between both induction methods (Analysis 35.9). Of the seven studies included for this comparison, two studies (490 women) reported on this outcome. No events of uterine rupture occurred in one of these studies.

Epidural analgesia

There may be little or no difference in epidural analgesia between both induction methods (average RR 1.00, 95% CI 0.91 to 1.10; 443 women; 3 studies; Analysis 35.10), although there was moderate heterogeneity for this outcome ($Tau^2 = 0.00$; $Chi^2 = 3.52$, df = 2 (P = 0.17); 43%).

No sensitivity analysis was performed as no potential high-risk studies were included for this outcome.

Instrumental vaginal delivery

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.93, 95% CI 0.58 to 1.51; 676 women; 3 studies; Analysis 35.11).

Meconium-stained liquor

A mechanical method combined with misoprostol may reduce the risk of meconium-stained liquor when compared to misoprostol alone (average RR 0.61, 95% CI 0.35 to 1.04; 1243 women; 6 studies; Analysis 35.12). However, the result is still too imprecise to make a valid judgement on this outcome. Also, there was substantial heterogeneity for this outcome ($Tau^2 = 0.24$; $Chi^2 = 11.55$, df = 5 (P = 0.04); $I^2 = 57\%$).

A sensitivity analysis, after eliminating one trial assessed as having a potentially higher risk of allocation or attrition bias (Husain 2017), did not alter the result nor did it lower heterogeneity (average RR 0.55, 95% CI 0.26 to 1.14; 925 women; 5 studies; $I^2 = 64\%$).

Apgar score less than seven at five minutes

It is uncertain whether there is a difference in Apgar score less than seven at five minutes between both induction methods (average RR 0.71, 95% CI 0.37 to 1.36; 802 women; 3 studies; Analysis 35.13). Also, there was substantial heterogeneity for this outcome ($Tau^2 = 0.11$; $Chi^2 = 2.89$, df = 2 (P = 0.24); $I^2 = 31\%$).

A sensitivity analysis, after eliminating one trial assessed as having a potentially higher risk of allocation or attrition bias (Husain 2017), did not alter the result, although heterogeneity was lost (RR 1.10, 95% CI 0.50 to 2.44; 484 women; 2 studies; $l^2 = 0\%$).

Neonatal intensive care unit admission

A mechanical method combined with misoprostol may reduce the risk of NICU admission when compared to misoprostol alone (RR 0.57, 95% CI 0.36 to 0.91; 1246 women; 6 studies; Analysis 35.14), the absolute effect being 30 fewer NICU admissions per 1000 deliveries.

Neonatal encephalopathy

Not reported.

Perinatal death

It is uncertain whether there is difference in perinatal death between both induction methods (RR 3.09, 95% CI 0.13 to 75.26; 347 women; 1 study; Analysis 35.15). One case of perinatal death was

reported by Matonhodze 2003, which occurred in the combined method group. No further information was given on timing or cause of the demise.

Disability in childhood

Not reported.

Maternal side effects (all)

It is uncertain whether there is a difference in maternal side effects between both induction methods (RR 1.06, 95% CI 0.87 to 1.30; 300 women; 1 study; Analysis 35.16).

Maternal nausea

It is uncertain whether there is a difference in maternal nausea between both induction methods (RR 1.37, 95% CI 0.84 to 2.23; 300 women; study; Analysis 35.17).

Maternal vomiting

Not reported.

Maternal diarrhoea

A mechanical method combined with misoprostol probably increases the risk of maternal diarrhoea when compared to misoprostol alone (RR 3.38, 95% CI 1.40 to 8.17; 298 women; 1 study; Analysis 35.18).

Other maternal side effects

Not reported.

Postpartum haemorrhage

It is uncertain whether there is difference in postpartum haemorrhage between both induction methods (RR 0.93, 95% CI 0.65 to 1.33; 466 women; 2 studies; Analysis 35.19).

Serious maternal complications

It is uncertain whether there is a difference in serious maternal complications between both induction methods (Analysis 35.20). One study (350 women) was included for this outcome in which no cases of septicaemia or intensive care unit admissions were seen.

Maternal death

Not reported.

Woman not satisfied

Not reported.

Caregiver not satisfied

Not reported.

Other outcomes (not pre-specified)

Maternal fever during labour

Not reported.

Antibiotics during labour



Chorioamnionitis

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (RR 0.63, 95% CI 0.28 to 1.38; 443 women; 3 studies; Analysis 35.21).

Endometritis

It is uncertain whether there is a difference in endometritis between both induction methods (RR 0.41, 95% CI 0.08 to 2.08; 435 women; 2 studies; Analysis 35.22).

Fetal distress

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (RR 0.78, 95% CI 0.53 to 1.14; 784 women; 4 studies; Analysis 35.23).

Umbilical artery pH < 7.10

Not reported.

Any mechanical method and oxytocin versus prostaglandin E2 alone (four trials involving 713 women)

Primary outcomes

Vaginal delivery not achieved within 24 hours

Not reported.

Uterine hyperstimulation with FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between a mechanical method combined with oxytocin and PGE2 (RR 1.48, 95% CI 0.55 to 3.95; 151 women; 1 study; Analysis 38.1).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Caesarean section

It is uncertain whether there is a difference in caesarean sections between both induction methods (RR 0.93, 95% CI 0.72 to 1.20; 713 women; 4 studies; Analysis 38.2).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Serious neonatal morbidity or perinatal death

Not reported.

Serious maternal morbidity or death

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods (Analysis 38.3). One study (200 women) was included for this composite outcome in which no events of maternal morbidity or death occurred.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Secondary outcomes

Cervix unfavourable/unchanged after 24 hours

Not reported.

Oxytocin augmentation

A mechanical method combined with oxytocin probably increases the risk of oxytocin augmentation when compared to PGE2 (RR 2.48, 95% CI 1.95 to 3.15; 200 women; 1 study; Analysis 38.4).

Uterine hyperstimulation without FHR changes

A mechanical method combined with oxytocin probably increases the risk of uterine hyperstimulation without FHR changes when compared to PGE2 (RR 2.19, 95% CI 1.39 to 3.46; 151 women; 1 study; Analysis 38.5).

Uterine rupture

Not reported.

Epidural analgesia

Not reported.

Instrumental vaginal delivery

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.35, 95% CI 0.08 to 1.58; 41 women; 1 study; Analysis 38.6).

Meconium-stained liquor

It is uncertain whether there is a difference in meconium-stained liquor between both induction methods (RR 1.13, 95% CI 0.43 to 2.95; 151 women; 1 study; Analysis 38.7).

Apgar score less than seven at five minutes

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 2.96, 95% CI 0.12 to 71.55; 151 women; 1 study; Analysis 38.8).

Neonatal intensive care unit admission

It is uncertain whether there is a difference in NICU admissions between both methods (RR 0.85, 95% CI 0.30 to 2.40; 151 women; 1 study; Analysis 38.9).

Neonatal encephalopathy

Not reported.

Perinatal death

Not reported.

Disability in childhood

Not reported.

Maternal side effects

Not reported.

Maternal nausea

Not reported.

Maternal vomiting

Not reported.

Maternal diarrhoea

Not reported.



Other maternal side effects

Not reported.

Postpartum haemorrhage

It is uncertain whether there is a difference in postpartum haemorrhage between both induction methods (RR 0.14, 95% CI 0.01 to 2.68; 151 women; 1 study; Analysis 38.10).

Serious maternal complications

Not reported.

Maternal death

Not reported.

Woman not satisfied

Not reported.

Caregiver not satisfied

Not reported.

Other outcomes (not pre-specified)

Maternal fever during labour

Not reported.

Antibiotics during labour

Not reported.

Chorioamnionitis

Not reported.

Endometritis

It is uncertain whether there is a difference in endometritis between both induction methods (Analysis 38.11). One study (41 women) reported on this outcome. No events of endometritis occurred in this study.

Fetal distress

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (average RR 0.97, 95% CI 0.61 to 1.56; 498 women; 3 studies; Analysis 38.12). Also, there was moderate heterogeneity for this outcome (Tau² = 0.06; Chi² = 2.93, df = 2 (P = 0.23); $I^2 = 32\%$).

No sensitivity analysis was performed as no potential high-risk studies were included for this outcome.

Umbilical artery pH < 7.10

Not reported.

Any mechanical method and oxytocin versus misoprostol alone (six trials involving 1779 women)

Primary outcomes

Vaginal delivery not achieved within 24 hours

A mechanical method combined with oxytocin probably reduces the risk of a vaginal delivery not being achieved within 24 hours when compared to misoprostol (RR 0.48, 95% CI 0.37 to 0.63; 362 women; 2 studies; Analysis 39.1), the absolute effect being 285 fewer per 1000 deliveries.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Uterine hyperstimulation with FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation with FHR changes between both induction methods (RR 0.43, 95% CI 0.17 to 1.11; 1463 women; 3 studies; Analysis 39.2).

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Caesarean section

There probably is little or difference in caesarean sections between both induction methods (RR 0.95, 95% CI 0.80 to 1.12; 1779 women; 5 studies; Analysis 39.3).

For the subgroup of primiparous women, no outcomes were reported. For multiparous women, it is uncertain whether there is a difference in caesarean sections between both induction methods (RR 0.45, 95% CI 0.19 to 1.11; 136 women; 1 study; Analysis 40.1).

Serious neonatal morbidity or perinatal death

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (RR 0.82, 95% CI 0.18 to 3.65;1263 women; 2 studies; Analysis 39.4). All the events included for this composite outcome were cases of neonatal death.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Serious maternal morbidity or death

Not reported.

Secondary outcomes

Cervix unfavourable/unchanged after 24 hours

Not reported.

Oxytocin augmentation

It is uncertain whether there is a difference in oxytocin augmentation between both induction methods (average RR 3.89, 95% CI 0.70 to 21.72; 336 women; 2 studies; Analysis 39.5). Also, there was substantial heterogeneity for this outcome ($Tau^2 = 1.46$; $Chi^2 = 18.47$, df = 1 (P < 0.0001); $I^2 = 95\%$).

A sensitivity analysis, after eliminating the one trial assessed as having a potentially higher risk of allocation or attrition bias (Garba 2016), changed the result in favour of misoprostol as it showed a mechanical method combined with oxytocin may increase the risk of oxytocin augmentation (RR 1.91, 95% CI 1.59 to 2.31; 200 women; 1 study).

Uterine hyperstimulation without FHR changes

A mechanical method combined with oxytocin probably reduces the risk of uterine hyperstimulation without FHR changes when compared to misoprostol (RR 0.52, 95% CI 0.30 to 0.92; 498 women; 3 studies; Analysis 39.6).

Uterine rupture

Not reported.



Epidural analgesia

It is uncertain whether there is a difference in epidural analgesia between both induction methods (RR 1.07, 95% CI 0.90 to 1.27; 162 women; 1 study; Analysis 39.7).

Instrumental vaginal delivery

Not reported.

Meconium-stained liquor

It is uncertain whether there is a difference in meconium-stained liquor between both induction methods (RR 0.72, 95% CI 0.43 to 1.19; 362 women; 2 studies; Analysis 39.8).

Apgar score less than seven at five minutes

It is uncertain whether there is a difference in Apgar scores less than seven at five minutes between both induction methods (RR 0.95, 95% CI 0.20 to 4.58; 162 women; 1 study; Analysis 39.9).

Neonatal intensive care unit admission

A mechanical method combined with oxytocin probably reduces the risk of a NICU admission when compared to misoprostol (RR 0.66, 95% CI 0.49 to 0.90; 1599 women; 4 studies; Analysis 39.10), the absolute effect being 37 fewer NICU admissions per 1000 deliveries.

Neonatal encephalopathy

Not reported.

Perinatal death

It is uncertain whether there is a difference in perinatal death between both induction methods (RR 0.82, 95% CI 0.18 to 3.65; 1263 women; 2 studies; Analysis 39.11). Perinatal death occurred in one of the included studies (Gilson 2017). All were cases of neonatal death. No further information was given on cause of the demise.

Disability in childhood

Not reported.

Maternal side effects

Not reported.

Maternal nausea

Not reported.

Maternal vomiting

Not reported.

Maternal diarrhoea

Not reported.

Other maternal side effects

Not reported.

Postpartum haemorrhage

Not reported.

Serious maternal complications

Not reported.

Maternal death

Not reported.

Woman not satisfied

A mechanical method combined with oxytocin may increase the risk of women not being satisfied when compared to misoprostol (RR 1.68, 95% CI 1.47 to 1.93; 866 women; 1 study; Analysis 39.12), the absolute effect being 260 more women not satisfied per 1000 deliveries. For this outcome, women in the study of Gilson 2017 were asked if they would choose the same method again if induction of labour was needed in a future pregnancy.

Caregiver not satisfied

Not reported.

Other outcomes (not pre-specified)

Maternal fever during labour

A mechanical method combined with oxytocin may reduce the risk of maternal fever during labour when compared to misoprostol (RR 0.13, 95% CI 0.04 to 0.50; 298 women; 2 studies; Analysis 39.13).

Antibiotics during labour

Not reported.

Chorioamnionitis

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (RR 0.65, 95% CI 0.32 to 1.31; 200 women; 1 study; Analysis 39.14).

Endometritis

Not reported.

Fetal distress

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (RR 0.55, 95% CI 0.25 to 1.21; 362 women; 2 studies; Analysis 39.15).

Umbilical artery pH < 7.10

Not reported.

Any mechanical method and oxytocin versus oxytocin alone (six trials involving 718 women)

Primary outcomes

Vaginal delivery not achieved within 24 hours

It is uncertain whether there is a difference in a vaginal delivery not being achieved within 24 hours between induction of labour with a mechanical method combined with oxytocin and oxytocin alone (average RR 0.71, 95% CI 0.21 to 2.40; 321 women; 2 studies; Analysis 41.1). Also, there was substantial heterogeneity for this outcome ($Tau^2 = 0.72$; $Chi^2 = 19.17$, df = 1 (P,0.0001); $P^2 = 95\%$).

A sensitivity analysis, after eliminating the one trial assessed as having a potentially higher risk of allocation or attrition bias (Mackeen 2018), changed the result in favour of a mechanical method combined with oxytocin as it showed it may reduce the risk of vaginal delivery not being achieved within 24 hours (RR 0.39, 95% CI



 $0.27\,to\,0.55;120$ women; 1 study), the absolute effect being 550 fewer per 1000 deliveries.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Uterine hyperstimulation with FHR changes

Not reported.

Caesarean section

It is uncertain whether there is a difference in caesarean sections between both induction methods (average RR 0.68, 95% CI 0.39 to 1.20; 718 women; 6 studies; Analysis 41.2). Also, there was substantial heterogeneity for this outcome ($Tau^2 = 0.32$; $Chi^2 = 17.15$, df = 5 (P = 0.004); $I^2 = 71\%$).

A sensitivity analysis, after eliminating the three trials assessed as having a potentially higher risk of allocation or attrition bias (Lyndrup 1989; Mackeen 2018; Tita 2006), did not alter the result nor did it lower heterogeneity (average RR 0.57, 95% CI 0.21 to 1.52; 319 women; 3 studies; I² = 82%).

Serious neonatal morbidity or perinatal death

It is uncertain whether there is a difference in serious neonatal morbidity or perinatal death between both induction methods (RR 0.71, 95% CI 0.12 to 4.13; 321 women; 2 studies; Analysis 41.3). All the events included for this composite outcome were cases of asphyxia.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Serious maternal morbidity or death

It is uncertain whether there is a difference in serious maternal morbidity or death between both induction methods (Analysis 41.4). Of the six included studies for this comparison, two studies (321 women) reported on this composite outcome. No events of maternal morbidity or death occurred in these studies.

For the subgroups of primiparous and multiparous women, no outcomes were reported.

Secondary outcomes

Cervix unfavourable/unchanged after 24 hours

Not reported.

Oxytocin augmentation

Not reported.

Uterine hyperstimulation without FHR changes

It is uncertain whether there is a difference in uterine hyperstimulation without FHR changes between both induction methods (RR 0.85, 95% CI 0.34 to 2.09; 199 women; 2 studies; Analysis 41.5).

Uterine rupture

It is uncertain whether there is a difference in uterine rupture between both induction methods (Analysis 41.6). Of the six included studies for this comparison, one study (120 women) reported on this outcome. No events of uterine rupture occurred in this study.

Epidural analgesia

There probably is little or no difference in epidural analgesia between both induction methods (RR 1.03, 95% CI 0.98 to 1.09; 127 women; 1 study; Analysis 41.7).

Instrumental vaginal delivery

It is uncertain whether there is a difference in instrumental vaginal deliveries between both induction methods (RR 0.99, 95% CI 0.48 to 2.02; 293 women; 3 studies; Analysis 41.8).

Meconium-stained liquor

It is uncertain whether there is a difference in meconium-stained liquor between both induction methods (RR 0.72, 95% CI 0.32 to 1.63; 319 women; 3 studies; Analysis 41.9).

Apgar score less than seven at five minutes

Not reported.

Neonatal intensive care unit admission

It is uncertain whether there is a difference in NICU admissions between both induction methods (RR 0.98, 95% CI 0.61 to 1.58; 400 women; 3 studies; Analysis 41.10).

Neonatal encephalopathy

Not reported.

Perinatal death

Not reported.

Disability in childhood

Not reported.

Maternal side effects

Not reported.

Maternal nausea

Not reported.

Maternal vomiting

Not reported.

Maternal diarrhoea

Not reported.

Other maternal side effects

Not reported.

Postpartum haemorrhage

It is uncertain whether there is a difference in postpartum haemorrhage between both induction methods (RR 1.18, 95% CI 0.44 to 3.18; 319 women; 3 studies; Analysis 41.11).

Serious maternal complications

It is uncertain whether there is a difference in serious maternal complications between both induction methods (Analysis 41.12). Of the six included studies for this comparison, one study (201 women) reported on maternal sepsis. No events occurred in this study.



Maternal death

Not reported.

Woman not satisfied

Not reported.

Caregiver not satisfied

Not reported.

Other outcomes (not pre-specified)

Maternal fever during labour

Not reported.

Antibiotics during labour

It is uncertain whether there is a difference in antibiotics during labour between both induction methods (RR 2.32, 95% CI 0.82 to 6.55; 201 women; 1 study; Analysis 41.13).

Chorioamnionitis

It is uncertain whether there is a difference in chorioamnionitis between both induction methods (average RR 4.34, 95% CI 0.55 to 34.01; 328 women; 2 studies; Analysis 41.14). Also, there was moderate heterogeneity for this outcome ($Tau^2 = 1.19$; $Chi^2 = 1.92$, $Chi^2 = 1.92$, Chi

A sensitivity analysis, after eliminating the one trial assessed as having a potentially higher risk of allocation or attrition bias (Mackeen 2018), did not alter the result (RR 2.16, 95% CI 0.57 to 8.28; 127 women; 1 study).

Endometritis

It is uncertain whether there is a difference in endometritis between both induction methods (RR 1.08, 95% CI 0.16 to 7.45; 374 women; 3 studies; Analysis 41.15).

Fetal distress

It is uncertain whether there is a difference in fetal distress for which a caesarean section is indicated between both induction methods (RR 1.37, 95% CI 0.68 to 2.77; 400 women; 3 studies; Analysis 41.16).

Umbilical artery pH < 7.10

Not reported.

DISCUSSION

We set out to explore the effectiveness of mechanical methods for labour induction and their adverse effects for women and their babies in comparison to different pharmacological methods. We included a total of 113 studies, with 105 studies contributing data involving 22,373 women. This updated review now consists of 21 different comparisons (and 20 subgroup comparisons), where in most of the comparisons a mechanical method (balloon, laminaria or extra-amniotic space infusion (EASI)) was compared with prostaglandin E2 (PGE2), misoprostol or oxytocin. We explored the combination of a mechanical method combined with a pharmacological method, as well as a single versus a double balloon.

Summary of main results

Balloon

Balloon versus PGE2

A balloon catheter is probably as effective for inducing labour as vaginal PGE2, as there was little or no difference in a vaginal delivery not achieved within 24 hours (low-quality evidence) and caesarean sections (moderate-quality evidence) between both induction methods. However, oxytocin augmentation is probably more often required when labour is induced with a balloon catheter. As for perinatal outcomes, a balloon catheter appears to have a more favourable safety profile compared to vaginal PGE2, as it probably reduces the risk of uterine hyperstimulation with and without fetal heart rate (FHR) changes (moderate-quality evidence), fetal distress for which a caesarean section is required and an umbilical artery pH less than 7.10. Also, a balloon catheter may slightly reduce the risk of a neonatal intensive care unit (NICU) admission (low-quality evidence), although conventional statistical significance was not reached as the result was still too imprecise to make a valid judgement. Of note, a balloon catheter probably reduces the risk of serious neonatal morbidity or perinatal death (moderate-risk evidence). However, this outcome should be interpreted with caution as only a few studies (eight out of 28 studies), reported on this composite outcome and therefore a bias for this result could exist. Most of the serious perinatal adverse events in this composite outcome were cases of perinatal asphyxia. Regarding our other main outcomes for this comparison, it was unclear if there is a difference in five-minute Apgar score less than seven (lowquality evidence) or serious maternal morbidity or death (very lowquality evidence).

There was no evidence of a difference in outcomes between induction of labour with a balloon compared to cervical PGE2, although the risk of fetal distress for which a caesarean section is indicated is probably reduced when a balloon is used.

Balloon versus misoprostol

A balloon catheter may be less effective for induction of labour when compared to low-dose oral misoprostol, as a balloon probably increases the risk of a vaginal delivery not achieved within 24 hours (moderate-quality evidence), oxytocin augmentation and probably slightly increases the risk of a caesarean section (moderate-quality evidence). Regarding safety outcomes for the neonate, which are hyperstimulation with (low-quality evidence) and without FHR changes, serious neonatal morbidity or perinatal death (low-quality evidence), NICU admission (low-quality evidence), five-minute Apgar score less than seven (low-quality evidence), fetal distress and umbilical artery pH less than 7.10, it is unclear if there is a difference between both methods as results were too imprecise to make a valid judgement. This was also the case for the composite outcome serious maternal morbidity or death (very low-quality evidence).

When compared to low-dose vaginal misoprostol, a balloon catheter may increase the risk of a caesarean section and oxytocin augmentation (low-quality evidence). However, there was substantial heterogeneity for both outcomes. For the outcome caesarean section, heterogeneity was not reduced after sensitivity analysis. The risk of hyperstimulation, with and without FHR changes, is probably reduced when a balloon catheter is used, as well as the risk of meconium-stained liquor (moderate-quality evidence). Re-



garding our other main outcomes for this comparison, it was unclear if there was a difference between serious neonatal morbidity or perinatal death (very low-quality evidence), serious maternal morbidity or death (very low-quality evidence), NICU admission (low-quality evidence) and five-minute Apgar score less than seven (low-quality evidence) as these results were too imprecise to make a valid judgement.

Epidural analgesia is probably used slightly more after induction of labour with a balloon compared to low-dose oral misoprostol, as well as vaginal misoprostol.

Balloon versus oxytocin

In women with an unfavourable cervix, cervical ripening with a balloon seems to be more effective than induction with oxytocin as it probably reduces the risk of caesarean section and the risk of fetal distress for which a caesarean section is indicated. For women with a previous caesarean section, a balloon catheter may slightly reduce the risk of a caesarean section when compared to oxytocin. However, the result is too imprecise to make a valid judgement on this outcome.

Single balloon versus double balloon

There is no evidence of benefit of a double balloon over a single balloon. There is little or no difference in vaginal deliveries not achieved within 24 hours and in oxytocin augmentation. No clear difference in caesarean section rate was seen between these induction methods. However, the result was still too imprecise to make a valid judgement. Hyperstimulation seems to occur infrequently with either balloons, as no events of uterine hyperstimulation with or without FHR changes were reported in the one study (217 women) which reported on these outcomes.

Laminaria tent

There was no evidence of a difference in outcomes between a laminaria tent compared to vaginal PGE2. However, results were too imprecise to make a valid judgement. Compared to cervical PGE2, a laminaria tent probably reduces the risk uterine hyperstimulation both with and without FHR changes.

EASI

Only a few small studies compared EASI with other methods. When compared to vaginal PGE2, EASI may increase the risk of a vaginal delivery not achieved within 24 hours and oxytocin augmentation.

Mechanical method combined with a pharmacological method

There was no evidence of clear benefit for a mechanical method combined with PGE2 compared to PGE2 alone or to oxytocin. When compared to low-dose misoprostol, a mechanical method combined with PGE2 may reduce the risk of a vaginal delivery not achieved within 24 hours. However, only one study (127 women) reported on this comparison. When a mechanical method is combined with misoprostol or with oxytocin, it may reduce the risk of a NICU admission when compared to misoprostol alone. However, regarding other perinatal outcomes for both comparisons, there was no evidence for a difference in serious neonatal morbidity or perinatal death, Apgar scores less than seven at five minutes or fetal distress.

Infection

Risk of infection may theoretically be associated with the insertion of foreign material in the cervix. Most studies did not report on this outcome, resulting in limited data, reported as various outcomes (maternal fever during labour, antibiotic use during labour, chorioamnionitis and endometritis). According to the limited data available, there is no evidence of an increased risk of infectious morbidity with mechanical methods. These data should however be cautiously interpreted as results were imprecise.

Women's view

Data on patient satisfaction or patient preferences are sparse and not all data could be included in the meta-analyses. When a balloon catheter was compared to vaginal PGE2, more women who were randomised to a balloon would choose the allocated induction method again in a subsequent pregnancy, as compared to women who were randomised to PGE2. However, when a balloon catheter was compared to oral misoprostol, more women would choose misoprostol in a subsequent pregnancy. For both outcomes, only one study was included.

Overall completeness and applicability of evidence

This review was previously one of a series of Cochrane Reviews examining various methods for induction of labour and now serves as a stand-alone review. Other reviews have examined pharmacological and non-pharmacological methods including vaginal prostaglandins (Thomas 2014); intracervical prostaglandins (Boulvain 2008); intravenous oxytocin (Alferivic 2009); amniotomy (Bricker 2000); intravenous oxytocin with amniotomy (Howarth 2001); vaginal misoprostol (Hofmeyr 2010); oral misoprostol (Alfirevic 2014), and other methods.

Despite including 113 studies and including data from 105 studies, there were relatively few clear results. Only for the comparison of a balloon versus vaginal prostaglandin E2, including 28 studies involving 6619 women, were there enough data to make a valid judgement on effectiveness and adverse events between these methods.

Most of the outcomes of interest were poorly reported in the included studies, especially serious maternal or perinatal morbidity or death. Also, for some outcomes such as duration from start of induction to vaginal delivery, Apgar score or umbilical cord pH, only continuous data were reported and therefore were not included in this review. Outcomes should therefore be interpreted with caution. Caesarean section on the other hand, was reported in almost every study. Therefore, caesarean section may be the most reliable outcome by which to assess the effectiveness of mechanical methods for cervical ripening and induction of labour.

The external validity of our results can be questioned as the policy of labour induction varies across the different settings in which trials took place. There was a difference seen in maximum ripening time (e.g. the maximum time cervical ripening was awaited, ranging from six hours to 96 hours) and for when induction of labour was declared as failed. As it may take longer to achieve successful cervical ripening when a balloon is used, this could influence the outcome measures of effectiveness used, such as caesarean section. Also, the caesarean rate differs according to the setting in which trials took place, ranging from 9% (Deshmukh 2011) to 70% (Hudon 1999).



Studies ranged in date of publication from 1982 to 2018. While we did not consider the potential influence of date on our results, it is possible that changes in management of labour can mean that for some comparisons, in which relatively older studies were included, may not be generalisable to the current clinical context.

Quality of the evidence

Risk of bias varied throughout the included trials (see Figure 2 and Figure 3). A great proportion of the trial methods were not well reported and were assessed to be at unclear risk of bias in many domains. Three trials were assessed as using inadequate random sequence generation, and in five trials no measures were taken to conceal allocation. In almost all studies, no blinding was done due to the nature of the intervention. However, blinding of the research personnel would have been possible, but was only described in four studies. Two studies reported to have performed a double-blind study, but did not describe how this was achieved. We rated many trials at unclear risk of attrition bias, mainly because it was not clear if intention-to-treat was performed. Although we did attempt to assess reporting bias, lack of trial protocols for most of the older studies, meant this assessment relied on information available in the published trial report.

The outcomes were assessed using the GRADE approach. We determined the evidence to be moderate-quality, low-quality or very low-quality. All evidence was downgraded for lack of blinding. Other reasons for downgrading were predominately for imprecision (uncertain effect estimates, small sample sizes and low event rates) and inconsistencies (heterogeneity). For our three main comparisons (balloon versus vaginal PGE2; balloon versus vaginal misoprostol; balloon versus oral misoprostol), a 'Summary of findings' table was produced (Summary of findings for the main comparison; Summary of findings 2; Summary of findings 3).

Although no publication bias was detected for our main outcomes, there is still a possibility of publication bias. Most comparisons had less than 10 studies included and therefore, a funnel plot could not be produced. Also, for 11 trial registrations the anticipated end date was overdue by two years and it was not clear if the trials had started, were ongoing or finished recruiting (Baacke 2006; Behrashi 2013; Cullimore 2009; Dias 2008; EUCTR 2012; Kamilya 2011; Park 2011; Pathiraja 2014; Reif 2012; Yazdani 2011; Zhang 2014). Therefore, a potential risk exists as results from these studies were not published.

We acknowledge that with so many comparisons within the review, there is also a risk of statistical type 1 error, meaning a false-positive result. The results where there are very few studies included, moderate or substantial heterogeneity, or those where the meta-analysis result is of borderline statistical significance must therefore be treated with caution.

Potential biases in the review process

We are aware that the possibility of introducing bias was present at every stage of the reviewing process. We attempted to minimise bias in a number of ways; two review authors assessed studies for eligibility, assessed risk of bias and carried out data extraction. Each review author worked independently. We resolved discrepancies through discussion, or if required we consulted a third review author. Nevertheless, the process of assessing risk of bias, for example, is not an exact science and includes many personal judge-

ments. Four review authors, Mieke ten Eikelder, Marta Jozwiak, Kitty Bloemenkamp and Ben Willem Mol are also trial authors for the following included studies: Jozwiak 2012; Jozwiak 2013; Jozwiak 2014; ten Eikelder 2016. Data extraction and risk of bias assessments were conducted by other review authors for these studies (Marieke de Vaan; Kirsten Palmer).

Agreements and disagreements with other studies or reviews

This review is one the most extensive reviews on mechanical methods of labour induction as most reviews on this subject only contain one or two of the comparisons included in this review. We found eight recent systematic reviews covering one or more of our main comparisons, being balloon versus vaginal PGE2, balloon versus vaginal misoprostol or balloon versus oral misoprostol.

Our review was in line with other systematic reviews on induction of labour with a balloon versus vaginal PGE2. Liu 2018 compared a double balloon with a vaginal PGE2 insert and they found no difference in vaginal deliveries achieved within 24 hours or caesarean section rate. They also found a reduction in uterine hyperstimulation and umbilical artery pH < 7.10 when a balloon was used. All of the five studies included in the review of Liu 2018, were also included in our review. Du 2017 compared a double balloon with PGE2 (vaginal as well as cervical) and produced the same results as described in our review and the review of Liu 2018. However, they found no difference in fetal distress for which a caesarean section was indicated. All eight studies were also included in this review. Zhu 2018 compared a Foley catheter with a vaginal PGE2 and included eight studies of which one (Ghanaie 2013) was excluded in our review because oxytocin was administered concurrent to both induction methods. Just as the other reviews, Zhu 2018 found no difference in caesarean section rate. They also looked at the induction to delivery interval on a continuous level and found no difference between both induction methods. Wang 2016 however, found a longer induction to delivery interval when a Foley catheter was used in comparison to PGE2 vaginal insert. The authors did not compare vaginal delivery rates within 24 hours.

Chen 2016 performed a network meta-analysis in which direct and indirect comparisons between different induction agents, including Foley catheter, vaginal PGE2, vaginal misoprostol and oral misoprostol were made. Studies with high-dose misoprostol were included in the review of Chen 2016 as opposed to our review and only indirect comparisons could be made between a Foley catheter and oral misoprostol in the review of Chen 2016. The outcomes of interest were vaginal delivery not achieved within 24 hours, uterine hyperstimulation with FHR changes and caesarean section. Not all results were in line with our results. In the network meta-analysis, a Foley catheter increased the risk of vaginal delivery not achieved within 24 hours compared to vaginal misoprostol, where in our review the outcome was uncertain. When compared to oral misoprostol, no clear difference in vaginal deliveries within 24 hours was seen by Chen 2016 compared to an increased risk in our review. In our review no clear difference was seen in uterine hyperstimulation with FHR changes, but in the network analysis of Chen 2016, a reduced risk was seen when a Foley catheter was used compared to oral misoprostol. For the outcome of caesarean section, the network meta-analyses of Chen 2016 showed the same results as our review. They found that a Foley catheter may slightly increase the risk of a caesarean section when compared to vaginal or oral miso-



prostol, with moderate heterogeneity for the comparison with vaginal misoprostol.

Alfirevic 2016 performed a extensive systematic review on induction of labour. The authors included 34 active treatment types/regimens including different dose regimens and routes of administration, and performed a network meta-analysis in which all different treatments were ranked in relation to each other, including direct as well as indirect comparisons. Ranking was done on absolute risks for all pre specified outcomes. Mechanical induction with a balloon was divided in a single or double balloon. Alfirevic 2016 used other cut-off points in dividing oral and vaginal tablets in dose regimens. In our review low dose was defined as ≤ 50 mcg every ≥ four hours, opposed to the cut-of point of ≥ 50 mcg in the review of Alfirevic 2016. Vaginal PGE2 was divided into tablets, gel, slowrelease and normal-release inserts. For the outcome of a vaginal delivery not achieved within 24 hours, low-dose vaginal misoprostol scored better, as well as all different regimens of vaginal PGE2 compared to induction with a balloon (single as well as double). For the outcome caesarean section, a single balloon and vaginal PGE2 gel had a similar mean ranking in the mid regions. Noteworthy is that low-dose titrated oral misoprostol had one of the lowest mean rankings, as compared to oral misoprostol < 50 mcg, which was ranked relatively high. The same high ranking for this outcome was seen for a double balloon. In line with our review, all mechanical methods had a low ranking regarding uterine hyperstimulation with FHR changes. Alfirevic 2016 also looked at neonatal and maternal mortality and severe morbidity, but for these composite outcomes no network meta-analysis was possible as events were rare and poorly reported in studies. For the outcomes of NICU-admission as well as five-minute Apgar score less than seven, there was considerable uncertainty on the probability of the mean ranking as the 95% confidence intervals (CIs) for these rankings were relatively broad.

Ten Eikelder 2016 looked at safety outcomes between induction of labour with a Foley catheter and misoprostol (any route, any dose) and found less uterine hyperstimulation with FHR changes and less fetal distress for which a caesarean section was indicated when a Foley was used. They found that a Foley catheter may slightly increase the caesarean section rate, although conventional statistical significance was not reached and there was moderate heterogeneity for this outcome. Studies with high-dose misoprostol were not excluded in the review of Ten Eikelder 2016. In subgroup analyses for 25 mcg and 50 mcg vaginal misoprostol, no evidence for a difference in safety outcomes were found.

In our review, there was no evidence for a difference in outcomes related to infection between mechanical induction and other methods for induction of labour. However, the results of outcomes covering infection were still too imprecise to make a valid judgement. McMaster 2015 addressed this question by comparing induction of labour with a balloon versus locally-applied prostaglandin and included 26 trials. Their results were in line with our results and found no evidence for a difference in chorioamnionitis, endometritis and neonatal infection. When infection outcomes were pooled, little or no difference was seen, suggesting a Foley catheter does not increase the risk of infection compared to locally-applied prostaglandin.

AUTHORS' CONCLUSIONS

Implications for practice

Mechanical induction with a balloon is probably as effective as induction of labour with vaginal PGE2 with little or no difference in vaginal deliveries not achieved within 24 hours and caesarean section rate between the two methods. However, a balloon seems to have a more favourable safety profile compared to vaginal PGE2, as it probably reduces the risk of uterine hyperstimulation with and without fetal heart rate (FHR) changes, fetal distress for which a caesarean section is indicated and serious neonatal morbidity or perinatal death.

A balloon catheter may be less effective for induction of labour when compared to low-dose oral misoprostol as a balloon probably increases the risk of a vaginal delivery not achieved within 24 hours and probably slightly increases the risk of a caesarean section. It is unclear if there is a difference in hyperstimulation with FHR changes. When compared to low-dose vaginal misoprostol, a balloon catheter may increase the risk of a caesarean section but probably reduces the risk of hyperstimulation, with and without FHR change as well as the risk of meconium-stained liquor.

Cervical ripening with a balloon seems to be more effective than induction with oxytocin as it probably reduces the risk of caesarean section and the risk of fetal distress. For women with a previous caesarean section, a balloon catheter may slightly reduce the risk of a caesarean section when compared to oxytocin.

There is no evidence of a benefit of a double balloon over a single balloon. For the comparisons of a laminaria tent or extra-amniotic space infusion (EASI) with other induction methods, results were mostly too imprecise to make a valid judgement.

There was no evidence of clear benefit for a mechanical method combined with PGE2 to PGE2 alone or to oxytocin. When a mechanical method is combined with misoprostol or with oxytocin, it may reduce the risk of neonatal intensive care unit (NICU) admissions when compared to misoprostol alone. However, regarding other perinatal outcomes for both comparisons, there was no evidence for a difference in serious neonatal morbidity or perinatal death, Apgar scores less than seven at five minutes or fetal distress.

The advantages of mechanical methods are their wide availability and the low cost of the devices, especially Foley catheters. Storage and preservation of mechanical devices is less problematic than PGE2, which should be kept refrigerated. However, special attention should be paid to contraindications (e.g. low-lying placenta) when inserting these devices.

Implications for research

There seems to be sufficient data to make a valid judgement on the safety and effectiveness of balloon in comparison to vaginal PGE2. More research on this comparison does not seem warranted as moderate-quality evidence suggests a balloon is equally effective, but has a better safety profile. GRADE assessment for important outcomes for this comparison can never be assessed as 'high quality' because blinding is not possible and this is the reason the evidence being downgraded from high-quality evidence to moderate-quality evidence for key outcomes. Future research could focus on comparing a balloon with low-dose misoprostol or a combination of mechanical methods with low-dose misoprostol. More



studies evaluating mechanical methods for induction of labour in women with a history of prior caesarean section could be of benefit.

To facilitate future meta-analyses of labour induction, we recommend the standardisation of outcomes through core outcome sets. This would minimise the reporting challenges experienced in this review, where many included studies reported outcomes in a highly varied manner, resulting in many being excluded from analyses. Also, while there were many large randomised trials included in this review, only a few reported on rare but serious adverse events or included women's views regarding induction methods. As safety aspects and maternal satisfaction become more and more important with rising induction rates, large multicentre studies focusing on safety aspects for the neonate and maternal satisfaction, could help clinicians make a more carefully balanced choice when arranging an induction of labour.

ACKNOWLEDGEMENTS

This review was originally conducted by Prof MJNC Keirse. We would like to thank Cornelia Lohse and Catalin Stan for their work on the Boulvain 2001 version of this review; and Benjamin Lamy, Pernille Lau and Aidan Tan for the translation of articles.

As part of the pre-publication editorial process, this review has been commented on by two peers (an editor and referee who is external to the editorial team), a member of Cochrane Pregnancy and Childbirth's international panel of consumers and the Group's Statistical Adviser. The authors are grateful to the following peer reviewer for her time and comments: Elaine Finucane, National University of Ireland Galway, Galway, Ireland.

This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Pregnancy and Childbirth. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIIHR, NHS or the Department of Health.



REFERENCES

References to studies included in this review

Aduloju 2016 (published data only)

Aduloju OP, Akintayo AA, Adanikin AI, Ade-Ojo IP. Combined Foley's catheter with vaginal misoprostol for pre-induction cervical ripening: A randomised controlled trial. *Australian & New Zealand Journal of Obstetrics & Gynaecology* 2016;**56**:578-84.

Ahmed 2016 (published data only)

Ahmed WA, Ibrahim ZM, Ashor OE, Mohamed ML, Ahmed MR, Elshahat AM. Use of the Foley catheter versus a double balloon cervical ripening catheter in pre-induction cervical ripening in postdate primigravidae. *Journal of Obstetrics and Gynaecology Research* 2016;**42**(11):1489-94.

Al-Ibraheemi 2018 (published data only)

Al-Ibraheemi Z, Brustman L, Bimson B, Porat N, Rosenn B. Misoprostol with foley bulb vs. misoprostol alone for cervical ripening: a randomized controlled trial. *American Journal of Obstetrics and Gynecology* 2017;**216**(1):S473, Abstract no: 825.

* Al-Ibraheemi Z, Brustman L, Bimson BE, Porat N, Rosenn B. Misoprostol with foley bulb compared with misoprostol alone for cervical ripening: a randomized controlled trial. *Obstetrics and Gynecology* 2018;**131**(1):23-9.

Al-Ibraheemi Z, NCT02566005. A randomized comparison of transcervical foley bulb with vaginal misoprostol to vaginal misoprostol alone for induction of labor. clinicaltrials.gov/ct2/show/record/NCT02566005 (first received 1 October 2015).

Allouche 1993 (published data only)

Allouche C, Dommesent D, Barjot P, Levy G. Cervical ripening: comparison of three methods. Preliminary results of a randomized prospective study. *Revue Francaise de Gynecologie et d'Obstetrique* 1993;**88**:492-7.

Al-Taani 2004 (published data only)

Al-Taani MI. Comparison of prostaglandin E2 tablets or foley catheter for labour induction in grand multiparas. *Eastern Mediterranean Health Journal* 2004;**10**(4/5):547-53.

Amorosa 2017 (published data only)

Amorosa J, Booker W, Miller M, Factor S, Stone J, Bianco A. A randomized trial of foley bulb for labor induction in premature rupture of membranes in nulliparas (flip). *American Journal of Obstetrics and Gynecology* 2017;**216**(1 Suppl):S31-S32, Abstract no: 44.

* Amorosa JM, Stone J, Factor SH, Booker W, Newland M, Bianco A. A randomized trial of foley bulb for labor induction in premature rupture of membranes in nulliparas (flip). *American Journal of Obstetrics and Gynecology* 2017;**217**(3):360.e1-7.

Atad 1996 {published data only}

Abramovici H, Hallak M, Zarfati D, Packer T, Calderon I, Auslender R, et al. Induction of labor in patients with unfavorable cervices: a randomized comparison among intravaginal prostaglandin E2 (PGE2), intravenous oxytocin,

and the double-balloon ripener device. *International Journal of Gynecology & Obstetrics* 1994;**46**:7.

* Atad J, Hallak M, Auslender R, Porat-Packer T, Zarfati D, Abramovici H. A randomized comparison of prostaglandin E2, oxytocin, and the double-balloon device in inducing labor. *Obstetrics & Gynecology* 1996;**87**:223-7.

Atad J, Porat-Pecker T. A randomized comparison of PGE2 vaginal tablets, oxytocin and the double balloon device for labor induction. 1st World Congress on Controversies in Obstetrics Gynecology and Infertility; 1999 Oct 28-31; Prague, Czech Republic. 1999.

Hallak M. Mechanical ripening of the unfavorable cervix for induction of labor. *Contemporary Reviews in Obstetrics and Gynaecology* 1997;**9**:99-105.

Bagratee 1990 {published data only}

Bagratee JS, Moodley J. Synthetic laminaria tent for cervical ripening. *South African Medical Journal* 1990;**78**:738-41.

Barda 2018 (published data only)

* Barda G, Ganer H, Sagiv R, Bar J. Foley catheter versus intravaginal prostaglandins E2 for cervical ripening in women at term with an unfavorable cervix: a randomized controlled trial. *Journal of Maternal-Fetal & Neonatal Medicine* 2018;**31**(20):2777-1.

Herman HG, NCT02486679. Cervical ripening at term with prostaglandin e2 tablets versus foley catheter: a randomized controlled trial. clinicaltrials.gov/show/NCT02486679 (first received 1 July 2015).

Benzineb 1996 {published data only}

Benzineb N, Bouhaouala S, Sfar R. Prostaglandin E2 versus Foley catheter for cervical maturation at term [Prostaglandines E2 versus sonde de Foley dans les maturations cervicales à terme]. Revue Francaise de Gynecologie et d'Obstetrique 1996;**91**:173-6.

Biron-Shental 2004 {published data only}

Biron-Shental T, Fishman A, Fejgin MD. Medical and mechanical methods for cervical ripening. *International Journal of Gynecology & Obstetrics* 2004;**85**:159-60.

Blumenthal 1990 {published data only}

Blumenthal PD, Ramanauskas R. Randomized trial of dilapan and laminaria as cervical ripening agents before induction of labor. *Obstetrics & Gynecology* 1990;**75**:365-8.

Browne 2011 {published data only}

Browne PC. Comparison of pre-induction cervical ripening using prepidil gel administered through a urinary balloon catheter. clinicaltrials.gov/ct2/show/results/NCT01390233 (first received 8 July 2011).

Carbone 2013 (published data only)

Carbone JF, NCT01279343. Cervical foley plus vaginal misoprostol versus vaginal misoprostol for cervical ripening and



labor induction: a randomized trial. clinicaltrials.gov/ct2/show/record/NCT01279343 (first received6 January 2011).

* Carbone JF, Tuuli MG, Fogertey PJ, Roehl KA, Macones GA. Combination of foley bulb and vaginal misoprostol compared with vaginal misoprostol alone for cervical ripening and labor induction: a randomized controlled trial. *Obstetrics and Gynecology* 2013;**121**(2 Pt 1):247-52.

Casey 1995 {published data only}

Casey BM, Smith LG, Wolf EJ. Combined therapy for preinduction cervical ripening is more effective than PGE2 alone. *American Journal of Obstetrics and Gynecology* 1995;**172**:424.

Chavakula 2015 {published data only}

* Chavakula PR, Benjamin SJ, Abraham A, Londhe V, Jeyaseelan V, Mathews JE. Misoprostol versus foley catheter insertion for induction of labor in pregnancies affected by fetal growth restriction. *International Journal of Gynaecology and Obstetrics* 2015;**129**(2):152-5.

Mathews J, CTRI/2014/02/004411. Intra-vaginal misoprostal versus Foley catheter for induction of labour in fetus with suspected fetal compromise. apps.who.int/trialsearch/ Trial2.aspx?TrialID=CTRI/2014/02/004411 (first received 17 February 2014).

Chua 1997 {published data only}

Chua S, Arulkumaran S, Vanaja K, Ratnam SS. Preinduction cervical ripening: prostaglandin E2 gel vs hygroscopic mechanical dilator. *Journal of Obstetrics and Gynaecology Research* 1997;**23**:171-7.

Cromi 2011 {published data only}

Cromi A, Ghezzi F, Agosti M, Serati M, Uccella S, Arlant V, et al. Is transcervical Foley catheter actually slower than prostaglandins in ripening the cervix? A randomized study. *American Journal of Obstetrics and Gynecology* 2011;**204**(4):338.e1-7.

Cromi 2012 {published data only}

* Cromi A, Ghezzi F, Uccella S, Agosti M, Serati M, Marchitelli G, et al. A randomized trial of preinduction cervical ripening: Dinoprostone vaginal insert versus double-balloon catheter. *American Journal of Obstetrics and Gynecology* 2012;**207**(2):125.e1-7.

Cromi A, NCT01170819. Double balloon catheter versus vaginal pge2 for pre-induction cervical ripening: a randomized study. https://clinicaltrials.gov/ct2/show/record/NCT01170819 (first received 27 July 2010).

Culver 2004 {published data only}

Culver J, Strauss R, Brody S, Dorman K, Timlin S, McMahon M. A randomized trial of intracervical foley catheter with concurrent oxytocin compared to vaginal misoprostol for labor induction in nulliparous women. *American Journal of Obstetrics and Gynecology* 2001;**185**(6 Suppl):S203.

* Culver J, Strauss RA, Brody S, Dorman K, Timlin S, McMahon MJ. A randomized trial comparing vaginal misoprostol versus foley catheter with concurrent oxytocin for labor induction in nulliparous women. *American Journal of Perinatology* 2004;**21**(3):139-46.

Dalui 2005 (published data only)

Dalui R, Suri V, Ray P, Gupta I. Comparison of extraamniotic foley catheter and intracervical prostaglandin E2 gel for preinduction cervical ripening. *Acta Obstetricia et Gynecologica Scandinavica* 2005;**84**(4):362-7.

Deo 2012 {published data only}

Deo S, Iqbal B, Das V, Agarwal A, Singh R. Evaluation of non-pharmacological method-transcervical foley catheter to intravaginal misoprostol and prostaglandin E2 gel for preinduction cervical ripening. *Biomedical Research* 2012;**23**(2):247-52.

Deo 2013 (published data only)

Deo S. Preinduction cervical ripening: a prospective randomised comparison of intracervical foley catheter versus PGE2 gel. *International Journal of Gynecology and Obstetrics* 2015;**131**(Suppl 5):E113.

* Deo S, Iqbal B, Das V, Agarwal A, Singh R. Preinduction cervical ripening: a prospective randomised comparison of intracervical foley catheter versus PGE2 gel. *BJOG: an international journal of obstetrics and gynaecology* 2013;**120**(Suppl s1):85.

Deshmukh 2011 (published data only)

Deshmukh VL, Yelikar KA, Deshmukh AB. Comparative study of intra-cervical Foley's catheter and PGE2 gel for pre-induction ripening (Cervical). *Journal of Obstetrics and Gynecology of India* 2011;**61**(4):418-21.

Dionne 2011 {published data only}

Dionne MD, Dube J, Chaillet N. Randomized study comparing Foley catheter and intravaginal misoprostol as cervical ripening. *American Journal of Obstetrics and Gynecology* 2011;**204**(1 Suppl 1):S48.

Edwards 2014c {published data only}

Edwards R, Szychowski J, Berger J, Petersen M, Ingersoll M, Bodea Braescu A, et al. Effect of obesity on duration and outcome of labor inductions with either the Foley catheter or the prostaglandin E2 vaginal insert. *American Journal of Obstetrics and Gynecology* 2014;**210**(1 Suppl):S278.

Edwards R, Szychowski J, Berger J, Petersen M, Ingersoll M, Bodea Braescu A, et al. Effect of parity on duration of labor inductions with either Foley catheter or the prostaglandin E2 vaginal insert. *American Journal of Obstetrics and Gynecology* 2014;**210**(1 Suppl):S292.

Edwards R, Szychowski J, Berger J, Petersen M, Ingersoll M, Bodea Braescu A, et al. Randomized trial comparing Foley catheter to the prostaglandin E2 vaginal insert for induction of labor. *American Journal of Obstetrics and Gynecology* 2014;**210**(1 Suppl):S39-40.

Edwards R, Szychowski J, Braescu AB, Biggio J, Lin M. Potential barriers to adopting foley catheter for induction of labor in women with an unfavorable cervix: does the labor curve differ?.



American Journal of Obstetrics and Gynecology 2015;**212**(1 Suppl 1):S413-4.

* Edwards RK, Szychowski JM, Berger JL, Petersen M, Ingersoll M, Bodea-Braescu AV. Foley catheter compared with the controlled-release dinoprostone insert. *Obstetrics & Gynecology* 2014;**123**:1280-7.

Edwards RK, Szychowski JM, Bodea-Braescu AV, Biggio JR, Lin MG. Foley catheter for induction of labor: potential barriers to adopting the technique. *Journal of Perinatology* 2015;**35**(12):996-9.

Lin MG, NCT01402050. A randomized controlled trial of transcervical foley balloon compared to controlled release prostaglandin (cervidil) for labor induction and cervical ripening in term and near term women. clinicaltrials.gov/show/NCT01402050 (first received 8 April 2011).

El Khouly 2017 (published data only)

* El Khouly NI. A prospective randomized trial comparing Foley catheter, oxytocin, and combination Foley catheter-oxytocin for labour induction with unfavourable cervix. *Journal of Obstetrics and Gynaecology* 2017;**37**(3):309-14.

Elkhouly N, PACTR201601001428921. A randomized trial comparing foley catheter, oxytocin and combination foley catheter-oxytocin for induction of labor with unfavourable cervix. http://www.pactr.org/ATMWeb/appmanager/atm/atmregistry?dar=true&tNo=PACTR201601001428921 2016; Vol. (first received 17 January 2016).

Filho 2002 {published data only}

Filho OBM. Misoprostol versus foley catheter and oxytocin for induction of labour [Misoprostol versus sonda foley e ocitocina para inducao do parto]. *Revista Brasileira de Ginecologia e Obstetricia* 2002;**24**(10):685.

* Moraes Filho OB, Albuquerque RM, Cecatti JG. A randomized controlled trial comparing vaginal misoprostol versus Foley catheter plus oxytocin for labor induction. *Acta Obstetricia et Gynecologica Scandinavica* 2010;**89**(8):1045-52.

Garba 2016 {published data only}

Garba I, Muhammed AS, Muhammad Z, Galadanci HS, Ayyuba R, Abubakar IS. Induction to delivery interval using transcervical Foley catheter plus oxytocin and vaginal misoprostol: A comparative study at Aminu Kano Teaching Hospital, Kano, Nigeria. *Annals of African Medicine* 2016;**15**(3):114-9.

Gelisen 2005 {published data only}

Gelisen O, Caliskan E, Dilbaz S, Ozdas E, Dilbaz B, Ozdas E, et al. Induction of labor with three different techniques at 41 weeks of gestation or spontaneous follow-up until 42 weeks in women with definitely unfavorable cervical scores. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 2005;**120**(2):164-9.

Gilson 2017 {published data only}

Gilson GJ. A randomized control trial of low dose oral liquid misoprostol versus foley balloon-oxytocin for induction

of labor. *American Journal of Obstetrics and Gynecology* 2017;**216**(1):S511, Abstract no: 895.

Glagoleva 1999 (published data only)

Glagoleva EA, Nikonov AP. Preinduction cervical ripening: a comparison of intracervical prostaglandin E2 versus the hygroscopic cervical dilator dilapan. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 1999;**86**:S67.

Goonewardene 2014 (published data only)

* Goonewardene M, Kumara DM, Ziard MH, Bhabu B. Intra cervical foley catheter vs oral misoprostol for pre induction cervical ripening of postdated pregnancies. *Sri Lanka Journal of Obstetrics and Gynaecology* 2014;**36**(3):66-70.

Goonewardene M, SLCTR/2011/002. Intra cervical foley catheter versus oral misoprostol for pre induction cervical ripening of post dated pregnancies. a randomized controlled trial. http://slctr.lk/trials/28 (first received 7 January 2011).

Kumara DM, Ziard MH, Bhabu B, Goonewardene M. Intra cervical foley catheter vs oral misoprostol for pre induction cervical ripening of post dated pregnancies. *Sri Lanka Journal of Obstetrics and Gynaecology* 2014;**36**(Suppl 1):5-6, Abstract no:FC 1.3.

Guinn 2000 {published data only}

* Guinn DA, Goepfert AR, Christine M, Owen J, Hauth JC. Extraamniotic saline, laminaria, or prostaglandin E2 gel for labor induction with unfavorable cervix: a randomized controlled trial. *Obstetrics & Gynecology* 2000;**96**:106-12.

Guinn DA, Goepfert AR, Owen J, Christine M, Hauth JC. Laminaria, extra-amniotic saline induction (EASI) or prepidil for cervical ripening prior to labor induction. *American Journal of Obstetrics and Gynecology* 1997;**176**:S143.

Gunawardena 2012 {published data only}

* Gunawardena LD, Gunawardana GH. Intracervical foley catheter insertion versus intracervical PGE2 gel application for cervical ripening in primi gravid – A randomized controlled trial. *Sri Lanka Journal of Obstetrics and Gynaecology* 2012;**34**(Suppl 1):111-2, Abstract no: OP 40.

Wasalthilaka CD, Gunawardana GH. Comparison of peripartum maternal and fetal outcomes in cervical ripening using foley catheter and prostaglandin E2. *International Journal of Gynecology and Obstetrics* 2015;**131**(Suppl 5):E44-5.

Wasalthilaka CD, Gunawardana GH. Comparison of peripartum maternal and fetal outcomes in cervical ripening using foley catheter and prostaglandin E2 gel. *Sri Lanka Journal of Obstetrics and Gynaecology* 2014;**36**(Suppl 1):20, Abstract no: FC 7 4

Haugland 2012 (published data only)

* Haugland B, Albrechtsen S, Lamark E, Rasmussen S, Kessler J. Induction of labor with single- versus double-balloon catheter - a randomized controlled trial. *Acta Obstetricia et Gynecologica Scandinavica* 2012;**91**(Suppl 159):84-5.

Haugland B, NCT01091285. Induction of labor with single and double balloon catheters, a randomized controlled study.



clinicaltrials.gov/show/NCT01091285 (first received 20 March 2010).

Hay 1995 {published data only}

Hay D, Robinson G, Filshie M, James D. Cervical ripening with prostaglandin E2 gel and hygroscopic cervical dilators. 27th British Congress of Obstetrics and Gynaecology; 1995 July 4-7; Dublin, Ireland. 1995:Abstract no: 480.

Hemlin 1998 (published data only)

Hemlin J, Möller B. Extraamniotic saline infusion is promising in preparing the cervix for induction of labor. *Acta Obstetricia et Gynecologica Scandinavica* 1998;**77**:45-9.

Henry 2013 (published data only)

Austin K, Chambers GM, De Abreu RL, Madan A, Susic D, Henry A. Cost-effectiveness of term induction of labour using inpatient prostaglandin gel versus outpatient Foley catheter. *Australian & New Zealand Journal of Obstetrics & Gynaecology* 2015;**55**(5):440-5.

Henry A, ACTRN12609000420246. An evaluation of outpatient foley (intracervical) catheter versus inpatient prostaglandin vaginal gel (PGE2) on the induction of labour at term. anzctr.org.au/Trial/Registration/TrialReview.aspx? ACTRN=12609000420246 (first received 10 May 2009).

Henry A, Madan A, Reid R, Tracy S, Sharpe V, Austin K, et al. Outpatient Foley catheter versus inpatient Prostin gel for cervical ripening: the FOG (Foley or Gel) trial. *Australian and New Zealand Journal of Obstetrics and Gynaecology* 2011;**51**:473-4.

* Henry A, Madan A, Reid R, Tracy SK, Austin K, Welsh A, et al. Outpatient Foley catheter versus inpatient prostaglandin E2 gel for induction of labour: a randomised trial. *BMC Pregnancy and Childbirth* 2013;**13**:25.

Henry A, Reid R, Madan A, Tracy S, Sharpe V, Welsh A, et al. Satisfaction survey: outpatient Foley catheter versus inpatient Prostin gel for cervical ripening. *Australian and New Zealand Journal of Obstetrics and Gynaecology* 2011;**51**:474.

Hibbard 1998 (published data only)

Hibbard JU, Shashoua A, Adamczyk C, Ismail M. Cervical ripening with prostaglandin gel and hygroscopic dilators. *Infectious Diseases in Obstetrics and Gynecology* 1998;**6**:18-24.

Hoppe 2016 (published data only)

Hoppe K, Schiff M, Peterson S, Gravett M. Randomized controlled trial: comparing 80mL double versus 30mL single balloon catheters for pre-induction cervical ripening. *American Journal of Obstetrics and Gynecology* 2014;**210**(1 Suppl):S326.

* Hoppe KK, Schiff MA, Peterson SE, Gravett MG. 30ml single-versus 80 ml double-balloon catheter for pre-induction cervical ripening: a randomized controlled trial. *Journal of Maternal-Fetal & Neonatal Medicine* 2016;**29**(12):1919-25.

Hudon 1999 {published data only}

Hudon L, Belfort MA, Dorman K, Wilkins IA, Moise KJ. Comparison between intracervical PGE2 and supracervical Foley catheter for cervical ripening. *American Journal of Obstetrics and Gynecology* 1999;**180**(1 Pt 2):S126.

Hughes 2002 {published data only}

Hughes L, El-Azeem S. Induction of labor: a randomized comparison between the intracervical balloon catheter and slow release dinoprostone. *American Journal of Obstetrics and Gynecology* 2002;**187**(6 Pt 2):S166.

Husain 2017 {published data only}

* Husain S, Husain S, Izhar R. Oral misoprostol alone versus oral misoprostol and foley's catheter for induction of labor: a randomized controlled trial. *Journal of Obstetrics and Gynaecology Research* 2017;**43**(8):1270-7.

Husain S, NCT02758340. Comparison of maternal outcome between patients undergoing induction of labor with oral misoprostol alone and oral misoprostol and foley's catheter both at a tertiary care hospital. clinicaltrials.gov/show/NCT02758340 (first received 2 May 2016).

Jagani 1982 (published data only)

Jagani N, Schulman H, Fleischer A, Mitchell J, Randolph G. Role of the cervix in the induction of labor. *Obstetrics & Gynecology* 1982;**59**:21-6.

Jalilian 2011 (published data only)

Jalilian N, Fakheri T, Ghadami MR. Intravaginal dinoprostone versus intra cervical foley catheter for induction of labor. *Acta Medica Iranica* 2011;**49**(12):831.

Jeeva 1982 (published data only)

Jeeva MA, Dommisse J. Laminaria tents or vaginal prostaglandins for cervical ripening. A comparative trial. *South African Medical Journal* 1982;**61**:402-3.

Johnson 1985 (published data only)

* Johnson IR, Macpherson MB, Welch CC, Filshie GM. A comparison of Lamicel and prostaglandin E2 vaginal gel for cervical ripening before induction of labor. *American Journal of Obstetrics and Gynecology* 1985;**151**:604-7.

MacPherson M. Comparison of Lamicel with prostaglandin E2 gel as a cervical ripening agent before the induction of labour. *Journal of Obstetrics and Gynaecology* 1984;**4**:205-6.

Joshi 2016 {published data only}

Joshi S, Dheeraj S, Fotedar S. Induction with transcervical foleys versus iv oxytocin for trial of labor after cesarean (TOLAC). *Indian Journal of Obstetrics and Gynecology Research* 2016;**3**(3):257-63.

Jozwiak 2012 (published data only)

Jozwiak M, Benthem M, Oude RK, Dijksterhuis M, de Graaf I, van Pampus M, et al. Randomized clinical trial for the comparison of Foley catheter and prostaglandin inserts in induction of labor at term (trial registration NTR 1646). *American Journal of Obstetrics and Gynecology* 2012;**206**(Suppl 1):S40.

Jozwiak M, NTR1646. Evaluation of chemical (Prostaglandins) versus mechanical (transcervical balloon) methods for



induction of labour at term. trialregister.nl/trialreg/admin/rctview.asp?TC=1646 (first received 30 January 2009).

* Jozwiak M, Oude Rengerink K, Benthem M, van Beek E, Dijksterhuis MG, de Graaf IM, et al. Foley catheter versus vaginal prostaglandin E2 gel for induction of labour at term (PROBAAT trial): an open-label, randomised controlled trial. *Lancet* 2012;**378**(9809):2095-103.

Jozwiak M, Rengerink KO, Doornbos H, Drogtrop A, de Groot C, Huisjes A, et al. Prediction of cesarean section in women with an unfavorable cervix at term. *American Journal of Obstetrics and Gynecology* 2012;**206**(Suppl 1):S146.

Jozwiak M. PROBAAT study. Prostaglandin or Balloon for Induction of labour at Term. http://www.studies-obsgyn.nl/home/page.asp?page_id=600.

Mol BW, Van der Post J, Rengerink KO, Papatsonis D, Jozwiak M, van Huizen M, et al. Induction of labor at term: a comparison of Foley catheter and prostaglandins (trial registration NTR 1646). *American Journal of Obstetrics and Gynecology* 2011;**204**(1 Suppl 1):S3-4.

van Baaren GJ, Jozwiak M, Opmeer BC, Oude Rengerink K, Benthem M, Dijksterhuis MG, et al. Cost-effectiveness of induction of labour at term with a foley catheter compared to vaginal prostaglandin E2 gel (PROBAAT trial). *BJOG: an international journal of obstetrics and gynaecology* 2013;**120**:987-95.

van Baaren GJ, Jozwiak M, Rengerink KO, Benthem M, Dijksterhuis MG, van Huizen ME, et al. Cost-effectiveness of induction of labor at term with a Foley catheter compared to prostaglandin E2 gel (based on the PROBAAT trial; registration NTR 1646). *American Journal of Obstetrics and Gynecology* 2012;**206**(Suppl 1):S139-40.

Jozwiak 2013 (published data only)

Jozwiak M, Oude Rengerink K, Ten Eikelder ML, van Pampus MG, Dijksterhuis MG, de Graaf IM, et al. Foley catheter or prostaglandin E2 inserts for induction of labour at term: an open-label randomized controlled trial (PROBAAT-P trial) and systematic review of literature. *European Journal of Obstetrics, Gynecology, and Reproductive Biology* 2013;**170**(1):137-45.

Jozwiak 2014 (published data only)

Jozwiak M, ten Eikelder M, Oude Rengerink K, de Groot C, Feitsma H, Spaanderman M, et al. Foley catheter versus vaginal misoprostol: randomized controlled trial (PROBAAT-M study) and systematic review and meta-analysis of literature. *American Journal of Perinatology* 2014;**31**(2):145-56.

Kandil 2012 (published data only)

Kandil M, Emarh M, Sayyed T, Masood A. Foley catheter versus intra-vaginal misoprostol for induction of labor in post-term gestations. *Archives of Gynecology and Obstetrics* 2012;**286**(2):303-7.

Khamaiseh 2012 {published data only}

Khamaiseh K, Al-Ma'ani W, Abdalla I. Prostaglandin E2 versus foley catheter balloon for induction of labor at term: A

randomized controlled study. *Journal of the Royal Medical Services* 2012;**19**(4):42-7.

Krammer 1995a {published data only}

Krammer J, O'Brien W, Williams M, Sawai S. A prospective randomized comparison of Dilapan vs PGE2 for preinduction cervical ripening and their effects on labor kinetics. *American Journal of Obstetrics and Gynecology* 1993;**170**:408.

Krammer J, O'Brien W, Williams M, Sawai S. Success of labor induction by post-ripening cervical dilatation and agent used. *American Journal of Obstetrics and Gynecology* 1993;**170**:408.

* Krammer J, Williams MC, Sawai SK, O'Brien WF. Pre-induction cervical ripening: a randomized comparison of two methods. *Obstetrics & Gynecology* 1995;**85**:614-8.

Williams MC, Krammer J, O'Brien WF. The value of the cervical score in predicting successful outcome of labor induction. *Obstetrics & Gynecology* 1997;**90**:784-9.

Kruit 2016 (published data only)

Kruit H, Tihtonen K, Raudaskoski T, Ulander VM, Aitokallio-Tallberg A, Heikinheimo O, et al. Foley catheter or oral misoprostol for induction of labor in women with term premature rupture of membranes: a randomized multicenter trial. *American Journal of Perinatology* 2016;**33**(9):866-72.

Kuppulakshmi 2016 {published data only}

Kuppulakshmi G, Vani K. Randomized controlled trial of preinduction cervical ripening - dinoprostone versus Foley's catheter. *Indian Journal of Research* 2016;**5**(9):41-2.

Laddad 2013 {published data only}

Laddad ML, Kshirsagar NS, Karale AV. A prospective randomized comparative study of intra-cervical foley's catheter insertion versus PGE2 gel for pre-induction cervical ripening. *International Journal of Reproduction, Contraception, Obstetrics and Gynecology* 2013;**2**(2):217-20.

Lanka 2014 {published data only}

Lanka S, CTRI/2012/12/003265. A clinical study to compare the combined efficacy of mechanical and pharmacological methods versus pharmacological method alone when used for induction of labor. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1301 (first received 27 December 2012).

* Lanka S, Surapaneni T, Nirmalan PK. Concurrent use of Foley catheter and misoprostol for induction of labor: A randomized clinical trial of efficacy and safety. *Journal of Obstetrics and Gynaecology Research* 2014;**40**(6):1527-33.

Lemyre 2006 {published data only}

Lemyre M, Verret N, Turcot-Lemay L, Brassard N, Morin V. Foley catheter or vaginal misoprostol for cervical ripening: a randomized controlled trial. *American Journal of Obstetrics and Gynecology* 2006;**195**(6 Suppl 1):S105.

Lewis 1983 {published data only}

Lewis GJ. Cervical ripening before induction of labour with prostaglandin E2 pessaries or a Foley's catheter. *Journal of Obstetrics and Gynaecology* 1983;**3**:173-6.



Lokkegaard 2015 (published data only)

* Lokkegaard E, Lundstrom M, Kjaer MM, Christensen IJ, Pedersen HB, Nyholm H. Prospective multi-centre randomised trial comparing induction of labour with a double-balloon catheter versus dinoprostone. *Journal of Obstetrics and Gynaecology* 2015;**35**(8):797-802.

Nyholm H, NCT01255839. A prospective multi-centre randomised comparison on induction of labour with double-balloon installation device versus prostaglandin e2 minprostin. clinicaltrials.gov/show/NCT01255839 (first received 27 December 20128 December 2010).

Lyndrup 1989 (published data only)

Lyndrup J, Legarth J, Dahl C, Philipsen T, Eriksen PS. Induction of labor: the effect of prostaglandin pessary, IV oxytocin and lamicel. Proceedings of 1st European Congress on Prostaglandins in Reproduction; 1988 July 6-9; Vienna, Austria. 1988:117.

* Lyndrup J, Legarth J, Dahl C, Philipsen T, Eriksen PS. Lamicel does not promote induction of labor. A randomized controlled trial. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 1989;**30**:205-8.

Lyndrup 1994 (published data only)

Lyndrup J, Nickelsen C, Weber T, Molnitz E, Guldbaek E. Induction of labour by balloon catheter with extra-amniotic saline infusion (BCEAS): a randomised comparison with PGE2 vaginal pessaries. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 1994;**53**:189-97.

Mackeen 2018 (published data only)

Mackeen AD, Durie D, Lin M, Huls C, Packard R, Sciscione A. Effect of obesity on labor inductions with foley plus oxytocin versus oxytocin alone. *Obstetrics and Gynecology* 2017;**129**(5 Suppl):142S.

* Mackeen AD, Durie DE, Lin M, Huls CK, Qureshey E, Paglia MJ, et al. Foley plus oxytocin compared with oxytocin for induction after membrane rupture: a randomized controlled trial. *Obstetrics and Gynecology* 2018;**131**(1):4-11.

Mackeen AD, NCT01973036. Foley catheter versus oxytocin for labor induction in women with term and near term premature rupture of membranes: a randomized clinical trial (FOLCROM trial). clinicaltrials.gov/ct2/show/record/NCT01973036 (first received 17 September 2013).

Mackeen AD, Paglia MJ, Durie DE, Lin M, Huls CK, Sun H, et al. Foley plus oxytocin versus oxytocin alone for labor induction > 34 weeks after premature rupture of membranes (PROM): a randomized controlled trial. *American Journal of Obstetrics and Gynecology* 2017;**216**(1 Suppl):S72-S73, Abstract no: 103.

Matonhodze 2003 {published data only}

Matonhodze BB, Hofmeyr GJ, Levin J. Labour induction at term--a randomised trial comparing Foley catheter plus titrated oral misoprostol solution, titrated oral misoprostol solution alone, and dinoprostone. *South African Medical Journal* 2003;**93**(5):375-9.

Mazhar 2003 (published data only)

Mazhar SB, Imran R, Alam K. Trial of extra amniotic saline infusion with oxytocin versus prostaglandin E2 pessary for induction of labor. *Journal of the College of Physicians & Surgeons Pakistan* 2003;**13**(6):317-20.

Meetei 2015 (published data only)

Meetei LT, Suri V, Aggarwal N. Induction of labor in patients with previous cesarean section with unfavorable cervix. *JMS - Journal of Medical Society* 2015;**28**(1):29-33.

Moini 2003 (published data only)

Moini A, Riazi K, Honar H, Hasanzadeh Z. Preinduction cervical ripening with the foley catheter and saline infusion vs. cervical dinoprostone. *International Journal of Gynecology & Obstetrics* 2003;**83**:211-3.

Mullin 2002 {published data only}

Mullin P, House M, Paul R, Wing D. A comparison of vaginally administered misoprostol with extraamniotic saline infusion for cervical ripening and labor induction. *American Journal of Obstetrics and Gynecology* 2001;**185**(6 Suppl):S203.

* Mullin PM, House M, Paul RH, Wing DA. A comparison of vaginally administered misoprostol with extra-amniotic saline infusion for cervical ripening and labor induction. *American Journal of Obstetrics and Gynecology* 2002;**187**:847-52.

Mundle 2017 (published data only)

Bracken H, Mundle S, Faragher B, Easterling T, Haycox A, Turner M, et al. Induction of labour in pre-eclamptic women: a randomised trial comparing the Foley balloon catheter with oral misoprostol. *BMC Pregnancy and Childbirth* 2014;**14**(1):308.

Mundle S, Bracken H, Faragher B, Alfirevic Z, Winikoff B, Weeks A. Induction of labour in hypertensive women in India: a randomised trial comparing the foley catheter with oral misoprostol. *BJOG: an international journal of obstetrics and gynaecology* 2016;**123**(Suppl 1):8-9.

Mundle S, Bracken H, Faragher B, Easterling T, Haycox A, Turner M, et al. Induction of labour in pre-eclamptic women: a randomised trial comparing the foley balloon catheter with oral misoprostol. *International Journal of Gynecology and Obstetrics* 2015;**131**(Suppl 5):E497.

Mundle S, Bracken H, Faragher B, Easterling T, Winikoff B, Weeks A. Induction of labor in preeclamptic women in India: A randomized trial comparing Foley catheter with oral misoprostol. *Obstetrics & Gynecology* 2016;**127**(Suppl 5):75S.

* Mundle S, Bracken H, Khedikar V, Mulik J, Faragher B, Easterling T, et al. Foley catheterisation versus oral misoprostol for induction of labour in hypertensive women in india (inform): a multicentre, open-label, randomised controlled trial. *Lancet* 2017;**390**(10095):669-80.

Mundle S, CTRI/2013/07/003859. Induction of labor in preeclamptic women: a randomised trial comparing the Foley balloon catheter with oral misoprostol. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=6670 (first received 31 July 2013).



Weeks AD. Induction of labour in pre-eclamptic women: a randomised trial comparing the foley balloon catheter with oral misoprostol. clinicaltrials.gov/ct2/show/NCT01801410 (first received 28 February 2013).

Niromanesh 2003 {published data only}

Niromanesh S, Mosavi-Jarrahi A, Samkhaniani F. Intracervical foley catheter balloon vs. prostaglandin in preinduction cervical ripening. *International Journal of Gynecology & Obstetrics* 2003;**81**:23-7.

Noor 2015 (published data only)

Noor N, Ansari M, Ali SM, Parveen SF. Foley catheter versus vaginal misoprostol for labour induction. *International Journal of Reproductive Medicine* 2015;**2015**:845735.

Ntsaluba 1997 {published data only}

Ntsaluba A, Bagratee J, Moodley J. The use of an indwelling catheter compared to intracervical prostaglandin gel for cervical ripening prior to induction of labour. *O&G Forum* 1997; **July**:17-21.

Oliveira 2010 (published data only)

* Oliveira MV, von Oberst P, Leite GK, Aguemi A, Kenj G, Leme VD, et al. Cervical Foley catheter versus vaginal misoprostol for cervical ripening and induction of labor: a randomized clinical trial [Sonda de Foley cervical versus misoprostol vaginal para o preparo cervical e inducao do parto: um ensaio clinico randomizado]. Revista Brasileira de Ginecologia e Obstetricia 2010;32(7):346-51.

Sass N, NCT01140971. Transcervical foley catheter (foley) versus intravaginal misoprostol for cervical ripening and induction of labor: a randomized clinical trial. clinicaltrials.gov/show/NCT01140971 (first received 8 June 2010).

Ophir 1992 (published data only)

Ophir E, Haj N, Korenblum R, Oettinger M. Cervical ripening before induction of labor: comparison of an intracervical Foley catheter and prostaglandin E2 tablets. *International Journal of Feto-Maternal Medicine* 1992;**5**:101-6.

Orhue 1995 {published data only}

Orhue AA. Induction of labour at term in primigravidae with low Bishop's score: a comparison of three methods. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 1995;**58**:119-25.

Peedicayil 1998 {published data only}

Peedicayil A, Jasper P, Francis S, Jayakrishnan K, Mathai M, Regi A. A randomized trial of extra-amniotic Foley catheter and intra-cervical prostaglandin E2 for cervical ripening. *Journal of Clinical Epidemiology* 1998;**51 Suppl 1**:21S.

Pennell 2009 {published data only}

* Pennell CE, Henderson JJ, O'Neill MJ, McCleery S, Doherty DA, Dickinson JE. Induction of labour in nulliparous women with an unfavourable cervix: a randomised controlled trial comparing double and single balloon catheters and PGE2 gel. *BJOG: an international journal of obstetrics and gynaecology* 2009;**116**(11):1143-52.

Pennell CE, Jewell M, Doherty D, Dickinson JE. Induction of labor with an unfavorable cervix. *American Journal of Obstetrics and Gynecology* 2003;**189**(6 Suppl 1):S207.

Perry 1998 (published data only)

Perry KG Jr, Larmon JE, May WL, Robinette LG, Martin RW. Cervical ripening: a randomized comparison between intravaginal misoprostol and an intracervical balloon catheter combined with intravaginal dinoprostone. *American Journal of Obstetrics and Gynecology* 1998;**178**:1333-40.

Pineda Rivas 2016 (published data only)

Lett C, NCT01962831. Randomized controlled trial: induction of labour of obese women with dinoprostone or single balloon catheter. clinicaltrials.gov/ct2/show/record/NCT01962831 (first received 19 September 2013).

* Pineda Rivas M, Hilton J, Karreman E, Lett C. Single balloon catheter versus dinoprostone vaginal insert for induction of labour of obese women. *Journal of Obstetrics and Gynaecology Canada* 2016;**38**(5):497-8.

Prager 2008 (published data only)

Marions L, NCT00602095. A randomised comparison between intravaginal dinoprostone intravaginal misoprostol and transcervical balloon catheter for labour induction. https://clinicaltrials.gov/ct2/show/record/NCT00602095 (first received 28 January 2008).

* Prager M, Eneroth-Grimfors E, Edlund M, Marions L. A randomised controlled trial of intravaginal dinoprostone intravaginal misoprostol and transcervical balloon catheter for labour induction. *BJOG: an international journal of obstetrics and gynaecology* 2008;**115**(11):1143-50.

Qamar 2012 {published data only}

Qamar S, Bashir A, Ibrar F. Comparison of prostaglandin E2 gel, prostaglandin E2 pessary and extra-amniotic saline infusion with oxytocin for induction of labour. *Journal of Ayub Medical College, Abbottabad: JAMC* 2012;**24**(2):22-5.

Ridgway 1991 (published data only)

Ridgway L, Berkus M, Wright J. A randomized comparison of intracervical PGE2 versus intracervical prostin and Lamicel cervical dilator for ripening of the unfavorable cervix. *American Journal of Obstetrics and Gynecology* 1991;**164**:307.

Roberts 1986 (published data only)

Roberts WE, North DH, Speed JE, Martin JN, Palmer SM, Morrison JC. Comparative study of prostaglandin, laminaria, and minidose oxytocin for ripening of the unfavorable cervix prior to induction of labor. *Journal of Perinatology* 1986;**6**:16-9.

Rouben 1993 {published data only}

Arias F, Rouben D. Extraamniotic saline infusion with foley catheter is better than 2.9mg prostaglandin E2 gel in ripening the cervix but does not result in vaginal delivery. *American Journal of Obstetrics and Gynecology* 1993;**168**:429.

* Rouben D, Arias F. A randomized trial of extra-amniotic saline infusion plus intracervical Foley catheter balloon versus prostaglandin E2 vaginal gel for ripening the cervix and



inducing labor in patients with unfavorable cervices. *Obstetrics & Gynecology* 1993;**82**:290-4.

Roudsari 2011 {published data only}

* Roudsari FV, Ayati S, Ghasemi M, Shakeri MT, Farshidi F, Shahabian M. Comparison of vaginal misoprostol with foley catheter for cervical ripening and induction of labor. *Iranian Journal of Pharmaceutical Research* 2011;**10**(1):149-54.

Roudsari FV, Ghasemi M, Ayati S, Shakeri MT, Farshidi F, Shahabian M. [Comparison of vaginal misoprostol with foley catheter for cervical ripening and induction of labor]. *Journal of Isfahan Medical School* 2010;**28**(106):177-85.

Roztocil 1998 {published data only}

Roztocil A. A comparison of three preinduction cervical priming methods: prostaglandin E2 gel, dilapan s rods, and estradiol gel. *Journal of Perinatal Medicine* 2013;**41**(Suppl 1):Abstract no:557.

* Roztocil A, Pilka L, Jelinek J, Koudelka M, Miklica J. A comparison of three preinduction cervical priming methods: prostaglandin E2 gel, dilapan S rods and estradiol gel. *Ceska Gynekologie* 1998;**63**:3-9.

Rudra 2012 (published data only)

Rudra T. Is Foley's catheter a safe and cost effective way of iol in low resource countries?. *International Journal of Gynecology and Obstetrics* 2012;**119**(Suppl 3):S468.

Saleem 2006 (published data only)

Saleem S. Efficacy of dinoprostone, intracervical foleys and misoprostol in labor induction. *Journal of the College of Physicians & Surgeons Pakistan* 2006;**16**(4):276-9.

Salim 2011 (published data only)

Salim R, NCT00690040. Single balloon catheter compared with double balloon catheter for ripening of the unfavorable cervix. https://clinicaltrials.gov/ct2/show/record/NCT00690040 (31 May 2008).

* Salim R, Zafran N, Nachum Z, Garmi G, Kraiem N, Shalev E. Single-balloon compared with double-balloon catheters for induction of labor: a randomized controlled trial. *Obstetrics and Gynecology* 2011;**118**(1):79-86.

Sanchez-Ramos 1992 {published data only}

Sanchez-Ramos L, Kaunitz AM, Connor PM. Hygroscopic cervical dilators and prostaglandin E2 gel for preinduction cervical ripening. A randomized, prospective comparison. *Journal of Reproductive Medicine* 1992;**37**:355-9.

Sarreau 2016 {published data only}

Sarreau M, Ragot S, Poulain P, Fontaine B, Morel O, Villemonteix P, et al. Balloon catheter vs. ocytocin for cervical ripening in patient with previous caesarean section: open-label multicenter randomised controlled trial. *European Journal of Obstetrics & Gynecology* 2016;**206**:e104.

Sciscione 1999 {published data only}

* Sciscione A, McCullough H, Manley P, Shlossman P, Pollock M, Colmorgen G. A prospective, randomized comparison of Foley catheter insertion versus intracervical prostaglandin E2 gel for preinduction cervical ripening. *American Journal of Obstetrics and Gynecology* 1999;**180**:55-60.

Sciscione A, McCullough H, Shlossman P, Manley P, Pollock M, Colmorgen G. A randomized prospective comparison of intracervical PGE2 gel (Prepidil) versus Foley bulb for preinduction cervical ripening. *American Journal of Obstetrics and Gynecology* 1997;**176**:S142.

Sharami 2005 {published data only}

Sharami SH, Milani F, Zahiri Z, Mansour-Ghanaei F. A randomized trial of prostaglandin E2 gel and extra-amniotic saline infusion with high dose oxytocin for cervical ripening. *Medical Science Monitor* 2005;**11**(8):CR381-CR386.

Shechter-Maor 2015 {published data only}

Biron-Shental T, NCT00815542. Induction of labor in oligohydramnios - a comparison between two modes of cervical ripening for patients with oligohydramnios at term. clinicaltrials.gov/show/NCT00815542 (first received 30 December 2008).

Shechter-Maor G, Biron-Shental T, Haran G, Ganor-Paz Y, Fejgin M. Intravaginal prostaglandin E2 versus double balloon catheter for labor induction in term isolated oligohydramnios. *American Journal of Obstetrics and Gynecology* 2013;**208**(1 Suppl):S78-9.

* Shechter-Maor G, Haran G, Sadeh-Mestechkin D, Ganor-Paz Y, Fejgin MD, Biron-Shental T. Intra-vaginal prostaglandin E2 versus double-balloon catheter for labor induction in term oligohydramnios. *Journal of Perinatology* 2015;**35**:95-8.

Sheikher 2009 {published data only}

Sheikher C, Suri N, Kholi U. Comparative evaluation of oral misoprostol, vaginal misoprostol and intracervical Foley's catheter for induction of labour at term. *JK Science* 2009;**11**(2):75-7.

Solt 2009 {published data only}

* Solt I, Ben-Harush S, Kaminskey S, Sosnovsky V, Ophir E, Bornstein J. A prospective randomized study comparing induction of labor with a foley catheter and the cervical ripening double balloon catheter in nulliparous and multiparous women. *American Journal of Obstetrics and Gynecology* 2009;**201**(6 Suppl 1):S124.

Solt NCT00501033. A prospective comparative study of induction of labor with a cervical ripening double balloon vs foley. clinicaltrials.gov/show/NCT00501033 (first received 12 July 2007).

Somirathne 2017 {published data only}

Goonewardene M, SLCTR/2014/030. A randomized control trial to compare the effectiveness of intracervical Foley catheter for 24 hours vs three doses of oral misoprostol for preinduction cervical ripening in post dated pregnancies. http://slctr.lk/trials/257 (first received 21 November 2014).

Somirathne D, Goonewardene M. Intracervical foley catheter for 24 hours vs three doses of oral misoprostol for preinduction cervical ripening in post dated pregnancies: a randomised



controlled trial. *Sri Lanka Journal of Obstetrics and Gynaecology* 2015;**37**(Suppl 1):4-5, Abstract no: OP 7.

* Somirathne D, Goonewardene M, Dahanayake L. Three doses of oral misoprostol versus an intra-cervical foley catheter for 24 hours for pre-induction cervical ripening in post-dated pregnancies: a randomized controlled trial. *Ceylon Medical Journal* 2017;**62**(2):77-82.

St Onge 1995 {published data only}

Lange I, St Onge G, Connors G, Ingelson B. A comparison of PGE2 gel versus the Foley catheter for pre-induction cervical ripening. *International Journal of Gynecology & Obstetrics* 1994;**46**:FC005.3.

* St Onge RD, Connors GT. Preinduction cervical ripening: a comparison of intracervical prostaglandin E2 gel versus the Foley catheter. *American Journal of Obstetrics and Gynecology* 1995;**172**(2):687-90.

Suffecool 2014 {published data only}

Suffecool K, Rosenn B, Forutan J, Herrera K. Labor induction in women with an unfavorable cervix: Randomized controlled trial of double balloon catheter versus dinoprostone. *Reproductive Sciences (Thousand Oaks, Calif.)* 2013;**20**(3 Suppl):333A.

* Suffecool K, Rosenn BM, Kam S, Mushi J, Foroutan J, Herrera K. Labor induction in nulliparous women with an unfavorable cervix: Double balloon catheter versus dinoprostone. *Journal of Perinatal Medicine* 2014;**42**(2):213-8.

Sullivan 1996 {published data only}

Sullivan CA, Benton LW, Roach H, Smith LG Jr, Martin RW, Morrison JC. Combining medical and mechanical methods of cervical ripening. Does it increase the likelihood of successful induction of labor?. *Journal of Reproductive Medicine* 1996;**41**:823-8.

Tabowei 2003 (published data only)

Tabowei TO, Oboro VO. Low dose intravaginal misoprostol versus intracervical balloon catheter for pre-induction cervical ripening. *East African Medical Journal* 2003;**80**(2):91-4.

Tan 2015 {published data only}

Tan TL, Ng GY, Lim SE, Tagore S, Kyaw EE, Yeo GS. Cervical ripening balloon as an alternative for induction of labour: A randomized controlled trial. *British Journal of Medical Practitioners* 2015;**8**(1):a806.

ten Eikelder 2016 {published data only}

Ten Eikelder ML, van Baaren GJ, Rengerink KO, Jozwiak M, de Leeuw JW, Kleiverda G, et al. Comparing induction of labour with oral misoprostol or foley catheter at term: cost effectiveness analysis of a randomised controlled multi-centre non-inferiority trial. *BJOG: an International Journal of Obstetrics and Gynaecology* 2018;**125**(3):375-83.

ten Eikelder ML, NTR3466. Induction of labour with oral misoprostol or Foley catheter at term. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=3466 (7 June 2012).

ten Eikelder ML, Neervoort F, Rengerink KO, van Baaren GJ, Jozwiak M, de Leeuw J, et al. Induction of labour with a Foley catheter or oral misoprostol at term: the PROBAAT-II study, a multicentre randomised controlled trial. *BMC Pregnancy and Childbirth* 2013;**13**(1):67.

* ten Eikelder ML, Oude Rengerink K, Jozwiak M, de Leeuw JW, de Graaf IM, van Pampus MG, et al. Induction of labour at term with oral misoprostol versus a foley catheter (PROBAAT-II): a multicentre randomised controlled non-inferiority trial. *Lancet* 2016;**387**(10028):1619-28.

ten Eikelder ML, Rengerink KO, Jozwiak M, de Leeuw JW, de Graaf I, van Pampus MG, et al. Induction of labor at term with oral misoprostol or Foley catheter, the PROBAAT-II trial (NTR3466). *American Journal of Obstetrics and Gynecology* 2015;**212**(1 Suppl 1):S14.

ten Eikelder ML, Rengerink KO, Jozwiak M, de Leeuw JW, de Graaf IM, van Pampus MG, et al. Induction of labor at term with oral misoprostol or foley catheter, the PROBAAT-II trial (NTR3466). *Journal of Paediatrics and Child Health* 2015;**51**(Suppl 1):55.

Thiery 1981 {published data only}

Thiery M, Parewijck W, Martens G, Derom R, Van Kets H. Extraamniotic prostaglandin E2 gel vs amniotomy for elective induction of labour. *Zeitschrift fur Geburtshilfe und Perinatologie* 1981;**185**:323-6.

Tita 2006 {published data only}

Tita A, NCT00290199. A randomized controlled trial of foley catheter for labor induction in women with term and near term prelabor rupture of membranes (prom). clinicaltrials.gov/ct2/show/record/NCT00290199 (first received 9 February 2006).

Turnquest 1997 {published data only}

Lemke M, Turnquest M. Laminaria tents plus vaginal prostaglandin versus vaginal prostaglandin alone for cervical ripening. *American Journal of Obstetrics and Gynecology* 1996;**174**:482.

* Turnquest MA, Lemke MD, Brown HL. Cervical ripening: randomized comparison of intravaginal prostaglandin E2 gel with prostaglandin E2 gel plus Laminaria tents. *Journal of Maternal-Fetal Medicine* 1997;**6**:260-3.

Wang 2012 {published data only}

* Wang ZM, Wang L, Han LL. Propess suppository and transcervical foley catheter balloon for cervical ripening and induction of labor: A prospective randomized controlled trial. *Journal of Chinese General Practice* 2012;**15**(10A):3264-7.

Zheng MM, Hu YL, Zhang SM, Ling JX, Wang ZQ. Trans-cervical foley catheter balloon versus vaginal prostaglandin E2 suppository for cervical ripening and induction of labor: a prospective randomized controlled trial. *Chinese Journal of Perinatal Medicine* 2011;**14**(11):648-52.

Wang 2014 (published data only)

Wang W, Zheng J, Fu J, Zhang X, Ma Q, Yu S, et al. Which is the safer method of labor induction for oligohydramnios



women? Transcervical double balloon catheter or dinoprostone vaginal insert?. *Journal of Maternal-Fetal and Neonatal Medicine* 2014;**27**(17):1805-8.

Wu 2017 {published data only}

Wu X, Li Y, Ouyang C, Liao J, Wang C, Cai W, et al. Cervical dilation balloon combined with intravenous drip of oxytocin for induction of term labor: a multicenter clinical trial. *Archives of Gynecology and Obstetrics* 2018;**297**(1):77-83.

Yuen 1996 (published data only)

* Yuen PM, Pang HY, Chung T, Chang A. Cervical ripening before induction of labour in patients with an unfavourable cervix: a comparative randomized study of the atad ripener device, prostaglandin E2 vaginal pessary, and prostaglandin E2 intracervical gel. *Australian and New Zealand Journal of Obstetrics and Gynecology* 1996;**36**(3):291-5.

Yuen PM, Pang YY. A randomized study of two different methods for cervical ripening. 2nd International Scientific Meeting of the Royal College of Obstetricians and Gynaecologists; 1993 Sept 7-10; Hong Kong. 1993:154.

Zahoor 2014 (published data only)

Zahoor S. Prostaglandin E2, intravaginal misoprostol and intracervical balloon catheter for induction of labour at term, a randomised controlled trial. *BJOG: an international journal of obstetrics and gynaecology* 2014;**121**(Suppl 2):147.

References to studies excluded from this review

Abramovici 1999 {published data only}

Abramovici D, Goldwasser S, Mabie B, Mercer B, Sibai B. Cervical ripening and labor induction, with oral misoprostol vs mechanical methods of cervical ripening and oxytocin. *American Journal of Obstetrics and Gynecology* 1999;**180 (1 Pt 2)**:S126.

* Abramovici D, Goldwasser S, Mabie BC, Mercer BM, Goldwasser R, Sibai BM. A randomized comparison of oral misoprostol versus Foley catheter and oxytocin for induction of labor at term. *American Journal of Obstetrics and Gynecology* 1999;**181**:1108-12.

Adeniji 2005a {published data only}

Adeniji AO, Olayemi O, Odukogbe AA, Oladokun A, Adeniji OI, Egbewale BE, et al. Cervico-vaginal foetal fibronectin: a predictor of cervical response at pre-induction cervical ripening. *West African Journal of Medicine* 2005;**24**(4):334-7.

Adeniji 2005b {published data only}

Adeniji OA, Oladokun A, Olayemi O, Adeniji OI, Odukogbe AA, Ogunbode O, et al. Pre-induction cervical ripening: transcervical foley catheter versus intravaginal misoprostol. *Journal of Obstetrics and Gynaecology* 2005;**25**(2):134-9.

Adeniji 2006 {published data only}

* Adeniji AO, Olayemi O, Odukogbe AA. Intravaginal misoprostol versus transcervical foley catheter in pre-induction cervical ripening. *International Journal of Gynecology & Obstetrics* 2006;**92**(2):130-2.

Adeniji AO, Olayemi O, Odukogbe AA, Aimakhu CO, Oladokun A, Akindele FO, et al. Comparison of changes in pre-induction cervical factors' scores following ripening with transcervical foley catheter and intravaginal misoprostol. *African Journal of Medicine & Medical Sciences* 2005;**34**(4):377-82.

Afolabi 2005 {published data only}

Afolabi BB, Oyeneyin OL, Ogedengbe OK. Intravaginal misoprostol versus foley catheter for cervical ripening and induction of labor. *International Journal of Gynecology & Obstetrics* 2005;**89**:263-7.

Ahmad 2015 (published data only)

Ahmad MF, Ruey S, Vijayarani S, Hussin N, Ahmad S. Evaluation of cervical ripening between transcervical foley catheter versus hygroscopic cervical dilator (laminaria tent) for induction of labour in women with previous caesarean delivery: prospective randomized study. *Journal of Obstetrics and Gynaecology Research* 2015;**41**(Suppl S1):20-1, Abstract no: FC 5.02.

Anabosy 2014 {published data only}

Anabosy SM, NCT02223949. Labor induction and maternal bmi: comparison of different pre-induction cervical ripening methods: the cook double balloon catheter vs pge1 tablets in lean, overweight, and obese women. a prospective randomized study. clinicaltrials.gov/show/NCT02223949 (first recevied 22 August 2014).

Arsenijevic 2012 {published data only}

Arsenijevic S, Vukcevic-Globarevic G, Volarevic V, Macuzic I, Todorovic P, Tanaskovic I, et al. Continuous controllable balloon dilation: a novel approach for cervix dilation. *Trials* 2012;**13**:196.

Arshad 2016 {published data only}

Arshad AH, Zainuddin AA, Ghani NA, Ali A. The efficiency of laminaria as an adjunct to induction of labour with prostin: A randomised controlled trial. *BJOG: an international journal of obstetrics and gynaecology* 2016;**123**(Suppl 2):156.

Atad 1991 {published data only}

Atad J, Bornstein J, Calderon I, Petrikovsky BM, Sorokin Y, Abramovici H. Nonpharmaceutical ripening of the unfavorable cervix and induction of labor by a novel double balloon device. *Obstetrics & Gynecology* 1991;**77**:146-52.

Atad 1999 {published data only}

Atad J, Calderon I, Hallah M, Peer G, Abramovici H. Labour induction - a new approach. Royal Australian and New Zealand College of Obstetrics and Gynaecology, New Zealand Committee Meeting; 2000 April 8-11; Queenstown, New Zealand. 2000:Abstract no: 8.

* Atad J, Peer G. Combination of the double balloon device (ARD) and half doses of PGE2 vaginal gel for labor induction. 1st World Congress on Controversies in Obstetrics Gynecology and Infertility; 1999 Oct 28-31; Prague, Czech Republic. 1999.

Baacke 2006 (published data only)

Baacke K, NCT00325026. Randomized trial comparing misoprostol and foley bulb for labor induction in the preterm



gestation. clinicaltrials.gov/ct2/show/record/NCT00325026 (first received 10 May 2006).

Barrilleaux 2002a {published data only}

Barrilleaux P, Bofill J, Rodts-Palenik S, Moore L, May W, Martin J Jr. A randomized clinical trial comparing three methods of cervical ripening to efficiently effect delivery [abstract]. *American Journal of Obstetrics and Gynecology* 2002;**187**(6 Pt 2):S174.

* Barrilleaux PS, Bofill JA, Terrone DA, Magann EF, May WL, Morrison JC. Cervical ripening and induction of labor with misoprostol, dinoprostone gel, and a foley catheter: a randomized trial of 3 techniques. *American Journal of Obstetrics and Gynecology* 2002;**186**:1124-9.

Behrashi 2013 (published data only)

Behrashi M, IRCT2013010712037N1. Vaginal misoprostol versus laminaria for cervical ripening in full term pregnants. a comparative randomized trial. http://en.irct.ir/trial/12185 (first received 23 January 2013).

Ben-Aroya 2001 (published data only)

Ben-Aroya Z, Hallak M, Segal D, Friger M, Katz M, Mazor M. Ripening of uterine cervix in a post cesarean parturient: PGE2 vs. intracervical Foley catheter. *American Journal of Obstetrics and Gynecology* 2001;**184**:S117.

Buccellato 2000 {published data only}

Buccellato CA, Stika CS, Frederiksen MC. A randomized trial of misoprostol versus extra-amniotic sodium chloride infusion with oxytocin for induction of labor. *American Journal of Obstetrics and Gynecology* 2000;**182**:1039-44.

Cahill 1988 {published data only}

Cahill DJ, Clark HS, Martin DH. Cervical ripening: the comparative effectiveness of Lamicel and prostaglandin E2 tablets. *Irish Journal of Medical Science* 1988;**157**(4):113-4.

Caughey 2007 {published data only}

Caughey A, NCT00451308. Induction of labor with a foley catheter balloon: a randomized trial comparing inflation with 30ml and 60ml. clinicaltrials.gov/ct2/show/record/NCT00451308 (first received 22 March 2007).

Sparks T, Caughey AB, Shaffer B, Cheng YW, Vargas J, Delaney S, et al. Predictors of cesarean delivery in women undergoing labor induction with a Foley balloon. *American Journal of Obstetrics and Gynecology* 2011;**204**(1 Suppl 1):S78.

Chipato 1997 {published data only}

Chipato T, Mawire CJ. RCT of extra-amniotic saline infusion versus extra-amniotic PGF2alpha for cervical ripening and induction of labor. *Journal of Clinical Epidemiology* 1997;**50 Suppl 1**:21S.

Chung 2003 (published data only)

* Chung JH, Huang WH, Rumney PJ, Garite TJ, Nageotte MP. A prospective randomized controlled trial that compared misoprostol, foley catheter, and combination misoprostol-foley catheter for labor induction. *American Journal of Obstetrics and Gynecology* 2003;**189**:1031-5.

Huang W, Chung J, Rumney P, Pattillo C, Garite T, Nageotte M. A prospective, randomized controlled trial comparing misoprostol, foley catheter, and combination misoprostol-foley for labor induction. *American Journal of Obstetrics and Gynecology* 2002;**187**(6 Pt 2):S57.

Huang W, Chung J, Rumney P, Pattillo C, Garite T, Nageotte M. A prospective, randomized controlled trial comparing misoprostol, foley catheter, and combination misoprostol-foley for labor induction. *American Journal of Obstetrics and Gynecology* 2002;**187**(6 Pt 2):S57.

Connolly 2016 (published data only)

* Connolly KA, Kohari KS, Rekawek P, Smilen B, Miller MR, Moshier E, et al. A randomized trial of Foley bulb induction of labor trial in nulliparas (FIAT). *American Journal of Obstetrics and Gynecology* 2016;**214**(1 Suppl):S30-S31, Abstract no: 43.

Connolly KA, Kohari KS, Rekawek P, Smilen BS, Miller MR, Moshier E, et al. A randomized trial of foley balloon induction of labor trial in nulliparas (fiat-n). American Journal of Obstetrics and Gynecology 2016; Vol. 215, issue 3:392.e1-6.

Connolly 2017 (published data only)

Connolly KA, Factor SH, Rekawek P, Smilen BS, Stone JL, Bianco AT, et al. A randomized trial of foley balloon induction of labor trial in multiparas (FIAT-M). *American Journal of Obstetrics and Gynecology* 2017;**216**(1):S433-S434, Abstract no: 746.

Connolly KA, Kohari KS, Factor SH, Rekawek P, Miller MR, Smilen BS, et al. A randomized trial of foley balloon induction of labor trial in multiparas (fiat-m). *American Journal of Perinatology* 2017;**34**(11):1108-14.

Cross 1978 {published data only}

Cross WG, Pitkin RM. Laminaria as an adjunct in induction of labor. *Obstetrics & Gynecology* 1978;**51**:606-8.

Cullimore 2009 (published data only)

Cullimore A, NCT00890630. Intracervical catheters for induction of labour in women with prelabour rupture of membranes at term: a pilot study. clinicaltrials.gov/show/NCT00890630 (first received 30 April 2009).

Delaney 2010 {published data only}

Delaney S, Shaffer B, Cheng Y, Vargas J, Sparks T, Paul K, et al. Labor induction with a foley balloon trial (LIFT) - a randomized controlled trial of 30mL versus 60mL foley balloon inflation. *American Journal of Obstetrics and Gynecology* 2009;**201**(6 Suppl 1):S23-4.

* Delaney S, Shaffer BL, Cheng YW, Vargas J, Sparks TN, Paul K, et al. Labor induction with a Foley balloon inflated to 30 mL compared with 60 mL: a randomized controlled trial. *Obstetrics & Gynecology* 2010;**115**(6):1239-45.

Demirel 2015 {published data only}

Demirel G, Guler H. The effect of uterine and nipple stimulation on induction with oxytocin and the labor process. *Worldviews on Evidence-Based Nursing / Sigma Theta Tau International, Honor Society of Nursing* 2015;**12**(5):273-80.



De Oliveira 2003 (published data only)

De Oliveira MG. A prospective randomized study of the foley catheter for ripening of the unfavourable cervix before induction of labour [Estudo prospectivo e randomizado da sonda foley na preparacao do colo uterino desfavoravel a inducao do parto]. *Revista Brasileira de Ginecologia e Obstetricia* 2003;**25**(5):375.

Dias 2008 (published data only)

Dias TD, SLCTR/2008/002. A randomised controlled trial comparing intra-vaginal Misoprostol with trans-cervical Foley catheter for the pre-induction cervical ripening. http://slctr.lk/trials/44 (first received 28 March 2008).

Du 2015 {published data only}

Du C, Liu Y, Liu Y, Ding H, Zhang R, Tan J. Double-balloon catheter vs. dinoprostone vaginal insert for induction of labor with an unfavorable cervix. *Archives of Gynecology and Obstetrics* 2015;**291**:1221-7.

Edwards 2017 {published data only}

Edwards RK, NCT03111316. Combined use of the controlled release dinoprostone insert and foley catheter compared to the foley catheter alone for cervical ripening and labor induction in term women: a randomized controlled trial. clinicaltrials.gov/ct2/show/record/NCT03111316 (first received 13 March 2017).

El-Khayat 2016 {published data only}

* El-Khayat W, Alelaiw H, El-Kateb A, Elsemary A. Comparing vaginal misoprostol versus foley catheter plus vaginal isosorbide mononitrate for labor induction. *Journal of Maternal-Fetal & Neonatal Medicine* 2016;**29**(3):487-92.

El-khayat W, NCT01506388. Foley catheter plus vaginal isosorbide mononitrate versus vaginal misoprostol for induction of labour: a randomised controlled trial. clinicaltrials.gov/ct2/show/record/NCT01506388 (first received 4 January 2012).

El Sharkwy 2017 {published data only}

El Sharkwy IA, Noureldin EH, Mohamed EA, Shazly SA. Sequential versus concurrent use of vaginal misoprostol plus foley catheter for induction of labor: a randomized clinical trial. *Journal of Obstetrics and Gynecology of India* 2018;**68**(5):408-13.

El-Sharkwy IA, NCT02952807. Sequential versus concurrent use of vaginal misoprostol plus foley catheter for induction of labor. https://clinicaltrials.gov/show/NCT02952807 (31 October 2016).

El-Torkey 1995 {published data only}

* El-Torkey M, Grant JM. Hydrostatic sweeping of the membranes is an effective method of preparing the unripe cervix for induction of labour. A random allocation prospective trial. *Journal of Obstetrics and Gynaecology* 1995;**15**:100-3.

Grant JM. Comparison of hydrostatic sweeping of the membranes (extra-amniotic foley catheter plus extra-amniotic water injection) and vaginal prostaglandin gel in women with an unfavourable cervix who require induction of labour [personal communication]. Letter to: Cochrane Pregnancy and Childbirth Group 1993.

Emery 1988 {published data only}

Emery S, Neal E, Ward S, Morrison R, Filshie M. Prospective controlled trial of three methods for ripening the unfavourable cervix prior to induction of term labour. Proceedings of 1st European Congress on Prostaglandins in Reproduction; 1988 July 6-9; Vienna, Austria. 1988.

EUCTR 2012 {published data only}

EUCTR2012-004880-36-AT. Efficacy of induction of labor on term using a double balloon catheter compared to Dinoprostone vaginal-insert – a multicenter randomized controlled trial. clinicaltrialsregister.eu/ctr-search/search? query=eudract_number:2012-004880-36 (first received 29 May 2013).

Filshie 1992 {published data only}

Filshie GM. Trial to determine the relative efficacy of prostaglandins vs dilapan in ripening the unripe cervix prior to induction of labour [personal communication]. Letter to: Cochrane Pregnancy and Childbirth Group 1992.

Forgie 2016 (published data only)

Forgie MM, Greer DM, Kram JJF, Vander KB, Salvo NP, Siddiqui DS. Foley catheter placement for induction of labor with or without stylette: a randomized clinical trial. *American Journal of Obstetrics and Gynecology* 2016;**214**(3):397.e1-397.e10.

Forooshani 2011 {published data only}

Forooshani M, IRCT201105016355N1. Comparison of transcervical catheter and laminaria efficacy on induction of labor in post term pregnancy. http://en.irct.ir/trial/6798 (first received 7 September 2011).

Fruhman 2017 {published data only}

Fruhman G, Gavard J, Amon E, Flick K, Gross G. Parity and foley catheter using tension or no tension: a randomized controlled trial. *Obstetrics and Gynecology* 2017;**129**(5 Suppl):125S.

Fruhman G, Gavard JA, Amon E, Flick KV, Miller C, Gross GA. Balloon catheter for induction of labor with or without tension applied: a randomized controlled trial. *American Journal of Obstetrics and Gynecology* 2016;**214**(1 Suppl):S253-S254, Abstract no: 462.

* Fruhman G, Gavard JA, Amon E, Flick KV, Miller C, Gross GA. Tension compared to no tension on a foley transcervical catheter for cervical ripening: a randomized controlled trial. *American Journal of Obstetrics and Gynecology* 2017;**216**(1):67.e1-9.

Fruhman G, NCT02606643. Balloon catheter for cervical ripening with or without traction: a randomized controlled trial. clinicaltrials.gov/ct2/show/NCT02606643 (first received 17 November 2015).

Gadel 2015 (published data only)

Gadel Rab MT, Mohammed AB, Zahran KA, Hassan MM, M Eldeen AR, Ibrahim EM, et al. Transcervical Foley's catheter versus Cook balloon for cervical ripening in stillbirth with a scarred uterus: a randomized controlled trial. *Journal of Maternal-Fetal & Neonatal Medicine* 2015;**28**(10):1181-5.



Garebedian 2016 (published data only)

Garebedian C, NCT02932319. Outpatient foley catheter for induction of labor in nulliparous for prolonged pregnancy. clinicaltrials.gov/ct2/show/record/NCT02932319 (first received 4 October 2016).

Ghanaei 2009 {published data only}

Ghanaei MM, Sharami H, Asgari A. Labor induction in nulliparous women: a randomized controlled trial of foley catheter with extra-amniotic saline infusion. *Journal of the Turkish German Gynecology Association Artemis* 2009;**10**(2):71-5.

Ghanaie 2013 (published data only)

Ghanaie MM, Jafarabadi M, Milani F, Asgary SA, Karkan MZ. A randomized controlled trial of foley catheter, extraamniotic saline infusion and prostaglandin E2 suppository for labor induction. *Journal of Family and Reproductive Health* 2013;**7**(2):49-55.

Gibson 2013 (published data only)

Gibson K, Mercer B, Louis J. A randomized control trial of inner thigh taping versus traction for cervical ripening with a Foley catheter. *American Journal of Obstetrics and Gynecology* 2013;**208**(1 Suppl):S145-6.

Gibson KS, Mercer BM, Louis JM. Inner thigh taping vs traction for cervical ripening with a Foley catheter: a randomized controlled trial. *American Journal of Obstetrics and Gynecology* 2013;**209**(3):272.e1-7.

Gibson KS, NCT00976703. Weighted bag versus inner thigh taping for cervical ripening with a foley catheter prior to an induction of labor. clinicaltrials.gov/ct2/show/record/NCT00976703 (first received 11 September 2009).

Gilson 1996 (published data only)

* Gilson GJ, Russell DJ, Izquierdo LA, Qualls CR, Curet LB. A prospective randomized evaluation of a hygroscopic cervical dilator, dilapan, in the preinduction ripening of patients undergoing induction of labor. *American Journal of Obstetrics and Gynecology* 1996;**175**:145-9.

Gilson GJ, Smith JF, Curet LB, Izquierdo LA, Chatterjee MS, Joffe GM, et al. Efficacy of preinduction dilapan on lowering the cesarean section rate. *American Journal of Obstetrics and Gynecology* 1992;**166**:423.

Gilson GJ, Smith JF, Curet LB, Izquierdo LA, Chatterjee MS, Joffe GM, et al. Efficacy of preinduction dilapan on lowering the cesarean section rate. *American Journal of Obstetrics and Gynecology* 1992;**166**:423.

Gonsoulin 1989 {published data only}

Gonsoulin W, Moise KJ, Cano L. Efficacy of dilapan laminaria to intracervical prostaglandin E2 gel in cervical ripening. Proceedings of 9th Annual Meeting of the Society of Perinatal Obstetricians;1989 February 1-4; New Orleans, Louisiana, USA. New Orleans, 1989:94.

Gower 1982 {published data only}

Gower RH, Toraya J, Miller JM, Jr. Laminaria for preinduction cervical ripening. *Obstetrics & Gynecology* 1982;**60**:617-9.

Greybush 2001 (published data only)

* Greybush M, Singleton C, Atlas RO, Balducci J, Rust OA. Preinduction cervical ripening techniques compared. *Journal of Reproductive Medicine* 2001;**46**(1):11-7.

Rust OA, Greybush M, Singleton C, Atlas RO, Balducci J. A comparison of preinduction cervical ripening techniques. *American Journal of Obstetrics and Gynecology* 1999;**180**:S126.

Gu 2015 (published data only)

Gu N, Ru T, Wang Z, Dai Y, Zheng M, Xu B, et al. Foley catheter for induction of labor at term: An open-label, randomized controlled trial. *PLOS One* 2015;**10**(8):e0136856.

Hu Y. Foley catheter balloon for cervical ripening in term pregnancy: a multicenter randomized controlled trial. http://www.chictr.org.cn/hvshowproject.aspx?id=5218 (first received 17 January 2013).

Guinn 2004 (published data only)

Guinn D, Davies J, Jones RO, Wolf D. Foley catheter with extraamniotic saline infusion (easi) versus foley catheter alone for induction of labor in gravidas with an unfavorable cervix. *American Journal of Obstetrics and Gynecology* 2002;**187**(6 Pt 2):S169.

* Guinn DA, Davies JK, Jones RO, Sullivan L, Wolf D. Labor induction in women with an unfavorable bishop score: randomized controlled trial of intrauterine foley catheter with concurrent oxytocin infusion versus foley catheter with extraamniotic saline infusion with concurrent oxytocin infusion. *American Journal of Obstetrics and Gynecology* 2004;**191**:225-9.

Haghighi 2015 {published data only}

Haghighi L, IRCT2015040721506N2. Comparison extra amniotic salin infusion and vaginal isoniazide for cervical ripening before induction and labour duration in term and post term pregnancy. http://en.irct.ir/trial/18839 (first received 28 April 2015).

Hallak 2008 (published data only)

Hallak M, NCT00604487. Induction of labor in patients with unfavorable cervical conditions. clinicaltrials.gov/ct2/show/record/NCT00604487 (first received 30 Jan 2008).

He 2000 {published data only}

He HY. Discussion on the nursing care of air-vesicle odinopoeia in post-term pregnancy. *Nursing Journal of Chinese People's Liberation Army* 2000;**17**(6):7-8.

Hill 2009 (published data only)

Hill JB, Thigpen BD, Bofill JA, Magann E, Moore LE, Martin JN Jr. A randomized clinical trial comparing vaginal misoprostol versus cervical Foley plus oral misoprostol for cervical ripening and labor induction. *American Journal of Perinatology* 2009;**26**(1):33-8.

Hill 2013 {published data only}

Hill M, NCT01866488. The obstetric cook double balloon catheter in combination with oral misoprostol for induction of labor: a double-blinded, randomized controlled trial. clinicaltrials.gov/show/NCT01866488 (first received 31 May 2013).



Hussein 2012 {published data only}

Hussein M. A comparison between vaginal misoprostol and a combination of misoprostol and Foley catheter for cervical ripening and labour induction in early third trimester pregnancy. *American Journal of Obstetrics and Gynecology* 2012;**206**(Suppl 1):S147.

Ifnan 2006 (published data only)

Ifnan F, Jameel MB. Ripening of cervix for induction of labour by hydrostatic sweeping of membrane versus foley's catheter ballooning alone. *Journal of the College of Physicians and Surgeons Pakistan* 2006;**16**(5):347-50.

Jagani 1984 (published data only)

Jagani N, Schulman H, Fleischer A, Mitchell J, Blattner P. Role of prostaglandin-induced cervical changes in labor induction. *Obstetrics & Gynecology* 1984;**63**:225-9.

Jasper 2000 {published data only}

Jasper MP, Blossom S, Peedicayil A. A randomised controlled trial of extra amniotic saline infusion and intracervical Foley catheter for cervical ripening. XVI FIGO World Congress of Obstetrics & Gynecology (Book 4); 2000 Sept 3-8; Washington DC, USA. 2000:69-70.

Jindal 2007 {published data only}

Jindal P, Gill BK, Tirath B. A comparison of vaginal misoprostol versus Foley's catheter with oxytocin for induction of labor. *Journal of Obstetrics and Gynaecology of India* 2007;**57**(1):42-7.

Jonsson 2011 (published data only)

Jonsson M, Hellgren C, Wiberg-Itzel E, Akerud H. Assessment of pain in women randomly allocated to speculum or digital insertion of the Foley catheter for induction of labor. *Acta Obstetricia et Gynecologica Scandinavica* 2011;**90**(9):997-1004.

Kamilya 2011 {published data only}

Kamilya G, CTRI/2011/08/001969. Randomized controlled trial of induction of labour comparing Foley balloon inflation to 60 ml with sublingual misoprostol. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=2999 (first received 26 August 2011).

Karjane 2006 {published data only}

Karjane NW, Brock EL, Walsh SW. Induction of labor using a foley balloon, with and without extra-amniotic saline infusion. *Obstetrics & Gynecology* 2006;**107**(2 Pt 1):234-9.

Kasdaglis 2007 (published data only)

Kasdaglis T, Adamczak J, Rinehart B, Antebi Y, Mendise T, Terrone D. A randomized controlled trial of cervical ripening in patients with PROM using an intracervical balloon catheter and oxytocin versus dinoprostone. *American Journal of Obstetrics and Gynecology* 2007;**197**(6 Suppl 1):S104.

Kashanian 2006 (published data only)

* Kashanian M, Akbarian AR, Fekrat M. Cervical ripening and induction of labor with intravaginal misoprostol and foley catheter cervical traction. *International Journal of Gynecology & Obstetrics* 2006;**92**(1):79-80.

Kashanian M, Fekrat M. The cervical ripening and induction of labor with intravaginal misoprostol, traction on the cervix with intracervical Foley catheter, and a combination of the two methods: a randomized trial of 3 techniques. *International Journal of Gynecology & Obstetrics* 2009;**107**(Suppl 2):S481.

Kashanian 2009a {published data only}

Kashanian M, Nazemi M, Malakzadegan A. Comparison of 30-mL and 80-mL Foley catheter balloons and oxytocin for preinduction cervical ripening. *International Journal of Gynecology & Obstetrics* 2009;**105**(2):174-5.

Kehl 2012 (published data only)

Kehl S, Welzel G, Ehard A, Berlit S, Spaich S, Siemer J, et al. Women's acceptance of a double-balloon device as an additional method for inducing labour. *European Journal of Obstetrics, Gynecology, and Reproductive Biology* 2013;**168**(1):30-5.

* Kehl S, Ziegler J, Schleussner E, Tuschy B, Berlit S, Mayer J, et al. Induction of labour with a balloon catheter and misoprostol - a randomised controlled multi centre study [Geburtseinleitung mit einem ballonkatheter und misoprostol - eine randomisierte kontrollierte multicenter-studie]. *Archives of Gynecology and Obstetrics* 2012;**286**(Suppl 1):S145-6.

Kehl 2015 (published data only)

Kehl S, Ziegler J, Schleussner E, Tuschy B, Berlit S, Kirscht J, et al. Sequential use of double-balloon catheter and oral misoprostol versus oral misoprostol alone for induction of labour at term (CRBplus trial): a multicentre, open-label randomised controlled trial. *BJOG: an international journal of obstetrics and gynaecology* 2015;**122**:129-36.

Kehl S/ACTRN12611000537954. Randomized multicenter study of mechanical ripening of the cervix by double balloon device (cook crb [cervical ripening balloon]) before oral misoprostol (om) versus om alone to improve efficacy in inducing labor. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx? ACTRN=12611000537954 (first received 10 May 2011).

Keirse 1983 {published data only}

Keirse MJ, Thiery M, Parewijck W, Mitchell MD. Chronic stimulation of uterine prostaglandin synthesis during cervical ripening before the onset of labor. *Prostaglandins* 1983;**25**:671-82.

Lackritz 1979 (published data only)

Lackritz R, Gibson M, Frigoletto FD, Jr. Preinduction use of laminaria for the unripe cervix. *American Journal of Obstetrics and Gynecology* 1979;**134**:349-50.

Lam 2006 {published data only}

Lam YR, NCT00366951. A randomized clinical trial comparing the efficacy and safety of foley catheter balloon with oxytocin and extraamniotic saline infusion (easi) with oxytocin for induction of labor requiring cervical ripening. clinicaltrials.gov/show/NCT00366951 (first received 18 August 2006).



Leiberman 1977 {published data only}

Leiberman JR, Piura B, Chaim W, Cohen A. The cervical balloon method for induction of labor. *Acta Obstetricia et Gynecologie Scandinavica* 1977;**56**:499-503.

Leong 2017 (published data only)

Leong YS, NCT03326557. Membrane sweeping versus transcervical foley catheter for induction of labour in women with previous caesarean delivery. clinicaltrials.gov/show/NCT03326557 (first received 22 October 2017).

Levine 2016 (published data only)

* Levine LD, Downes KL, Elovitz MA, Parry S, Sammel MD, Srinivas SK. Mechanical and pharmacologic methods of labor induction: a randomized controlled trial. *Obstetrics and Gynecology* 2016;**128**(6):1357-64.

Levine LD, Sammel MD, Parry S, Williams CT, Elovitz MA, Srinivas SK. Foley or Misoprostol for the Management of Induction (The 'FOR MOMI' trial): A four-arm randomized clinical trial. *American Journal of Obstetrics and Gynecology* 2016;**214**(1 Suppl):S4, Abstract no: 5.

NCT01916681. Foley OR MisO for the Management of Induction (FOR MOMI) Trial. clinicaltrials.gov/show/NCT01916681 (first received 30 July 2013).

Levy 2000 (published data only)

Levy R, Ben-Arie A, Paz B, Hazen I, Blickstein I, Hagay Z. Randomized clinical trial of early vs late amniotomy following cervical ripening with a Foley catheter. *American Journal of Obstetrics and Gynecology* 2000;**182**:S136.

Levy 2004 (published data only)

Levy R, Kanengiser B, Furman B, Ben-Arie A, Brown D, Hagay ZJ. A randomized trial comparing a 30-ml and an 80-ml foley catheter balloon for preinduction cervical ripening. *American Journal of Obstetrics and Gynecology* 2004;**191**:1632-6.

Lin 1995 {published data only}

Lin A, Kupferminc M, Dooley SL. A randomized trial of extraamniotic saline infusion versus laminaria for cervical ripening. *Obstetrics & Gynecology* 1995;**86**:545-9.

Lin 2006 (published data only)

Lin MG, Ramsey PS. Foley catheter for labor induction in women with term or near term membrane rupture. clinicaltrials.gov/ct2/show/NCT00290199 (first received 10 February 2006).

Lin 2007 {published data only}

Lin M, Ramsey P, Reid K, Treaster M, Nuthalapaty F, Lu G. The impact of maternal BMI, parity and GA on the comparative efficacy of transcervical foley catheter with or without an extraamniotic saline infusion for cervical ripening and labor induction in women with an unfavorable cervix. *American Journal of Obstetrics and Gynecology* 2006;**195**(6 Suppl 1):S109.

Lin M, Treaster M, Reid K, Nuthalapaty F, Ramsey P, Lu G. A randomized controlled trial of transcervical foley catheter with and without extra-amniotic saline infusion (EASI) for labor induction. *American Journal of Obstetrics and Gynecology* 2006;**195**(6 Suppl 1):S30.

Lin MG, Lu G, Ramsey PS, NCT00442663. Randomized trial of transcervical foley catheter with and without extra-amniotic saline infusion for labor induction. clinicaltrials.gov/ct2/show/record/NCT00442663 (first received 28 February 2007).

* Lin MG, Reid KJ, Treaster MR, Nuthalapaty FS, Ramsey PS, Lu GC. Transcervical foley catheter with and without extraamniotic saline infusion for labor induction: a randomized controlled trial. *Obstetrics & Gynecology* 2007;**110**(3):558-65.

Lutgendorf 2012 {published data only}

Lutgendorf MA, Johnson A, Terpstra ER, Snider TC, Magann EF. Extra-amniotic balloon for preinduction cervical ripening: A randomized comparison of weighted traction versus unweighted. *Journal of Maternal-Fetal and Neonatal Medicine* 2012;**25**(6):581-6.

Macpherson 1983 (published data only)

Macpherson M, Welch C, Powell M, Filshie M. A trial to compare lamicel, a new induction agent with prostaglandin E2 gel to ripen the cervix prior to induction of labour. Proceedings of 23rd British Congress of Obstetrics and Gynaecology; 1983 July 12-15; Birmingham, UK. 1983:79.

Mahomed 1988 {published data only}

Mahomed K. Foley catheter under traction versus extraamniotic prostaglandin gel in pre-treatment of unripe cervix - a randomised controlled trial. *Central African Journal of Medicine* 1988;**34**:98-102.

Manabe 1985 {published data only}

Manabe Y, Yoshimura S, Mori T, Aso T. Plasma levels of 13,14-dihydro-15-keto prostaglandin F2-alpha, estrogens and progesterone during stretch-induced labor at term. *Prostaglandins* 1985;**30**(1):141-51.

Manish 2016 (published data only)

* Manish P, Rathore S, Benjamin SJ, Abraham A, Jeyaseelan V, Mathews JE. A randomised controlled trial comparing 30 ml and 80 ml in foley catheter for induction of labour after previous caesarean section. *Tropical Doctor* 2016;**46**(4):205-11.

Mathews J, CTRI/2014/02/004412. Randomised trial comparing intrauterine balloon catheter with 30ml fluid with intrauterine balloon catheter with 80ml of fluid to start labor in women with one previous caesarean section. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=4199 (first received 17 February 2014).

Manyonda 2007 {published data only}

Manyonda IT. A randomised controlled trial of the use of the Foley catheter balloon for induction of labour to reduce the incidence of caesarean section in diabetic pregnancies: a prospective clinical, economic and psychological evaluation. isrctn.com/ISRCTN39708525 (first received 28 September 2007).

Martin 1989 (published data only)

Martin JN Jr, Sessums JK, Howard P, Martin RW, Morrison JC. Alternative approaches to the management of gravidas with prolonged-postterm-postdate pregnancies. *Journal of the Mississippi State Medical Association* 1989;**30**:105-11.



Mattingly 2015 (published data only)

* Mattingly P, Temming L, Bliss S. Cervical ripening with a double-lumen balloon catheter for six versus twelve hours: a randomized controlled trial. *American Journal of Obstetrics and Gynecology* 2015;**212**(1 Suppl 1):S264.

Mattingly PJ, Temming LA, Bliss SA. Cervical ripening with a double-lumen balloon catheter for 6 compared with 12 hours. A randomized controlled trial. *Obstetrics & Gynecology* 2015;**125**(5 Suppl):71S.

Mawire 1999 {published data only}

Mawire CJ, Chipato T, Rusakaniko S. Extra-amniotic saline infusion versus extra-amniotic prostaglandin F2alpha for cervical ripening and induction of labor. *International Journal of Gynecology & Obstetrics* 1999;**64**:35-41.

McGee 2016 {published data only}

McGee T, ACTRN12615000795594. Foley catheter latex versus silicone for cervical ripening prior to term induction of labour: a randomized controlled trial. anzctr.org.au/ACTRN12615000795594.aspx (first received 18 June 2016).

Mei-Dan 2009 {published data only}

Mei-Dan E, Walfisch A, Easton SS, Hallak M. Foley's catheter with extra-amniotic saline infusion - a faster and sheaper ripener device: prospective randomized trial. *American Journal of Obstetrics and Gynecology* 2009;**201**(6 Suppl 1):S125.

Mei-Dan 2012 {published data only}

Mei-Dan E, NCT01615107. Comparison between the use of standard oxytocin induction protocol and the double-balloon catheter device with concurrent oxytocin. clinicaltrials.gov/ct2/show/record/NCT01615107 (first received 8 June 2012).

Mei-Dan 2012a {published data only}

* Mei-Dan E, Walfisch A, Suarez-Easton S, Hallak M. Comparison of two mechanical devices for cervical ripening: A prospective quasi-randomized trial. *Journal of Maternal-Fetal and Neonatal Medicine* 2012;**25**(6):723-7.

Mei-Dan E, Walfisch A, Valencia C, Hallak M. Cervical ripening with extra amniotic saline infusion: a randomized comparison of two mechanical devices. *Reproductive Sciences* 2012;**19**(3Suppl):229A.

Mei-Dan 2014 (published data only)

Mei-Dan E, Walfisch A, Valencia C, Hallak M. Making cervical ripening EASI: A prospective controlled comparison of single versus double balloon catheters. *Journal of Maternal-Fetal & Neonatal Medicine* 2014;**27**(17):1765-70.

Miller 2015 (published data only)

* Miller NR, Cypher RL, Foglia LM, Pates JA, Nielsen PE. Elective induction of labor compared with expectant management of nulliparous women at 39 weeks of gestation: a randomized controlled trial. *Obstetrics and Gynecology* 2015;**126**(6):1258-64.

Miller NR, NCT01076062. Elective induction of nulliparous labor: a randomized clinical trial elective induction of nulliparous labor: a randomized clinical trial. clinicaltrials.gov/ct2/show/NCT01076062 (first received 25 February 2010).

Moise 1991 (published data only)

Moise KJ, Cano LE, Hesketh DE. A prospective, randomized comparison of a new synthetic laminaria, intracervical prostaglandin E2 gel, and oxytocin for preinduction ripening of the term cervix. Proceedings of 39th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists; 1991; USA. 1991:24.

Morrison 1993 (published data only)

Morrison JC. Cervical ripening techniques [personal communication]. Letter to: Cochrane Pregnancy and Childbirth Group 1993.

Movahed 2016 (published data only)

Movahed F, Seyed E, Pakniat H, Iranipour M, Yazdi Z. Comparison of the effects of transcervical catheter, laminaria and isosorbide mononitrate on cervical ripening. *Journal of Babol University of Medical Sciences* 2016;**18**(3):19-24.

Mullin 2014 (published data only)

Mullin PM, NCT02210598. Outpatient labor induction with the transcervical foley balloon: a randomized trial comparing outpatient immediate removal foley versus standard inpatient foley induction. clinicaltrials.gov/ct2/show/record/NCT02210598 (first received 19 March 2014).

Naseem 2007 {published data only}

Naseem A, Nouman D, Iqbal J, Majeed MA, Khan MM. Intracervical foley`s catheter balloon versus prostaglandin e2 vaginal pessary for induction of labor. Journal Rawalpindi Medical College 2007; Vol. 12, issue 2:94-9.

Nasir 2012 (published data only)

Nasir S, Chaudhry R. Comparison of intracervical foley catheter plus oral misoprostol with oral misoprostol alone for cervical ripening in primigravidas at term. *BJOG: an international journal of obstetrics and gynaecology* 2012;**119**(Suppl 1):11-2.

Neethurani 2013 {published data only}

Neethurani VK, CTRI/2013/10/004106. The efficacy of transcervical Foley catheter with extra amniotic saline infusion in cervical ripening before the induction of labour with intravaginal Prostaglandin E1- a randomized controlled trial. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php? trialid=5865 (first received 28 October 2013).

Owolabi 2005 (published data only)

Owolabi AT, Kuti O, Ogunlola IO. Randomised trial of intravaginal misoprostol and intracervical foley catheter for cervical ripening and induction of labour. *Journal of Obstetrics and Gynaecology* 2005;**25**(6):565-8.

Park 2011 (published data only)

Park KH, NCT01317862. A comparison of transcervical foley catheter and prostaglandins for induction of labor at term. clinicaltrials.gov/show/NCT01317862 (first received 15 March 2011).

Pathiraja 2014 (published data only)

Pathiraja PD, SLCTR/2014/025. Induction of multiparous women at term using different methods: Prostaglandin E2



(dinopristone) vaginal gel, intracervical foley catheter insertion and sweeping of membrane: an open-label, randomised controlled trial. http://slctr.lk/trials/244 (first received 9 October 2014).

Pedersen 1981 {published data only}

Pedersen S, Moller-Petersen J, Aegidius J. The effect on induction of labour of endocervical balloon catheter with and without oestradiol therapy. *Ugeskrift for Laeger* 1981;**143**:3379-81.

Pettker 2008 (published data only)

Pettker CM, Pocock SB, Smok DP, Devine PC. A prospective, randomized trial of transcervical foley catheter with or without oxytocin for preinduction cervical ripening. *American Journal of Obstetrics and Gynecology* 2006;**195**(6 Suppl 1):S27.

* Pettker CM, Pocock SB, Smok DP, Lee SM, Devine PC. Transcervical foley catheter with and without oxytocin for cervical ripening: a randomized controlled trial. *Obstetrics & Gynecology* 2008;**111**(6):1320-6.

Rameez 2007 {published data only}

Rameez MF, Goonewardene IM. Nitric oxide donor isosorbide mononitrate for pre-induction cervical ripening at 41 weeks' gestation: a randomized controlled trial. *Journal of Obstetrics and Gynaecology Research* 2007;**33**(4):452-6.

Reif 2012 (published data only)

Reif P, NCT01720394. Efficacy of induction of labor on term using a double balloon catheter compared to dinoprostone vaginal-insert - a multicenter randomized controlled trial. https://clinicaltrials.gov/show/NCT01720394 (first received 2 November 2012).

Rezk 2014 (published data only)

Rezk M, Sanad Z, Dawood R, Masood A, Emarh M, Halaby AA. Intracervical foley catheter versus vaginal isosorbid mononitrate for induction of labor in women with previous one cesarean section. *Journal of Clinical Gynecology and Obstetrics* 2014;**3**(2):55-61.

Rust 2001 {published data only}

Rust O, Greybush M, Atlas R, Balducci J, Jones K. Does combination pharmacologic and mechanical preinduction cervical ripening improve ripening to delivery interval?. *American Journal of Obstetrics and Gynecology* 2000;**182**(1 Pt 2):S136.

* Rust OA, Greybush M, Atlas RO, Jones KJ, Balducci J. Preinduction cervical ripening A randomized trial of intravaginal misoprostol alone vs a combination of transcervical foley balloon and intravaginal misoprostol. *Journal of Reproductive Medicine* 2001;**46**:899-904.

Saad 2016 (published data only)

Saad A, NCT02899689. Induction of labor in women with unfavorable cervix: randomized control study comparing dilapan to foley bulb. clinicaltrials.gov/ct2/show/record/NCT02899689 (first received 31 August 2016).

Saito 1999 {published data only}

Saito K, Shoda T, Tani A, Yoshihara H, Amano K, Shimada N, et al. Pre-induction priming method for unripe cervix - comparative study with laminaria tents and metreurynter. *Acta Obstetrica et Gynaecologica Japonica* 1999;**51**(7):474-8.

Salmeen 2012 (published data only)

Salmeen K, NCT01641601. Randomized controlled trial of prehospital cervical ripening with an outpatient transcervical foley balloon and the duration of induction and maternal satisfaction. clinicaltrials.gov/show/NCT01641601 (first received 3 July 2012).

Sanchez-Ramos 1990 {published data only}

Sanchez-Ramos L, Conner PM, Kaunitz AM. Prostaglandin E2 gel vs hypan in cervical ripening before induction of labor. Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23-27; Houston, Texas, USA. 1990:481.

Sandberg 2017 (published data only)

* Sandberg EM, Schepers EM, van Sitter RL, Huisman CM, van Wijngaarden WJ. Foley catheter for induction of labour filled with 30ml or 60ml: a randomized controlled trial. *European Journal of Obstetrics, Gynecology, and Reproductive Biology* 2017;**211**:150-5.

van Wijngaarden WJ, NTR5578. Foley catheter for induction of labour filled with 30mL or 60mL - FILL study. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=5578 (first received 9 December 2015).

Schoen 2017 (published data only)

Schoen C, Berghella V, Grant G, Hoffmann M, Sciscione A. The intracervical foley catheter with and without oxytocin for labor induction: a randomized trial. *American Journal of Obstetrics and Gynecology* 2017;**216**(1 Suupl):S30-S31, Abstract no: 43.

Schoen C, NCT02273115. Foley with oxytocin versus foley no oxytocin for induction of labor (NOFOX): a randomized control trial. clinicaltrials.gov/ct2/show/record/NCT02273115 (first received 20 October 2014).

* Schoen CN, Grant G, Berghella V, Hoffman MK, Sciscione A. Intracervical foley catheter with and without oxytocin for labor induction: a randomized controlled trial. *Obstetrics and Gynecology* 2017;**129**(6):1046-53.

Schreyer 1989 {published data only}

Schreyer P, Sherman DJ, Ariely S, Herman A, Caspi E. Ripening the highly unfavorable cervix with extra-amniotic saline instillation or vaginal prostaglandin E2 application. *Obstetrics & Gynecology* 1989;**73**:938-42.

Sciscione 2001 {published data only}

Manley J, Nguyen L, Shlossman P, Colmorgen G, Sciscione A. A randomized prospective comparison of the intracervical Foley bulb to intravaginal misoprostol (cytotec) for preinduction cervical ripening. *American Journal of Obstetrics and Gynecology* 1999;**180**:S76.

Sciscione AC, Muench M, Pollock M, Jenkins TM, Tildon-Burton J, Colmorgen GH. Transcervical foley catheter for



preinduction cervical ripening in an outpatient versus inpatient setting. *Obstetrics & Gynecology* 2001;**98**:751-6.

* Sciscione AC, Nguyen L, Manley J, Pollock M, Maas B, Colmorgen G. A randomized comparison of transcervical Foley catheter to intravaginal Misoprostol for preinduction cervical ripening. *Obstetrics & Gynecology* 2001;**97**(4):603-7.

Sciscione AC, Nguyen L, Manley JS, Shlossman PA, Colmorgen GH. Uterine rupture during preinduction cervical ripening with misoprostol in a patient with a previous Caesarean delivery. *Australian and New Zealand Journal of Obstetrics and Gynaecology* 1998;**38**:96-7.

Sharma 2015a {published data only}

Sharma K, Grubbs B, Mullin P, Opper N, Lee R. Labor induction utilizing the Foley balloon: a randomized trial comparing delayed verus immediate removal. *American Journal of Obstetrics and Gynecology* 2014;**210**(1 Suppl):S326.

Sharma KJ, Grubbs BH, Mullin PM, Opper N, Lee RH. Labor induction utilizing the foley balloon: a randomized trial comparing standard placement versus immediate removal. *Journal of Perinatology* 2015;**35**(6):390-5.

Sharma 2017 {published data only}

Sharma C, Soni A, Gupta A, Verma A, Verma S. Mifepristone vs balloon catheter for labor induction in previous cesarean: a randomized controlled trial. *Archives of Gynecology and Obstetrics* 2017;**296**(2):241-8.

Sharma C, Soni A, Thakur S, Verma S. Induction of labour in women with previous one caesarean section; mifepristone versus transcervical Folley's catheter. A randomised controlled trial. *BJOG: an international journal of obstetrics and gynaecology* 2015;**122**(Suppl S1):303.

Sherman 2001 {published data only}

Sherman DJ, Frenkel E, Pansky M, Caspi E, Bukovsky I, Langer R. Balloon cervical ripening with extra-amniotic infusion of saline or prostaglandin E2: a double blind, randomized controlled study. *Obstetrics & Gynecology* 2001;**97**(3):375-80.

Siddiqui 2013 {published data only}

Siddiqui DS, NCT02044458. A randomized control trial of foley catheter placement for induction of labor: stylette versus no stylette. clinicaltrials.gov/ct2/show/record/NCT02044458 (first received 9 July 2013).

Suri 2000 {published data only}

Suri V, Dalui R, Gupta I, Ray P. Preinduction cervical ripening: a comparison of extraamniotic Foley catheter balloon and intracervical prostaglandin E2 gel. XVI FIGO World Congress of Obstetrics and Gynecology; 2000 Sept 3-8; Washington DC, USA. Washington DC, 2000; Vol. 4:69.

Thigpen 2004 (published data only)

Thigpen B, Bofill J, Bufkin L, Woodring T, Moore L, Morrison J. A randomized controlled trial comparing vaginal misoprostol to cervical foley plus oral misoprostol for cervical ripening and labor induction. *American Journal of Obstetrics and Gynecology* 2004;**191**(6 Suppl 1):S18.

Thomas 1986 {published data only}

Thomas IL, Chenoweth JN, Tronc GN, Johnson IR. Preparation for induction of labour of the unfavourable cervix with Foley catheter compared with vaginal prostaglandin. *Australian and New Zealand Journal of Obstetrics and Gynaecology* 1986;**26**:30-5.

Torbenson 2015 {published data only}

Torbenson V, NCT02546193. Outpatient foley catheter compared to usual inpatient care for cervical ripening: a randomized controlled trial. clinicaltrials.gov/show/NCT02546193 (first received 10 September 2015).

Ugwu 2013 {published data only}

Ugwu EO, Onah HE, Obi SN, Dim CC, Okezie OA, Chigbu CO, et al. Effect of the Foley catheter and synchronous low dose misoprostol administration on cervical ripening: a randomised controlled trial. *Journal of Obstetrics and Gynaecology* 2013;**33**(6):572-7.

Vengalil 1998 (published data only)

Vengalil SR, Guinn DA, Olabi NF, Burd LI, Owen J. A randomized trial of misoprostol and extra-amniotic saline infusion for cervical ripening and labor induction. *Obstetrics & Gynecology* 1998;**91**:774-9.

Walfisch 2014 (published data only)

Walfisch A. Management of labor in patients with previous cesarian section and premature rupture of membranes who desire TOLAC: comparison between the use of standard expectant management and the double-balloon catheter device. a prospective randomized study. clinicaltrials.gov/ct2/show/NCT02196103 (first received 21 April 2014).

Walfisch 2015 {published data only}

Anabusi S, Mei-Dan E, Hallak M, Walfisch A. Mechanical labor induction in the obese population: a secondary analysis of a prospective randomized trial. *Archives of Gynecology and Obstetrics* 2016;**293**(1):75-80.

* Walfisch A, Mei-Dan E, Hallak M. Trans-cervical double balloon catheter with and without extra-amniotic saline infusion for cervical ripening: A prospective quasi-randomized trial. *Journal of Maternal-Fetal & Neonatal Medicine* 2015;**28**(7):848-53.

Welt 1987 {published data only}

Welt SI. Comparison of mechanical and pharmacologic means for induction of labor [personal communication]. Letter to: Oxford Database of Perinatal Trials 1987.

Wickramasinghe 2014 (published data only)

Wickramasinghe W, SLCTR/2014/006. Effectiveness and safety in keeping the intra uterine Foley catheter for 24 hours versus 48 hours for induction of labour: a randomized controlled trial. http://slctr.lk/trials/209 (first received 25 March 2014).

Wilkinson 2015 {published data only}

Wilkinson C, ACTRN12612001184864. A pilot randomised controlled trial of outpatient balloon catheter priming for induction of labour. https://www.anzctr.org.au/Trial/



Registration/TrialReview.aspx?ACTRN=12612001184864 (first received 8 November 2012).

* Wilkinson C, Adelson P, Turnbull D. A comparison of inpatient with outpatient balloon catheter cervical ripening: a pilot randomized controlled trial. *BMC Pregnancy and Childbirth* 2015;**15**(1):126.

Yaddehige 2015 (published data only)

Yaddehige SS, Kalansooriya HD, Rameez MF. Comparison of cervical massage with membrane sweeping for pre-induction cervical ripening at term - A randomized control trial. *Sri Lanka Journal of Obstetrics and Gynaecology* 2015;**37**(Suppl 1):5-6, Abstract no: OP 10.

Yazdani 2011 {published data only}

Yazdani S, IRCT201012071760N10. Efficacy of prostaglandine e2 and intra-cervical foley balloon in labor induction. http://en.irct.ir/trial/1274 (first received 2 February 2011).

Zakaria 2017 {published data only}

Zakaria RB, ISRCTN21224268. A randomized trial of labour induction using the Foley catheter of different bores (French sizes 16, 22 and 28: 1 French size equals 0.33 mm). isrctn.com/ISRCTN21224268 (first received 29 October 2017).

Zhang 2014 (published data only)

Zhang L, NCT02202083. The comparison of oxytocin induced labor and cook balloon induced labor. clinicaltrials.gov/show/NCT02202083 (first received 28 July 2014).

Zimmer 1996 {published data only}

Zimmer EZ, Jakobi P, Weissman A. The effect of ripening the cervix with PGE2 or trancervical catheter on breathing and body movements. *Journal of Maternal-Fetal Investigation* 1996;**6**:104-6.

References to studies awaiting assessment

ACTRN12618000510246 2018 (published data only)

ACTRN12618000510246. Amongst women undergoing induction of labour using a balloon catheter, is leaving the balloon in for 6 hours, compared to 12 hours, associated with similar changes in the cervix to prepare for labour, similar clinical outcomes, and a similar healthcare experience?. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12618000510246. (2 April 2018) 2018.

Agboghoroma 2015 (published data only)

Agboghoroma CO, Ngonadi N. A randomized controlled study comparing prostaglandin e2 vaginal suppository with intracervical foleys catheter balloon for preinduction cervical ripening at term. West African Journal of Medicine 2015; Vol. 34, issue 2:77-82.

Amorosa 2017a {published data only}

Amorosa JM, Stone J, Factor SH, Booker W, Newland M, Bianco A. A randomized trial of foley bulb for labor induction in premature rupture of membranes in nulliparas (flip). *American Journal of Obstetrics and Gynecology* 2017;**217**(3):360.

Bauer 2018 (published data only)

Bauer AM, Lappen JR, Gecsi KS, Hackney DN. Cervical ripening balloon with and without oxytocin in multiparas: a randomized controlled trial. *American Journal of Obstetrics and Gynecology* 2018;**219**(3):294.e1-294.e6.

Chai 2018 (published data only)

Chai Y. Application effect of single balloon catheters in labor induction of pregnant women in late-term pregnancy and their influences on stress and inflammatory responses. *Experimental and Therapeutic Medicine* 2018;**15**(3):2968-72.

Cherian 2018 (published data only)

Cherian AG, CTRI/2018/10/016154. A randomized controlled trial comparing a 30-ml Foley catheter balloon without weight and a 30-ml Foley catheter balloon with 500gm weight [500ml of 5% DEXTROSE] for preinduction cervical ripening for women with past dates requiring Induction of labour. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=28074. (first received 25 October 2018) 2018.

CTRI/2018/01/011574 (published data only)

CTRI/2018/01/011574. Comparative evaluation of intravaginal slow release dinoprostone insert vs transcervical foleys catheter for induction of labour, in patients with poor bishops score - a randomized control study. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=21188 (first received 25 January 2018).

DeCesare 2018 {published data only}

DeCesare A, Decesare J, Manek K. Transcervical balloon catheter for cervical ripening: weighted traction or tension. *Obstetrics and Gynecology* 2018;**131**:47S.

de Vaan 2019 {published data only}

de Vaan M, Blel D, Bloemenkamp K, de Heus R, Willem de Leeuw J, Oudijk M, et al. 30: does mechanical induction of labor increase the risk of preterm birth in a subsequent pregnancy?. *American Journal of Obstetrics and Gynecology* 2019;**220**(1):S24.

Diguisto 2017 (published data only)

Diguisto C, Le Gouge A, Giraudeau B, Perrotin F. Mechanical cervicAl ripeninG for women with PrOlongedPregnancies (MAGPOP): protocol for a randomised controlled trial of a silicone double balloon catheter versus the Propess system for the slow release of dinoprostone for cervical ripening of prolonged pregnancies. *BMJ Open* 2017;**7**(9):e016069.

EUCTR2017-001914-27-GB 2018 {published data only}

EUCTR2017-001914-27-GB. Prostaglandin insert (Propess) versus tran-scervical balloon catheter for out-patient labour induction: A randomised controlled trial of feasibility (PROBIT-F) - Trans-cervical balloon catheter and prostaglandin for labour induction. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001914-27 (14 May 2018).

IRCT20170326033142N2 2018 {published data only}

IRCT20170326033142N2. Comparison of vaginal misoprostol with Foley catheter for cervical ripening and labor induction. https://en.irct.ir/trial/25642 (28 July 2018).



IRCT20170513033941N39 2018 {published data only}

IRCT20170513033941N39. Comparison of intravaginal misoprostol, seaweed Laminaria and Foley catheter for cervical ripening and induction of labor in term pregnant women. https://en.irct.ir/trial/33983 (21 October 2018).

IRCT20181123041731N1 2019 {published data only}

IRCT20181123041731N1. Investigation of the effect of misoprostol alone in comparison with misoprostol with Foley catheter on cervical ripening for labor induction in women with preterm premature rupture of the membrane. https://en.irct.ir/trial/35515. IRCT20181123041731N1 (27 January 2019).

Khatib 2019 (published data only)

Khatib N, Dabaja H, Lauterbach R, Beloosesky R, Ginsberg Y, Weiner Z, et al. 790: outcomes following medical induction compared to mechanical induction of labor in obese pregnant women. *American Journal of Obstetrics and Gynecology* 2019;**220**(1):S516.

Leigh 2018 (published data only)

Leigh S, Granby P, Haycox A, Mundle S, Bracken H, Khedikar V, et al. Foley catheter vs. Oral misoprostol to induce labour among hypertensive women in india: a cost-consequence analysis alongside a clinical trial. *BJOG*: an International Journal of Obstetrics and Gynaecology 2018;**125**(13):1734-42.

Lim 2018 {published data only}

Lim SE, Tan TL, Ng GY, Tagore S, Kyaw EE, Yeo GS. Patient satisfaction with the cervical ripening balloon as a method for induction of labour: a randomised controlled trial. *Singapore Medical Journal* 2018;**59**(8):419-24.

Mallah 2011 {published data only}

Mallah F, IRCT201012225448N1. Efficacy and side effects of transcervical catheter and vaginal misoprostol on cervical ripening. http://en.irct.ir/trial/5860 (first received 4 May 2011).

McGee 2018 (published data only)

McGee TM, Gidaszewski B, Khajehei M, Tse T, Gibbs E. Foley catheter silicone versus latex for term outpatient induction of labour: a randomised trial. Australian & New Zealand Journal of Obstetrics & Gynaecology 2018 [epub ahead of print].

Mohamad 2018 (published data only)

Mohamad A, Ismail NA, Rahman RA, Kalok AH, Ahmad S. A comparison between in-patient and out-patient balloon catheter cervical ripening: A prospective randomised controlled trial in PPUKM. *Medical Journal of Malaysia* 2018;**73**:22.

NCT03172858 2017 {published data only}

NCT03172858. A randomized trial of intracervical balloon placement versus intravenous oxytocin in women with premature rupture of membranes and unripe cervices. https://clinicaltrials.gov/ct2/show/NCT03172858 (1 June 2017).

NCT03399266 2018 {published data only}

NCT03399266. Mechanical induction of labor in women with previous cesarean section and premature rupture of membranes who desire TOLAC: a prospective randomized

study. https://clinicaltrials.gov/ct2/show/NCT03399266 (16 January 2018).

NCT03435458 2018 {published data only}

NCT03435458. Balloon to induce labor in generous women. https://clinicaltrials.gov/ct2/show/NCT03435458 (16 February 2018).

NCT03588585 2018 {published data only}

NCT03588585. A prospective, randomized comparison of tension versus no tension with foley transcervical catheters for pre-induction cervical ripening. https://clinicaltrials.gov/ct2/show/NCT03588585 (17 July 2018).

NCT03629548 (published data only)

NCT03629548. Comparing combined foley catheter balloon and pge2 vaginal ovule with early amniotomy and pge2 for induction of labor at term: a randomized study. https://clinicaltrials.gov/ct2/show/NCT03629548 (14 August 2018).

NCT03629548 2018 {published data only}

NCT03629548. Comparing foley catheter balloon with early amniotomy for induction of labor at term. Https://clinicaltrials.gov/show/nct03629548 (14 August 2018).

NCT03670836 2018 (published data only)

NCT03670836. Comparison of misoprostol ripening efficacy with Dilapan. Https://clinicaltrials.gov/show/nct03670836 (14 September 2018).

NCT03682718 2018 {published data only}

NCT03682718. Vaginal misoprostol with intracervical foley catheter in induction of labor. Https://clinicaltrials.gov/show/nct03682718 (25 September 2018).

NCT03744078 2018 {published data only}

NCT03744078. A randomized trial of foley bulb and pge2 for labor induction in premature rupture of membranes. https://clinicaltrials.gov/ct2/show/NCT03744078 (16 November 2018).

NCT03752073 2018 {published data only}

NCT03752073. Comparison of two mechanical methods of outpatient ripening of the cervix. https://clinicaltrials.gov/ct2/show/NCT03752073 (22 November 2018).

NCT03866772 2019 {published data only}

NCT03866772. Labor induction with double balloon device, oral misoprostol and concomitant use of both. multicenter randomized controlled trial- idom trial. https://clinicaltrials.gov/ct2/show/NCT03866772 (7 March 2019).

Oskei 2018 (published data only)

Oskei AD, Bayat F, Haji ZM, Kolifarhood G. Individual and combined administration of intravaginal misoprostol and transcervical foley catheter in cervical ripening in nulliparous women. *Iranian Journal of Obstetrics, Gynecology and Infertility* 2018;**21**(2):16-22.

Osoti 2018 {published data only}

Osoti A, Kibii DK, Tong TM, Maranga I. Effect of extra-amniotic Foley's catheter and vaginal misoprostol versus vaginal



misoprostol alone on cervical ripening and induction of labor in Kenya, a randomized controlled trial. *BMC Pregnancy and Childbirth* 2018;**18**(1):300.

Saad 2019 {published data only}

Saad A, Villareal J, Eid J, Spencer N, Ellis V, Hankins GD, et al. 21: a randomized controlled trial of pre-induction cervical ripening comparing dilapan-s versus foley balloon (dilafol trial). American Journal of Obstetrics and Gynecology 2019; Vol. 220, issue 1.

Saad AF, Villarreal J, Eid J, Spencer N, Ellis V, Hankins GD, et al. A randomized controlled trial of dilapan-s vs foley balloon for preinduction cervical ripening (dilafol trial). American Journal of Obstetrics and Gynecology 2019; Vol. 220, issue 3:275.e1-9.

Sanmugam 2018 (published data only)

Sanmugam S, ISRCTN16957529. Comparing two methods of stimulating the cervix (neck of the womb) to become ready for childbirth in women who have had one previous Caesarean and are at term in their pregnancy. http://www.isrctn.com/ISRCTN16957529. ISRCTN16957529 (14 November 2018) 2018.

Souizi 2018 (published data only)

Souizi B, Mortazavi F, Haeri S, Borzoee F. Comparison of vaginal misoprostol, laminaria, and isosorbide dinitrate on cervical preparation and labor duration of term parturient: a randomized double-blind clinical trial. *Electronic Physician* 2018;**10**(5):6756-63.

ten Eikelder 2017 {published data only}

ten Eikelder ML, van de Meent MM, Mast K, Rengerink KO, Jozwiak M, de Graaf IM, et al. Women's experiences with and preference for induction of labor with oral misoprostol or foley catheter at term. *American Journal of Perinatology* 2017;**34**(2):138-46.

Tulek 2018 (published data only)

Tulek F, Gemici A, Soylemez F. Double balloon catheters: a promising tool for induction of labor in multiparous women with unfavourable cervices. Journal of the Turkish German Gynecological Association 2018 [epub ahead of print].

Viteri 2019 {published data only}

Viteri OA, Tabsh KK, Lopez J, Fok R, Salazar XC, Alrais MA, et al. 22: transcervical ballon+vaginal misoprostol versus misoprostol for cervical ripening in nulliparous-obese women: a multicenter randomized trial. *American Journal of Obstetrics and Gynecology* 2019;**220**(1):S19-S20.

References to ongoing studies

Argilagos 2016 (published data only)

Argilagos AV, NCT02762942. Prospective randomized clinical trial comparing the effect of vaginal misoprostol synchronously with supracervical balloon versus vaginal misoprostol alone for induction of labor. clinicaltrials.gov/ct2/show/NCT02762942 (first received 5 May 2016).

Beckmann 2013 (published data only)

Beckmann M, ACTRN12614000039684. Prostaglandin inpatient induction of labour compared with balloon outpatient induction of labour: a randomised controlled trial. anzetr.org.au/Trial/Registration/TrialReview.aspx? ACTRN=12614000039684 (first received 9 December 2013).

Bekele 2017 (published data only)

Bekele D, PACTR201709002509200. A randomized controlled trial of sequential versus simultaneous use of foley balloon and oxytocin for induction of labor in nulliparous pregnant women. pactr.org/ATMWeb/appmanager/atm/atmregistry? dar=true&tNo=PACTR201709002509200 (first received 9 August 2017).

Berndl 2016 (published data only)

Berndl A, NCT02993432. High volume foleys increasing vaginal birth (high five birth) pilot trial. clinicaltrials.gov/ct2/show/record/NCT02993432 (first received 5 December 2016).

Bhide 2017 (published data only)

Bhide A, NCT03199820. Prostaglandin insert (propess) versus trans-cervical balloon catheter for out-patient labour induction: a randomised controlled trial of feasibility. clinicaltrials.gov/ct2/show/record/NCT03199820 (first received 27 June 2017).

Eser 2016 (published data only)

Eser A, NCT02861079. Compare prostaglandin e2 against to combined transcervical foley catheter balloon and vaginal prostaglandin e2 for induction of labor at term: a randomized study. clinicaltrials.gov/ct2/show/record/NCT02861079 (first received 1 August 2016).

Goli 2017 {published data only}

Goli G, IRCT2017052710340N13. Comparison the results of induction of vaginal misoprostol with Foley catheter in prolonged pregnancy with unripe cervix. http://en.irct.ir/trial/10863 (first received 26 June 2017).

Goonewardene 2016 {published data only}

Goonewardene M, SLCTR/2016/024. Oral misoprostol for 48 hours versus an intracervical Foley catheter for 48 hours for induction of labour in post dated pregnancies: a randomized control trial. http://slctr.lk/trials/551 (first received 12 October 2016).

Gupta 2016 {published data only}

Gupta J, NCT03001661. A randomised controlled trial of a synthetic osmotic cervical dilator for induction of labour in comparison to dinoprostone vaginal insErt: the SOLVE Trial. clinicaltrials.gov/ct2/show/record/NCT03001661 (first received 11 November 2016).

Hassanzadeh 2017 {published data only}

Hassanzadeh E, IRCT2017010731725N1. Misoprostol versus foley catheter for cervical ripening in women with preeclampsia or gestational hypertension. http://en.irct.ir/trial/24897http://en.irct.ir/trial/24897 (first received 20 February 2017).



Igwe 2017 (published data only)

Igwe M, NCT02574338. Cervical ripening: a comparison between intravaginal misoprostol tablet and intracervical foley's catheter in a low resource setting. clinicaltrials.gov/ct2/show/record/NCT02574338 (first received 20 February 2017).

Lacarin 2017 {published data only}

Lacarin P, NCT03310333. Comparison between two strategies of induction in case of unfavourable cervix after 12 hours of premature rupture of membranes (prom) at term: cook cervical ripening + oxytocine from 6 hours versus dinoprostone vaginal insert. clinicaltrials.gov/show/NCT03310333 (first received16 October 2017).

Lauterbach 2017 (published data only)

Lauterbach R, NCT03033264. A comparison between labor induction with dinoprostone and a cervical ripening balloon in women with a BMI>30 as oppose with a BMI<30. clinicaltrials.gov/ct2/show/record/NCT03033264 (first received 26 January 2017).

Levy 2016 (published data only)

Levy R, NCT02815865. A randomized controlled study comparing cervical foley catheter, vaginal dinoprostone and a combination of the two methods for induction of labor. clinicaltrials.gov/ct2/show/record/NCT02815865 (first received26 February 2016).

Osoti 2016 (published data only)

Osoti A, PACTR201604001535825. A combination of foley balloon and misoprostol versus misoprostol alone for induction of labour at Kenyatta national hospital, a randomized controlled trial. http://www.pactr.org/ATMWeb/appmanager/atm/atmregistry?dar=true&tNo=PACTR201604001535825 (first received 14 March 2016).

Park 2012 (published data only)

Park KH, NCT01596296. Foley catheter versus dinoprostone vaginal insert for induction of labor in parous women at term: a randomized trial. clinicaltrials.gov/ct2/show/record/NCT01596296 (first received 9 May 2012).

Perrotin 2016 (published data only)

Perrotin F, NCT02907060. Propess® versus double balloon for cervical ripening of prolonged pregnancies: a randomised controlled trial. clinicaltrials.gov/ct2/show/record/NCT02907060 (first received 6 September 2016).

Tagore 2015 {published data only}

Tagore S, NCT02620215. Cervical ripening balloon in induction of labour at term (crbii) - a prospective randomized controlled trial. clinicaltrials.gov/show/NCT02620215 (first received 2 December 2015).

Viteri 2015 {published data only}

Viteri OA, NCT02639429. The efficacy of transcervical foley balloon plus vaginal misoprostol versus vaginal misoprostol alone for cervical ripening in nulliparous obese women: a randomized, comparative effectiveness trial. clinicaltrials.gov/show/NCT02639429 (first received 15 December 2015).

Wise 2016 (published data only)

Wise M, ACTRN12616000739415. Comparison of low-risk pregnant women undergoing induction of labour at term by outpatient balloon or inpatient prostaglandin in order to assess vaginal birth rate; a randomised controlled trial. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx? ACTRN=12616000739415 (first received 15 March 2016).

Yildirim 2017 {published data only}

Yildirim GY/NCT03016442. Dinoprostone vaginal insert versus double balloon catheter for preinduction cervical ripening. clinicaltrials.gov/ct2/show/record/NCT03016442 (first received 10 January 2017).

Additional references

Abramovici 1994

Abramovici H, Hallak M, Zarfati D, Packer T, Calderon I, Auslender R, et al. Induction of labor in patients with unfavorable cervices: a randomized comparison among intravaginal prostaglandin E2 (PGE2), intravenous oxytocin, and the double-balloon ripener device. *International Journal of Gynecology & Obstetrics* 1994;**46**:7.

Alferivic 2009

Alfirevic Z, Kelly AJ, Dowswell T. Intravenous oxytocin alone for cervical ripening and induction of labour. *Cochrane Database of Systematic Reviews* 2009, Issue 4. [DOI: 10.1002/14651858.CD003246.pub2]

Alfirevic 2014

Alfirevic Z, Aflaifel N, Weeks A. Oral misoprostol for induction of labour. *Cochrane Database of Systematic Reviews* 2014, Issue 6. [DOI: 10.1002/14651858.CD001338.pub3]

Alfirevic 2016

Alfirevic Z, Keeney E, Dowswell T, Welton NJ, Medley N, Dias S, et al. Which method is best for the induction of labour? A systematic review, network meta-analysis and cost-effectiveness analysis. *Health Technology Assessment* 2016;**20**:65.

Boulvain 2005

Boulvain M, Stan CM, Irion O. Membrane sweeping for induction of labour. *Cochrane Database of Systematic Reviews* 2005, Issue 1. [DOI: 10.1002/14651858.CD000451.pub2]

Boulvain 2008

Boulvain M, Kelly AJ, Irion O. Intracervical prostaglandins for induction of labour. *Cochrane Database of Systematic Reviews* 2008, Issue 1. [DOI: 10.1002/14651858.CD006971]

Bricker 2000

Bricker L, Luckas M. Amniotomy alone for induction of labour. *Cochrane Database of Systematic Reviews* 2000, Issue 4. [DOI: 10.1002/14651858.CD002862]

Chen 2016

Chen W, Xue J, Peprah MK, Wen SW, Walker M, Gao Y, et al. A systematic review and network meta-analysis comparing



the use of Foley catheters, misoprostol, and dinoprostone for cervical ripening in the induction of labour. *BJOG:* an international journal of obstetrics and gynaecology 2016;**123**(3):346-54.

Curtis 1987

Curtis P, Evans S, Resnick J. Uterine hyperstimulation. The need for standard terminology. *Journal of Reproductive Medicine* 1987;**32**:91-5.

Du 2017

Du YM, Zhu LY, Cui LN, Jin BH, Ou JL. Double-balloon catheter versus prostaglandin E2 for cervical ripening and labour induction: a systematic review and meta-analysis of randomised controlled trials. *BJOG: an international journal of obstetrics and gynaecology* 2017;**124**:891-9.

Higgins 2011

Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Hofmeyr 2009

Hofmeyr GJ, Alfirevic Z, Kelly AJ, Kavanagh J, Thomas J, Neilson JP, Dowswell T. Methods for cervical ripening and labour induction in late pregnancy: generic protocol. *Cochrane Database of Systematic Reviews* 2009, Issue 3. [DOI: 10.1002/14651858.CD002074.pub2]

Hofmeyr 2010

Hofmeyr GJ, Gülmezoglu AM, Pileggi C. Vaginal misoprostol for cervical ripening and induction of labour. *Cochrane Database of Systematic Reviews* 2010, Issue 2. [DOI: 10.1002/14651858.CD000941]

Howarth 2001

Howarth G, Botha DJ. Amniotomy plus intravenous oxytocin for induction of labour. *Cochrane Database of Systematic Reviews* 2001, Issue 3. [DOI: 10.1002/14651858.CD003250]

Krammer 1995b

Krammer J, O'Brien WF. Mechanical methods of cervical ripening. *Clinical Obstetrics and Gynecology* 1995;**38**(3):280-6.

Liu 2018

Liu YR, Pu CX, Wang XY, Wang XY. Double-balloon catheter versus dinoprostone insert for labour induction: a meta-analysis. Archives of Gynecology and Obstetrics 2018;299:7-12.

McMaster 2015

McMaster K, Sanchez-Ramos L, Kaunitz AM. Evaluation of a transcervical Foley catheter as a source of infection: a systematic review and meta-analysis. *Obstetrics and Gynecology* 2015;**126**(3):539-51.

NHS 2017

NHS Digital. NHS Maternity Statistics 2016-2017. https://files.digital.nhs.uk/pdf/l/1/hosp-epis-stat-mat-repo-2016-17.pdf.

NICE 2008

NICE. Induction of Labour. Clinical Guideline CG70. https://www.nice.org.uk/guidance/CG70.

RevMan 2014 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Ten Eikelder 2016

Ten Eikelder ML, Mast K, van der Velden A, Bloemenkamp KW, Mol BW. Induction of labor using a Foley catheter or misoprostol: a systematic review and meta-analysis. *Obstetrical and Gynecological Survey* 2016;**71**(10):620-30.

Thiery 1989

Thiery M, Baines CJ, Keirse MJ. The development of methods for inducing labour. In: Chalmers I, Enkin MW, Keirse MJNC editor(s). Effective Care in Pregnancy and Childbirth. Oxford: Oxford University Press, 1989:971.

Thomas 2014

Thomas J, Fairclough A, Kavanagh J, Kelly AJ. Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. *Cochrane Database of Systematic Reviews* 2014, Issue 6. [DOI: 10.1002/14651858.CD003101.pub3]

Wang 2016

Wang H, Hong S, Liu Y, Duan Y, Yin H. Controlled-release dinoprostone insert versusFoley catheter for labor induction: a meta-analysis. *Journal of Maternal-Fetal & Neonatal Medicine* 2016;**29**(14):2382-8.

WHO 2011

World Health Organization. WHO recommendations for Induction of labour. http://apps.who.int/iris/bitstream/handle/10665/44531/9789241501156_eng.pdf?sequence=1 2011.

Zhu 2018

Zhu L, Zhang C, Cao F, Liu Q, Gu X, Xu J, et al. Intracervical Foley catheter balloon versus dinoprostone insert for induction cervical ripening: a systematic review and meta-analysis of randomized controlled trials. *Medicine* 2018;**97**(48):e13251.

References to other published versions of this review

Boulvain 2001

Boulvain M, Kelly AJ, Lohse C, Stan CM, Irion O. Mechanical methods for induction of labour. *Cochrane Database of Systematic Reviews* 2001, Issue 4. [DOI: 10.1002/14651858.CD001233]

Jozwiak 2012

Jozwiak M, Bloemenkamp KW, Kelly AJ, Mol BW, Irion O, Boulvain M. Mechanical methods for induction of labour. *Cochrane Database of Systematic Reviews* 2012, Issue 3. [DOI: 10.1002/14651858.CD001233.pub2]



Keirse 1995

Keirse MJNC. Mechanical methods for cervical ripening. [revised 03 April 1992] In: Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C (eds.) Pregnancy and Childbirth Module. In: The Cochrane Pregnancy and Childbirth Database [database on

disk and CDROM]. The Cochrane Collaboration; Issue 2, Oxford: Update Software:Update Software; 1995.

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Aduloju 2016

Methods	RCT	
Participants	Inclusion: life singleton pregnancy, cephalic presentation, intact membranes, > 37 weeks, indication for IOL, reactive non stress test. unfavourable cervix (BS < 6)	
	Exclusion: IFD, no prenatal care in study centre, contraindication for vaginal delivery	
Interventions	A: Foley catheter: 16F, 30 mL (n = 70), max 12 hours, if necessary another Foley for 12 hours (n = 70)	
	B: Foley catheter (16F, 30 cc) + vaginal misoprostol 25 ug every 6 hours(n = 70), max dose 100 ug (4 gifts) $(n = 70)$	
	C: Vaginal misoprostol alone 25 ug every 6 hours (n = 70) max dose 100 ug (4 gifts) (n = 70)	
	Max induction time all groups: 24 hours	
Outcomes	Vaginal delivery rate, time interval to achieve favourable cervix, induction delivery interval, oxytocin use, AS at 1 and 5 minutes, asphyxia, NICU admission, uterine tachysystole, uterine hypertonus, hyperstimulation, uterine rupture, FHR abnormalities	
Notes	Setting: Ekiti State University Teaching tertiary healthcare institution; referral centre for primary and secondary healthcare facilities, 2400 deliveries annually, Nigeria	
	Study period: 1 September, 2014 and 31 August, 2015.	
	Funding: no grant or fund was received	
	Declaration of interest: no conflict of interest	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Blocked randomisation using random table computer-generated numbers
Allocation concealment (selection bias)	Low risk	Sealed opaque envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not mentioned



Aduloju 2016 (Continued)		
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT not mentioned, but is probably the case looking at Figure 1. no missing data or cases. $ \\$
Selective reporting (reporting bias)	Low risk	All pre-specified outcome measures were reported,
Other bias	Low risk	No other bias detected

Ahmed 2016

Methods	RCT		
Participants	Inclusion: postdate pregnancy (> 40 weeks) singleton gestation, intact membranes, cephalic fetal BS \leq 4		
	Exclusion: previous caesarean deliveries, EFW > 4000 g, non-reassuring fetal conditions, ruptured membranes, placenta previa, malpresentation		
Interventions	Foley catheter (n = 39), 18 F, filled with 50 mL		
	Cook balloon (n = 39), filled with 80/80 mL		
	Max of 12 hours of priming		
Outcomes	Cervical ripening and BS after 12 hours, VAS for catheter insertion, catheter insertion (easy, moderate or difficult), VAS for patient satisfaction after birth, insertion expulsion time, insertion amniotomy time, insertion delivery time and mode of delivery. Abnormal fetal presentation, cord prolapse, bleeding related to catheter insertion that required removal of the catheter and AS		
Notes	Setting: Gynaecology, Suez Canal University Hospital, Egypt		
	Study period: March 2013 to April 2014		
	Funding: not mentioned		
	Declaration of interest: none declared		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Shuffling 78 envelopes, 1:1
Allocation concealment (selection bias)	Low risk	Sealed envelopes, opaque?
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described



Ahmed 2016 (Continued)		
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT not mentioned, 2 women excluded because of failed placement. no missing data mentioned
Selective reporting (re-	High risk	Pre-specified outcomes bleeding after insertion, cord prolapse and abnormal
porting bias)	6	fetal presentation not described in results

Al-Ibraheemi 2018

Methods	RCT	
Participants	Inclusion: > 37 weeks, singleton fetus, cephalic, BS ≤ 6	
	Exclusion: rupture of membranes, regular uterine contractions (3 or more contractions per 10 minutes), prior uterine surgery, multiple gestations, malpresentation, contraindication to PGs, non-reassuring FHR tracing, vaginal bleeding, fetal demise, anomalous fetus, or any contraindication to vaginal delivery	
Interventions	Foley catheter + misoprostol: (n = 100) 30 mL balloon, filled with 60 mL, gentle traction, max 24 hours and misoprostol vaginal 4-hourly with a max of 6 doses,	
	Misoprostol (n = 100) 25 ug vaginally, 4-hourly with a max of 6 doses	
Outcomes	Time from placement of the first misoprostol dose to delivery, time to active phase (6 cm or greater), time from active phase to delivery, caesarean delivery rate, uterine tachysystole, estimated blood loss, chorioamnionitis, cord blood pH, 5-minute AS, NICU admission.	
Notes	Setting: from the Department of Obstetrics and Gynecology, Mount Sinai West Hospital, New York	
	Study period: September 2015 to July 2016	
	Funding: not described	
	Declaration of interest: none declared	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated sequence
Allocation concealment (selection bias)	Low risk	Sequentially-numbered opaque, sealed envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not reported



Al-Ibraheemi 2018 (Continued)		
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis, no missing data or cases
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Al-Taani 2004

Methods	Randomised trial, random number table, blinding unclear.	
Participants	Grand multiparous women, BS 5 or less, singleton term pregnancy, intact membranes, cephalic presentation, good fetal condition.	
	Exclusion: previous CS, contraindications for vaginal birth, suspected cephalopelvic disproportion, unexplained antenatal haemorrhage.	
Interventions	Foley catheter 50 mL (72).	
	(PGE2) tablet 3 mg (75), 6-hourly.	
Outcomes	Route of delivery, change in BS, intrapartum complications, need for augmentation.	
Notes	Setting: Queen Alia military hospital, Amman, Jordan	
	Dates of study:September 2001 - August 2003	
	Funding: not reported	
	Declarations of interest: not reported	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table.
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT nor reported, bu seems reasonable as the numbers in both groups are equal to randomised numbers. missing outcome data mentioned.



Al-Taani 2004 (Continued)		
Selective reporting (reporting bias)	Low risk	All primary and secondary outcomes are reported as pre-specified.
Other bias	Low risk	No other bias detected

Allouche 1993

Methods	RCT. No details were given on the method for concealment of the allocation.		
Participants	BS < 6, vertex, singleton, no previous CS.		
Interventions	PGE2 (Prepidil 0.5 mg) intracervical (59 women); Foley 50 mL (60 women); PGE2 (Prepidil 0.5 mg) and Foley 50 mL extra-amniotic (63 women).		
Outcomes	Uterine hyperstimulation, discomfort during the procedure, maternal and neonatal infection.		
Notes	Setting: not reported		
	Dates of study:between April and December 1992		
	Funding sources: not reported		
	Declarations of interest: not reported		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only stated women were randomly allocated
Allocation concealment (selection bias)	Unclear risk	Unclear
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT not mentioned, no missing data or cases reported
Selective reporting (reporting bias)	Unclear risk	No outcomes pre-specified
Other bias	Low risk	No other bias detected



Methods	RCT		
Participants	Inclusion: PROM, age ≥	: 18 years, viable fetus, cephalic, singleton, GA > 34 weeks, < 3 cm dilation	
	Exclusion: multifetal gestation, a known anomalous fetus, malpresentation, latex allergy, unexp vaginal bleeding or contraindication to vaginal delivery (such as a placenta previa), antibiotics, pous uterine surgery, spontaneous labour		
Interventions	Foley catheter (n = 61) 16F, 30 mL balloon filled with 60 mL saline, traction applied (no max time described), oxytocin started after 1 hour		
	Oxytocin alone directly (n = 68)		
	Oxytocin in both group	os, started 2 mU/minute, max 30 mU/minute	
Outcomes	The primary outcome measure was time from start of induction to delivery. Secondary outcomes included mode of delivery, tachysystole, chorioamnionitis, postpartum haemorrhage, neonatal AS, and admission to the NICU.		
Notes	Setting: Mount Sinai Hospital, New York, USA		
	Study period: August 2014 to September 2016		
	Funding: not reported		
	Declaration of interest: none declared		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence generation (selection bias)	Low risk	Computer-generated numbers	
Allocation concealment (selection bias)	Low risk	Sequential numbered sealed, opaque envelopes	
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention	
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported	
Incomplete outcome data (attrition bias) All outcomes	Low risk	Modified ITT, (1 woman excluded who afterwards did not met the inclusion criteria), no missing data or cases	
Selective reporting (re-	Low risk	All pre-specified outcome measures were reported in results	

Low risk

porting bias)

Other bias

No other bias detected



Atad 1996		
Methods	RCT. Computer-generated sequence. No details were given on the method for concealment of the allocation.	
Participants	Singleton vertex term pregnancies with intact membranes, BS < 5 without previous CS.	
Interventions	Atad ripening device (35 women); PGE2 intravaginal tablets 3 mg (30 women); oxytocin (30 women).	
Outcomes	Need for another method, CS, change in BS.	
Notes	Also reported as abstract (Abramovici 1994).	
	Setting: Israel	
	Study period: not reported	
	Funding: not reported	
	Declarations of interest: J Atad has a patent licensing arrangement for Atad ripening device and thus has the potential gain from its sales	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer random-generated allocation list
Allocation concealment (selection bias)	Unclear risk	Unclear
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	No ITT reported, but seems reasonable as numbers in tables are equal to randomised numbers, no missing data or cases
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported
Other bias	Low risk	No other bias detected

Bagratee 1990

Methods	RCT. Random number tables, stratified for parity. No details were given on the method for concealment of the allocation.
Participants Women with unfavourable cervix (BS < 7).	
Interventions	Lamicel (40 women);



Bagratee 1990 (Continued)	(PGE2) (2 mg tablet) (40 women). After 6 hours, oxytocin was started in both groups.	
Outcomes	CS, hyperstimulation, fetal distress, perinatal death.	
Notes	No outcome reported in subgroups.	
	setting: king Edward VIII hospital, Durban, South Africa	
	Study period: for 6 months, no exact dates reported	
	Funding: not reported	
	Declarations of interest: not reported	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number tables
Allocation concealment (selection bias)	Unclear risk	Unclear, not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	No ITT mentioned, in table 4 cases missing, not clear why.
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported
Other bias	Low risk	No other bias detected

Barda 2018

Methods	RCT	
Participants	Inclusion criteria: GA \geq 37 weeks, parity 1 to 3, singleton pregnancy with a vertex presentation, BS less than 5) and intact membranes.	
	Exclusion criteria: previous CS, lack of prenatal care, contraindication for vaginal delivery	
Interventions	Foley catheter (n = 150): 22 F, 80 mL balloon (max 18 hours)	
	Dinoproston (n = 150): 3 mg tablets (every 8 hours, max 2 gifts)	



Barda 2018 (Continued)	
Outcomes	Start induction to active labour (4 cm dilatation and 80% effacement), labour within 24 hours, CS rate, excessive haemorrhage, chorioamnionitis, non-reassuring FHR, fetal pH, NICU admission, early neonatal sepsis
Notes	Setting: Edith Wolfson Medical Centre, Holon, Israel
	Study period: June 2015 - July 2016
	Funding: not reported
	Declarations of interest: none declared

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Random assigned; not described how this was done. In trial registration => parallel assignment.
Allocation concealment (selection bias)	Unclear risk	Random assigned; not described how this was done. In trial registration => parallel assignment.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT, no tables available, so incomplete data can not be judged, no missing data described
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Unclear risk	Full text is an accepted manuscript without tables, therefore risk of bias can- not properly be determined

Benzineb 1996

Methods	RCT. Blocks of 10 women. No other details were given on the method for randomisation and on concealment of the allocation.	
Participants	Singleton vertex term pregnancies with intact membranes, BS < 6.	
Interventions	Foley catheter inflated with 40 mL of water (50 women); PGE2 intracervical gel 0.5 mg every 24 hours. (n = 50?)	
Outcomes	Vaginal delivery not achieved within 24 hours, CS, perinatal deaths, cervix unchanged after 24 hours, postpartum haemorrhage.	
Notes	Setting: Charles Nicolle Hospital, Tunis	
	Dates of study: not reported	



Benzineb 1996 (Continued)

Funding: not reported

Declarations of interest: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only reported women were random allocated in blocks of 10
Allocation concealment (selection bias)	Unclear risk	Unclear. not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT not mentioned, no missing data or cases reported
Selective reporting (reporting bias)	Unclear risk	Outcomes not pre-specified
Other bias	Low risk	No other bias detected

Biron-Shental 2004

Methods	Randomised trial.			
Participants	Term, singleton pregnancy BS 4 or less, medical indication for labour induction.	Term, singleton pregnancy BS 4 or less, medical indication for labour induction.		
Interventions	PGE 2 gel 2 mg (27).			
	Double balloon catheter (26)			
	combined (24)			
Outcomes	Change in BS, need for oxytocin augmentation.			
Notes	Outcomes of interest not reported.			
	Setting: Israel			
	Study period: not reported			
	Funding: not reported			
	Declarations of interest: not reported			



Biron-Shental 2004 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated sequence.
Allocation concealment (selection bias)	Unclear risk	Not mentioned.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Brief communication, for the reported data no missing. Incomplete outcome data not further mentioned in this report.
Selective reporting (reporting bias)	Unclear risk	Our outcomes of interest are not reported here, main outcome is change in BS.
Other bias	Unclear risk	Hard to say, very short report, our outcomes of interest not mentioned, not clear how sample size was calculated.

Blumenthal 1990

Methods	RCT. Randomisation by drawing a blank envelope from a stack of 50 identical envelopes containing the group allocation.		
Participants	Vertex, intact membranes, BS < 5, no previous CS.		
Interventions	Dilapan (polyacrilonitrile hydrogel) inserted in the cervix, up to 6 sticks (23 women); Laminaria inserted in the cervix, as many as possible (18 women).		
Outcomes	CS.		
Notes	Results for a 3rd group of women with favourable cervix treated with oxytocin are presented. These women are not be included in the analysis, as they were not randomly allocated to the intervention.		
	Setting: Michael Reese hospital, Chicago, USA		
	Study period:January 1987 to January 1988		
	Funding: not reported		
	Declarations of interest: not reported		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Shuffling envelopes



Blumenthal 1990 (Continued)		
Allocation concealment (selection bias)	Low risk	Women choose from stack of all blank, identical envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT not reported. no explanation what happened to the rest of the randomised women
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported
Other bias	Low risk	No other bias detected

Browne 2011

Methods	RCT		
Participants	Inclusion criteria: single, live fetus, cephalic, presentation,reassuring fetal health assessment, GA between 26 and 42 weeks, Maternal age 18 and above, BS less than 5		
	Exclusion criteria: multiple gestation (twins, triplets, quadruplets), fetal demise		
	Fetal malpresentation, EFW less than 500 g or more than 4000 g, placenta previa, non-reassuring fetal health assessment		
	Maternal asthma, Latex allergy, spontaneous labour, other contraindication to vaginal delivery		
Interventions	Balloon: (n = 34): 40 mL, under traction, max 6 hours.		
	PGE2 vaginal (36): prepidil gel in fornix posterior, no oxytocin in 6 hours after gel is applied		
	balloon and PGE2 (31): 40 mL, under traction. prepidil gel inserted through catheter.		
Outcomes	CS		
Notes	Grey literature: not published. primary outcomes reported in trial registration		
	Setting: USA		
	Study period: July 2010 - February 2013		
	Funding: not reported		
	Declarations of interest: not reported		
Risk of bias			
Bias	Authors' judgement Support for judgement		



Browne 2011 (Continued)		
Random sequence generation (selection bias)	Low risk	Randomisation envelopes prepared by statisticians at the University of South Carolina Arnold School of Public Health. The investigator was given the next sequentially-numbered study envelope by the patient's nurse.
Allocation concealment (selection bias)	Low risk	Sealed envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT not reported. case missing for relevant outcome (CS)
Selective reporting (reporting bias)	High risk	Only primary outcome en adverse events reported
Other bias	Unclear risk	Study not published, not clear why.

Carbone 2013

Bias	Authors' judgement Support for judgement		
Risk of bias			
	Declarations of interest: none declared		
	Funding: not reported		
	Study period: January 2011 to April 2012		
Notes	Setting: USA		
Outcomes	Induction to delivery time, mode of delivery, tachysystole, postpartum haemorrhage (> 500 cc), chorioamnionitis, neonatal AS and NICU admission.		
	Not mentioned for how long misoprostol and/or Foley was given in total.		
	misoprostol alone (n = 61): 25 mcg vaginal misoprostol every 4 hours		
Interventions	Foley + misoprostol (n = 56): 25 mcg vaginal misoprostol every 4 hours AND Foley catheter filled with 60 mL saline; taped to the inner thigh under gentle traction.		
	Exclusion: malpresentation, multifetal gestation, spontaneous labour, contraindication to PGs, fetal growth restriction, anomalous fetus, fetal demise, previous CS, or other uterine surgery.		
Participants	Inclusion: singleton, viable gestation (≥ 24 weeks), cephalic, intact membranes, BS < 7		
Methods	RCT		



Carbone 2013 (Continued)		
Random sequence generation (selection bias)	Low risk	Computer-generated sequence
Allocation concealment (selection bias)	Low risk	Opaque envelopes, not stated if these were sequential numbered
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT, no missing data or cases
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Casey 1995

Methods	RCT. No details were given on the method for concealment of the allocation.		
Participants	Singleton term pregnancies, BS < 6.		
Interventions	PGE2 intracervical gel and intracervical Foley catheter inflated with 50 cc (78 women); PGE2 intracervical gel (68 women).		
Outcomes	CS.		
Notes	Abstract only.		
	Setting: USA		
	Study period: not reported, 11-month period		
	Funding: not reported		
	Declarations of interest: not reported		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only reported it was a RCT
Allocation concealment (selection bias)	Unclear risk	Not reported



Casey 1995 (Continued)		
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Too little information to judge
Selective reporting (reporting bias)	Unclear risk	Too little information to judge
Other bias	Unclear risk	Abstract only

Chavakula 2015

Methods	RCT
Participants	Inclusion: singleton, cephalic, fetal growth restriction, ≥ 34 weeks.
	Exclusion: previous caesarean deliveries, uterine surgery, a multiple pregnancy, ruptured membranes, a BS > 6, severe fetal growth restriction, abnormal FHR prior to induction, pre-partum haemorrhage.
Interventions	1. Foley catheter (n = 54) 16F, 30 mL, catheter was removed after 12 hours.
	2. Vaginal misoprostol (n = 46) every 6 hours, 25 mcg, max 3 doses
Outcomes	Hyperstimulation with FHR changes, BS at AROM, duration of induction to delivery, vaginal delivery within 12 hours and 24 hours, CS, oxytocin, chorioamnionitis, antibiotics, NICU admission, AS < 7 at 5 minutes, patients and caregiver satisfaction (VAS score)
Notes	Setting: tertiary care teaching hospital in South India with approximately 13,000 deliveries per year.
	Study period:December 2011 to June 2012.
	Funding: not stated
	Declarations of interest: none declared

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated sequence, block randomisation
Allocation concealment (selection bias)	Low risk	Sequentially-numbered opaque, sealed envelopes
Blinding of participants and personnel (perfor- mance bias)	Unclear risk	Not feasible due to nature of intervention



Chavakula 2015 (Continued)

All outcomes

Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis, no missing data or cases
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Chua 1997

Methods	RCT. Random number table, no details on the method of concealment of the allocation.		
Participants	Singleton vertex presentation, unfavourable cervix (BS < 6). 185 women recruited (90 in Dilapan group, 95 in PGE2 group).		
Interventions	Dilapan group: 4 dilators. PGE2 Gel (Prepidil): 0.5 mg. In both groups, ripening was followed by rupture of membranes and oxytocin after 12 hours.		
Outcomes	Need for oxytocin, CS, instrumental delivery, uterine rupture, uterine hyperstimulation, admission to NICU, perinatal death.		
Notes	Setting: National University hospital, Singapore		
	Study period: not reported		
	Funding: not reported		
	Declarations of interest: not reported		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported



Chua 1997 (Continued)		
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT not mentioned but seems reasonable as numbers in tables are equal to randomised numbers, no reporting of missing cases or outcomes
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported
Other bias	Low risk	No other bias detected

Cromi 2011

Methods	RCT	
Participants	Inclusion: singleton gestation, vertex presentation, BS \leq 6, intact membranes, GA \geq 34 weeks, reassuring FHR tracing	
	Exclusion: Women with antepartum bleeding, intrauterine fetal death, previous uterine scars, known allergy to latex, placenta previa, contraindication to vaginal delivery	
Interventions	24-hour Foley (n = 133): 18F, 50cc, 24 hours	
	12-hour Foley (n = 132): 18F, 50cc, 12 hours	
	PGE2 vaginal insert 10 mg (n = 132): vaginal fornix, 24 hours	
Outcomes	vaginal delivery within 24 hours, improvement in BS after ripening, caesarean delivery, ripening-to-de- livery interval, oxytocin administration, epidural request, neonatal outcomes.	
Notes	Setting:Obstetrics Department of University of Insubria, Varese, Italy.	
	Study period: July 2008 to June 2010	
	Funding: none reported	
	Declarations of interest: not reported	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated block randomisation
Allocation concealment (selection bias)	Unclear risk	Allocation not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias)	Low risk	ITT, no missing data or cases.



Cromi 2011 (Continued)

All outcomes

Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Cromi 2012

Methods	RCT
Participants	210 patients. Inclusion: singleton gestation, vertex presentation, BS ≤ 6, intact membranes, GA > 34 weeks, and reassuring fetal heart tracing on admission. Exclusion:antepartum bleeding, intrauterine fetal death, prior uterine scars, positive vaginal or rectal group B streptococcus screening cultures, placenta previa, other contraindication to vaginal delivery.
Interventions	Double-balloon catheter (n = 105): inflated with 50 mL in either balloon. The double-balloon device was left in place for approximately 12 hours. Dinoprostone vaginal insert 10-mg controlled-release (n = 105): in the vaginal fornix, max 24 hours
Outcomes	Vaginal delivery within 24 hours, improvement in the BS after ripening, caesarean delivery rates, ripening-to-delivery interval, oxytocin administration, epidural request, NICU admission, AS < 7 at 5 minutes, umbilical artery pH < 7.00.
Notes	Setting: University of In-subria, Varese, Italy
	Study period: October 2010 to October 2011
	Funding: not reported
	Declarations of interest: none declared

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated randomisation scheme
Allocation concealment (selection bias)	Low risk	Concealment by keeping random allocation sequence in a file cabinet with access restricted to research staff?
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	Not an ITT analysis, women excluded after failed placement balloon or need for PGE2 gel after suppository expulsion.



Cromi 2012 (Continued)		
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in result
Other bias	Low risk	No other bias detected

Culver 2004

Methods	RCT, computer-generated block randomisation 4 and 6, consecutively numbered envelopes.
Participants	Nulliparous women GA 28 or more weeks, BS < 6, intact membranes, singleton, cephalic presentation,
	Exclusion: previous uterine surgery, non-reassuring FHR, latex allergy, contraindication to vaginal birth.
Interventions	Foley 30 cc + concurrent oxytocin (83 patients analysed).
	Misoprostol 25 mcg intravaginally 4-hourly, oxytocin augmentation after ripening. (79 patients analysed.)
Outcomes	Primary: CS
	Secondary: tachysystole, hyperstimulation, abnormal FHR tracing, intrapartum and postpartum fever, use of antibiotics, estimated blood loss, blood transfusions, AS, neonatal resuscitation, admission to ICU, meconium aspiration, sepsis, death.
Notes	Power analysis showed 266 patients were to be included, 173 were randomised. Study was stopped because principle investigator moved to other hospital. 11 patients were excluded from analysis, either received other treatment, or incomplete data.
	Setting: North Caroline Women's hospital and WakeMed hospital, North Carolina, USA
	Study period: June 1999 to April 2001
	Funding: not reported
	Declarations of interest: not reported

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated sequence.
Allocation concealment (selection bias)	Low risk	Consecutively numbered envelopes.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	9 patients had incomplete records (4 and 5 in both groups), they were excluded.



Culver 2004 (Continued)		2 patients (1 in every group) who did not receive the treatment were excluded, but otherwise ITT.
Selective reporting (reporting bias)	Low risk	All pre-specified outcome measures are reported.
Other bias	High risk	Recruitment goal was not reached, because PI moved to another institution.

Dalui 2005

Methods	Randomised prospective study, randomisation method unclear.
Participants	Singleton live fetus in cephalic presentation, 33-42 weeks GA, intact membranes, BS < 4
	Exclusion: APH, scarred uterus, low-located placenta, cervicovaginal infection, history of cardiac disease, glaucoma, convulsive disorder, asthma, jaundice.
Interventions	Foley catheter 30 mL 12 hours, followed by oxytocin (n = 50).
	PGE2 gel 0.5 mg endocervically oxytocin augmentation after 12 hours (n = 50).
Outcomes	Bischop score after 12 hours, percentage of subjects entering spontaneous labour, insertion-expulsion interval Foley, induction-delivery interval, amount of oxytocin used, mode of delivery, side effects.
Notes	No power calculation, BS lower than most studies, no notes on method of randomisation
	Setting: Nehru Hospital, PGIMER, Chandigarh, India
	Study period: not reported
	Funding: not reported
	Declarations of interest: not reported

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	'Randomised' method not described.
Allocation concealment (selection bias)	Unclear risk	'Randomised' method not described.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	Although ITT not mentioned, it seems ITT was used. no missing cases or data



Dalui 2005 (Continued)		
Selective reporting (reporting bias)	Low risk	All pre=specified data are reported, except for expulsion interval of Foley catheter (this is not an outcome of interest for this review).
Other bias	Low risk	No other bias detected

Deo 2012

Methods	RCT
Participants	Inclusion: full-term singleton gestation, cephalic presentation, indication for IOL. BS < 6. Exclusion: rupture of membranes, antepartum bleeding, placenta praevia, previous induction or preinduction agent during the pregnancy.
Interventions	Foley catheter (n = 50): 16 F with 30 mL balloon, traction applied. no max hours described. Misoprostol vaginal (n = 54): 25 ug post fornix, every 4 hours max 8 doses. Dinoprostone vaginal gel (n = 52), 2 mg, once every 6 hours, max of 3 doses
Outcomes	Change in BS, total time for induction, delivery route, uterine tachysystole (defined as 6 contractions in 10 minutes, in 2 consecutive 10 minutes periods), uterine hypertonus (contraction lasting longer than 3 minutes), subject comfort as women were asked to evaluate their discomfort on a visual scale from 0 to 10.
Notes	Setting: CSM Medical University (India). Study period: not reported, 1 year duration
	Funding: not reported
	Declarations of interest: not reported

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated random allocation numbers
Allocation concealment (selection bias)	Low risk	Consecutive, opaque envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	As treated analysis (2 or 4 exclusions? (158 cases analysed, but total of included patients makes 156) Primary outcome: unclear how many women in Foley were analysed, in comparison groups 4 cases missing without explanation



Deo 2012 (Continued)		
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Deo 2013

Methods	RCT		
Participants	Inclusion: full-term singleton gestation, cephalic presentation, indication for IOL. BS < 6. Exclusion: rupture of membranes, antepartum bleeding, placenta praevia, previous induction or preinduction agent during the pregnancy.		
Interventions	Foley catheter (n = 100): 16 F with 30 mL balloon, traction applied. no max hours described.		
	dinoprostone vagina gel (n = 104), 2 mg, once every 6 hours, max of 3 doses		
Outcomes	post induction BS at 6 and 13 hours,		
Notes	Abstract only, no outcomes of interested reported		
	Setting: KGMU Lucknow India		
	Study period: not reported		
	Funding: not reported		
	Declarations of interest: not reported		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only described women were randomly allocated, no more information available
Allocation concealment (selection bias)	Unclear risk	Only described women were randomly allocated, no more information available
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT not reported, too little information to judge
Selective reporting (reporting bias)	Unclear risk	Insufficient information to judge
Other bias	Unclear risk	Abstract only, too little information to judge risk of bias



Deshmukh 2011

Methods	RCT	
Participants	Inclusion: primigravida > 37 weeks of gestation, singleton pregnancy, cephalic presentation BS ≤ 3, Intact membranes Exclusion: multiple pregnancy, malpresentation, absent membranes, APH, medical disease, e.g. heart disease, renal disease	
Interventions	Intracervical Foley (n = 200): if BS < 7 after 6 hours, PGE2 was given	
	PGE2 gel vaginal (n = 200), dose repeated after 6 hours	
	Failure of induction was declared if patient failed to go in active phase of labour within 24 hours of induction	
Outcomes	Improvement of BS, induction-delivery interval, mode of delivery and feto-maternal outcomes	
Notes	Setting: India	
	Study period:July 2005 to January 2008	
	Funding: not reported	
	Declarations of interest: not reported	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only reported women were randomly assigned
Allocation concealment (selection bias)	Unclear risk	Allocation concealment not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT. no missing cases or data. no women excluded
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported
Other bias	Low risk	No other bias detected



Dionne 2011	
Methods	RCT, stratified for parity
Participants	Inclusion: indication for induction, BS < 6
Interventions	Foley catheter with oxytocin (n = 93)
	Foley catheter with intravaginal misoprostol (n = 84)
	Intravaginal misoprostol (n = 87)
Outcomes	Delivery within 24 hours, CS rate, maternal or fetal complications
Notes	Abstract only, no information about dosage misoprostol
	Setting: UK
	Study period: October 2001 to October 2004
	Funding: no information
	Declaration of interest: no information
-	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation not described
Allocation concealment (selection bias)	Unclear risk	No information
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT not mentioned, too little information to judge
Selective reporting (reporting bias)	Unclear risk	Pre-specified outcome CS reported, too little information to judge
Other bias	Unclear risk	Abstract only, too little information to judge risk of bias

Edwards 2014c

Methods	RCT
Participants	Inclusion criteria: GA > 36 weeks, live singleton fetus in cephalic presentation, unfavourable cervix (less than 3 cm dilated; if 2 cm dilated, less than 80% effaced).



Edwards 2014c (Continued)	Exclusion criteria: < 18 years, no informed consent in English, > 1 contraction/5 minutes, ruptured membranes, a prior caesarean delivery or any other prior uterine incision, a temperature of 38°C or higher, lethal fetal anomalies, placenta previa, other contraindication to vaginal delivery, suspected placental abruption or undiagnosed bleeding, a category II or III FHR pattern, HIV infection or any other immune dysfunction, an allergy to latex or dinoprostone, previous attempt of cervical ripening.	
Interventions	Foley catheter (n = 185): 16F, 30 mL, minimal tension, removed after 12 hours	
	Dinoprostone vaginal insert (n = 191): removed after 12 hours	
Outcomes	Induction to delivery time, (vaginal) delivery within 12 hours, (vaginal) delivery within 24 hours, tachysystole, clinical chorioamnionitis, endometritis, other postpartum complications, caesarean delivery, early neonatal outcomes	
Notes	Setting: multicentre, USA	
	period: July 2010 to February 2013	
	Funding: not reported	
	Declarations of interest: none declared	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Allocated by an online randomisation system 1 to 1
Allocation concealment (selection bias)	Low risk	Allocation web-based
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analyses reported, but women who did not deliver and went home were excluded (5 to 77. Patients with missing values for arterial cord pH level. properly described how this was dealt with
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

El Khouly 2017

Methods	RCT
Participants	Inclusion criteria: singleton pregnancy, cephalic presentation, GA > 28 weeks and the BS < 6.



El Khouly 2017 (Continued)	Exclusion criteria: contraindication vaginal delivery, EFW > 4500 g, a previous uterine scar, clinically significant cervical or vaginal infection, chorioamnionitis, unexplained vaginal bleeding, low-lying placenta, abnormal cervical anatomy or cervical cerclage.
Interventions	Foley catheter (n = 36): 18F, 30 mL, max of 12 hours
	Foley catheter + oxytocin (n = 36): 18F, 30 mL balloon, oxytocin, Foley max of 12 hours)
	Oxytocin alone (n = 36): increased by 2 mU/minute at 30-minute intervals until adequate uterine activity was maintained, max dose 32 mU/minute, AROM at 3 cm
Outcomes	Duration and dose of required oxytocin, induction to delivery interval, mode of delivery and reason (in case of CS), maternal and neonatal complications
Notes	Setting: Menoufia University Hospital, Egypt
	Study period: between January 2015 and February 2016.
	Funding: no funding
	Declarations of interest: none declared

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated sequence
Allocation concealment (selection bias)	Low risk	Sequentially-numbered opaque, sealed envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	Although ITT is not mentioned, figure 1 and results are plausible for ITT, all cases analysed, no missing data described
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Filho 2002

Methods	RCT.
Participants	Term or post-term, live, singleton fetus in cephalic presentation, intact membranes, BS < 6, not in labour, medically indicated for labour induction.



Filho 2002 (Continued)	Exclusion criteria: multiple gestations, non-cephalic presentation, previous caesarean delivery or uterine scar, rupture of membranes, antepartum bleeding, genital herpes infection, fetal death, placenta previa or previous attempts to induce labour.	
Interventions	Misoprostol (n = 119): 25 mcg 6-hourly, max 4 doses.	
	Foley (n = 121): 30cc traction applied 24 hours followed by oxytocin.	
Outcomes	Induction-to-vaginal delivery time, deliveries within 24 hours, mode of delivery, uterine contraction abnormalities, puerperal infection or neonatal outcomes.	
Notes	Setting: Maternidade Monteiro de Morais, Recife, Brazil	
	Dates of study: between September 2000 and December 2001	
	Funding sources: financial support from CAPES	
	Declarations of interest: none declared	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated sequence.
Allocation concealment (selection bias)	Low risk	Consecutively numbered sealed opaque envelopes.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow up, analysis ITT.
Selective reporting (reporting bias)	Low risk	All pre-specified data reported.
Other bias	Low risk	No other bias detected

Garba 2016

Methods	RCT	
Participants	Inclusion: multiparae, postdate (41+3), singleton, unfavourable cervix	
	Exclusion: not mentioned	
Interventions	Foley catheter + oxytocin (n = 66) (no more info available)	



Garba 2016 (Continued)	Vaginal misoprostol (n = 70), (no more information available	
Outcomes	Mode of delivery, maternal and perinatal outcomes, induction to delivery interval, AS, maternal vital signs, estimated blood loss.	
Notes	Setting: antenatal clinic at Aminu Kano Teaching Hospital, Nigeria	
	Study period: February to May, 2015	
	Funding: no funding	
	Declaration of interest: none declared	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated sequence
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT not reported, in table 4 there are cases missing, not reported why. no missing data reported
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Unclear risk	All eligible patients where randomised. Inclusion rate of 100% of all eligible patients is doubtful

Gelisen 2005

Methods	RCT, randomisation by sealed opaque envelopes, no mentioning of sequence.	
Participants	Singleton live pregnancy, GA 41 completed weeks, BS < 5, no contractions, AFI > 5, estimated fetal body weight < 4500 g.	
	Exclusion: known hypersensitivity to PG, previous caesarean delivery or other uterine surgery, MBI > 30, parity > 4, low-lying placenta.	
Interventions	Foley catheter 50 mL (n = 100).	
	Vaginal misoprostol 50 mcg 6-hourly, max 24 hours (n = 100). (group excluded because of high dose)	
	Oxytocin low dose protocol (n = 100).	



Gelisen 2005 (Continued)	Spontaneous follow-up (n = 300). (not in analyses)	
Outcomes	CS rate, neonatal outcomes: meconium, arterial pH, acidaemia, admissions to NICU secondary, tachysystole, hyperstimulation, fetal distress.	
Notes	Primary goals of study is to compare induction versus expectant management.	
	Setting: tertiary training centre in Turkey	
	Study period: not reported	
	Funding: not reported	
	Declarations of interest: not reported	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	600 opaque envelopes, 1 was drawn every time.
Allocation concealment (selection bias)	Low risk	Opaque envelopes.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinded assessment of fetal monitor strips. (to assess hyperstimulation).
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not addressed, seems like all data complete.
Selective reporting (reporting bias)	Low risk	All pre-specified outcome measures are reported.
Other bias	Low risk	No other bias detected

Gilson 2017

Methods	RCT	
Participants	Patients eligible for medical induction	
Interventions	Foley catheter + oxytocin (n = 526)	
	Low dose titrated oral misoprostol (n = 575) dose not mentioned in abstract	
Outcomes	Effectiveness, safety	
Notes	Abstract only	



Gilson 2017 (Continued)

Setting: Rwanda

Study period: not reported

Funding: not reported

Declaration of interest: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation not described
Allocation concealment (selection bias)	Unclear risk	No information
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT mentioned, not clear why groups are different in size.
Selective reporting (reporting bias)	Unclear risk	Insufficient information
Other bias	Unclear risk	Abstract only, to little information to judge risk of bias

Glagoleva 1999

Methods	RCT. No details were given on the method for concealment of the allocation.	
Participants	BS < 5. Women with a past history of CS were excluded.	
Interventions	Dilapan (4 tents) removed after 12 hours (27 women). PGE2 intracervical gel 0.5 mg (1-2 doses) (26 women).	
Outcomes	CS.	
Notes	Abstract only	
	Setting: Russia	
	Dates of study: not reported	
	Funding sources: not reported	
	Declarations of interest: not reported	



Glagoleva 1999 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only reported women were randomly assigned.
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to judge
Selective reporting (reporting bias)	Unclear risk	Insufficient information to judge
Other bias	Unclear risk	Abstract only, insufficient information to judge risk of bias

Goonewardene 2014

Participants	Inclusion: singleton pregnancy, cephalic, cervix unfavourable (MBS < 6), 40 weeks and 6 days Exclusion: multiple pregnancies, malpresentation, previous CS or any contraindication for normal de-		
	livery or misoprostol, prior intervention for ripening of the cervix, non-reactive CTG after fetal acoustic stimulation test.		
Interventions	Oral misoprostol (n = 74) 25 ug, every 4 hours, max of 2 gifts		
	Foley catheter (n = 78) max 24 hours		
Outcomes	Modified BS ≥ 6 day 2 after the intervention; Induction to delivery interval, mode of delivery, side effects of misoprostol (only reported in trial register)		
Notes	Setting: Academic Obstetric Unit, Teaching Hospital, Mahamodara, Galle, India		
	Study period: January 2011 to March 2012		
	Funding: not reported		
	Declarations of interest: none declared		
Risk of bias			
Bias	Authors' judgement Support for judgement		



Goonewardene 2014 (Continue	ed)	
Random sequence generation (selection bias)	Low risk	Computer-generated sequence, block randomisation, stratified for parity
Allocation concealment (selection bias)	Low risk	Sequentially-numbered opaque, sealed envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT not mentioned, no Figure 1, cases excluded for some selective outcomes because of spontaneous labour after intervention, no missing data reported.
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results, except secondary outcome 'side effects misoprostol' not reported.
Other bias	Low risk	No other bias detected

Guinn 2000

Methods	RCT. Computer-generated sequence. Opaque, sealed, sequentially numbered envelopes.		
Participants	Singleton, vertex presentation, intact membranes. Unfavourable cervix (< 2 cm dilated and effacement < 75%). Exclusion: bleeding, labour, asthma. prior vertical uterine incision, acute fetal compromise		
Interventions	Laminaria and IV oxytocin: as many laminaria as possible were kept for 12 hours, unless expelled or membranes ruptured. IV oxytocin was simultaneously given (165 women); EASI + IV oxytocin: Foley catheter balloon filled with 30 mL of water followed by saline infusion 30 mL/hour. IV oxytocin was simultaneously given (169 women); PGE2 intracervical gel 0.5 mg/6H, max 2 doses. IV oxytocin was started if not in labour after 2 doses of PGE2 (110 women).		
Outcomes	CS, delay to delivery, delivery within 24 hours, infections, haemorrhage.		
Notes	After interim analysis, the authors stopped recruiting in the PGE2 group. 68 protocol violations, but ITT analysis was conducted.		
	Setting: University of Alabama and Cooper Green Hospitals Birmingham, Alabama		
	Dates of study: January 1994 to August 1997		
	Funding sources: UpJohn Pharmaceuticals provided funds to purchase study drugs		
	Declarations of interest: not reported		
Risk of bias			
Bias	Authors' judgement Support for judgement		



Guinn 2000 (Continued)		
Random sequence generation (selection bias)	Low risk	Computer-generated random number table
Allocation concealment (selection bias)	Low risk	Opaque sealed envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	ІТТ
Selective reporting (reporting bias)	Unclear risk	All pre-specified outcomes reported for laminaria and EASI
Other bias	Unclear risk	After interim analysis, the authors stopped recruiting in the PGE2 group.

Gunawardena 2012

Bias	Authors' judgement Support for judgement		
Risk of bias			
	Declaration of interest: not reported		
	Funding: not reported		
	Study period: not reported		
	Setting: Ward 5, Teaching Hospital, Kandy, India		
Notes	Abstract only		
Outcomes	Change in mean MBS, uterine hyper-stimulation, Broncho-constriction, nausea and vomiting, postpartum haemorrhage and maternal fever, meconium at membrane rupture, AS at 5 minutes and PBU admission		
	Foley (73)		
Interventions	PGE2 intracervical (72)		
Participants	Uncomplicated primipara with singleton pregnancies who underwent IOL at 40 weeks + 5 days		
Methods	RCT		

Unclear risk

Random sequence genera-

tion (selection bias)

Not reported



Gunawardena 2012 (Continued)	
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT not mentioned, no missing data or cases reported
Selective reporting (reporting bias)	Unclear risk	Maternal and neonatal adverse outcomes were not given in numbers
Other bias	Low risk	No other bias detected

Haugland 2012

Methods	RCT		
Participants	Inclusion: singleton pregnancy, > 37 weeks, indication to induce birth, BS < 2 cm, term date set by US before week 21		
	Exclusion: IUFD, fetal malformations, low lying placenta, rupture of membranes, no understanding of Norwegian language		
Interventions	Foley catheter (n = 90), 16-19 hours		
	Cook double balloon (n = 88), 16-19 hours		
Outcomes	Cervix dilatation ≥ 3 cm after removal or active labour		
Notes	Abstract only		
	Setting: Haukeland university hospital, Bergen, Norway		
	Study period: March 2010 - January 2011		
	Funding: not reported		
	Declarations of interest: not reported		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation not described
Allocation concealment (selection bias)	Unclear risk	No information



Haugland 2012 (Continued)		
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Double-blind, says in the protocol that participants and outcome assessor will be blind to allocated treatment, but not clinicians
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind, in the study protocol says participant and outcome assessor will be blind to allocated treatment
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT not described mentioned, to little information to judge
Selective reporting (reporting bias)	Unclear risk	Insufficient information
Other bias	Unclear risk	Abstract only, too little information to judge risk of bias

Hay 1995

. ,		
Methods	RCT. No details were given on the method for concealment of the allocation. 28 women in the comparison between Dilapan and PGE2, with a total of 39 women recruited (15 Dilapan group, 13 PGE2 group, 11 amniotomy).	
Participants		
Interventions	Dilapan versus PGE2, no details on dosage provided.	
Outcomes	CS, hyperstimulation, nausea.	
Notes	Abstract only.	
	Setting: UK	
	Study period: not reported	
	Funding: not reported	
	Declarations of interest: not reported	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias)	Unclear risk	Not reported



Hay 1995 (Continued)

All outcomes

Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to judge
Selective reporting (reporting bias)	Unclear risk	Insufficient information to judge
Other bias	Unclear risk	Abstract only

Hemlin 1998

Methods	RCT	
Participants	Singleton vertex term pregnancies, BS < 5	
Interventions	EASI 30 to 60 mL/hour infusion (43 women) PGE2 0.5 mg intracervical (42 women)	
Outcomes	CS, instrumental delivery, painful contractions, vaginal delivery achieved within 12 to 24 h0urs.	
Notes	Setting: County hospital of Ekinstuna, Sweden	
	Study period: November 1990 to November 1995	
	Funding: not reported	
	Declarations of interest: not reported	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only reported women were randomised using sealed envelopes
Allocation concealment (selection bias)	Low risk	Sealed envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT not mentioned, women delivered by CS and women with quote: "unsuccessful" treatment were excluded for some of the outcome measures. no missing cases of missing data for outcomes of interest.
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported



Hemlin 1998 (Continued)

Other bias Low risk No other bias detected

Henry 2013

Methods	RCT	
Participants	Inclusion: women ≥ 18 years gestational > 37 weeks requiring IOL with a cervical preparation procedure	
	Exclusion: unsuitable for outpatient management, unsuitable for randomisation to either PGE2 (e.g. previous CS) or catheter use (e.g. latex allergy), or prior attempted IOL in this pregnancy, ruptured membranes, regular uterine contractions, multiple pregnancy or non-vertex presentation, unable to give informed consent	
Interventions	Foley catheter (n = 50): 30 mL, slight traction, spigot inserted to occlude the lumen, PCM 1 g/60 mg codeine, 20 mg temazepam., went home. Next morning AROM or priming by choice of clinician (n = 50)	
	PG gel (n = 51): (2 mg nulliparous – 1 mg multi parous), fornix posterior, repeated if necessary after 6 hours (1 mg), PCM 1 g/60 codeine, temazepam 20 mg, next morning AROM or priming by choice of clinician	
Outcomes	Delivering vaginally within 12 hours of admission to Delivery Unit; total inpatient hours from induction to delivery, syntocinon for induction or augmentation of labour, mode of delivery, vaginal delivery within 24 hours of insertion of Foley catheter or first dose PGE2 gel, Induction to delivery interval, i.e. time from commencement of cervical ripening to delivery, delivery within 24 hours of insertion of Foley catheter or first dose PGE2 gel, requirement for second method of cervical ripening or (in Prostir group) 3rd dose of PG, patient satisfaction using questionnaire created for purposes of this study, return to hospital (Foleys group) prior to planned readmission and not in labour, maternal febrile morbi ity, non-reassuring FHR trace, CS or instrumental delivery for fetal distress, Admission to newborn care AS 1 and 5 minutes, epidural.	
Notes	Setting: Australian metropolitan tertiary teaching hospital, Australia	
	Time period: June 2009 to December 2010	
	Funding: not reported	
	Declarations of interest: none declared	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table was performed prior to trial commencement.
Allocation concealment (selection bias)	Low risk	Sealed in sequentially-numbered, opaque envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported



Henry 2013 (Continued)		
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT, no missing data reported, no missing cases
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results, except secondary outcome 'epidural' (pre specified in trial registration)
Other bias	Low risk	No other bias detected

Hibbard 1998

Methods	RCT. Computer-generated sequence. Opaque, sequentially-numbered envelopes.		
Participants	Vertex, > 34 weeks, intact membranes, BS < 5. Exclusion of previous CS, cervicitis, macrosomia.		
Interventions	PGE2 (Prepidil) gel (17 women); PGE2 (Prepidil) and Dilapan (22 women).		
Outcomes	CS, instrumental delivery, painful contractions, vaginal delivery not achieved in 24 hours, uterine hyperstimulation, infection.		
Notes	Setting: University of Chicago, USA		
	Study period: August 1994 - May 1995		
	Funding: not reported		
	Declarations of interest: not reported		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated randomisation chart
Allocation concealment (selection bias)	Low risk	Sequential opaque envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT not mentioned, no missing cases or data
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported
Other bias	High risk	Study ended prematurely (before power was reached) as Dilapan was removed of the USA market



Hoppe 2016

Methods	RCT	
Participants	Inclusion: ≥ 18 years, singleton, vertex, BS of ≤ 5, < 4 contractions in 10 minutes, category I fetal monitoring.	
	Exclusion: contraindication for vaginal delivery, planned or received exogenous PG administration, unexplained vaginal bleeding, active herpes simplex, previous caesarean delivery, previous attempt at IOL, non-English speaking	
Interventions	Single balloon 18F Foley, 30 mL, traction applied, max 12 hours	
	Double balloon, Cook 80 mL/80 mL, max 12 hours	
Outcomes	BS of > 6 at time of catheter removal, change in BS, time from catheter insertion to spontaneous expulsion or removal, mean time from catheter insertion to vaginal	
	delivery, vaginal delivery in 24 hours, the use of pharmacologic methods for further cervical ripening or augmentation of labour, AROM, epidural use, mode of delivery, indications	
	for CS, chorioamnionitis, AS at 5 minutes < 7, meconium, NICU admissions	
Notes	Setting: University of Washington Medical Center Labor and Delivery, USA	
	Study period: January 2010 and November 2013	
	Funding: no funding by Cook	
	Declarations of interest: none declared	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Block randomisation, stratified for parity, not clear how this was done.
Allocation concealment (selection bias)	Low risk	Sequentially-numbered opaque, sealed envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No ITT reported, most likely per protocol, missing data in baseline characteristic, not in outcomes, no cases missing
Selective reporting (reporting bias)	Low risk	All pre-specified outcome data reported
Other bias	Low risk	No other bias detected



Hudon 1999

Methods	RCT. No details on the method of randomisation or on concealment of the allocation.	
Participants	Term, unfavourable cervix (BS < 5).	
Interventions	Foley catheter placed above the internal os and inflated with 40 mL left in place for a max of 16 hours (56 women); intracervical PGE2 (0.5 mg), repeated if BS unfavourable (55 women). Oxytocin was given after achievement of cervical ripening.	
Outcomes	CS.	
Notes	Setting: USA	
	Study period: not reported	
	Funding: not reported	
	Declarations of interest: not reported	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only reported women were randomised
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to judge
Selective reporting (reporting bias)	Unclear risk	Insufficient information to judge
Other bias	Unclear risk	Abstract only

Hughes 2002

Methods	Randomised trial.		
Participants	Singleton gestation, cephalic presentation, intact membranes, GA 36-42, indicated labour induction.		
Interventions	PGE 2 pessary (n = 34).		



Hughes 2002 (Continued)			
(continued)	Foley + EASI + oxytocin	(n = 33).	
Outcomes	Change in BS, inductio	n-delivery time.	
Notes	Outcomes of interest n	ot reported in this abstract.	
	Setting: USA		
	Study period: not repo	rted	
	Funding: not reported		
	Declarations of interest: not reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence generation (selection bias)	Unclear risk	Randomly assigned, no further details	
Allocation concealment (selection bias)	Unclear risk	Randomly assigned, no further details	
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention	
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported	

Husain 2017

Incomplete outcome data

Selective reporting (re-

(attrition bias) All outcomes

porting bias)

Other bias

Unclear risk

Unclear risk

Unclear risk

Methods	RCT
Participants	Inclusion: age 20 to 40 years, singleton pregnancy, cephalic presentation ≥ 37 weeks
	Exclusion: BS of > 4, cephalopelvic disproportion on examination, history of placenta previa or unexplained vaginal bleeding, history of previous CS or other uterine surgery, active herpes simplex infection, chorioamnionitis, contraindication to use of PGs, acute pelvic inflammatory disease, contraindication to vaginal delivery, a non reassuring FHR pattern prior to induction.
Interventions	Oral misoprostol (n = 157): 50 mcg, every 4 hours, max 4 gifts

Only reported as abstract

2 patients excluded after randomisation in Foley group, unclear

Study protocol/predefined outcomes not available



Husain 2017 (Continued)	Foley catheter + oral misoprostol (n = 161): 16 or 18F, filled with 30 mL + oral misoprostol (50 mcg) every 4 hours, max 4 gifts both groups: if labour was not established within 4 hours of the 4th dose of misoprostol, induction was considered to have failed and such cases were then delivered by CS.	
Outcomes	Failure to achieve vaginal delivery after 24 hours, induction-to-delivery interval, mode of delivery, reason for CS maternal complications, NICU admissions	
Notes	Setting: Abbasi Shaheed Hospital in Karachi, Pakistan, tertiary care centre	
	Study period: May 2016 to October 2016.	
	Funding: no funding reported	
	Declarations of interest: none declared	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated sequence, block randomisation
Allocation concealment (selection bias)	Low risk	Sequentially-numbered opaque, sealed envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT analysis not reported, cases excluded because of protocol violation. no missing data or cases
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Jagani 1982

Methods	RCT. Randomisation based on case number. No measure taken to conceal the allocation.	
Participants	Intact membranes.	
Interventions	5 groups: no treatment (n = 10; exclude); laminaria n = 10 (as many as possible); Foley catheter n = 10 (inflated with 70 - 80 mL water) under traction; amniotomy (n = 10); oxytocin (n = 10) increased by 5 mU/minute every 10 -15 minutes. In all groups, each of 10 women, an extraovular catheter with a 5 mL balloon was used to record uterine activity.	
Outcomes	CS.	
Notes	Setting: USA	



Jagani 1982 (Continued)

Study period: not reported

Funding: not reported

Declarations of interest: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Method selected by last digit of the chart number
Allocation concealment (selection bias)	High risk	Inadequate.No measure taken to conceal the allocation.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT not mentioned, not clear how many women were actually included.
Selective reporting (reporting bias)	Low risk	All outcome measures were reported
Other bias	Low risk	No other bias detected

Jalilian 2011

Methods	RCT
Participants	Inclusion criteria: singleton gestation, cephalic presentation, reactive FHR pattern, intact membranes and GA between 37-41 weeks
	Exclusion criteria: BS at least 7 or cervical dilatation greater than 3 cm, EFW > 4500 g or < 2000 g, evidence of cephalopelvic disproportion, placenta previa or unexplained vaginal bleeding, previous section caesarean or uterine surgery and contraindications to PG
Interventions	Intravaginal dinoprostone (n = 20), 3 mg every 6 hours, max 4 doses
	Foley catheter, 16F, 30 mL (n = 20), removed after 12 hours
Outcomes	Not mentioned in method section
Notes	Article is submitted as letter to the editor. no relevant outcomes reported
	Setting: Iran
	Study period: not reported
	Funding: not reported



Jalilian 2011 (Continued)

Declarations of interest: not reported

Ris		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only described women were randomly allocated, no more info available
Allocation concealment (selection bias)	Unclear risk	Only described women were randomly allocated, no more info available
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT not reported, too little information to judge
Selective reporting (reporting bias)	Unclear risk	Insufficient information to judge
Other bias	Unclear risk	Abstract only (letter to editor), too little information to judge risk of bias

Jeeva 1982

Methods	RCT. No details on the method of randomisation or on concealment of the allocation.	
Participants	No description of inclusion/exclusion criteria. 10 primigravidas and 10 multigravidas.	
Interventions	Laminaria tents (2 - 3 tents) (10 women); (PGE2) 4 mg tablets vaginally.	
Outcomes	Change in BS after 16 hours, CS.	
Notes	Setting: South Africa	
	Dates of study: not reported	
	Funding sources: not reported	
	Declarations of interest: not reported	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only reported women were randomised



Jeeva 1982 (Continued)		
Allocation concealment L (selection bias)	Jnclear risk	Not reported
Blinding of participants U and personnel (perfor- mance bias) All outcomes	Jnclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Jnclear risk	Not reported
Incomplete outcome data L (attrition bias) All outcomes	ow risk	ITT not mentioned, but seems reasonable as numbers in tables are equal to randomised numbers, no cases missing
Selective reporting (reporting bias)	Jnclear risk	Insufficient information as no outcome measures were pre-specified in report
Other bias L	_ow risk	No other bias detected

Johnson 1985

Methods	RCT. Sequence based on a random number table. No details were given on the method for concealment of the allocation.	
Participants	Term, primiparas, BS < 6.	
Interventions	Lamicel (40 women); PGE2 vaginal gel (4 mg) (40 women).	
Outcomes	Epidural analgesia, CS, instrumental delivery, uterine hyperstimulation, fetal distress.	
Notes	Setting: UK	
	Dates of study: not reported	
	Funding: not reported	
	Declarations of interest: not reported	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention



Johnson 1985 (Continued)		
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT unclear, no missing cases or data
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported
Other bias	Low risk	No other bias detected

Joshi 2016

Methods	RCT	
Participants	Inclusion criteria: 1 previous low transverse CS, singleton live pregnancy with cephalic presentation, reassuring fetal status, $>$ 37 weeks and BS $<$ 6	
	Exclusion criteria: placenta praevia, CPD, various mal presentations, short interconceptional period of 18 months, previous 2 caesareans, in a case of previous myomectomy or hysterectomy, patient demands repeat elective CS	
Interventions	Foley catheter (n = 100), 16F, 30 mL, max 24 hours in situ	
	Oxytocin (n = 100): starting from 1 mU/minute, increased to 2 mU/minute and max up to 32 mU/minute	
Outcomes	Induction delivery interval, indications for CS, mode of delivery, neonatal outcome and NICU admissions were studied in both groups	
Notes	Setting: Swami Dayanand Hospital Dilshad Garden New Delhi, India	
	Study period: January 2015 - June 2015	
	Funding: not reported	
	Declarations of interest: not reported	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only stated that women were randomly allocated
Allocation concealment (selection bias)	Unclear risk	Only stated that women were randomly allocated
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias)	Unclear risk	Not reported



Joshi 2016 (Continued)

All outcomes

Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT not reported, no figure 1 to check allocation, all cases analysed, no missing data described
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Jozwiak 2012

Methods	RCT		
Participants	Inclusion criteria: pregnant women scheduled for IOL beyond 37 weeks of gestation with a vital singleton pregnancy in cephalic presentation, intact membranes, and an unfavourable cervix (BS < 6). Exclusion criteria: women younger than 18 years, with a previous CS, placenta praevia, lethal fetal congenital anomaly, or known hypersensitivity for one of the products used for induction were ineligible		
Interventions	Foley catheter (n = 411): 18F, 30 cc sterile saline.		
	PG E2 gel (408): 1 mg, followed by 1 mg after 6 hours, with a max of 2 doses per 24 hours inserted into the posterior vaginal fornix. An initial dose of 2 mg was allowed in nulliparous women.		
	2 days of induction, 1 day of " rest" followed by 2 more days of induction in case of BS < 6		
Outcomes	CS, maternal and neonatal morbidity and time from start induction to birth.		
Notes	Setting: multicentre, the Netherlands		
	Study period: Feb 2009 - May 2010		
	Funding: none		
	Declarations of interest: none declared		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated randomisation
Allocation concealment (selection bias)	Low risk	Web-based
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported



Jozwiak 2012 (Continued)		
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT, missing outcome data (pH and BMI) balanced in numbers across intervention groups, with similar reasons for missing data across groups. no missing cases
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Jozwiak 2013

Methods	RCT
Participants	Women > 18 years with term pregnancy and unfavourable cervix, requiring IOL. Exclusion criteria were previous CS, non-vertex presentation of the fetus, ruptured membranes, hypersensitivity for one of the products used for induction, or a lethal congenital anomaly of the fetus
Interventions	Foley catheter (107),18F 30 cc sterile saline.
	10 mg slow release PG vaginal insert (n = 119). Removed after 12 hours, if BS < 6, after 24 hours new PG vaginal insert was used
	2 days of induction, 1 day of " rest" followed by 2 more days of induction in case of BS < 6
Outcomes	CS, maternal and neonatal morbidity and time from start induction to birth.
Notes	Setting: multicentre, the Netherlands
	Study period: February 2009 - May 2010
	Funding: none
	Declarations of interest: none declared

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated randomisation
Allocation concealment (selection bias)	Low risk	Web-based
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis, missing outcome data (pH and BMI) balanced in numbers across intervention groups, with similar reasons for missing data across groups. no missing cases



Jozwiak 2013 (Continued)		
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Jozwiak 2014

Methods	Pilot study within RCT		
Participants	Women > 18 years, ≥ 37 weeks, BS < 6, planned for IOL.		
	Exclusion:previous CS, non vertex presentation, ruptured membranes, hypersensitivity for one of the products used for induction, lethal congenital anomaly		
Interventions	Foley catheter (n = 56), 16 or 18F, 30 mL		
	Vaginal misoprostol (n = 64) 25 mcg tablets every 4 hours, max 3 doses in 24 hours.		
	In both groups, if the cervix was still unfavourable for amniotomy after 48 hours of treatment, women were generally assigned a day of rest followed by another 48 hours of induction		
Outcomes	CS, instrumental vaginal delivery, reasons for operative delivery, time from induction to delivery, uterine hyperstimulation, uterine rupture, analgesics, antibiotics, maternal suspected intrapartum infection, maternal postpartum infection, postpartum haemorrhage (> 1000 cc) postpartum blood transfusion, AS of < 7 at 1 minute and 5 minutes, arterial cord blood pH < 7·10, neonatal admissions neonatal ward/NICU		
Notes	Setting:multicenter, the Netherlands		
	Study period: February 2009 and May 2010		
	Funding: no funding reported		
	Declarations of interest: none declared		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated sequence, block randomisation
Allocation concealment (selection bias)	Low risk	Sequentially-numbered opaque, sealed envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis, missing data reported, but even distributed over groups and likely for the same reasons. no missing cases



Jozwiak 2014 (Continued)		
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results, except secondary outcome maternal postpartum infection
Other bias	Low risk	No other bias detected

Kandil 2012

Methods	Prospective quasi-RCT		
Participants	Inclusion criteria: 41 weeks or more, primigravida, BS < 4, singleton living fetus, vertex presentati evidence of active labour, a reassuring FHR pattern, no evidence of intrauterine infection. Exclusion criteria: contra-indication for vaginal delivery, previous uterine surgery, non-reassuring IUFD, ruptured membranes, vaginal infection, malpresentation, macrosomic fetus, cephalopelvic proportion, history of APH, contra-indication to PGs		
Interventions	 1. 18F Foley catheter, 30 cc sterile saline. Taped to the inner thigh. Each patient received 1 g of ampicillin/6 hours. Removed after 12 hours. (N = 50) 2. 25 ug misoprostol vaginally every 4 hours (N = 50) 		
	2. 23 ug misoprostot vaginatty every 4 nours (N = 30)		
Outcomes	Induction to delivery time, oxytocin use, route of delivery, occurrence of chorioamnionitis, AS, admission to NICU, tachysystole, hypertonus, hyperstimulation		
Notes	9 patients were insertion of Foley was not possible were replaced by 9 other patients!		
	Setting: Menofyia University Hospital, Egypt		
	Study period: from January 2010 to October 2010		
	Funding: not reported		
	Declarations of interest: none declared		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Randomisation by odd or even admission date
Allocation concealment (selection bias)	High risk	Randomisation by odd or even admission date
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT was not mentioned. 9 patients in Foley group were replaced by 9 others because insertion of Foley was not possible. No flow chart, no description of lost to follow-up.



Kandil 2012 (Continued)		
Selective reporting (reporting bias)	Low risk	All pre-described outcome measures were mentioned.
Other bias	Low risk	No other bias detected

Khamaiseh 2012

Methods	RCT	
Participants	Inclusion criteria: age 15 years or more, term, singleton, live fetus in vertex presentation, intact membranes and BS < 6.	
	Exclusion criteria: previous CS or history of other uterine surgery, history of ante partum haemorrhage, cephalopelvic disproportion, acute fetal distress revealed by a non stress test prior to induction, signs of infection, ruptured membranes, EFW > 4300, or known allergy to PG	
Interventions	PG E2 (n = 204) tablets 3 mg, max 2 dose. AROM performed if labour did not commence after 2 doses	
	Foley catheter (n = 210): 22/24F, 50-60 mL in balloon.Removed after 24 hours and AROM if possible	
Outcomes	Mode of delivery, time interval between the start of induction and delivery, oxytocin requirement, the indications for CS and adverse neonatal and maternal reactions to the cervical ripening agent. Hyperstimulation with and without FHR changes, failed induction.	
Notes	Setting: King Hussein Medical Centre and Prince Ali Bin Al-Hussein hospital, Jordan	
	Study period: July 2009 - July 2010	
	Funding: not reported	
	Declarations of interest: not reported	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random sequence generated by computer
Allocation concealment (selection bias)	Unclear risk	Not described, only description: Randomisation was done by a computer-generated list of random numbers
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT analysis not reported and not clear if used, no missing data or cases



Khamaiseh 2012 (Continued)		
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Krammer 1995a

Methods	RCT. Computer-generated sequence. No details were given on the method for concealment of the allocation.			
Participants	Term women with a BS < 9, absence of contraindication for labour and fetal distress. 441 women (224 in the Dilapan group and 217 in the PGE2 group).			
Interventions	Dilapan, as many dilators as possible (224 randomised, 214 analysed); intracervical PGE2 0.5 mg (217 women randomised, 202 analysed). In both groups, ripening was followed 6 hours later by oxytocin.			
Outcomes	CS, uterine hyperstimulation, fetal and neonatal infection.			
Notes	25 women excluded: 10 in the Dilapan group (8 protocol violations, 2 entered spontaneous labour before insertion) and 15 in the PG group (10 protocol violations, 3 entered labour before ripening and 2 delivered before the 6-hour interval). Authors stated that including these excluded women do not alter the results. Numbers of CS derived from Williams 1997.			
	Setting: Tampa general hospital, USA			
	Dates of study: June 1991 - December 1993			
	Funding sources: not reported			
	Declarations of interest: not reported			

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated sequence
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT was performed, but 25 women excluded: 10 in the Dilapan group (8 protocol violations, 2 entered spontaneous labour before insertion) and 15 in the PG group (10 protocol violations, 3 entered labour before ripening and 2 delivered before the 6-hour interval)



Krammer 1995a (Continued)		
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported
Other bias	Low risk	No other bias detected

Kruit 2016

Methods	RCT		
Participants	Inclusion: PROM > 18 hours, ≥ 37 weeks, BS < 6, vital singleton pregnancy, cephalic		
	Exclusion: previous CS, placenta previa, vaginal bleeding, HIV, hepatitis B or C, maternal infection, fetal anomaly		
Interventions	Foley (n = 89): 22ch Rush balloon, traction, 40-50 cc, max 8 hours. if unripe, further management by discretion of clinician		
	oral misoprostol (n = 99): 50 mcg misoprostol every 4 hours, after 3 gifts dosis increased to 100 mcg or 25 to 50 mcg vaginal every 3-4 hours		
Outcomes	CS rate, maternal and neonatal infections. Reason for CS (fetal distress, suspected infection, prolonged labour, failed induction, postpartum infection, postpartum haemorrhage, uterine hyperstimulation, fetal tachycardia, use of analgesics, AS, umbilical arterial pH, admission to neonatal care, induction to delivery interval.		
Notes	Trial stopped prematurely due to insufficient patient enrolment		
	Setting: multicentre, Finland		
	Study period: March 2012 to September 2014		
	Funding: grant from the Finnish medical society duodecim and Helsinky University Central Hospital research grant		
	Declarations of interest: none declared		

Authors' judgement	Support for judgement
Unclear risk	Not reported how this was done (only that they used sealed envelopes)
Low risk	Sealed, opaque envelopes
Unclear risk	Not feasible due to nature of intervention
Unclear risk	Not reported
High risk	Seems to be per protocol analysis. Patients excluded after enrolment for cross-over during analysing data, 3rd arm formed
	Unclear risk Low risk Unclear risk Unclear risk



Kruit 2016 (Continued)

All outcomes

Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported
Other bias	High risk	Trial stopped prematurely due to insufficient patient enrolment

Kuppulakshmi 2016

Methods	RCT		
Participants	Not mentioned		
Interventions	intracervical dinoprostone (n = 100): 0.5 mg, 6-hourly, max 2 doses		
	Foley catheter (n = 100), 30 mL, max 12 hours in place.		
Outcomes	Vaginal delivery within 24 hours, improvement in BS, induction to onset of active labour and induction to delivery interval, mode of delivery, occurrence of maternal complications and fetal outcome, cost-effectiveness		
Notes	Setting: India		
	Study period: June 2015 - July 2016		
	Funding: not reported		
	Declarations of interest: not reported		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only described that patients were randomly allocated
Allocation concealment (selection bias)	Unclear risk	Only described that patients were randomly allocated
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No missing data described, difficult to judge how selection of patients was done, if there was ITT, if patients were excluded. no numbers of analysed patient in result section
Selective reporting (reporting bias)	Low risk	Pre specified outcomes reported in method section were all reported
Other bias	Low risk	No other bias detected



Laddad 2013

Methods	RCT	
Participants	Inclusion criteria: primigravida, > 37 weeks of gestation, singleton pregnancy, cephalic presentation, BS < 4, Intact membranes	
	Exclusion criteria: multiple pregnancy, mal-presentation, absent membranes, APH, medical disease e.g. heart disease, renal disease, previous LSCS	
Interventions	Foley catheter (n = 200):	
	PGE2 gel intracervical (n = 200), max 2 doses, failed induction declared if patient was not in active labour after 48 hours	
Outcomes	Not mentioned in method section	
Notes	PGE2 dose not described	
	Setting: KIMSDU; India,	
	Study period: January 2011 - December 2012	
	Funding: none	
	Declarations of interest: none declared	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only stated that women were randomly assigned
Allocation concealment (selection bias)	Unclear risk	Only stated that women were randomly assigned
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear if analysis was ITT, (no figure 1) all cases analysed, no missing data described
Selective reporting (reporting bias)	Unclear risk	No pre -specified outcome measures reported, so cannot be determined
Other bias	Low risk	No other bias detected



Lanka 2014		
Methods	RCT	
Participants	Inclusion: GA > 28 weeks, singletons, intact membranes, absence of labour, cephalic presentation, BS < 5.	
	Exclusion: multifetal gestations, congenital malformations, Gravidity > 4, non-reassuring FHR trace, ruptured membranes, active genital infection, previous uterine surgery (including CS), low-lying placenta, chorioamnionitis, EFW > 4000 g, IUFD, known allergies to latex or PGs	
Interventions	Foley + misoprostol (n = 63): 16F Foley catheter, 30 cc, traction applied, max 12 hours - 25 mcg vaginal misoprostol, every 4 hours up to a max of 8 doses.	
	vaginal misoprostol (n = 63): 25 mcg vaginal misoprostol every 4 hours, with a max of 8 doses	
Outcomes	induction to delivery interval, rate of vaginal deliveries, hyperstimulation, CS rate, neonatal outcome, chorioamnionitis, oxytocin use	
Notes	Setting: tertiary care centre, India	
	Study period: 2-year period	
	Funding: no funding	
	Declarations of interest: none declared	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated sequence, block randomisation
Allocation concealment (selection bias)	Low risk	Sequentially-numbered opaque, sealed envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis, no missing data or cases
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Lemyre 2006

Methods RCT.



Lemyre 2006 (Continued)			
Participants	Term pregnancy requiring cervical ripening.		
Interventions	Foley catheter for 12 hours (n = 31).		
	Vaginal misoprostol 25 mcg 4-hourly (n = 31).		
Outcomes	Induction-active labour, induction-delivery, delivery within 12 and 20 hours, oxytocin, obstetric outcome, maternal and neonatal morbidity		
Notes	Reported as abstract, only outcome of interest reported is oxytocin infusion.		
	Setting: Canada		
	Study period: not reported		
	Funding: not reported		
	Declarations of interest: not reported		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomly assigned, no details on sequence generation.
Allocation concealment (selection bias)	Unclear risk	No details on allocation concealment given.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not reported in this abstract.
Selective reporting (reporting bias)	Unclear risk	In this abstract from the outcomes of interest only oxytocin infusion reported, other outcomes not reported.
Other bias	Unclear risk	Only abstract available.

Lewis 1983

Methods	RCT. No details were given on the method for concealment of the allocation.	
Participants	Singleton vertex term pregnancy, unfavourable cervix.	
Interventions	Vaginal pessary 3 mg PGE2 (22 women); Foley catheter in the extra-amniotic space 30 mL (22 women); Control group with no treatment (22 women; exclude)	



Lewis 1983 (Continued)	
Outcomes	Change in BS, CS, uterine hyperstimulation, AS.
Notes	Data on induction-delivery intervals not interpretable to derive proportion of women with vaginal de- livery not achieved in 24 hours.
	Setting: Manchester, UK
	Study period: not reported
	Funding: not reported
	Declarations of interest: not reported

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Random allocation, no more details reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear if ITT was performed. no missing cases or data reported
Selective reporting (reporting bias)	Unclear risk	No specific pre specified outcomes reported in method section.
Other bias	Low risk	No other bias detected

Lokkegaard 2015

Methods	RCT
Participants	Inclusion criteria: intact membranes, cephalic position, BS ≤ 6, indication of IOL.
	Exclusion criteria: ruptured membranes, spontaneous labour, placenta praevia, acute fetal distress, asthma, glaucoma, latex allergy, infections (acute herpes, GBS, condylomata), previous CS
Interventions	1. Double balloon catheter (n = 412); 80 mL, max 12 hours, thereafter either AROM or start of oxytocin.
	2. PGE2 3 mg tablet (n = 413), 2 dose a day (4-5 hourly), max 2 days
Outcomes	Failed inductions, time interval from induction to delivery, mode of delivery, neonatal outcome as assessed by the AS after 5 minutes and referral to a neonatal care unit, subgroups by parity and indica-



Lokkegaard	2015 (0	Continued)
------------	----------------	------------

tion for induction. Post hoc analyses included the percentage of women who gave birth within 24 hours and the need for additional oxytocin stimulation

Notes

Setting: multicentre, Denmark

Study period: September 2002 to December 2005

Funding: the randomisation procedure was funded by 'Snedkermester Sophus Jacobsen & Astrid Jacobsens fond and the Danish Toyota Foundation.

Declarations of interest: none declared

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated and was stratified for parity and department.
Allocation concealment (selection bias)	Low risk	Central allocation by telephone
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT, missing data reported, but evenly distributed.
Selective reporting (reporting bias)	Low risk	All pre-specified outcome measures were reported
Other bias	Low risk	No other bias detected

Lyndrup 1989

Methods	RCT.		
Participants	Woman with unfavourable cervix.		
Interventions	4 groups:		
	1. oxytocin without Lamicel (according to a fixed schedule, with a max of 32 mU per minute) (24 women);		
	2. oxytocin with Lamicel (1 unit) (22 women);		
	3. PGs without Lamicel (2.5 mg PGE2) (19 women);		
	4. PGs with Lamicel (1 unit) (20 women).		
Outcomes	CS, forceps or vacuum extraction, endometritis.		
Notes	Setting: Denmark		



Lyndrup 1989 (Continued)

Study period: not reported

Funding: not reported

Declarations of interest: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only reported women were randomised by sealed envelope method
Allocation concealment (selection bias)	Low risk	Sealed envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	6 women excluded for protocol violation.
Selective reporting (reporting bias)	Unclear risk	No outcomes were pre specified in method section.
Other bias	Low risk	No other bias detected

Lvndrup 1994

Bias

Methods	RCT
Participants	Singleton vertex pregnancy, intact membranes with unfavourable cervix.
Interventions	Foley extra-amniotic 30 mL (59 women) PGE2 2.5 mg pessaries (50 women)
Outcomes	Vaginal delivery not achieved within 24 hours, CS, instrumental delivery, women not satisfied, caregiver not satisfied, pH, AS.
Notes	Setting: Denmark
	Study:period: June 1990 - March 1993
	Funding sources: not reported
	Declarations of interest: not reported
Risk of bias	

Authors' judgement Support for judgement



Lyndrup 1994 (Continued) Random sequence generation (selection bias)	Unclear risk	No details on the method of generation of the sequence.
Allocation concealment (selection bias)	Low risk	Concealment of allocation by sealed envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT reported, but 4 women were lost to follow-up. Women were excluded if delivered after 48 hours
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported
Other bias	Low risk	No other bias detected

Mackeen 2018

Methods	RCT			
Participants	Inclusion criteria: women with a live, singleton gestation in cephalic presentation at 34 weeks of gestation or greater with PROM (at least 60 minutes prior to randomisation), an unfavourable cervical examination (less than 2 cm or 80% effaced), and no contraindication to labour. English speaking with a plan for vaginal delivery.			
	Exclusion criteria: active labour and those with suspected intra-amniotic infection, abruption or significant haemorrhage, latex allergy, greater than 1 prior caesarean delivery, any contraindication to vaginal delivery, or human immunodeficiency virus or acquired immunodeficiency syndrome, multifetal gestations, lethal fetal anomalies, intrauterine fetal demise, and category II or III FHR tracings.			
Interventions	Oxytocin only (n = 108): start 2 mUh/minute, increase 2 mUh/minute every 30 minute, max 30 mUh/minute			
	Foley catheter + oxytocin (n = 93): 16F, 30 mL, traction applied, max 12 hours, oxytocin concurrent (as above)			
	If not in labour after 24 hours, management per discretion of clinician			
Outcomes	Interval from induction to delivery, interval from induction to vaginal delivery, induction to delivery excluding patients with PPROM before 34 weeks of GA, CS rate, rate of vaginal delivery within 12 or 24 hours, indication for CS, infection complications, maternal LOS, 5-minute AS < 5, neonatal infectious evaluation and diagnosis of sepsis, maternal and neonatal length of stay, NICU admission, chorioamnionitis, fetal tachycardia, endomyometritis,			
Notes	Setting: multicentre, USA			
	Study period: March 2014 to July 2016			
	Funding: small internal grants to assist with the conduct and statistical analyses for the entire study.			



Mackeen 2018 (Continued)

Declarations of interest: none declared

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated schema in random-sized blocks stratified by multiparity or primiparity, preterm or term gestation, and hospital site.
Allocation concealment (selection bias)	High risk	Not concealed.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT, no missing data or cases
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Matonhodze 2003

Methods	RCT: Computer-generated random sequence, sealed opaque envelopes.		
Participants	Inclusion: completed 34 weeks GA, intact membranes		
	Exclusion: uterine scar, uncontrolled medical complication, non-vertex presentation, multiple pregnancy, fetal distress, APH.		
Interventions	Foley catheter + misoprostol (n = 174): 50 mL, traction, max 24 hours, followed by oral misoprostol solution 20 mcg every 2 hours, 40 mcg 2-hourly after 3 doses, until active labour had started. If after established labour contractions became inadequate: augmentation with misoprostol solution 5-20 mcg hourly. If ineffective: oxytocin.		
	Titrated oral misoprostol (n = 176): as described above		
	Dinoprostone vaginal (n = 176). 2 mg in posterior fornix, repeated after 6 hours. If no active labour after 12 hours: oxytocin		
Outcomes	Failed vaginal delivery within 24 hours, augmentation, tachysystole, hypersystole, hyperstimulation syndrome, tocolysis, analgesia, meconium, CS, instrumental delivery, maternal side effects, AS < 7, NICU admission, perinatal death, neonatal sepsis.		
Notes	It is not clear if all patients had an unfavourable cervix (not mentioned in baseline characteristics. Data reported for different numbers of subjects depending on outcome (selective reporting or missing outcome data?).		



Matonhodze 2003 (Continued)

Setting: Pakistan

Study period: October 2000 - December 2001

Funding: not reported

Declaration of interest: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated random sequence,
Allocation concealment (selection bias)	Low risk	Sequentially-numbered opaque, sealed envelopes out of a dispenser. intact membranes/unfavourable cervix, intact membranes/favourable cervix
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT analysis, data reported for different numbers of subjects depending on outcome. not clear why
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Mazhar 2003

Methods	RCT randomisation: computer-generated random numbers, concealed.	
Participants	Inclusion: singleton pregnancy, cephalic presentation, reassuring fetal status, GA 37 completed weeks, BS 6 or lower.	
	Exclusion: placenta praevia, chorioamnionitis, polyhydramnios, parity > 5, SROM, previous CS, contraindication to labour induction.	
Interventions	(PGE2) vaginal pessary max 2×6 hours (dose not mentioned) followed by ARM and oxytocin infusion (n = 100).	
	Foley catheter 45 mL + EASI for 12 hours followed by ARM and oxytocin infusion (n = 100).	
Outcomes	Primary: time from insertion to delivery, mode of delivery.	
	secondary: change is BS after 6 hours, neonatal AS.	
Notes	No sample size calculation.	



Mazhar 2003 (Continued)

4 patients were excluded (1 left against medical advice, 1 had SROM, 2 failed inductions were induced at later stage).

Setting: Pakistan

Dates of study: October 2000 to December 2001

Funding sources: not reported

Declarations of interest: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated sequence.
Allocation concealment (selection bias)	Unclear risk	Randomised numbers concealed in the delivery suite?
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No mention of incomplete data, however unlikely due to nature of outcome measures.
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported.
Other bias	Low risk	No other bias detected

Meetei 2015

Methods	RCT	
Participants	Inclusion: 1 previous low transverse CS, singleton live pregnancy, cephalic presentation, > 28 weeks and BS < 5.	
	Exclusion: previous classical or T-shaped incision, unknown scar, transfundal uterine surgery, medical or obstetric complications that preclude vaginal delivery, placenta previa, low-lying placenta undiagnosed vaginal bleeding, maternal heart disease, rupture of membranes, interval between previous CS and present pregnancy/conception < 6 months, cervico-vaginal infection, unclean vaginal examination, infection in previous CS	
Interventions	1. Foley catheter (n = 30): 16F, 30 mL balloon, max 12 hours, thereafter start of oxytocin augmentation	
	2. Oxytocin (n = 30): 1 mUh/minute, after 1 hour 2/mUh/minute, after 1 hour 4 mUh/minute (max 12 hours). oxytocin augmentation as above	



Meetei 2015 (Continued)		
Outcomes	Change in BS before and after 12 hours of ripening, percentage and time interval of spontaneous labour, insertion and expulsion interval of Foley catheter, route of delivery/outcome of delivery, time required from the beginning of cervical ripening to delivery, hyperstimulation, fetal distress, scar dehiscence, uterine rupture	
Notes	Setting: Department of Obstetrics and Gynecology, PGIMER, Chandigarh, India	
	Study period: July 2004 and November 2005,	
	Funding: no funding	
	Declarations of interest: none declared	
•		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation by Tippet's table
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Analysing method not reported and not clear, no missing data or cases
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Moini 2003

Methods	RCT: quote: "randomly assigned".	
Participants	Singleton gestation, cephalic presentation, GA between 37 and 42 weeks, BS < 6.	
	Exclusion: malpresentation, ruptured membranes, active genial herpes, antepartum bleeding, fetal death, cephalopelvic disproportion, indication for emergency termination of pregnancy, history of infertility or CS, women who had undergone induction before presenting.	
Interventions	Dinoprostone intracervical 0.5 mg, oxytocin infusion after 6 hours (n = 35).	
	Foley catheter 30 mL + EASI (n = 35).	



Moini 2003 (Continued)		
Outcomes	Change in BS (after 6 hours), induction-delivery interval, need for oxytocin, mode of delivery, fetal complications, maternal complications.	
Notes	No sample size calculation.	
	Setting: Roointan-Arash Maternity Hospital, Iran	
	Dates of study: April 2000 - April 2001	
	Funding sources: not reported	
	Declarations of interest: not reported	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information about sequence generation process quote: "randomly assigned".
Allocation concealment (selection bias)	Unclear risk	Insufficient information.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not mentioned.
Selective reporting (reporting bias)	Unclear risk	All pre-specified outcomes are reported, it is however unclear what is meant by 'fetal complications', and it is likely that there were more outcomes noted.
Other bias	Low risk	No other bias detected

Mullin 2002

Methods	RCT: randomisation by computerised random number generator, consecutively-numbered sealed envelopes.	
Participants	Singleton gestation, cephalic presentation intact membranes, BS 4 or less, < 8 contractions per hour, reactive FHR tracing.	
	EFW > 4500 g or < 1800 g, low-lying placenta, placenta praevia, unexplained vaginal bleeding, active genital herpes, vasa praevia, chorioamnionitis, contraindication for PGs, previous uterine surgical procedure, parity > 5.	
Interventions	Foley 30 mL+ EASI (max 12 hours) + IV oxytocin infusion (n = 100).	
	Vaginal misoprostol 25 mcg every 4 hours max 24 hours (n = 100).	



Mullin 2002 (Continued)			
Outcomes	Primary: mean time from start induction to delivery.		
	Secondary: route of delivery, success of induction (vaginal delivery within 24 hours), uterine contraction abnormalities, chorioamnionitis, route of delivery, AS < 7, NICU admission, neonatal resuscitation.		
Notes Power calculation states that 140 patients were necessary, yet 200 were included			
	Setting: Los Angeles County–University of Southern California Medical Center, USA		
	Dates of study: February 1999 to July 2001		
	Funding sources: not reported		
	Declarations of interest: not reported		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computerised random number generator.
Allocation concealment (selection bias)	Low risk	Sealed opaque envelopes.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	No withdrawals from protocol, no mention of incomplete data.
Selective reporting (reporting bias)	Low risk	All predefined outcomes are reported.
Other bias	Unclear risk	Unclear why 200 patients were included, while 140 were calculated in the power calculation.

Mundle 2017

Methods	RCT
Participants	Inclusion: age ≥ 18 years, ≥ 20 weeks' gestation or later with a live fetus, decision made to induce vaginal birth because of pre-eclampsia or hypertension
	Exclusion: unable to give informed consent, previous CS, multiple pregnancy, ruptured membranes, chorioamnionitis, allergy to misoprostol.
Interventions	1. Foley catheter (n = 300): 18F, 30 mL balloon, traction applied, max 12 hours, afterward start oxytocin or AROM



Mundle 2017 (Continued)	2. Oral misoprostol (n = 302) 25 mcg, 2-hourly, max of 12 dose (24 hours). In primigravid women the dose could be increased to 50 mcg 2-hourly after the first 2 doses oxytocin administered through gravity infusion set
Outcomes	Vaginal birth within 24 hours, induction to birth interval (vaginal births, CSs, and all births), vaginal births within 12 hours, cervix unchanged at 12 hours and 24 hours, need for oxytocin augmentation, time from randomisation to start of induction and birth, total dose of misoprostol used and the number of participants given a 50 µg dose. Maternal complications, satisfaction, fetal/neonatal complications
Notes	Fetal surveillance with doptone
	Setting: 2 public hospitals in Nagpur, India
	Study period: December 2013 to June 2015
	Funding: Department for International Development, Medical Research Council, and Wellcome Trust Joint Global Health Trials Scheme. The funder of the study had no role in data collection
	Declarations of interest: ADW is a scientific adviser to Azanta, a Danish pharmaceutical company, MAT has provided consultancy services to Chiesi, Bristol–Myers Squibb, Novartis, Shire, Janssen, and Grunenthal. both authors received no personal payment,

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated pseudo-random numbers, block randomisation, stratified by centre
Allocation concealment (selection bias)	Low risk	Sequentially-numbered, sealed, opaque envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT, missing data reported, but small numbers and not in outcomes of interest for this review, no cases missing
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Niromanesh 2003

Methods	Quote:"randomly assigned".
Participants	BS < 5, maternal age 20 to 30 years, gravidity 1 - 3, parity 1 - 2, < 6 contractions per hour, singleton pregnancy.



Niromanesh 2003 (Continued)	Exclusion: history of preterm labour, antepartum bleeding, low-lying placenta, history of caesarean deliveries, active herpes infection, acute poly or oligohydramnios, high blood pressure, IUFD, GA < 40 weeks, chronic condition or contraindication for use of PGs.
Interventions	Foley catheter 30 mL max 8 hours (n = 45).
	(PGE2) tablet 6-hourly, max 6 doses (n = 44).
Outcomes	Primary: BS (after ripening).
	Secondary: ripening time, induction time, total time, delivery route, uterine hyperstimulation, adverse side effects, non-reassuring FHR tracing, AS.
Notes	No sample size calculation.
	1 patient withdrew due to 'complications'.
	Time of ripening in Foley group 8 hours, PG group 12 hours
	Setting: Mirza Kochkhan Hospital, Tehran, Iran.
	Study period: March 2000 to May 2001
	Funding sources: not reported
	Declarations of interest: not reported

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table.
Allocation concealment (selection bias)	Low risk	Sealed opaque envelope.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No mention of incomplete data, insufficient information to permit judgment.
Selective reporting (reporting bias)	Unclear risk	1 patient was withdrawn due to 'complications', data for this patient not reported, other than this, data reported for all patients on the prespecified outcomes.
Other bias	Low risk	No other bias detected



Methods	RCT	
Participants	Singleton pregnancies, cephalic presentation, > 37 weeks, intact membranes, BS ≤ 4	
	Exclusion: rupture of the membranes, chorioamnionitis, APH, cervical dilatation > 2.5 cm, temperature > 38 degrees Celsius, contracted pelvis, fetal distress, polyhydramnios, indication for immediate delivery previous CS or other uterine surgeries.	
Interventions	1. Vaginal misoprostol (n = 60): 25 mcg, 4-hourly, with a max of 6 doses. no effective uterine contractions after the 6th dose, then it was considered as failure of induction.	
	2. Foley catheter (n = 44): 18F Foley 50 mL, traction applied, no max time period reported	
Outcomes	induction to delivery interval, uterine tachysystole, uterine hypertonus, uterine hyperstimulation (tachysystole + FHR changes), meconium-stained liquor, mode of delivery, maternal and neonatal ou come, AS.	
Notes	Setting: Department of Obstetrics and Gynaecology in collaboration with the Department of Paediatrics, JNMCH,AMU, Aligarh (UP), India	
	Study period: May 2013–August 2014.	
	Funding: not reported	
	Declarations of interest: none declared	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only reported they were randomly assigned, unequal numbers in groups? (60 vs 44)
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT not reported, although this is likely as numbers are equal to randomised numbers. no missing data or cases
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected



Ntsaluba 1997	
Methods	RCT
Participants	Singleton vertex presentation with intact membranes, BS < 6, no previous CS.
Interventions	Intracervical PGE2 (0.5 mg) (59 women) Foley catheter with a 30 mL balloon extra-amniotic (53 women)
Outcomes	Change in BS, CS, uterine hyperstimulation, fever, neonatal sepsis, fetal distress.
Notes	Setting: KIng Henry 8th hospital, Durban, South Africa
	Study period: not reported
	Funding: not reported
	Declarations of interest: not reported

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No other details on the randomisation process.
Allocation concealment (selection bias)	Low risk	Sealed envelopes.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	No ITT reported (although it's likely as numbers are equal as randomised numbers), no missing cases or data
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported.
Other bias	Low risk	No other bias detected

Oliveira 2010

Methods	RCT
Participants	Inclusion: singletons in cephalic presentation, GA > 37 weeks, live fetus, BS ≤ 4.
	Exclusion: ruptured membranes, uterine scar, placenta praevia, chorioamnionitis, EFW > 4000 g, hypersensitivity for products used in intervention
Interventions	1. Foley catheter (n = 80): 14 or 16F, 30 cc, max 48 hours



Oliveira 2010 (Continued)	2. Misoprostol (n = 80) 25 mcg a 6 hours, with a max dose of 200 mcg max 48 hours of induction	
Outcomes	Oxytocin use, tachysystole, hypertonus of the uterus, BS > 6, total time until cervical modification, delivery route, FHR abnormalities, meconium stained liquor, AS	
Notes	In Portuguese, but translated	
	Setting: Maternidade Escola de Vila Nova Cachoeirinha, public institution which is administrated by the Secretaria Municipal da Saúde de São Paulo, Brazil	
	Study period:January 2006 to January 2008.	
	Funding: not reported	
	Declarations of interest: not reported	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated random number sequence.
Allocation concealment (selection bias)	Low risk	Sequentially-numbered, sealed, opaque envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT, no missing data or cases reported
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Unclear risk	Based on translated article

Ophir 1992

Methods	RCT
Participants	Singleton vertex presentation, BS 0-4.
Interventions	PGE2 (6 tablets 0.5 mg) intravaginally (27 women); Foley catheter with a balloon filled with 40 mL water (27 women).
Outcomes	CS
Notes	Setting: Israel



Ophir 1992 (Continued)

Study period: not reported

Funding: not reported

Declarations of interest: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Allocation sequence from a random numbers table
Allocation concealment (selection bias)	High risk	Allocation by odd and even number
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT not reported, 8 women missing in Foley group and 7 in PGE2 group. not clear why.
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported
Other bias	Low risk	No other bias detected

Orhue 1995

Methods	RCT
Participants	Singleton, vertex, term fetus, adequate pelvis, maternal height > 155 cm, BS < 5. Exclusion if previous uterine scar, placenta praevia or abruptio, age > 35 years.
Interventions	(PGE2) 3 mg every 6 hours, max 3 doses (34 women randomised, 30 women analysed) oxytocin (2 mU/minute, doubled every 30 minutes, max 32 mU/minute) and ARM (30 women) Foley 30 mL (30 women)
Outcomes	CS, instrumental delivery, uterine hyperstimulation, fetal distress, postpartum haemorrhage.
Notes	4 women excluded in PG group were re-included for CS results only.
	Setting: University of Benin Teaching Hospital, Benin City, Nigeria
	Study period: April 1990 - October 1991
	Funding: not reported
	Declarations of interest: not reported



Orhue 1995 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Allocation sequence from a table of random numbers
Allocation concealment (selection bias)	Low risk	Concealment of allocation by sequentially numbered, sealed, opaque envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT not reported, 4 women excluded in PG group were because of unripe cervix after 12 hours
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported
Other bias	Low risk	No other bias detected

Peedicayil 1998

Funding sources: not reported		
Dates of study: not reported		
Setting: tertiary level teaching hospital, India		
None of our outcomes of interest were reported		
n = 60 'randomised into 2 groups'		
Primigravid, requiring IOL, BS < 5		
_		



Peedicayil 1998 (Continued)		
Random sequence generation (selection bias)	Unclear risk	Not described.
Allocation concealment (selection bias)	Low risk	Sequentially-numbered opaque sealed envelopes.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Person assessing BS was blinded to what agent was used (after 12 hours and removal of agent I presume).
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not reported how many women were randomised to which group, thus unclear.
Selective reporting (reporting bias)	Unclear risk	The methods section states that only BS and ripening to delivery interval were the outcomes of interest, which is questionable.
Other bias	High risk	Retrospective power calculation, unclear how many women in which group.

Pennell 2009

Methods	RCT: generation of sequence unclear, sealed opaque envelopes, patient chose from a selection of 12.
Participants	Inclusion: primipara, GA > 36 weeks, intact membranes, BS < 4.singleton fetus, cephalic presentation, intact membranes.
	Exclusion criteria were age < 16 years, previous uterine surgery, low-lying placenta, any active or purulent infection of the lower vaginal tract, or an abnormal pre-induction FHR tracing
Interventions	Foley catheter 30cc. (110).
	Atad catheter 80 cc. (107).
	PGE 2 gel 2 mg, 6-hourly. (113).
Outcomes	Vaginal delivery within 24 hours, uterine hyperstimulation with/without FHR changes, CS, epidural analgesia, instrumental vaginal delivery, antibiotics during labour, postpartum haemorrhage, maternal fever during labour, pH < 7.10, placental abruption, endometritis, wound infection.
Notes	Data for Foley catheter and double balloon catheter were entered in 1 comparison (any mechanical method versus PG).
	Setting: King Edward Memorial Hospital (KEMH) in Perth, Western Australia
	Dates of study: July 2001 to December 2003
	Funding sources: supported by a grant from the Women and Infants Research Foundation, King Edward Memorial Hospital, Perth, Australia. Adeza Biomedical Corporation contributed support for the fetal fibronectin test kits.
	Declarations of interest: none declared



Pennell 2009 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information about sequence generation process in the paper.
Allocation concealment (selection bias)	Low risk	Sealed opaque envelopes (but why selection of 12??).
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Research midwives were blinded to treatment allocation, especially important for satisfaction questionnaires.
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT, loss to follow-up is described, incomplete data not mentioned.
Selective reporting (reporting bias)	Low risk	All outcomes prespecified in methods were reported, report includes all expected outcomes.
Other bias	Low risk	No other bias detected.

Perry 1998

Bias	Authors' judgement Support for judgement		
Risk of bias			
	Declarations of interest: not reported		
	Funding: not reported		
	Study period: August 1996 - April 1997		
Notes	Setting: University of Mississippi Medical Center Labor and Delivery Unit, Jackson, USA		
Outcomes	CS, instrumental delivery, uterine hyperstimulation, AS, NICU admission, chorioamnionitis, perinatal death.		
Interventions	Vaginal misoprostol 25 mcg every 4 hours (65 women) intracervical Foley of 50cc and PGE2 (4 mg) every 4 hours (62 women)		
	Exclusion: spontaneous uterine contractions, rupture of membranes, placenta previa, unexplained vaginal bleeding, a non-reactive nonstress test, an EFW > 4500 g, a prior vertical uterine incision, parity of > 5, active genital herpes infection, or a contraindication to receiving PGs		
Participants	Inclusion: singleton gestation, cephalic presentation, BS of ≤ 4.		
Methods	RCT.		
·			



Perry 1998 (Continued)		
Random sequence generation (selection bias)	Low risk	Computer-generated random schedule.
Allocation concealment (selection bias)	Low risk	The allocation of assignment was concealed by placement in a numbered, opaque, sealed envelope
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT not reported, although this is likely as numbers are equal to randomised numbers. No missing cases or data in outcomes of interest
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported
Other bias	Low risk	No other bias detected

Pineda Rivas 2016

Methods	RCT		
Participants	Inclusion criteria: obese (BMI > 30 before 20 weeks' GA). Singleton pregnancy. Vertex presentation, BS < 6, Intact membranes,GA 37 + 0 to 42 + 0. Normal fetal heart tracing on admission for ripening		
	Exclusion: IOL for intrauterine fetal demise, Intrauterine growth restriction, Suspected abruption at the start of induction, contraindication for a vaginal delivery		
Interventions	Foley catheter (n = 20):		
	PGE2 (n = 21): dinoprostone 10 mg slow release for 24 hours		
Outcomes	Time from initiation of IOL to vaginal delivery, number of vaginal deliveries within 24 hours in each group, CS operative vaginal deliveries chorioamnionitis oxytocin administration, epidural, ICU (NICU) admission, arterial pH < 7, AS < 7 at 5 minutes		
Notes	Abstract only		
	Setting: Canada		
	Study period: not reported		
	Funding: not reported		
	Declarations of interest: not reported		
Risk of bias			
Bias	Authors' judgement Support for judgement		



Pineda Rivas 2016 (Continued)		
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	insufficient information to judge
Selective reporting (reporting bias)	Unclear risk	insufficient information to judge
Other bias	Unclear risk	Abstract only

Prager 2008

Bias

Methods	RCT, not blinded.
Participants	Term pregnancy, BS 6 or less, different indication for IOL, including PROM
	Exclusion criteria: previous CS, malpresentation, immediate delivery indicated, contraindication to vaginal delivery, contraindication to PGs.
Interventions	Foley catheter 30 cc (199).
	Dinoproston 2 mg 6-hourly (191).
	Misoprostol 25 mcg vaginally 4-hourly (199).
Outcomes	Uterine hyperstimulation, CS, epidural analgesia, instrumental delivery, meconium, AS, NICU admissions, fever during delivery.
Notes	Hyperstimulation is not further specified (with of without FHR changes).
	Patients who did not meet inclusion criteria were not excluded retrospectively
	Setting: Karolinska university Hospital, Sweden
	Dates of study: December 2004 to March 2008
	Funding sources: not reported

Support for judgement

Authors' judgement



Prager 2008 (Continued)			
Random sequence generation (selection bias)	Low risk	Computer-generated sequence.	
Allocation concealment (selection bias)	Low risk	Opaque numbered envelopes.	
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention	
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported	
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing data described: 3 dinoprostone and 1 catheter. these were excluded.	
Selective reporting (reporting bias)	Low risk	All outcomes prespecified in methods were reported, report includes all expected outcomes.	
Other bias	Unclear risk	Patients who did not meet inclusion criteria were not excluded retrospectively ($n = 32$).	

Qamar 2012

Quasi-experimental		
Inclusion: singleton alive fetus, cephalic presentation, gestation at or beyond 37 weeks, para 4 or less, BS less than 5, obstetric and medical indication for induction		
Exclusion: congenital anomalies, multiple pregnancies, mal-presentation, CPD, placenta praevia or APH, previous CS, and PROM		
PGE2 pessary (80) dosage not known, failure of improvement of modified BS after 6 hours (< 5), a second PG E2 gel/pessary was applied and patient reassessed again after 6 hours. If still there was no improvement in BS (< 5) a 3rd PG E2 gel/pessary was applied.		
PGE2 intracervical (80): as above		
EASI with oxytocin IV (80) Foleys catheter of 24 or 26 Fr, inflated with 45 mL of distilled water. Traction applied and then saline infusion was started extra-amniotically at 30 mL per hour for 12 hours. oxytocir infusion was started at 2 mU/minute and the dose was doubled at half-hourly interval up to the max dose of 40 mU/minute		
induction labour interval, induction delivery interval, mode of delivery, AS at 1 and 5 minutes, and neonatal morbidity and mortality including ICU admission.		
No relevant outcomes reported in article		
Setting: Pakistan		
Study period: not reported		
Funding: not reported		



Qamar 2012 (Continued)

Declarations of interest: not reported

Ris	ı	~£	L	:
KISI	ĸ	UI	U	ıus

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Allocation in order of admission
Allocation concealment (selection bias)	High risk	Method of induction could be foreseen as a rotation was used
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear if ITT was used, missing cases or outcomes not reported
Selective reporting (reporting bias)	High risk	Neonatal mortality not reported in numbers, only reported they dit not differ. neonatal morbidity not reported in results
Other bias	Low risk	No other bias detected

Ridgway 1991

Bias	Authors' judgement Support for judgement		
Risk of bias			
	Declarations of interest: not reported		
	Funding: not reported		
	Study period: not reported		
Notes	Setting: San Antonio, USA		
Outcomes	CS.		
	intracervical PGE2 (0.5 mg) alone (49 women).		
Interventions	Intracervical PGE2 (0.5 mg) and Lamicel (52 women);		
Participants	BS < 5.		
Methods	RCT. No details were given on the method for generating the allocation sequence or for the concealment of the allocation.		
Mothods	PCT. No details were given on the method for generating the allocation sequence or for the conseal		



Ridgway 1991 (Continued)		
Random sequence generation (selection bias)	Unclear risk	Randomisation not described
Allocation concealment (selection bias)	Unclear risk	No information
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT not mentioned, insufficient information to judge
Selective reporting (reporting bias)	Unclear risk	Insufficient information to judge
Other bias	Unclear risk	Abstract only, insufficient information to judge risk of bias

Roberts 1986

Methods	RCT
Participants	Unfavourable cervix (BS < 5). Women with previous history of uterine surgery, fetal malpresentation or multiple gestation were excluded.
Interventions	4 groups:
	PGE1 in Tylose gel 3 mg (27 women) (exclude);
	laminaria tents (28 women);
	oxytocin 1 mU/minute (25 women);
	no treatment (24 women exclude).
	Then oxytocin was given in all groups.
Outcomes	CS.
Notes	Successful IOL and fetal distress not defined.
	Setting: Jackson, USA
	Dates of study: not reported
	Funding: supported by the Vicksburg hospital medical foundation:
	Declarations of interest: not reported
Risk of bias	



Ro	berts :	1986	(Continued)
----	---------	------	-------------

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomly ordered envelopes, not clear how
Allocation concealment (selection bias)	Low risk	Drawing a sealed envelope by a third party
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT not reported, although this is likely as numbers are equal to randomised numbers. no missing cases or data
Selective reporting (reporting bias)	Unclear risk	No outcomes pre specified in method section
Other bias	Low risk	No other bias detected

Rouben 1993

erest: not reported		
erest: not reported		
and the second s		
ted		
od: not reported		
JSA		
Also reported as abstract (Arias 1993).		
rine hyperstimulation, NICU admission, chorioamnionitis, spontaneous labour, fail- ndometritis.		
Foley catheter inflated with 30 mL water and extra-amniotic infusion of 1 mL/minute saline during up to 8 hours (56 women); PGE2 vaginal gel 2.85 mg (56 women).		
rm pregnancies, intact membranes, BS < 6. Excluded if non-reassuring FHR, placenta		
RCT. Allocation sequence from a table of random numbers. Blocks of 6 women. Concealment of alloc tion by sequentially-numbered, sealed, opaque envelopes.		



Rouben 1993 (Continued)		
Random sequence generation (selection bias)	Low risk	Random number table
Allocation concealment (selection bias)	Low risk	Consecutively-numbered, opaque, sealed envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT not reported, women with failed induction excluded from further analysis
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported
Other bias	Low risk	No other bias detected

Roudsari 2011

Methods	RCT		
Participants	Indication for IOL, GA > 37 weeks, BS < 7, singleton, gestational diabetes mellitus, reassuring FHR tracing, cephalic presentation, intact membranes, low-located placenta (no definition), and mild preeclampsia. Excluded hypersensitivity to PG, temp > 38, previous CS delivery or other uterine surgery, placenta previa, chorioamnionitis, vaginal bleeding, fetal distress, macrosomia and polyhydramnios.		
Interventions	Low-dose vaginal misoprostol: 25 mcg, repeated up to 6 doses every 4 hours. If no BS > 7 after 24 hours, oxytocin was started		
	Foley catheter (n = 59) 18 F, 50 mL. After 12 hours oxytocin was started.		
Outcomes	interval time from the first intervention to the time of delivery. Uterine tachysystole, uterine hyperstimulation		
Notes	Setting: Department of Obstetrics, teaching hospitals, Mashhad University of Medical Sciences, Iran		
	Study period: September 2007 to March 2008		
	Funding: not reported		
	Declarations of interest: not reported		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported how



Roudsari 2011 (Continued) Allocation concealment (selection bias)	Unclear risk	Not reported how
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No ITT mentioned, no missing data, 1 woman excluded because of bad participation?
Selective reporting (reporting bias)	Unclear risk	Time to delivery: not clear from when till delivery, most likely from active phase. primary outcome was for first intervention to delivery. other pre-specified outcomes reported
Other bias	Low risk	No other bias detected

Roztocil 1998

Methods	Allocation according to the week of admission. No concealment of allocation.	
Participants	Singleton vertex term pregnancies, BS < 5. Excluded if labour, fetal hypoxia, previous CS.	
Interventions	Dilapan S 4 units, removed after 14 hours (82 women); PGE2 intracervical gel 0.5 mg, 1 dose (83 women). In both groups, PGE2 vaginal tablets were administered after 14 hours for labour induction.	
Outcomes	CS, hyperstimulation with FHR changes, instrumental vaginal delivery, AS < 7, GI side effects, haemor-rhage.	
Notes	Inadequate method of random allocation and of concealment of allocation.	
	Setting: obstetrics department Brno, Chech Republic	
	Study period: January 1994 to December 1996	
	Funding: not reported	
	Declarations of interest: not reported	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Allocation according to the week of admission.
Allocation concealment (selection bias)	High risk	No concealment of allocation



Roztocil 1998 (Continued)		
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias)	Low risk	ITT not reported, but seems reasonable as numbers are equal to randomised numbers. no missing cases or data
All outcomes		
•	Low risk	Pre-specified outcomes reported
All outcomes Selective reporting (re-	Low risk Low risk	

Rudra 2012

Methods	RCT	
Participants	Inclusion criteria: low BS, AROM not possible	
	Exclusion criteria: grande multiparas, preterm induction	
Interventions	1. Foley catheter (n = 200), 40 mL, 24 hours	
	2. PGE2 vaginal; 2 mg	
Outcomes	Duration of labour, mode of delivery, postpartum infection and haemorrhage and perinatal, AS	
Notes	Abstract only	
	Setting: Batticaloa General Hospital, Sri Lanka	
	Study period: 18 months from 2004	
	Funding: not reported	
	Declarations of interest: not reported	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Low risk	Double-blind? Not clear how this is possible



Rudra 2012 (Continued)		
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind? Not clear how this is possible
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Too little information to judge
Selective reporting (reporting bias)	Unclear risk	Too little information to judge
Other bias	Unclear risk	Abstract only

Saleem 2006

Methods	Patients randomly selected, randomisation method not described.		
Participants	Singleton live pregnancy BS 5 or lower, requiring induction between 37 and 42 weeks of gestation.		
Interventions	Foley catheter 40-45 mL, after 8-10 hours oxytocin infusion was started (n = 78).		
	Dinoprostone pessary 3 mg 6-hourly max 2 doses, followed by oxytocin infusion (n = 75).		
	Oral misoprostol 50 mcg 4-hourly, max 4 doses, followed by oxytocin infusion (n = 73).		
Outcomes	Vaginal delivery rate, Induction to delivery interval < 12 hours, postpartum haemorrhage, tachysystole.		
Notes	Methods describe random selection of patients, not randomisation.		
	No neonatal outcomes.		
	Setting: Hamdard University Hospital and Patel Hospital, Pakistan		
	Dates of study: July 2005 - June 2005		
	Funding sources: not reported		
	Declarations of interest: not reported		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	'Random selection' of patients, insufficient information for judgement.
Allocation concealment (selection bias)	Unclear risk	'Random selection' of patients, insufficient information for judgement.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported



Saleem 2006 (Continued)		
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	It is unclear how many patients were assessed for randomisation or randomised, therefore it is also unclear if incomplete data were reported. There is no mention of this in the paper.
Selective reporting (reporting bias)	Unclear risk	All outcomes mentioned in the methods section are reported, it is however interesting why they did not report any neonatal data.
Other bias	Unclear risk	No sample size calculated

Salim 2011

Methods	RCT		
Participants	Inclusion: viable singleton pregnancy, cephalic presentation, intact membranes, BS of ≤ 6.		
	Exclusion: contraindication for vaginal delivery, previous caesarean delivery, a low-lying placenta, fetal malformations that were incompatible with postpartum life, intrauterine fetal death, clinical amnionitis, carriers of hepatitis B/C, HIV, allergy to latex.		
Interventions	1. Foley: (n = 145) 24 F, 60 mL, max 12 hours		
	2. Double balloon (n = 148), 80/80 mL, max 12 hours		
Outcomes	Time from insertion of the catheter to delivery, mode of delivery, vaginal deliveries within 24 hours, abnormal fetal presentation, cord prolapse, intrapartum fever more than 38°C, bleeding related to catheter insertion, AS.		
Notes	Setting: Emek medical centre, Afula, Israel. (teaching medical centre)		
	Study period: June 2008 and December 2010		
	Funding: Department of obstetrics, Emek medical centre		
	Declarations of interest: none reported		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated numbers, block randomisation
Allocation concealment (selection bias)	Low risk	Sequentially-numbered allocation, stored in a box.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias)	Unclear risk	ITT not reported and not clear if done, no missing data or cases.



Salim 2011 (Continued)

All outcomes

Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Sanchez-Ramos 1992

Methods	RCT. Computer-generated allocation sequence. No details on concealment of allocation.		
Participants	Singleton vertex term pregnancies, intact membranes, BS < 6. Excluded if non-reassuring FHR, placenta praevia, previous uterine scar, cervicitis.		
Interventions	Hygroscopic cervical dilators (as many as possible) (36 women); (PGE2) 4 mg gel applied to the cervical os (n = 38). After 8-12 hours, repeat in both groups if cervix unfavourable. Followed by oxytocin and amniotomy.		
Outcomes	CS, instrumental vaginal delivery, haemorrhage, admission to NICU, infection.		
Notes	Unclear whether PG was intracervical or intravaginal.		
	Setting: Univerity medical Center of Jacksonville, USA. largely high risk, low income obstetric population		
	Study period: June 1988 to July 1989		
	Funding: not reported		
	Declarations of interest: not reported		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated randomisation list
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT not reported and not clear if done, no missing data or cases reported
Selective reporting (reporting bias)	Unclear risk	No outcomes pre specified in method section



Sanchez-Ramos 1992 (Continued)

Other bias Low risk No other bias detected

Sarreau 2016

Methods	RCT		
Participants	Inclusion: indication for IOL, vertex, singleton, > 37 weeks of GA, previous CS (transverse incision), BS < 5, no premature rupture of membranes, singleton in vertex presentation.		
	Exclusion: < 18 years, placenta praevia, cervical infection, malpresentation, latex allergy, induction for CS		
Interventions	1. Foley catheter (n = 101): 50 mL, max 12 hours (N = 101)		
	2. oxytocin (N = 103), low-dose perfusion		
Outcomes	Vaginal birth rate, maternal and neonatal complications		
Notes	Abstract only (awaiting publication)		
	Setting: France, multicentre		
	Study period: December 2010 tot December 2013		
	Funding: not reported		
	Declarations of interest: not reported		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT, too little information to judge incomplete outcome data
Selective reporting (reporting bias)	Unclear risk	Too little information to judge
Other bias	Unclear risk	Abstract only



Sciscione 1999

Methods	RCT. Computer-generated allocation sequence. Concealment of allocation by opaque, sealed, consecutively-numbered envelopes.		
Participants	Singleton vertex pregnancies with intact membranes, BS < 6. Term > 28 weeks. Inclusion of women with previous CS.		
Interventions	Intracervical PGE2 (0.5 mg) every 6 hours (72 women). Intracervical Foley catheter inflated with 30 mL (77 women).		
Outcomes	Spontaneous onset of labour, nausea, maternal discomfort measured with an analogue scale 0-10, non-reassuring FHR, hyperstimulation, use of epidural, use of oxytocin, shoulder dystocia, vaginal delivery.		
Notes	12 women excluded (6 women in PGE2 group because of use of Foley catheter, 2 removed consent, 1 pre-eclampsia, 1 BS of 7 and 2 breech).		
	Setting: Medical centre of Delaware, USA. tertiary referral centre,		
	Study period: July 1995 to July 1996		
	Funding: not reported		
	Declarations of interest: not reported		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated random allocation.
Allocation concealment (selection bias)	Low risk	Sealed, opaque envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	No ITT, women excluded because of protocol violation. no missing data.
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported
Other bias	Low risk	No other bias detected



Sharami 2005	
Methods	Randomised trial: computer-generated random number table, blocks of 4, sequentially-numbered opaque sealed envelopes.
Participants	Nulliparous women, admitted for induction, between 34 and 42 weeks GA, singleton in cephalic presentation, BS < 4, intact membranes, reassuring FHR tracing, < 6 contractions per hour
	Exclusion: significant vaginal bleeding, fetal chorioamnionitis, any contraindication to vaginal delivery, previous uterine scar, FHR abnormalities, severe pre-eclampsia, contraindication to PG.
Interventions	Foley 30 mL + EASI + concurrent IV oxytocin for 12 hours (n = 76).
	PGE2 gel 0.5 mg intracervical 6-hourly, max 3 doses (n = 75).
Outcomes	Interval from start induction to active phase, abnormal FHR tracing, tachysystole, hyperstimulation, meconium passage, caesarean delivery, chorioamnionitis, endometritis, AS < 7, admission NICU
	Secondary: start induction to delivery, change in dilation at 1, 6, 12 hours, CS for failed induction.
Notes	No sample size calculation.
	Prophylactic antibiotics after 12 hours of start induction
	Setting: Prenatal Clinic in Al-Zahra Maternity
	Hospital, Iran
	Dates of study: March 2002 - September 2003
	Funding sources: not reported
	Declarations of interest: not reported

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated sequence.
Allocation concealment (selection bias)	Low risk	Sequentially-numbered opaque sealed envelopes.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Good description of excluded patients, quite evenly spread over the groups. There is no information about missing/incomplete outcome data.
Selective reporting (reporting bias)	Low risk	It seems that all outcomes prespecified in methods were reported, report includes all expected outcomes.
Other bias	Low risk	No other bias detected



Shechter-Maor 2015

Methods	RCT
Participants	Inclusion criteria: singleton, GA 37 weeks or more, cephalic presentation, intact membranes, unfavourable cervix (BS =/< 6), oligohydramnios (AFI =/< 5)
	Exclusion criteria: multifetal gestation, fetal malpresentation, spontaneous labour, contraindication to PGs or a vaginal delivery (e.g. placenta previa), non-reassuring FHR tracing, a fetus with major anomalies or previous CS
Interventions	1. Propess (10 mg slow release PGE), n = 26
	2. Double balloon (Cook), n = 26
Outcomes	Time from induction to active labour (defined as cervical dilation of at least 5 cm), induction to delivery time, CS and operative delivery rates, oxytocin augmentation, uterine tachysystole (defined as greater than 5 uterine contractions in 5 minutes), meconium passage, FHR changes, AS and maternal satisfaction
Notes	Setting: Israël
	Study period: not reported
	Funding: none received
	Declarations of interest: none declared

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Using computer-generated, random sequences
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT not reported, no missing data described. No figure 1, all women analysed
Selective reporting (reporting bias)	High risk	All pre-specified outcomes reported but secondary outcome 'AS'
Other bias	Unclear risk	Not mentioned in method section how long balloon/dinoprostone was given and what happened after ripening process.



Methods	RCT		
Participants	Inclusion: 1st or 2nd gr sence of uterine contra	ravida, single, live fetus, cephalic, indication for IOL, GA 37-42 weeks, BS ≤ 5, abactions.	
	Exclusion: previous uterine surgery, non reassuring FHR tracing, IUGR, oligohydramnios, placenta praevia, multifetal pregnancy, chorioamnionitis, active herpes, EFW > 4 kg, renal or hepatic disease		
Interventions	1. Oral misoprostol (n =	= 30):, 50 mcg, repeated every 4 hours to a max of 5 doses.	
	2. Vaginal misoprostol	(n = 30): 25 mcg, repeated every 4 hours to a max of 5 dosis. n = 30	
	3. Foley catheter (n = 3	0): 16 or 18 F, 35 mL. max of 16 hours	
	In all 3 groups after 16	hours oxytocin was started.	
Outcomes	interval from induction duction	n to birth, mode of delivery, maternal complication, neonatal outcome, failed in	
Notes	Setting: SMGS hospital, Jammu, India		
	Study period: over 1 year		
	Funding: not reported		
	Declarations of interest: not reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence generation (selection bias)	Unclear risk	Random assigned, no more information reported	
Allocation concealment (selection bias)	Unclear risk	Not reported	
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention	
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported	

No ITT reported, cases missing in table 2, not clear why

delivery interval is given but no SDs,

No other bias detected

No outcome measures were mentioned in the method section, induction to

High risk

High risk

Low risk

Incomplete outcome data

Selective reporting (re-

(attrition bias) All outcomes

porting bias)

Other bias



Solt 2009	
Methods	RCT
Participants	100 primiparae and 100 multiparae women with an unfavourable BS
Interventions	Foley catheter:(nulliparae n = 50)
	Double balloon:(nulliparae n = 45)
Outcomes	Primary outcomes were BS increment, time from catheter withdrawal to delivery, CS rate and post cae sarean febrile morbidity.
Notes	Abstract only, numbers only given for nulliparae
	Setting: Israel
	Study period: not reported
	Funding: not reported
	Declarations of interest: not reported
Risk of bias	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated numbers
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Reported it was a single-blinded study, not how blinding was performed.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	20 women excluded from analyses, not clear why
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported
Other bias	Unclear risk	Abstract only

Somirathne 2017

Methods	RCT
Participants	Inclusion criteria: not delivered by 40 weeks + 5 days gestation, having uncomplicated pregnancies with a singleton fetus, longitudinal lie and cephalic presentation.



Somirathne 2017 (Continued)	Exclusion criteria were pregnancy-induced hypertension, gestational diabetes mellitus, multiple pregnancies, planned CS, fetal growth restriction and scarred uterus
Interventions	1. Foley catheter, (n = 89), 60 mL, max 24 hours
	2. Low dose oral misoprostol (n = 91), 50 mcg, 3 gifts, 4 hourly (N = 91)
	In both groups, if cervix is unfavourable after 24 hours Foley group PGE2, oral misoprostol group Foley catheter)
Outcomes	The induction delivery interval following IOL, the mode of delivery, the reasons for operative delivery, maternal morbidity, hyperstimulation, uterine rupture, peripartum hysterectomy, postpartum blood transfusion or crystalloid transfusion, IV antibiotics, maternal pyrexia of > 38°C, fetal and neonatal outcome and morbidity, suspicious or pathological CTG according NICE guidelines, meconium-stained liquor, birthweight, 1 minute AS, NICU and reason for admission
Notes	Setting: University Unit of the THMG, Sri Lanka
	Study period: September 2014 to April 2015.
	Funding: none
	Declarations of interest: none declared

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated numbers, block randomisation, stratified by parity
Allocation concealment (selection bias)	Low risk	Sequentially-numbered, sealed, opaque envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT not reported, no missing data or cases. referred to Figure 1, but not available
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

St Onge 1995

Methods	RCT. Computer-generated allocation sequence. Concealment of allocation by sealed envelopes.



St Onge 1995 (Continued)	
Participants	Singleton vertex term pregnancies with intact membranes, BS < 5. Exclusion of women with previous CS, low-lying placenta.
Interventions	Intracervical PGE2 (0.5 mg) (30 women). Intracervical Foley catheter inflated with 30 mL (36 women).
Outcomes	CS, instrumental delivery, maternal side effects, maternal pyrexia, fetal distress.
Notes	2 women excluded in each group. Also reported as abstract (Lange 1994).
	Setting: Foothills Hospital in Calgary, Alberta, Canada
	Study period: October 1991 to November 1993
	Funding: not reported
	Declarations of interest: not reported

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated allocation sequence.
Allocation concealment (selection bias)	Low risk	Concealment of allocation by sealed envelopes.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	2 women in each group excluded (not meeting inclusion criteria or in labour directly after randomisation). no missing cases or data
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported
Other bias	Low risk	No other bias detected

Suffecool 2014

Methods	RCT
Participants	Inclusion criteria: nulliparous, 18 years or older, GA 37 weeks or more, singleton, cephalic presentation, intact membranes, BS < 6, admission for IOL.
	Exclusion criteria: contraindication for vaginal delivery (placenta praevia, non vertex presentation), ruptured membranes, severe pre-eclampsia, suspected fetal growth restriction with abnormal dopplers, presence of a uterine scar, non reassuring FHR trace requiring medical intervention.



Suffecool 2014 (Continued)		
Interventions	1. 10 mg dinoprostone vaginal insert (n = 31), max 12 hours, if after 12 hours unfavourable cervix start with oxytocin	
	2. Double balloon (Cook) (n = 31), 80 mL, oxytocin started 6 hours after placement. Balloon removed after max 12 hours.	
Outcomes	Time from insertion of ripening method until delivery, delivery rate < 24 hours, CS rate, time to active labour, rate of operative vaginal delivery, maternal or fetal adverse events	
Notes	Setting: USA	
	Study period: February 2011 - September 2012	
	Funding: not reported	
	Declarations of interest: none declared	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated numbers
Allocation concealment (selection bias)	Low risk	The allocation assignment was sealed in sequentially-numbered, opaque envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT, no missing data or cases.
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Sullivan 1996

Methods	RCT. Concealment of allocation by opaque, sealed envelopes.	
Participants	BS < 6 and indication/no contraindication for IOL.	
Interventions	Intracervical PGE2 (0.5 mg) and Foley catheter inflated with 50 mL of water (41 women); intracervical PGE2 (0.5 mg) repeated after 4 to 6 hours if needed (37 women).	
Outcomes	CS, uterine hyperstimulation with and without FHR changes, infection.	
Notes	Setting: Jackson, USA	



Sullivan 1996 (Continued)

Study period: October 1993 - May 1994

Funding: supported by the Vicksburg hospital medical foundation

Declarations of interest: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Low risk	Concealment of allocation by opaque, sealed envelopes.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT not reported, but is reasonable as numbers are equal to randomised numbers, no missing cases or data
Selective reporting (reporting bias)	Low risk	All pre-specified outcome reported.
Other bias	Low risk	No other bias detected

Tabowei 2003

Methods	Random number table, opaque sealed envelopes.	
Participants	Term pregnancy, singleton fetus in cephalic presentation, BS < 4.	
	Exclusion: ruptured membranes, placenta praevia, non-reactive non-stress test, EFW > 4000 g, prior uterine incision, parity > 4, contraindication to PGs.	
Interventions	Foley 50 mL max 12 hours (n = 61).	
	Vaginal misoprostol 25 mcg every 4 hours, max 6 doses (n = 60).	
Outcomes	Failure to achieve ripening within 12 hours, vaginal delivery within 24 hours, need for oxytocin augmentation, CS rate, tachysystole, hypertonus, meconium, maternal and neonatal complications, AS < 7, NICU admissions, febrile morbidity.	
Notes	Prior uterine incision is exclusion criterion, but 18 women with previous CS included.	
	Setting: Zonal general hospital, Nigeria	
	Study period: June 1998 to May 2001	
	Funding: not reported	



Tabowei 2003 (Continued)

Declarations of interest: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table.
Allocation concealment (selection bias)	Low risk	Opaque sealed envelopes.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Incomplete outcome data were not mentioned in the report.
Selective reporting (reporting bias)	Low risk	All outcomes prespecified in methods were reported, report includes all expected outcomes.
Other bias	Unclear risk	Prior uterine incision is exclusion criterion, but 18 women with previous CS included, they were evenly divided between the groups.

Tan 2015

uii 2025		
Methods	RCT	
Participants	Inclusion criteria: pregnant women aged 21 to 40 years old with a singleton pregnancy with no major fetal anomaly who were suitable for vaginal delivery and scheduled for a planned IOL at 37-41 + 6 weeks of gestation.	
	Exclusion criteria: spontaneous labour, had a cervical dilatation of 3 cm or more, confirmed rupture of membrane, had abnormal cardiotocogram, a scarred uterus such as previous CS, malpresentation in labour, or if CS delivery was indicated	
Interventions	1. Double balloon (80 mL, balloon started with 40 mL, every following hour 20 mL inserted until 80 mL total), max 12 hours (N = 31)	
	2. PG 3 mg tablet, repeat once after 6 hours (N = 54)	
	If not in labour or AROM possible after 12 hours, further management by local physician.	
Outcomes	Not clearly mentioned in method section	
Notes	Setting: tertiary referral maternity unit in Singapore.	
	Study period: not reported	
	Funding: double balloons provided by Cook Medica	



Tan 2015 (Continued)

Declarations of interest: none declared

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Shuffling of 150 envelopes with equal numbers of chance for intervention or control, labelled sequentially
Allocation concealment (selection bias)	Low risk	Sealed envelope, next allocated number of envelope
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT not described, seems per protocol as woman in pain and breech during labour were excluded; no missing data described
Selective reporting (reporting bias)	Unclear risk	No pre specified outcomes reported, so cannot be judged
Other bias	Low risk	No other bias detected

ten Eikelder 2016

Methods	RCT	
Participants	Inclusion: singleton, scheduled for labour induction, GA ≥ 37 wk; BS < 6, vertex presentation, intact membranes.	
	Exclusion: placenta previa, previous uterine scar. contraindication to receive or known allergy to latex or PG.	
Interventions	1. Foley catheter (n = 921): 30 mL, no traction, replaced after 48 hours, max 4 days	
	2. Low dose oral misoprostol (n = 924): 50 mg every 4 hours, max 3 times a day, max 4 days	
Outcomes	Primary outcome for safety was composite of fluxus postpartum and asphyxia, and for effectiveness CS rate. Secondary outcomes included maternal and neonatal outcomes, total induction time, interval between randomisation and active phase	
Notes	Setting: multicentre, 6 tertiary-care and 23 secondary-care hospitals, the Netherlands	
	Study period: July 2012 to October 2013,	
	Funding: FondsNutsOhra, no role in study design, data collection, data analysis, data interpretation, writing of the report or publication	
	Declarations of interest: none declared	



ten Eikelder 2016 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated numbers, block randomisation, stratified by parity and centre
Allocation concealment (selection bias)	Low risk	Web-based allocation
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT, no missing cases. missing data in primary outcome (pH in umbilical artery). similar reasons for missing data across groups, pre-specified in protocol, anticipated on as followed: data missing for umbilical artery pH and a 5-minute AS of less than 7, the outcome was classified as abnormal; for patients with missing data for umbilical artery pH and a 5-minute AS of 7 or more, the neonatal outcome was classified as normal.
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported in results
Other bias	Low risk	No other bias detected

Thiery 1981

Bias

Methods	RCT. Concealment of allocation by envelopes.		
Participants	Singleton vertex term pregnancies. Favourable cervix (BS > 5).		
Interventions	Foley catheter with a balloon inflated with 30 mL saline and PGE2 0.5 mg extra-amniotic (48 women); PGE2 0.5 mg extra-amniotic (43 women); amniotomy and oxytocin if needed (52 women).		
Outcomes	No outcomes reported.		
Notes	No relevant outcomes reported.		
	Setting: Belgium		
	Study period: not reported		
	Funding: received free PGE2. not clear if this gift is related to a pharmaceutical company		
	Declarations of interest: not reported		

Support for judgement

Authors' judgement



Thiery 1981 (Continued)		
Random sequence generation (selection bias)	Unclear risk	Prepared envelopes with numbers
Allocation concealment (selection bias)	Low risk	Concealment of allocation by envelopes.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	Unclear if ITT was performed, but is reasonable as numbers are equal to randomised numbers), no missing cases or data
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported
Other bias	Low risk	No other bias detected

Tita 2006

Bias

Methods	RCT
Participants	Inclusion: preterm rupture of membranes, cervix ≤ 2 cm
	GA ≥ 34 weeks, singleton gestation, cephalic,
	Exclusion: regular uterine contractions (contractions more frequent than every 5 minutes), 2 prior transverse uterine incisions/vertical uterine incision/transmural myomectomy or any obstetric contraindication to labour, evidence of chorioamnionitis, lethal fetal anomalies, intrauterine fetal demise, placenta previa, suspected abruption/significant haemorrhage, non-reassuring FHR pattern
Interventions	Foley + oxytocin (n = 87)
	oxytocin only (n = 82)
Outcomes	Reported outcomes: hours from placement of Foley or initiation of oxytocin to delivery, rate of delivery (vaginal or caesarean) within 24 hours caesarean rate, induction to vaginal delivery interval.
Notes	Grey literature: study terminated, primary outcomes reported in trial registration.
	Setting; USA
	Study period: December 2005 - May 2008
	Funding: not reported
	Declarations of interest: not reported
Risk of bias	

Support for judgement

Authors' judgement



Tita 2006 (Continued)		
Random sequence generation (selection bias)	Unclear risk	Randomisation process unclear
Allocation concealment (selection bias)	Unclear risk	Unclear
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	Unclear if ITT analyses was used. for CS there are missing cases
Selective reporting (reporting bias)	High risk	Only primary outcomes were reported in trial registration
Other bias	Unclear risk	Study was terminated (not clear why)

Turnquest 1997

Methods	RCT	
Participants	Term women with unfavourable cervix (BS < 5), intact membranes.	
Interventions	Laminaria (as many as possible) and (PGE2) vaginal gel (4 mg) (21 women); (PGE2) vaginal gel (4 mg) alone (27 women).	
Outcomes	Need for oxytocin, CS, uterine hyperstimulation, admission to NICU, chorioamnionitis.	
Notes	Setting: memorial hospital Indianapolis, USA	
	Study period: October 1994 to May 1995	
	Funding: not reported	
	Declarations of interest: not reported	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated allocation sequence.
Allocation concealment (selection bias)	Low risk	Concealment of allocation by consecutively-numbered, opaque, sealed envelopes.
Blinding of participants and personnel (perfor- mance bias)	Unclear risk	Not feasible due to nature of intervention



Turnquest 1997 (Continued)

All outcomes

Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	4 women excludes because of protocol violation, no missing cases or data
Selective reporting (reporting bias)	Low risk	All outcomes reported
Other bias	Low risk	No other bias detected

Wang 2012

Methods	RCT	
Participants	Inclusion criteria: primiparae, full-term, singleton with cephalic presentation; indication for labour induction; intact membranes; BS < 6; no contra indication for vaginal delivery	
Interventions	Foley catheter (n = 138); 16F Foley, 80cc fluid, max 24 hours	
	Propess: (n = 124), 10 mg slow release dinoprostone, fornix posterior, max 24 hours	
	afterwards started with oxytocin. if after 3 days labour did not started, IOL was declared failed	
Outcomes	The duration of placement (of Propess or catheter, mode of delivery and time from IOL to delivery; usage of oxytocin, postpartum haemorrhage; meconium-stained amnion fluid, AS, post-delivery temperature monitoring (for a total of 10 days); 42 days after delivery follow-up interview to check for lochia appearance or signs of infection.	
Notes	Article in Chinese => translated by native speaker	
	Setting: China	
	Study period; not reported	
	Funding: not reported	
	Declarations of interest: not reported	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention



Wang 2012 (Continued)		
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	No ITT, women were excluded for different reasons during the trial (n = 8)
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported
Other bias	Unclear risk	Judged from a translated article

Wang 2014

Methods	RCT	
Participants	Inclusion: oligohydramnios (AFI < 5 cm). GA beyond 37 0/7 weeks', singleton pregnancy, vertex presentation, BS ≤ 6, intact membranes, the absence of documented uterine contractions, the absence of prior CS delivery, reassuring antenatal fetal testing (non-stress test) active, and oxytocin challenge test negative upon study entry.	
	Exclusion: antepartum bleeding, chorioamnionitis, placenta previa, or any other contraindication to vaginal delivery, women with documented PG allergy, maternal asthma history, vaginitis or cervicitis at presentation, and/or glaucoma history were not eligible for the pharmacological treatment arm	
Interventions	Double balloon (n = 67): 80/80cc, no traction, max 12 hours. After 24 hours unsuccessful ripening states oxytocin	
	10 mg dinoprostone insert (n = 59), fornix posterior, max 24 hours, After 24 hours unsuccessful ripening start oxytocin	
Outcomes	Pregnancy outcomes and success of induction	
Notes	Setting: The People's Liberation Army 174th Hospital, Xiamen, China,	
	Study period: April 2010 - February 2011	
	Funding: financial support of The People's Liberation Army Nanjing Military Area Command Medicine Health Department in China.	
	Declarations of interest: none declared	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described how random sequence was generated.
Allocation concealment (selection bias)	Low risk	Sealed envelope randomisation, opaque?
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention



Wang 2014 (Continued)		
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	No ITT => 5 woman reassigned after randomisation (non re-assuring FHR, failed placement) no missing data or cases
Selective reporting (reporting bias)	Unclear risk	No pre specified outcomes reported, so can't be judged
Other bias	Low risk	No other bias detected

Wu 2017

Methods	RCT	
Participants	Inclusion: 18–40 years old; $37 + 0-41 + 6$ gestational weeks; BS \leq 6; single alive fetus with cephalic presentation; in cephalopelvic proportion; without premature rupture of membrane; NST reaction type before labour induction. The indications of labour induction included delayed pregnancy, oligohydramnios (AFI = $3.0-8.0$ cm), gestational diabetes mellitus, intrahepatic cholestasis of pregnancy, good control of gestational hypertension, with vaginal trial production condition and required pregnancy termination.	
	Exclusion: placenta previa, vasa previa and APH; invasive cervical carcinoma; untreated HIV infection; allergic to induction drugs.	
Interventions	Double-balloon combined with IV drip of oxytocin (n = 60) AROM after 12 hours.	
	IV drip of oxytocin at a concentration of 0.5% (n = 60); AROM after 12 hours	
	If the patients did not enter the stage of active labour within 48 hours, the labour induction was regard ed as failing, and other methods for pregnancy termination were used	
Outcomes	Postpartum haemorrhage, cervical laceration, uterine rupture, puerperal infection, neonatal asphyxia, neonatal infection and meconium aspiration syndrome	
Notes	Setting: China	
	Study period: January 2014 - June 2015	
	Funding: grants received from the Nature Science Foundation of China, the Science and Technology Project of Special Funds of Guangzhou, Guangdong Science and Technology Project, the Natural Science Foundation of Guangdong Province and Guangzhou Science and Technology Project	
	Declarations of interest: none declared	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Women randomly divided, no information given
Allocation concealment (selection bias)	Unclear risk	No information reported on allocation concealment



Wu 2017 (Continued)		
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT not mentioned, but is reasonable as numbers are equal to randomised numbers. no missing cases or data
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes were reported
Other bias	Low risk	No other bias detected

Yuen 1996

Methods	RCT	
Participants	Singleton vertex presentation, intact membranes, BS < 5, no previous CS.	
Interventions	Atad device (100 mL) (36 women); intracervical PGE2 (0.5 mg) (39 women); vaginal pessary 0.5 mg PGE2 (39 women).	
Outcomes	Change in BS, vaginal delivery achieved within 12 and 24 hours, CS, instrumental delivery, vaginal bleeding, uterine hyperstimulation, AS.	
Notes	5 women were excluded (2, 2 and 1, respectively).	
	Setting: Prince of Wales Hospital, Honkong teaching hospital, China	
	Dates of study: period of 18 months	
	Funding sources: not reported	
	Declarations of interest: not reported	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated number
Allocation concealment (selection bias)	Low risk	Sealed, opaque envelopes
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention



Yuen 1996 (Continued)		
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	5 women excluded because of protocol violation, no other missing cases or data
Selective reporting (reporting bias)	Low risk	All pre-specified outcome reported
Other bias	Low risk	No other bias detected

Zahoor 2014

Methods	RCT
Participants	Women requiring IOL for common indications, no previous CS
Interventions	PGE2 tablets (n = 100) dosage of 2 mg, every 6 hours, max of 4 doses
	transcervical balloon catheter(n = 100) filled with 60 mL of saline.
Outcomes	Induction to delivery interval, mode of delivery, meconium staining, CTG abnormalities, admission in NICU, low AS
Notes	No relevant outcomes were reported in the abstract
	Setting: Pakistan
	Study period: not reported
	Funding: not reported
	Declarations of interest: not reported

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation not described
Allocation concealment (selection bias)	Unclear risk	No information
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Not feasible due to nature of intervention
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information
Incomplete outcome data (attrition bias)	Unclear risk	ITT not reported, insufficient information.



Zahoor 2014 (Continued)

All outcomes

Selective reporting (reporting bias)

Unclear risk Insufficient information.

Other bias Unclear risk Abstract only, too little information to judge risk of bias

AFI: amniotic fluid index APH: antepartum haemorrhage

ARM/AROM: artificial rupture of membranes

AS: Apgar score BMI: body mass index BS: Bishop score

CPD: cephalopelvic disproportion

CS: caesarean section CTG: Cardiotocography

EASI: extra-amniotic saline infusion EFW: estimated fetal weight

FHR: fetal heart rate

GA: gestational age

GBS: group B Streptococcus

GI: gastrointestinal ICU: intensive care unit IOL: induction of labour

IFD/IUFD intrauterine fetal death

ITT: intention-to-treat IV: intravenous

LSCS: lower segment caesarian section

max: maximum

Mbs: modified Bishop Score

mcg: microgram mL: millilitre mg: milligram mU: milliunits

NICU: neonatal intensive care unit

NST: non-stress test PBU: premature baby unit

PCM:

PG: prostaglandin PGE2: prostaglandin E2

PROM: pre labour rupture of membranes

RCT: randomised controlled trial

SROM: spontaneous rupture of membranes

US: ultrasound

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Abramovici 1999	It is unclear whether all women had Foley catheter (included as 'intention to ripe the cervix' with Foley catheter). Women only received a Foley catheter when they had no dilation at the start of induction (for this study this was the control group), and concurrent oxytocin was started. It is unclear how many women received a Foley catheter.
Adeniji 2005a	Primary outcome fibronectin, other outcomes not mentioned.
Adeniji 2005b	High-dose misoprostol



Study	Reason for exclusion	
Adeniji 2006	Outcome cervical scores, other outcomes not mentioned.	
Afolabi 2005	Only reports outcomes for the successfully induced, thus not useful.	
Ahmad 2015	laminaria vs Foley => not within scope of review	
Anabosy 2014	Trial stopped before start patient inclusion because of technical issues	
Arsenijevic 2012	No dilatator vs hegar vs continues, controlled, balloon dilator => not within scope of review	
Arshad 2016	Laminaria prior to PGE2 vs nothing prior to PGE2 => not within scope of review	
Atad 1991	No randomised comparison of mechanical methods. A subgroup of women were randomised to receive PGE2 or placebo.	
Atad 1999	Compares 2 mechanical regimens.	
Baacke 2006	Trial registration, expected end date expired > 2 years. no information could be obtained (authors were contacted)	
Barrilleaux 2002a	High-dose misoprostol	
Behrashi 2013	Trial registration with no publication. anticipated end date 2013 => no information could be obtained (authors were contacted)	
Ben-Aroya 2001	There is no mention of randomisation in the abstract. Retrospective cohort study.	
Buccellato 2000	High-dose misoprostol	
Cahill 1988	Alternate randomisation.	
Caughey 2007	Balloon high vs low volume => not within scope of review	
Chipato 1997	2 regimens of extra-amniotic infusion compared.	
Chung 2003	High-dose misoprostol	
Connolly 2016	Foley+ oxytocin vs Foley => not within scope of review	
Connolly 2017	Foley + oxytocin vs Foley (multiparae) => not within scope of review	
Cross 1978	Randomisation based on the last digit of the hospital chart number. 6 women were excluded in the laminaria group, and 1 in the control group. No clinical outcomes were reported.	
Cullimore 2009	Trial registration. study terminated after n = 5).no information could be obtained (authors were contacted)	
De Oliveira 2003	Foley vs no ripening => not in scope	
Delaney 2010	Comparison of 2 mechanical methods.	
Demirel 2015	Nipple stimulation, no mechanical method included	
Dias 2008	Trial registration, expected end date expired > 2 years. no information could be obtained (authors were contacted)	



Study	Reason for exclusion
Du 2015	Not randomised. women could choose induction method
Edwards 2017	Foley + PGE2 vs Foley => not within scope of review
El Sharkwy 2017	Foley + miso vs Foley (and miso after 12 hours) => not within scope of review
El-Khayat 2016	Foley + isorbide mononitrate vs misoprostol => not within scope of review
El-Torkey 1995	Foley + EASI vs Foley => not in scope
Emery 1988	No information.
EUCTR 2012	Trial registration, expected end date expired > 2 years. no information obtained (authors were contacted)
Filshie 1992	Insufficient information.
Forgie 2016	Placement stylette vs no stylette => not within scope of review
Forooshani 2011	Foley vs laminaria => not within scope of review
Fruhman 2017	Tension vs no tension => not within scope of review
Gadel 2015	Cervical ripening in case of stillbirth
Garebedian 2016	Foley vs expectative management
Ghanaei 2009	Foley + oxytocin vs EASI + oxytocin
Ghanaie 2013	Foley +oxytocin vs EASI + oxytocin vs PGE2 + oxytocin => not within scope of review
Gibson 2013	different kind of traction applied => not within scope of review
Gilson 1996	Dilapan vs no treatment => not in scope
Gonsoulin 1989	No clinical outcome reported.
Gower 1982	Laminaria vs placebo => not in scope
Greybush 2001	High-dose misoprostol
Gu 2015	Low- vs high-volume balloon => not within scope of review
Guinn 2004	Compares 2 mechanical regimens.
Haghighi 2015	EASI vs isoniazide => not within scope of review
Hallak 2008	Foley vs Foley + EASI vs ATAD + EASI => not in scope
He 2000	Air vesicle odinopoeia => not within scope of review
Hill 2009	High-dose misoprostol
Hill 2013	Balloon + miso vs balloon + placebo => not within scope of review



Study	Reason for exclusion
Hussein 2012	Induction for fetal demise or early PE (begin third trimester), so no viable fetus
Ifnan 2006	Hydrostatic membrane sweeping vs Foley => not within scope of review
Jagani 1984	An extra-amniotic catheter is used in all groups to record the uterine activity. This catheter uses a 5 mL balloon, which is much lower than the volume used by the other authors (30 mL to 40 mL). Thus, this study is a comparison between oxytocin and PG, with a control group without intervention.
Jasper 2000	No clinical outcome reported (reported as abstract).
Jindal 2007	Methods are interchanged after 24 hours, outcomes are given for the totals.
Jonsson 2011	Digital vs manual placement Foley => not within scope of review
Kamilya 2011	Trial registration, expected end date expired > 2 years. no information could be obtained (authors were contacted)
Karjane 2006	Compares 2 mechanical regimens.
Kasdaglis 2007	The randomisation scheme is unclear and the numbers in both groups are very different (32 and 24).
Kashanian 2006	High-dose misoprostol
Kashanian 2009a	Comparison of 2 mechanical regimens.
Kehl 2012	2 hours cook balloon before vaginal miso vs no balloon before vaginal miso => not within scope of review
Kehl 2015	Balloon before oral misoprostol vs no balloon before oral misoprostol => not within scope of review
Keirse 1983	No clinical outcome reported.
Lackritz 1979	Laminaria vs no treatment => not in scope
Lam 2006	Foley +oxytocin vs EASI + oxytocin => not within scope of review
Leiberman 1977	Alternate inclusion in each group. Imbalance between groups in numbers and prognostic factors.
Leong 2017	Menbrane sweeping vs Foley => not within scope of review
Levine 2016	High-dose misoprostol
Levy 2000	Comparison between early and late amniotomy.
Levy 2004	Comparison between 2 mechanical regimens.
Lin 1995	Laminaria vs EASI => not in scope
Lin 2006	Trial registration only, study terminated.
Lin 2007	Compares 2 mechanical regimens.



were contacted) Pathiraja 2014 Trial registration, anticipated end date (2014) has expired > 2 years. No information could be obtained (authors were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Study	Reason for exclusion
Mahomed 1988 Foley catheter under traction compared with Foley catheter with extra-amniotic PGE2. Manabe 1985 No clinical outcomes. Manish 2016 High- vs low-volume balloon Manyonda 2007 Balloon vs expectant management ⇒ not in scope Martin 1989 Comparison of induction of labour vs surveillance in post-term pregnancy. Mattingly 2015 Double balloon 12 hours vs double balloon 24 hours Mawire 1999 EASI vs PGE f2 alpha ⇒ not in scope McGee 2016 Foley silicone vs Foley latex Mei-Dan 2009 Comparison of 2 mechanical regimens. Mei-Dan 2012 Trial terminated before start. Mei-Dan 2012 Foley +EASI vs Cook balloon Mei-Dan 2014 Single balloon + EASI vs double balloon + EASI Millier 2015 Induction vs expectant management. (choice of induction method was up to clinician.) Moise 1991 Duplicate information, already included. Morrison 1993 Insufficient information. Movahed 2016 Foley vs laminaria vs isorbide mononitrate Mullin 2014 Direct removal of Foley or not Naseem 2007 Quasi-experimental, every second patient gets Foley Nasir 2012 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Lutgendorf 2012	Traction vs no traction => not within scope of review
Manabe 1985 No clinical outcomes. Manish 2016 High- vs low-volume balloon Manyonda 2007 Balloon vs expectant management ⇒ not in scope Martin 1989 Comparison of induction of labour vs surveillance in post-term pregnancy. Mattingly 2015 Double balloon 12 hours vs double balloon 24 hours Mawire 1999 EASI vs PGE f2 alpha ⇒ not in scope McGee 2016 Foley silicone vs Foley latex Mei-Dan 2009 Comparison of 2 mechanical regimens. Mei-Dan 2012 Trial terminated before start. Mei-Dan 2012 Foley +EASI vs Cook balloon Mei-Dan 2014 Single balloon + EASI vs double balloon + EASI Miller 2015 Induction vs expectant management. (choice of induction method was up to clinician.) Moise 1991 Duplicate information, already included. Morrison 1993 Insufficient information. Movahed 2016 Foley vs laminaria vs isorbide mononitrate Mullin 2014 Direct removal of Foley or not Naseem 2007 Quasi-experimental, every second patient gets Foley Nasir 2012 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (authors were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Macpherson 1983	No clinical outcomes mentioned.
Manish 2016 High- vs low-volume balloon Manyonda 2007 Balloon vs expectant management => not in scope Martin 1989 Comparison of induction of labour vs surveillance in post-term pregnancy. Mattingly 2015 Double balloon 12 hours vs double balloon 24 hours Mawire 1999 EASI vs PGE f2 alpha => not in scope McGee 2016 Foley silicone vs Foley latex Mei-Dan 2009 Comparison of 2 mechanical regimens. Mei-Dan 2012 Trial terminated before start. Mei-Dan 2012 Foley +EASI vs Cook balloon Mei-Dan 2014 Single balloon + EASI vs double balloon + EASI Miller 2015 Induction vs expectant management. (choice of induction method was up to clinician.) Moise 1991 Duplicate information, already included. Morrison 1993 Insufficient information. Movahed 2016 Foley vs laminaria vs isorbide mononitrate Mullin 2014 Direct removal of Foley or not Naseem 2007 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Mahomed 1988	Foley catheter under traction compared with Foley catheter with extra-amniotic PGE2.
Manyonda 2007 Balloon vs expectant management ⇒ not in scope Martin 1989 Comparison of induction of labour vs surveillance in post-term pregnancy. Mattingly 2015 Double balloon 12 hours vs double balloon 24 hours Mawire 1999 EASI vs PGE f2 alpha ⇒ not in scope McGee 2016 Foley silicone vs Foley latex Mei-Dan 2009 Comparison of 2 mechanical regimens. Mei-Dan 2012 Trial terminated before start. Mei-Dan 2012 Foley +EASI vs Cook balloon Mei-Dan 2014 Single balloon + EASI vs double balloon + EASI Miller 2015 Induction vs expectant management. (choice of induction method was up to clinician.) Moise 1991 Duplicate information, already included. Morrison 1993 Insufficient information. Movahed 2016 Foley vs laminaria vs isorbide mononitrate Mullin 2014 Direct removal of Foley or not Naseem 2007 Quasi-experimental, every second patient gets Foley Nasir 2012 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Manabe 1985	No clinical outcomes.
Martin 1989 Comparison of induction of labour vs surveillance in post-term pregnancy. Mattingly 2015 Double balloon 12 hours vs double balloon 24 hours Mawire 1999 EASI vs PGE f2 alpha ⇒ not in scope McGee 2016 Foley silicone vs Foley latex Mei-Dan 2009 Comparison of 2 mechanical regimens. Mei-Dan 2012 Trial terminated before start. Mei-Dan 2012a Foley +EASI vs Cook balloon Mei-Dan 2014 Single balloon + EASI vs double balloon + EASI Miller 2015 Induction vs expectant management. (choice of induction method was up to clinician.) Moise 1991 Duplicate information, already included. Morrison 1993 Insufficient information. Movahed 2016 Foley vs laminaria vs isorbide mononitrate Mullin 2014 Direct removal of Foley or not Naseem 2007 Quasi-experimental, every second patient gets Foley Nasir 2012 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Manish 2016	High- vs low-volume balloon
Mattingly 2015 Double balloon 12 hours vs double balloon 24 hours Mawire 1999 EASI vs PGE f2 alpha ⇒ not in scope McGee 2016 Foley silicone vs Foley latex Mei-Dan 2009 Comparison of 2 mechanical regimens. Mei-Dan 2012 Trial terminated before start. Mei-Dan 2012a Foley +EASI vs Cook balloon Mei-Dan 2014 Single balloon + EASI vs double balloon + EASI Miller 2015 Induction vs expectant management. (choice of induction method was up to clinician.) Moise 1991 Duplicate information, already included. Morrison 1993 Insufficient information. Movahed 2016 Foley vs laminaria vs isorbide mononitrate Mullin 2014 Direct removal of Foley or not Naseem 2007 Quasi-experimental, every second patient gets Foley Nasir 2012 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Manyonda 2007	Balloon vs expectant management => not in scope
Mawire 1999 EASI vs PGE f2 alpha ⇒ not in scope McGee 2016 Foley silicone vs Foley latex Mei-Dan 2009 Comparison of 2 mechanical regimens. Mei-Dan 2012 Trial terminated before start. Mei-Dan 2012a Foley +EASI vs Cook balloon Mei-Dan 2014 Single balloon + EASI vs double balloon + EASI Miller 2015 Induction vs expectant management. (choice of induction method was up to clinician.) Moise 1991 Duplicate information, already included. Morrison 1993 Insufficient information. Movahed 2016 Foley vs laminaria vs isorbide mononitrate Mullin 2014 Direct removal of Foley or not Naseem 2007 Quasi-experimental, every second patient gets Foley Nasir 2012 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Martin 1989	Comparison of induction of labour vs surveillance in post-term pregnancy.
McGee 2016 Foley silicone vs Foley latex Mei-Dan 2009 Comparison of 2 mechanical regimens. Mei-Dan 2012 Trial terminated before start. Mei-Dan 2012a Foley +EASI vs Cook balloon Mei-Dan 2014 Single balloon + EASI vs double balloon + EASI Miller 2015 Induction vs expectant management. (choice of induction method was up to clinician.) Moise 1991 Duplicate information, already included. Morrison 1993 Insufficient information. Movahed 2016 Foley vs laminaria vs isorbide mononitrate Mullin 2014 Direct removal of Foley or not Naseem 2007 Quasi-experimental, every second patient gets Foley Nasir 2012 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pathiraja 2014 Comparison of the addition or not of estradiol to Foley catheter.	Mattingly 2015	Double balloon 12 hours vs double balloon 24 hours
Mei-Dan 2012 Trial terminated before start. Mei-Dan 2012 Foley +EASI vs Cook balloon Mei-Dan 2014 Single balloon + EASI vs double balloon + EASI Miller 2015 Induction vs expectant management. (choice of induction method was up to clinician.) Moise 1991 Duplicate information, already included. Morrison 1993 Insufficient information. Movahed 2016 Foley vs laminaria vs isorbide mononitrate Mullin 2014 Direct removal of Foley or not Naseem 2007 Quasi-experimental, every second patient gets Foley Nasir 2012 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pathiraja 2014 Trial registration, anticipated end date (2014) has expired > 2 years. No information could be obtained (authors were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Mawire 1999	EASI vs PGE f2 alpha => not in scope
Mei-Dan 2012 Foley +EASI vs Cook balloon Mei-Dan 2014 Single balloon + EASI vs double balloon + EASI Miller 2015 Induction vs expectant management. (choice of induction method was up to clinician.) Moise 1991 Duplicate information, already included. Morrison 1993 Insufficient information. Movahed 2016 Foley vs laminaria vs isorbide mononitrate Mullin 2014 Direct removal of Foley or not Naseem 2007 Quasi-experimental, every second patient gets Foley Nasir 2012 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pathiraja 2014 Comparison of the addition or not of estradiol to Foley catheter.	McGee 2016	Foley silicone vs Foley latex
Mei-Dan 2014 Single balloon + EASI vs double balloon + EASI Miller 2015 Induction vs expectant management. (choice of induction method was up to clinician.) Moise 1991 Duplicate information, already included. Morrison 1993 Insufficient information. Movahed 2016 Foley vs laminaria vs isorbide mononitrate Mullin 2014 Direct removal of Foley or not Naseem 2007 Quasi-experimental, every second patient gets Foley Nasir 2012 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pathiraja 2014 Trial registration, anticipated end date (2014) has expired > 2 years. No information could be obtained (authors were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Mei-Dan 2009	Comparison of 2 mechanical regimens.
Mei-Dan 2014 Single balloon + EASI vs double balloon + EASI Miller 2015 Induction vs expectant management. (choice of induction method was up to clinician.) Moise 1991 Duplicate information, already included. Morrison 1993 Insufficient information. Movahed 2016 Foley vs laminaria vs isorbide mononitrate Mullin 2014 Direct removal of Foley or not Naseem 2007 Quasi-experimental, every second patient gets Foley Nasir 2012 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pathiraja 2014 Trial registration, anticipated end date (2014) has expired > 2 years. No information could be obtained (authors were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Mei-Dan 2012	Trial terminated before start.
Miller 2015 Induction vs expectant management. (choice of induction method was up to clinician.) Moise 1991 Duplicate information, already included. Morrison 1993 Insufficient information. Movahed 2016 Foley vs laminaria vs isorbide mononitrate Mullin 2014 Direct removal of Foley or not Naseem 2007 Quasi-experimental, every second patient gets Foley Nasir 2012 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pathiraja 2014 Trial registration, anticipated end date (2014) has expired > 2 years. No information could be obtained (authors were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Mei-Dan 2012a	Foley +EASI vs Cook balloon
Morrison 1993 Insufficient information. Movahed 2016 Foley vs laminaria vs isorbide mononitrate Mullin 2014 Direct removal of Foley or not Naseem 2007 Quasi-experimental, every second patient gets Foley Nasir 2012 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pathiraja 2014 Trial registration, anticipated end date (2014) has expired > 2 years. No information could be obtained (authors were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Mei-Dan 2014	Single balloon + EASI vs double balloon + EASI
Morrison 1993 Insufficient information. Movahed 2016 Foley vs laminaria vs isorbide mononitrate Mullin 2014 Direct removal of Foley or not Naseem 2007 Quasi-experimental, every second patient gets Foley Nasir 2012 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pathiraja 2014 Trial registration, anticipated end date (2014) has expired > 2 years. No information could be obtained (authors were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Miller 2015	Induction vs expectant management. (choice of induction method was up to clinician.)
Movahed 2016 Foley vs laminaria vs isorbide mononitrate Mullin 2014 Direct removal of Foley or not Naseem 2007 Quasi-experimental, every second patient gets Foley Nasir 2012 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pathiraja 2014 Trial registration, anticipated end date (2014) has expired > 2 years. No information could be obtained (authors were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Moise 1991	Duplicate information, already included.
Mullin 2014 Direct removal of Foley or not Quasi-experimental, every second patient gets Foley Nasir 2012 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pathiraja 2014 Trial registration, anticipated end date (2014) has expired > 2 years. No information could be obtained (authors were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Morrison 1993	Insufficient information.
Nasir 2012 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pathiraja 2014 Trial registration, anticipated end date (2014) has expired > 2 years. No information could be obtained (authors were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Movahed 2016	Foley vs laminaria vs isorbide mononitrate
Nasir 2012 Quasi-experimental Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pathiraja 2014 Trial registration, anticipated end date (2014) has expired > 2 years. No information could be obtained (authors were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Mullin 2014	Direct removal of Foley or not
Neethurani 2013 Foley + EASI followed by miso vs miso Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pathiraja 2014 Trial registration, anticipated end date (2014) has expired > 2 years. No information could be obtained (authors were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Naseem 2007	Quasi-experimental, every second patient gets Foley
Owolabi 2005 High-dose misoprostol Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pathiraja 2014 Trial registration, anticipated end date (2014) has expired > 2 years. No information could be obtained (authors were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Nasir 2012	Quasi-experimental
Park 2011 Trial registration, expected end date expired > 2 years. No information could be obtained (author were contacted) Pathiraja 2014 Trial registration, anticipated end date (2014) has expired > 2 years. No information could be obtained (authors were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Neethurani 2013	Foley + EASI followed by miso vs miso
were contacted) Pathiraja 2014 Trial registration, anticipated end date (2014) has expired > 2 years. No information could be obtained (authors were contacted) Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Owolabi 2005	High-dose misoprostol
Pedersen 1981 Comparison of the addition or not of estradiol to Foley catheter.	Park 2011	Trial registration, expected end date expired > 2 years. No information could be obtained (authors were contacted)
	Pathiraja 2014	
	Pedersen 1981	Comparison of the addition or not of estradiol to Foley catheter.
Pettker 2008 Comparison of 2 mechanical regimens.	Pettker 2008	Comparison of 2 mechanical regimens.



Study	Reason for exclusion
Rameez 2007	Nitric oxide vs vitamin C
Reif 2012	Trial registration, anticipated end date (2015) has expired > 2 years. No information could be obtained (authors were contacted)
Rezk 2014	Foley vs isorbide mononitrate
Rust 2001	High-dose misoprostol
Saad 2016	Foley vs laminaria
Saito 1999	Comparison of 2 mechanical regimens.
Salmeen 2012	Outpatient, pre-induction Foley before pharmacological hospital induction
Sanchez-Ramos 1990	Insufficient information.
Sandberg 2017	High vs low volume
Schoen 2017	Foley + oxytocin vs Foley
Schreyer 1989	Allocation of women was performed according to alternate weeks.
Sciscione 2001	High-dose misoprostol
Sharma 2015a	Foley: direct removal or not.
Sharma 2017	Foley vs mifepristone => not in scope
Sherman 2001	Comparison of PGE2 infusion vs saline infusion extra-amniotically. This comparison is not included in this review.
Siddiqui 2013	Placement Foley: stylette vs no stylette
Suri 2000	No clinical outcome reported (reported only as abstract).
Thigpen 2004	Compares a mechanical method with very high dose misoprostol (250 mcg).
Thomas 1986	Randomisation by odd and even numbers of hospital charts
Torbenson 2015	Outpatient Foley vs inpatient miso or Foley. Choice of inpatient method by clinician, so no RCT
Ugwu 2013	Balloon vs misoprostol, crossover after 24 hours
Vengalil 1998	High-dose misoprostol
Walfisch 2014	Foley vs expectative management
Walfisch 2015	Balloon + EASI vs balloon
Welt 1987	Insufficient information.
Wickramasinghe 2014	Foley 24 hours vs Foley 48 hours
Wilkinson 2015	Inpatient vs outpatient double balloon



Study	Reason for exclusion
Yaddehige 2015	Membrane sweeping vs massage => not in scope
Yazdani 2011	Trial registration of which anticipated end date (2008) has expired > 2 years. Trial was registered in retrospect. not clear why there is no publication. no information could be obtained (author contacted)
Zakaria 2017	Different charriere Foley catheter
Zhang 2014	Trial registration, anticipated end date (2015) has expired > 2 years. No information could be obtained (authors contacted)
Zimmer 1996	No outcomes reported. The authors focused on breathing movements of the fetus.

EASI: extra-amniotic space infusion

PG: prostaglandin PGE2: prostaglandin E2

RCT: randomised controlled trial

vs: versus

characteristics of staates and	aiting assessment [ordered by study ID]
ACTRN12618000510246 2018	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
gboghoroma 2015	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Publication could not be obtained. To try again in next update
amorosa 2017a	
Methods	
Participants	



Amorosa 2017a (Continued)	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
Bauer 2018	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
Chai 2018	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
Cherian 2018 Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
CTRI/2018/01/011574	
Methods	
Participants	
1	



CTRI/2018/01/011574 (Continued)	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
de Vaan 2019	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
DeCesare 2018	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
Diguisto 2017	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
EUCTR2017-001914-27-GB 2018	
Methods	
Participants	



EUCTR2017-001914-27-GB 2018 (Continu	ued)
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
IRCT20170326033142N2 2018	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
IRCT20170513033941N39 2018	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
IRCT20181123041731N1 2019	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
Khatib 2019	
Methods	
Participants	



Khatib 2019 (Continued)	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
Leigh 2018	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
Lim 2018	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
Mallah 2011	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Authors contacted. outcomes reported in Iranian magazine, asked authors for reference
McGee 2018	
Methods	
Participants	



McGee 2018 (Continued)	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
Mohamad 2018	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
NCT03172858 2017	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
NCT03399266 2018	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
NCT03435458 2018	
Methods	
Participants	



Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03588585 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03629548 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03629548 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03629548 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03670836 2018 Methods Participants NCT03670836 2018 Methods Participants	NCT03435458 2018 (Continued)	
NCT03588585 2018 McHods Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03629548 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03629548 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03629548 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03629548 2018 Methods NCT03629548 2018 Notes Found in search update of March 2019 ⇒ classification will be done in next update	Interventions	
Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03629548 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03629548 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03629548 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update	Outcomes	
Methods Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03629548 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03629548 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03629548 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update	Notes	Found in search update of March 2019 => classification will be done in next update
Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03629548 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03629548 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03629548 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update		
Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03629548 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03629548 2018 Methods Participants Interventions Outcomes NCT03629548 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update		
Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03629548 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03629548 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03629548 2018 Methods Found in search update of March 2019 ⇒ classification will be done in next update		
Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03629548 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03629548 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03629548 2018 Methods Found in search update of March 2019 ⇒ classification will be done in next update		
Notes Found in search update of March 2019 >> classification will be done in next update NCT03629548 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 >> classification will be done in next update NCT03629548 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 >> classification will be done in next update NCT03629548 2018 Methods NCT03670836 2018 Methods	Interventions	
NCT03629548 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03629548 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update	Outcomes	
Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03629548 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update	Notes	Found in search update of March 2019 => classification will be done in next update
Methods Participants Interventions Outcomes Notes Found in search update of March 2019 > classification will be done in next update NCT03629548 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 > classification will be done in next update		
Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03629548 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update		
Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03629548 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update		
Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03629548 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 ⇒ classification will be done in next update NCT03670836 2018 Methods	Participants	
Notes Found in search update of March 2019 => classification will be done in next update NCT03629548 2018 Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03670836 2018 Methods	Interventions	
Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03670836 2018 Methods	Outcomes	
Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03670836 2018 Methods	Notes	Found in search update of March 2019 => classification will be done in next update
Methods Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03670836 2018 Methods		
Participants Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03670836 2018 Methods		
Interventions Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03670836 2018 Methods		
Outcomes Notes Found in search update of March 2019 => classification will be done in next update NCT03670836 2018 Methods	Participants ————————————————————————————————————	
Notes Found in search update of March 2019 => classification will be done in next update NCT03670836 2018 Methods	Interventions	
NCT03670836 2018 Methods	Outcomes	
Methods	Notes	Found in search update of March 2019 => classification will be done in next update
Methods		
Participants		
	Participants	



NCT03670836 2018 (Continued)	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
NCT03682718 2018	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
NCT03744078 2018	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
NCT03752073 2018	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
NCT03866772 2019	
Methods	
Participants	



NCT03866772 2019 (Continued)	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
Oskei 2018	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
Osoti 2018	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
Saad 2019	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
Sanmugam 2018	
Methods	
Participants	



Sanmugam 2018 (Continued)	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
Souizi 2018	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
ten Eikelder 2017	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
Tulek 2018	
Methods	
Participants	
Interventions	
Outcomes	
Notes	Found in search update of March 2019 => classification will be done in next update
Viteri 2019	
Methods	
Participants	



Viter	i 201	(Continued)
-------	-------	-------------

nt				

Outcomes

Notes Found in search update of March 2019 => classification will be done in next update

Characteristics of ongoing studies [ordered by study ID]

Argilagos 2016

Trial name or title	Comparison of vaginal misoprostol plus supracervical balloon versus vaginal misoprostol alone for induction of labor
Methods	RCT
Participants	
Interventions	Foley + vaginal misoprostol
	Vaginal misoprostol
Outcomes	
Starting date	Unknown
Contact information	
Notes	Author contacted: still recruiting

Beckmann 2013

Trial name or title	Prostaglandin Inpatient iNduction of labour Compared with BALLOon Outpatient iNduction of labour: a randomised controlled trial - The PINC BALLOON Study
Methods	RCT
Participants	
Interventions	Foley
	Vaginal PGE2
Outcomes	
Starting date	Unknown
Contact information	
Notes	Author contacted: recruiting



Bekele 2017	
Trial name or title	A randomised controlled trial of sequential versus simultaneous use of Foley balloon and oxytocin for induction of labour in nulliparous pregnant women
Methods	
Participants	Foley + oxytocin
	Foley
Interventions	
Outcomes	
Starting date	9 August 2017
Contact information	
Notes	Status unknown. author contacted
Berndl 2016 Trial name or title	High volume Foleys increasing vaginal birth (high 5 birth) pilot trial
Methods	
Participants	
Interventions	Balloon
	Prostaglandin
Outcomes	
Starting date	December 2016
Contact information	
Notes	Recruiting (estimated end date: September 2019)
Bhide 2017	
Trial name or title	Prostaglandin insert (propess) versus trans-cervical balloon catheter for out-patient labour induction: a randomised controlled trial of feasibility
Methods	
Participants	
Interventions	Foley
	Vaginal PGE2
Outcomes	



September 2017
Recruiting (anticipated end date: August 2018)
Compare prostaglandin e2 against to combined transcervical Foley catheter balloon and vaginal prostaglandin e2 for induction of labour at term: a randomised study
Foley + vaginal PGE2
Vaginal PGE2
January 2016
Recruitment completed in January 2018
Comparison the results of induction of vaginal misoprostol with Foley catheter in prolonged pregnancy with unripe cervix
Foley
Vaginal misoprostol
March 2017
Estimated end date: June 2017 => author contacted. status unknown



Trial name or title	Oral misoprostol for 48 hours versus an intracervical Foley catheter for 48 hours for induction of labour in post dated pregnancies: a randomised control trial
Methods	
Participants	
Interventions	Foley catheter
	Oral misoprostol
Outcomes	
Starting date	October 2016
Contact information	
Notes	Recruitment completed
Supta 2016	
Trial name or title	A randomised controlled trial of a synthetic osmotic cervical dilator for induction of labour in comparison to dinoprostone vaginal insErt: the SOLVE Trial
Methods	
Participants	
Interventions	Laminaria
	Vagina PGE2
Outcomes	
Starting date	
Contact information	
Notes	Not yet recruiting
lassanzadeh 2017	Microscopic Color and the second and
Trial name or title	Misoprostol versus Foley catheter for cervical ripening in women with pre-eclampsia or gestational hypertension
Methods	
Participants	
Interventions	Foley
	Misoprostol



Hassanzadeh 2017 (Continued)	
Outcomes	
Starting date	February 2017
Contact information	
Notes	Authors contacted. Still recruiting?
Igwe 2017	
Trial name or title	Comparison between intravaginal misoprostol tablet and intracervical Foley's catheter in a low resource setting
Methods	
Participants	
Interventions	Foley
	Vaginal misoprostol (dosage unclear)
Outcomes	
Starting date	
Contact information	
Notes	Recruitment completed in April 2018
Lacarin 2017	
Trial name or title	Comparison between two strategies of induction in case of unfavourable cervix after 12 hours of premature rupture of membranes (prom) at term: cook cervical ripening + oxytocine from 6 hours versus dinoprostone vaginal insert
Methods	
Participants	
Interventions	Foley
	Vaginal PGE2
Outcomes	
Starting date	October 2017
Contact information	
Notes	Expected end date: July 2020



Lauterbach 2017	
Trial name or title	A comparison between labour induction with dinoprostone and a cervical ripening balloon in women with a BMI > 30 as oppose with a BMI < 30
Methods	
Participants	
Interventions	Balloon
	PGE2
Outcomes	
Starting date	January 2017
Contact information	
Notes	Expected end date: January 2019
Levy 2016	
Trial name or title	A randomised controlled study comparing cervical Foley catheter, vaginal dinoprostone and a combination of the two methods for induction of labor
Methods	
Participants	
Interventions	Foley + PGE2
	PGE2
Outcomes	
Starting date	February 2016
Contact information	
Notes	Not yet recruiting
Osoti 2016	
Trial name or title	A combination of Foley balloon and misoprostol versus misoprostol alone for induction of labour at Kenyatta national hospital, a randomised controlled trial
Methods	
Participants	
Interventions	Foley + misoprostol
	Misoprostol



Osoti 2016 (C	ontinued)		
Outcomes			
Starting date	2	March 2016	

Starting date March 2016

Contact information

Notes Recruitment completed

Park 2012

Trial name or title	Foley catheter versus dinoprostone vaginal insert for induction of labour in parous women at term: a randomised trial
Methods	
Participants	
Interventions	
Outcomes	
Starting date	May 2012
Contact information	
Notes	Trial status unclear. expected end date 2017 => authors contacted

Perrotin 2016

Trial name or title	Propess® versus double balloon for cervical ripening of prolonged pregnancies: a randomised controlled trial
Methods	
Participants	
Interventions	Double balloon
	Vaginal PGE2
Outcomes	
Starting date	September 2016
Contact information	
Notes	Expected end date: January 2020



Tagore 2015	
Trial name or title	Cervical ripening balloon in induction of labour at term (crbii) - a prospective randomised controlled trial
Methods	
Participants	
Interventions	PGE2
	Balloon
Outcomes	
Starting date	December 2015
Contact information	
Notes	Expected end date: March 2018 => recruiting
Viteri 2015	
Trial name or title	The efficacy of transcervical Foley balloon plus vaginal misoprostol versus vaginal misoprostol alone for cervical ripening in nulliparous obese women: a randomised, comparative effectiveness trial
Methods	
Participants	
Interventions	Foley + misoprostol
	Misoprostol
Outcomes	
Starting date	December 2015
Contact information	
Notes	Recruiting
Wise 2016	
Trial name or title	Comparison of low-risk pregnant women undergoing induction of labour at term by outpatient balloon or inpatient prostaglandin in order to assess vaginal birth rate; a randomised controlled trial
Methods	
Participants	
Interventions	Balloon



Wise 2016 (Continued)	PGE2
Outcomes	
Starting date	March 2016
Contact information	
Notes	Not yet recruiting

Yildirim 2017

Trial name or title	Dinoprostone vaginal insert versus double balloon catheter for preinduction cervical ripening
Methods	
Participants	
Interventions	Double balloon
	PGE2
Outcomes	
Starting date	January 2017
Contact information	
Notes	Recruitment completed

BMI: body, mass index PGE2: prostaglandin E2

RCT: randomised controlled trial

DATA AND ANALYSES

Comparison 1. Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	7	1685	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.82, 1.26]
2 Uterine hyperstimulation with FHR changes	6	1966	Risk Ratio (M-H, Fixed, 95% CI)	0.35 [0.18, 0.67]
3 Caesarean section	28	6619	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.92, 1.09]
4 Serious neonatal morbidity/perinatal death	8	2757	Risk Ratio (M-H, Fixed, 95% CI)	0.48 [0.25, 0.93]




Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size		
5 Serious maternal morbidity or death	4	1481	Risk Ratio (M-H, Fixed, 95% CI)	0.20 [0.01, 4.12]		
6 Oxytocin augmentation	16	4828	Risk Ratio (M-H, Random, 95% CI)	1.54 [1.35, 1.76]		
7 Uterine hyperstimulation without fetal heart rate changes	15	2444	Risk Ratio (M-H, Random, 95% CI)	0.27 [0.11, 0.66]		
8 Uterine rupture	2	1045	Risk Ratio (M-H, Fixed, 95% CI)	0.20 [0.01, 4.12]		
9 Epidural analgesia	8	2828	Risk Ratio (M-H, Random, 95% CI)	1.14 [1.00, 1.29]		
10 Instrumental vaginal delivery	16	4514	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.79, 1.09]		
11 Meconium-stained liquor	4	964	Risk Ratio (M-H, Fixed, 95% CI)	0.89 [0.67, 1.19]		
12 Apgar score < 7 at 5 minutes	14	4271	Risk Ratio (M-H, Fixed, 95% CI)	0.74 [0.49, 1.14]		
13 Neonatal intensive care unit admission	12	3647	Risk Ratio (M-H, Fixed, 95% CI)	0.82 [0.65, 1.04]		
14 Perinatal death	5	1036	Risk Ratio (M-H, Fixed, 95% CI)	0.21 [0.01, 4.27]		
15 Postpartum haemorrhage	8	2215	Risk Ratio (M-H, Fixed, 95% CI)	0.82 [0.63, 1.06]		
16 Women not satisfied	1	93	Risk Ratio (M-H, Fixed, 95% CI)	0.61 [0.39, 0.97]		
17 Maternal fever during labour	7	2362	Risk Ratio (M-H, Fixed, 95% CI)	0.87 [0.65, 1.17]		
18 Antibiotics during labour	1	330	Risk Ratio (M-H, Fixed, 95% CI)	1.43 [0.89, 2.29]		
19 Chorioamnionitis	1	376	Risk Ratio (M-H, Fixed, 95% CI)	0.69 [0.32, 1.49]		
20 Endometritis	2	706	Risk Ratio (M-H, Fixed, 95% CI)	0.49 [0.19, 1.27]		
21 Fetal distress	20	4753	Risk Ratio (M-H, Fixed, 95% CI)	0.71 [0.60, 0.83]		
22 Umbilical artery pH < 7.10	8	2675	Odds Ratio (M-H, Fixed, 95% CI)	0.65 [0.44, 0.94]		

Analysis 1.1. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.

Study or subgroup	Balloon	Vaginal PGE2	2 Risk Ratio		Weight	Risk Ratio					
	n/N	n/N n/N				ndom	, 95% CI			M-H, Random, 95% CI	
Al-Taani 2004	21/72	5/75						+	$\overline{}$	4.37%	4.38[1.74,10.98]
Cromi 2011	158/265	68/132				+				17.67%	1.16[0.95,1.4]
Cromi 2012	33/105	52/103				-				13.62%	0.62[0.44,0.88]
Edwards 2014c	103/185	134/191				-				18.52%	0.79[0.68,0.93]
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours PGE2	






Analysis 1.2. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 2 Uterine hyperstimulation with FHR changes.

Study or subgroup	Balloon	Vaginal PGE2	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Henry 2013	0/50	2/51	+ +	7.64%	0.2[0.01,4.14]
Jozwiak 2012	8/411	12/408		37.15%	0.66[0.27,1.6]
Pennell 2009	0/217	5/113	+	22.28%	0.05[0,0.85]
Prager 2008	2/198	6/191		18.84%	0.32[0.07,1.57]
Wang 2012	0/128	4/124		14.1%	0.11[0.01,1.98]
Yuen 1996	0/36	0/39			Not estimable
Total (95% CI)	1040	926	•	100%	0.35[0.18,0.67]
Total events: 10 (Balloon), 29 (Vagir	al PGE2)				
Heterogeneity: Tau ² =0; Chi ² =4.61, d	f=4(P=0.33); I ² =13.319	%			
Test for overall effect: Z=3.17(P=0)					
		Favours balloon	0.05 0.2 1 5 20	Favours PGE2	

Analysis 1.3. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 3 Caesarean section.

Study or subgroup	Balloon	Vaginal PGE2	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Al-Taani 2004	12/72	10/75		1.24%	1.25[0.58,2.71]
Atad 1996	7/35	4/30		0.55%	1.5[0.49,4.63]
Barda 2018	17/150	26/150		3.3%	0.65[0.37,1.15]
Browne 2011	14/35	10/31		1.35%	1.24[0.65,2.38]
Cromi 2011	84/265	40/132		6.78%	1.05[0.76,1.43]
Cromi 2012	25/105	27/103		3.46%	0.91[0.57,1.46]
Deo 2012	9/50	12/52		1.49%	0.78[0.36,1.69]
Deshmukh 2011	28/200	37/200		4.7%	0.76[0.48,1.19]
Edwards 2014c	53/185	72/191		9%	0.76[0.57,1.02]
Henry 2013	17/50	15/51		1.89%	1.16[0.65,2.05]
Jozwiak 2012	93/411	82/408	+	10.46%	1.13[0.87,1.47]
Jozwiak 2013	21/107	26/119		3.13%	0.9[0.54,1.5]
Khamaiseh 2012	72/210	70/204	-	9.02%	1[0.77,1.3]
Lewis 1983	7/22	3/22		0.38%	2.33[0.69,7.88]
		Favours balloon	0.1 0.2 0.5 1 2 5 10	Favours PGE2	






Analysis 1.4. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 4 Serious neonatal morbidity/perinatal death.

Study or subgroup	Balloon	Vaginal PGE2		Risk Ratio	Weight	Risk Ratio	
	n/N	n/N		M-H, Fixed, 95% CI		M-H, Fixed, 95% CI	
Cromi 2011	0/265	0/132				Not estimable	
Deshmukh 2011	7/200	9/200			34.05%	0.78[0.3,2.05]	
Edwards 2014c	0/185	2/191	\leftarrow		9.31%	0.21[0.01,4.27]	
Jozwiak 2012	1/411	6/408	-	-	22.78%	0.17[0.02,1.37]	
Jozwiak 2013	1/107	4/119			14.33%	0.28[0.03,2.45]	
Pennell 2009	0/217	1/113	\leftarrow		7.45%	0.17[0.01,4.24]	
Tan 2015	0/31	0/52				Not estimable	
Wang 2014	3/67	3/59			12.07%	0.88[0.18,4.2]	
Total (95% CI)	1483	1274		•	100%	0.48[0.25,0.93]	
Total events: 12 (Balloon), 25 (V	/aginal PGE2)						
Heterogeneity: Tau ² =0; Chi ² =3.4	43, df=5(P=0.63); I ² =0%						
Test for overall effect: Z=2.18(P	=0.03)		_				
		Favours balloon	0.01	0.1 1 10	100 Favours PGE2		


Analysis 1.5. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 5 Serious maternal morbidity or death.

Study or subgroup	Balloon	Vaginal PGE2		Risk Ratio					Weight	Risk Ratio	
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Edwards 2014c	0/185	0/191									Not estimable
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours PGE2	






Analysis 1.6. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 6 Oxytocin augmentation.




Analysis 1.7. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 7 Uterine hyperstimulation without fetal heart rate changes.

Study or subgroup	Balloon	Vaginal PGE2	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Random, 95% CI		M-H, Random, 95% CI
Deo 2012	0/50	3/52	+ • • • • • • • • • • • • • • • • • • •	6.13%	0.15[0.01,2.8]
Edwards 2014c	0/185	5/191		6.28%	0.09[0.01,1.69]
Jozwiak 2013	2/107	2/119		9.81%	1.11[0.16,7.76]
Khamaiseh 2012	1/210	6/204	★	9.06%	0.16[0.02,1.33]
		Favours balloon	0.1 0.2 0.5 1 2 5 10	Favours PGE2	






Analysis 1.8. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 8 Uterine rupture.




Analysis 1.9. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 9 Epidural analgesia.

Study or subgroup	Balloon	Vaginal PGE2	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Random, 95% CI		M-H, Random, 95% CI
Cromi 2011	211/265	71/132	-+-	13.79%	1.48[1.25,1.75]
Cromi 2012	87/105	63/103		13.49%	1.35[1.14,1.62]
Edwards 2014c	158/185	166/191	+	17.13%	0.98[0.91,1.07]
Jozwiak 2012	122/411	120/408	+	12.08%	1.01[0.82,1.25]
Jozwiak 2013	30/107	29/119		5.65%	1.15[0.74,1.78]
Pennell 2009	176/217	92/113	+	16.19%	1[0.89,1.11]
Prager 2008	145/198	117/191	+	14.96%	1.2[1.04,1.38]
Tan 2015	18/31	29/52		6.72%	1.04[0.71,1.53]
Total (95% CI)	1519	1309	•	100%	1.14[1,1.29]
		Favours balloon	0.2 0.5 1 2 5	Favours PGE2	





Analysis 1.10. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 10 Instrumental vaginal delivery.




Analysis 1.11. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 11 Meconium-stained liquor.

Study or subgroup	Balloon	Vaginal PGE2			Ri	sk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	95% CI				M-H, Fixed, 95% CI
Al-Taani 2004	13/72	15/75				+	_			17.89%	0.9[0.46,1.76]
Edwards 2014c	24/185	19/191				+				22.76%	1.3[0.74,2.3]
Prager 2008	33/198	42/191			-	-				52.05%	0.76[0.5,1.14]
Shechter-Maor 2015	3/26	6/26	-		+	+	_			7.3%	0.5[0.14,1.79]
Total (95% CI)	481	483				•				100%	0.89[0.67,1.19]
Total events: 73 (Balloon), 82 (Vag	inal PGE2)										
Heterogeneity: Tau ² =0; Chi ² =3.12,	df=3(P=0.37); I ² =3.87%										
Test for overall effect: Z=0.8(P=0.4	2)										
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours PGE2	



Analysis 1.12. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 12 Apgar score < 7 at 5 minutes.



Analysis 1.13. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 13 Neonatal intensive care unit admission.

Study or subgroup	Balloon	Vaginal PGE2	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Al-Taani 2004	6/72	5/75		3.7%	1.25[0.4,3.92]
Cromi 2011	11/265	7/132		7.07%	0.78[0.31,1.97]
Cromi 2012	8/105	5/103	- +	3.82%	1.57[0.53,4.64]
Deshmukh 2011	37/200	42/200		31.76%	0.88[0.59,1.31]
Edwards 2014c	29/185	34/191		25.3%	0.88[0.56,1.38]
Jozwiak 2012	3/411	4/408	+	3.04%	0.74[0.17,3.31]
Jozwiak 2013	4/107	8/119		5.73%	0.56[0.17,1.79]
Khamaiseh 2012	6/210	9/204		6.91%	0.65[0.23,1.79]
Prager 2008	7/198	12/191		9.24%	0.56[0.23,1.4]
Suffecool 2014	0/31	0/31			Not estimable
Tan 2015	0/31	2/52	+	1.42%	0.33[0.02,6.68]
Wang 2014	0/67	2/59	+	2.01%	0.18[0.01,3.6]
Total (95% CI)	1882	1765	•	100%	0.82[0.65,1.04]
Total events: 111 (Balloon), 130 (Va	ginal PGE2)				
Heterogeneity: Tau ² =0; Chi ² =4.77, d	f=10(P=0.91); I ² =0%				
Test for overall effect: Z=1.61(P=0.1	1)				
		Favours balloon	0.1 0.2 0.5 1 2 5	10 Favours PGE2	



Analysis 1.14. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 14 Perinatal death.

Study or subgroup	Balloon	Balloon Vaginal PGE2		Risk R	atio		Weight	Risk Ratio
	n/N	n/N		M-H, Fixed	l, 95% CI			M-H, Fixed, 95% CI
Cromi 2011	0/265	0/132						Not estimable
Edwards 2014c	0/185	2/191	\leftarrow	1		_	100%	0.21[0.01,4.27]
Ophir 1992	0/27	0/27	_					Not estimable
Tan 2015	0/31	0/52		İ				Not estimable
Wang 2014	0/67	0/59						Not estimable
Total (95% CI)	575	461					100%	0.21[0.01,4.27]
Total events: 0 (Balloon), 2 (Vaginal PG	E2)			ĺ				
Heterogeneity: Not applicable				İ				
Test for overall effect: Z=1.02(P=0.31)								
		Favours balloon	0.1	0.2 0.5 1	2	5 :	10 Favours PGE2	

Analysis 1.15. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 15 Postpartum haemorrhage.

Study or subgroup	Balloon	Vaginal PGE2	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Henry 2013	8/50	11/51		9.61%	0.74[0.33,1.69]
Jozwiak 2012	26/411	38/408		33.67%	0.68[0.42,1.1]
Jozwiak 2013	8/107	7/119		5.85%	1.27[0.48,3.39]
Orhue 1995	3/30	1/30	-	0.88%	3[0.33,27.23]
Pennell 2009	10/217	12/113		13.93%	0.43[0.19,0.97]
Rudra 2012	29/200	26/200	- •-	22.95%	1.12[0.68,1.82]
Saleem 2006	1/78	1/75	•	0.9%	0.96[0.06,15.1]
Wang 2014	11/67	13/59		12.2%	0.75[0.36,1.53]
Total (95% CI)	1160	1055	•	100%	0.82[0.63,1.06]
Total events: 96 (Balloon), 109 (Vaginal PGE2)				
Heterogeneity: Tau ² =0; Chi ² =6.7	'1, df=7(P=0.46); I ² =0%				
Test for overall effect: Z=1.55(P=	=0.12)			T.	
		Favours balloon	0.1 0.2 0.5 1 2 5	10 Favours PGE2	

Analysis 1.16. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 16 Women not satisfied.

Study or subgroup	Balloon	Vaginal PGE2			Ris	k Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, Fi	xed,	95% CI				M-H, Fixed, 95% CI
Henry 2013	17/48	26/45			-					100%	0.61[0.39,0.97]
Total (95% CI)	48	45			•	-				100%	0.61[0.39,0.97]
Total events: 17 (Balloon), 26 (Vagina	l PGE2)										
Heterogeneity: Not applicable											
Test for overall effect: Z=2.1(P=0.04)											
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours PGE2	




Analysis 1.17. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 17 Maternal fever during labour.

Study or subgroup	Balloon	Vaginal PGE2			Risk Ratio		Weight	Risk Ratio
	n/N	n/N		М-Н	Fixed, 95% CI			M-H, Fixed, 95% CI
Henry 2013	5/50	4/51					4.63%	1.27[0.36,4.48]
Jozwiak 2012	12/411	18/408			-+-		21.11%	0.66[0.32,1.36]
Jozwiak 2013	5/107	8/119		_			8.85%	0.7[0.23,2.06]
Khamaiseh 2012	12/210	14/204					16.6%	0.83[0.39,1.76]
Pennell 2009	37/217	20/113			-		30.73%	0.96[0.59,1.58]
Prager 2008	13/198	13/191					15.46%	0.96[0.46,2.03]
Tan 2015	2/31	3/52		_			2.62%	1.12[0.2,6.33]
Total (95% CI)	1224	1138			•		100%	0.87[0.65,1.17]
Total events: 86 (Balloon), 80 ((Vaginal PGE2)							
Heterogeneity: Tau ² =0; Chi ² =1	.41, df=6(P=0.97); I ² =0%							
Test for overall effect: Z=0.9(P	=0.37)					1		
		Favours balloon	0.01	0.1	1 10	100	Favours PGE2	

Analysis 1.18. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 18 Antibiotics during labour.


Study or subgroup	Balloon	Balloon Vaginal PGE2			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		М-Н	, Fixed, 95%	6 CI			M-H, Fixed, 95% CI
Pennell 2009	52/217	19/113			-			100%	1.43[0.89,2.29]
Total (95% CI)	217	113			•			100%	1.43[0.89,2.29]
Total events: 52 (Balloon), 19 (Vaginal PGE2)								
Heterogeneity: Tau ² =0; Chi ² =0	, df=0(P<0.0001); I ² =100%								
Test for overall effect: Z=1.47(F	P=0.14)						1		
		Favours balloon	0.01	0.1	1	10	100	Favours PGE2	

Analysis 1.19. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 19 Chorioamnionitis.






Analysis 1.20. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 20 Endometritis.



Analysis 1.21. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 21 Fetal distress.





Analysis 1.22. Comparison 1 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all women, Outcome 22 Umbilical artery pH < 7.10.

Study or subgroup	Balloon	Vaginal PGE2	Odds Ratio	Weight	Odds Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Barda 2018	0/150	0/150			Not estimable
Cromi 2011	1/265	1/132		1.97%	0.5[0.03,8]
Edwards 2014c	3/185	1/191		1.43%	3.13[0.32,30.38]
Henry 2013	2/50	4/51		5.63%	0.49[0.09,2.8]
Jozwiak 2012	25/411	31/408	-	43.29%	0.79[0.46,1.36]
Jozwiak 2013	6/107	8/119		10.59%	0.82[0.28,2.46]
Pennell 2009	10/217	8/113		14.87%	0.63[0.24,1.65]
Wang 2014	4/67	15/59		22.22%	0.19[0.06,0.6]
Total (95% CI)	1452	1223	•	100%	0.65[0.44,0.94]
Total events: 51 (Balloon), 68 (Vag	ginal PGE2)				
Heterogeneity: Tau ² =0; Chi ² =7.04,	, df=6(P=0.32); I ² =14.77 ⁰	%			
Test for overall effect: Z=2.27(P=0	.02)				
		Favours balloon	0.01 0.1 1 10	100 Favours PGE2	

Comparison 2. Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all primiparae

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	1	330	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.83, 1.23]
2 Uterine hyperstimulation with FHR changes	1	330	Risk Ratio (M-H, Fixed, 95% CI)	0.05 [0.00, 0.85]
3 Caesarean section	5	828	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.59, 1.33]
4 Serious neonatal morbidity/perinatal death	1	330	Risk Ratio (M-H, Fixed, 95% CI)	0.17 [0.01, 4.24]
5 Serious maternal morbidity or death	1	60	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]


Analysis 2.1. Comparison 2 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.

Study or subgroup	Balloon	Vaginal PGE2		Risk Ratio				Weight	Risk Ratio
	n/N	n/N		М-Н	, Fixed, 95%	CI			M-H, Fixed, 95% CI
Pennell 2009	124/217	64/113			+			100%	1.01[0.83,1.23]
Total (95% CI)	217	113			\			100%	1.01[0.83,1.23]
Total events: 124 (Balloon), 64 (Vag	ginal PGE2)								
Heterogeneity: Not applicable									
		Favours balloon	0.01	0.1	1	10	100	Favours PGE2	




Study or subgroup	Balloon n/N	Vaginal PGE2 n/N		Risk Ratio M-H, Fixed, 95% CI				Weight	Risk Ratio M-H, Fixed, 95% CI
Test for overall effect: Z=0.09(P=0.93)									
		Favours balloon	0.01	0.1	1	10	100	Favours PGE2	


Analysis 2.2. Comparison 2 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all primiparae, Outcome 2 Uterine hyperstimulation with FHR changes.



Analysis 2.3. Comparison 2 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all primiparae, Outcome 3 Caesarean section.



Analysis 2.4. Comparison 2 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all primiparae, Outcome 4 Serious neonatal morbidity/perinatal death.






Analysis 2.5. Comparison 2 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all primiparae, Outcome 5 Serious maternal morbidity or death.

Study or subgroup	Balloon	Vaginal PGE2			Ri	sk Rat	tio			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	95% CI				M-H, Fixed, 95% CI
Orhue 1995	0/30	0/30									Not estimable
Total (95% CI)	30	30									Not estimable
Total events: 0 (Balloon), 0 (Vaginal PGE	2)										
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours PGE2	

Comparison 3. Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all multiparae

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	1	147	Risk Ratio (M-H, Fixed, 95% CI)	4.38 [1.74, 10.98]
2 Caesarean section	2	180	Risk Ratio (M-H, Fixed, 95% CI)	1.31 [0.65, 2.63]


Analysis 3.1. Comparison 3 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.



Analysis 3.2. Comparison 3 Balloon (Foley or ATAD) versus vaginal prostaglandin E2: all multiparae, Outcome 2 Caesarean section.

Study or subgroup	balloon	vaginal PGE2		Risk Ratio				Weight	Risk Ratio		
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Al-Taani 2004	12/72	10/75			_		_			83.47%	1.25[0.58,2.71]
Yuen 1996	3/16	2/17					+		_	16.53%	1.59[0.3,8.33]
					1						
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours PGE2	






Comparison 4. Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	2	200	Risk Ratio (M-H, Random, 95% CI)	1.01 [0.35, 2.91]
2 Uterine hyperstimulation with FHR changes	4	447	Risk Ratio (M-H, Fixed, 95% CI)	0.37 [0.02, 8.90]
3 Caesarean section	9	1309	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.81, 1.15]
4 Serious neonatal morbidity/perinatal death	2	500	Risk Ratio (M-H, Fixed, 95% CI)	0.78 [0.29, 2.05]
5 Cervix unfavourable/unchanged after 24 hours	2	219	Risk Ratio (M-H, Fixed, 95% CI)	0.96 [0.70, 1.34]
6 Oxytocin augmentation	1	400	Risk Ratio (M-H, Fixed, 95% CI)	1.08 [0.93, 1.26]
7 Uterine hyperstimulation without FHR changes	5	654	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.09, 10.38]
8 Epidural analgesia	1	149	Risk Ratio (M-H, Fixed, 95% CI)	0.91 [0.81, 1.02]
9 Instrumental vaginal delivery	3	337	Risk Ratio (M-H, Fixed, 95% CI)	1.18 [0.68, 2.05]
10 Meconium-stained liquor	1	118	Risk Ratio (M-H, Fixed, 95% CI)	1.17 [0.42, 3.26]
11 Apgar score < 7 at 5 minutes	2	475	Risk Ratio (M-H, Fixed, 95% CI)	0.79 [0.41, 1.53]
12 Neonatal intensive care unit admission	1	400	Risk Ratio (M-H, Fixed, 95% CI)	0.88 [0.60, 1.31]
13 Perinatal death	2	500	Risk Ratio (M-H, Fixed, 95% CI)	0.78 [0.29, 2.05]
14 Maternal side effects	2	211	Risk Ratio (M-H, Fixed, 95% CI)	0.15 [0.02, 1.24]



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
15 Postpartum haemorrhage	1	100	Risk Ratio (M-H, Fixed, 95% CI)	0.2 [0.01, 4.06]
16 Chorioamnionitis	1	118	Risk Ratio (M-H, Fixed, 95% CI)	1.0 [0.21, 4.75]
17 Endometritis	1	118	Risk Ratio (M-H, Fixed, 95% CI)	1.0 [0.06, 15.61]
18 Fetal distress	6	1023	Risk Ratio (M-H, Fixed, 95% CI)	0.61 [0.42, 0.89]

Analysis 4.1. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.



Analysis 4.2. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 2 Uterine hyperstimulation with FHR changes.

Study or subgroup	Balloon	Balloon Intracervi- cal PGE2			Risk Ratio					Risk Ratio
	n/N	n/N		M-H	Fixed,	95% CI				M-H, Fixed, 95% CI
Hudon 1999	0/56	0/55								Not estimable
Ntsaluba 1997	0/53	1/59	+	-				_	100%	0.37[0.02,8.9]
Sciscione 1999	0/77	0/72								Not estimable
Yuen 1996	0/36	0/39								Not estimable
Total (95% CI)	222	225							100%	0.37[0.02,8.9]
Total events: 0 (Balloon), 1 (Intracervic	al PGE2)									
Heterogeneity: Not applicable										
Test for overall effect: Z=0.61(P=0.54)										
		Favours halloon	0.1	0.2 0.5	1	2	5	10	Favours PGF2	



Analysis 4.3. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 3 Caesarean section.

Study or subgroup	Balloon	Intracervi- cal PGE2	Risk Ratio	Weight	Risk Ratio M-H, Fixed, 95% CI	
	n/N	n/N	M-H, Fixed, 95% CI			
Benzineb 1996	9/50	6/50		3.55%	1.5[0.58,3.9]	
Dalui 2005	8/50	13/50		7.69%	0.62[0.28,1.35]	
Hudon 1999	39/56	37/55	+	22.09%	1.04[0.8,1.33]	
Kuppulakshmi 2016	28/100	29/100		17.16%	0.97[0.62,1.5]	
Laddad 2013	35/200	40/200		23.67%	0.88[0.58,1.32]	
Ntsaluba 1997	8/53	9/59		5.04%	0.99[0.41,2.38]	
Sciscione 1999	21/77	21/72		12.84%	0.94[0.56,1.56]	
St Onge 1995	6/34	7/28		4.54%	0.71[0.27,1.86]	
Yuen 1996	10/36	6/39	+	3.41%	1.81[0.73,4.46]	
Total (95% CI)	656	653	•	100%	0.97[0.81,1.15]	
Total events: 164 (Balloon), 168	3 (Intracervical PGE2)					
Heterogeneity: Tau ² =0; Chi ² =4.8	84, df=8(P=0.77); I ² =0%					
Test for overall effect: Z=0.39(P	=0.7)					
		Favours balloon 0.1	1 0.2 0.5 1 2 5 1	¹⁰ Favours PGE2		

Analysis 4.4. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 4 Serious neonatal morbidity/perinatal death.


Study or subgroup	Balloon	Intracervi- cal PGE2			Ris	sk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, Fi	ixed,	95% CI				M-H, Fixed, 95% CI
Benzineb 1996	1/50	1/50	$\overline{+}$			+			$\overline{}$	11.11%	1[0.06,15.55]
Laddad 2013	6/200	8/200		-		+				88.89%	0.75[0.27,2.12]
Total (95% CI)	250	250								100%	0.78[0.29,2.05]
Total events: 7 (Balloon), 9 (Intra	acervical PGE2)										
Heterogeneity: Tau ² =0; Chi ² =0.0	4, df=1(P=0.85); I ² =0%										
Test for overall effect: Z=0.51(P=	0.61)										
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours PGE2	

Analysis 4.5. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 5 Cervix unfavourable/unchanged after 24 hours.


Study or subgroup	Balloon	Intracervi- cal PGE2			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		M-I	H, Fixed, 95% Cl	I			M-H, Fixed, 95% CI
Allouche 1993	30/60	29/59			#			69.23%	1.02[0.71,1.46]
Benzineb 1996	11/50	13/50			-			30.77%	0.85[0.42,1.71]
Total (95% CI)	110	109			•			100%	0.96[0.7,1.34]
Total events: 41 (Balloon), 42 (Ir	ntracervical PGE2)								
Heterogeneity: Tau ² =0; Chi ² =0.2	2, df=1(P=0.64); I ² =0%								
Test for overall effect: Z=0.22(P=	=0.83)					,			
		Favours balloon	0.01	0.1	1	10	100	Favours PGE2	




Analysis 4.6. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 6 Oxytocin augmentation.



Analysis 4.7. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 7 Uterine hyperstimulation without FHR changes.



Analysis 4.8. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 8 Epidural analgesia.






Analysis 4.9. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 9 Instrumental vaginal delivery.

Study or subgroup	Balloon	Intracervi- cal PGE2		Risk Ratio			Weight	Risk Ratio			
	n/N	n/N			M-H, F	ixed, 9	95% CI				M-H, Fixed, 95% CI
Laddad 2013	7/100	5/100				-		_		26.92%	1.4[0.46,4.26]
St Onge 1995	13/34	8/28			_	-				47.24%	1.34[0.65,2.76]
Yuen 1996	3/36	5/39			•					25.84%	0.65[0.17,2.53]
Total (95% CI)	170	167			-		-			100%	1.18[0.68,2.05]
Total events: 23 (Balloon), 18 (I	ntracervical PGE2)										
Heterogeneity: Tau ² =0; Chi ² =0.9	95, df=2(P=0.62); I ² =0%										
Test for overall effect: Z=0.58(P	=0.57)										
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours PGE2	

Analysis 4.10. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 10 Meconium-stained liquor.




Analysis 4.11. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 11 Apgar score < 7 at 5 minutes.


Study or subgroup	Balloon	Intracervi- cal PGE2	Risk Ratio						Weight		Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	5% CI				M-H, Fixed, 95% CI
Laddad 2013	14/200	17/200			-	-	-			92.18%	0.82[0.42,1.63]
Yuen 1996	0/36	1/39	•		•					7.82%	0.36[0.02,8.57]
Total (95% CI)	236	239					-			100%	0.79[0.41,1.53]
Total events: 14 (Balloon), 18 (Intracervical PGE2)										
Heterogeneity: Tau ² =0; Chi ² =0	.25, df=1(P=0.62); I ² =0%										
Test for overall effect: Z=0.71(F	P=0.48)										
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours PGE2	



Analysis 4.12. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 12 Neonatal intensive care unit admission.



Analysis 4.13. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 13 Perinatal death.




Analysis 4.14. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 14 Maternal side effects.


Study or subgroup	Balloon	Intracervi- cal PGE2	Risk Ratio							Weight	Risk Ratio	
	n/N	n/N			M-H, F	ixed, 9	5% CI				M-H, Fixed, 95% CI	
Sciscione 1999	0/77	4/72	-				_			73.92%	0.1[0.01,1.9]	
St Onge 1995	0/34	1/28	•	-						26.08%	0.28[0.01,6.53]	
Total (95% CI)	111	100								100%	0.15[0.02,1.24]	
Total events: 0 (Balloon), 5 (Int	racervical PGE2)											
Heterogeneity: Tau ² =0; Chi ² =0	.21, df=1(P=0.65); I ² =0%											
Test for overall effect: Z=1.76(F	P=0.08)								1			
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours PGE2		




Analysis 4.15. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 15 Postpartum haemorrhage.



Analysis 4.16. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 16 Chorioamnionitis.




Analysis 4.17. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 17 Endometritis.





Analysis 4.18. Comparison 4 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all women, Outcome 18 Fetal distress.



Comparison 5. Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all primiparae

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Uterine hyperstimulation with FHR changes	1	53	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Caesarean section	3	245	Risk Ratio (M-H, Fixed, 95% CI)	1.30 [0.86, 1.95]

Analysis 5.1. Comparison 5 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all primiparae, Outcome 1 Uterine hyperstimulation with FHR changes.

Study or subgroup	Balloon	Intracervi- cal PGE2			Ri	sk Rat	tio			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Ntsaluba 1997	0/25	0/28									Not estimable
Total (95% CI)	25	28									Not estimable
Total events: 0 (Balloon), 0 (Intrace	ervical PGE2)										
Heterogeneity: Not applicable											
Test for overall effect: Not applicab	ole										
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours PGE2	




Analysis 5.2. Comparison 5 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all primiparae, Outcome 2 Caesarean section.

Study or subgroup	Balloon	Intracervi- cal PGE2			Ri	sk Rati	0			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	5% CI				M-H, Fixed, 95% CI
Kuppulakshmi 2016	25/74	20/78				+	-			66.58%	1.32[0.8,2.16]
Ntsaluba 1997	5/25	4/28				+				12.9%	1.4[0.42,4.64]
Yuen 1996	7/20	6/20				+				20.51%	1.17[0.48,2.86]
Total (95% CI)	119	126					-			100%	1.3[0.86,1.95]
Total events: 37 (Balloon), 30 (I	ntracervical PGE2)										
Heterogeneity: Tau ² =0; Chi ² =0.0	07, df=2(P=0.96); I ² =0%										
Test for overall effect: Z=1.25(P	=0.21)										
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours PGE2	

Comparison 6. Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all multiparae

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Uterine hyperstimulation with FHR changes	1	53	Risk Ratio (M-H, Fixed, 95% CI)	0.30 [0.01, 7.02]
2 Caesarean section	3	136	Risk Ratio (M-H, Random, 95% CI)	0.66 [0.16, 2.78]


Analysis 6.1. Comparison 6 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all multiparae, Outcome 1 Uterine hyperstimulation with FHR changes.



Analysis 6.2. Comparison 6 Balloon (Foley or ATAD) versus intracervical prostaglandin E2: all multiparae, Outcome 2 Caesarean section.

Study or subgroup	Balloon	Intracervi- cal PGE2						Weight	Risk Ratio		
	n/N	n/N			M-H, Raı	ndom	ı, 95% CI				M-H, Random, 95% CI
Kuppulakshmi 2016	3/26	9/22	+	,		-				42.76%	0.28[0.09,0.92]
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours PGE2	





Comparison 7. Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	2	340	Risk Ratio (M-H, Fixed, 95% CI)	1.09 [0.85, 1.39]
2 Uterine hyperstimulation with FHR changes	8	1322	Risk Ratio (M-H, Fixed, 95% CI)	0.39 [0.18, 0.85]
3 Caesarean section	12	1756	Risk Ratio (M-H, Random, 95% CI)	1.28 [1.02, 1.60]
4 Serious neonatal morbidity/perinatal death	3	381	Risk Ratio (M-H, Fixed, 95% CI)	0.58 [0.12, 2.66]
5 Serious maternal morbidity or death	4	464	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
6 Cervix unfavourable/unchanged after 12 hours	2	200	Risk Ratio (M-H, Random, 95% CI)	2.66 [0.60, 11.89]
7 Oxytocin augmentation	9	911	Risk Ratio (M-H, Random, 95% CI)	1.62 [1.38, 1.90]
8 Uterine hyperstimulation without FHR changes	9	1139	Risk Ratio (M-H, Fixed, 95% CI)	0.25 [0.14, 0.44]
9 Uterine rupture	3	364	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
10 Epidural analgesia	2	517	Risk Ratio (M-H, Fixed, 95% CI)	1.22 [1.06, 1.41]
11 Instrumental vaginal delivery	4	721	Risk Ratio (M-H, Fixed, 95% CI)	0.72 [0.50, 1.05]
12 Meconium-stained liquor	7	1268	Risk Ratio (M-H, Fixed, 95% CI)	0.64 [0.48, 0.87]




Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
13 Apgar score < 7 at 5 minutes	7	941	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.50, 1.97]
14 Neonatal intensive care unit admission	9	1302	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.61, 1.63]
15 Perinatal death	1	121	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
16 Maternal vomiting	1	60	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
17 Postpartum haemorrhage	1	120	Risk Ratio (M-H, Fixed, 95% CI)	1.14 [0.24, 5.44]
18 Maternal fever during labour	3	617	Risk Ratio (M-H, Random, 95% CI)	1.84 [0.22, 15.62]
19 Chorioamnionitis	2	200	Risk Ratio (M-H, Fixed, 95% CI)	1.24 [0.31, 4.88]
20 Endometritis	1	240	Risk Ratio (M-H, Fixed, 95% CI)	2.95 [0.12, 71.72]
21 Fetal distress	7	1127	Risk Ratio (M-H, Fixed, 95% CI)	0.84 [0.67, 1.05]
22 Umbilical artery pH <7.10	1	120	Risk Ratio (M-H, Fixed, 95% CI)	1.14 [0.35, 3.74]

Analysis 7.1. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.


Study or subgroup	Balloon	vaginal misoprostol			Ri	sk Rati	0			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	5% CI				M-H, Fixed, 95% CI
Chavakula 2015	21/54	17/46			_	-	_			26.31%	1.05[0.64,1.74]
Filho 2002	57/121	51/119				+				73.69%	1.1[0.83,1.46]
Total (95% CI)	175	165				•				100%	1.09[0.85,1.39]
Total events: 78 (Balloon), 68 (vaginal misoprostol)										
Heterogeneity: Tau ² =0; Chi ² =0.	.02, df=1(P=0.88); I ² =0%										
Test for overall effect: Z=0.66(F	P=0.51)										
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	



Analysis 7.2. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 2 Uterine hyperstimulation with FHR changes.




Analysis 7.3. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 3 Caesarean section.






Analysis 7.4. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 4 Serious neonatal morbidity/perinatal death.



Analysis 7.5. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 5 Serious maternal morbidity or death.

Study or subgroup	Balloon	vaginal misoprostol			Ri	isk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Aduloju 2016	0/70	0/70									Not estimable
Chavakula 2015	0/54	0/46									Not estimable
Jozwiak 2014	0/56	0/64									Not estimable
Noor 2015	0/44	0/60									Not estimable
Total (95% CI)	224	240									Not estimable
Total events: 0 (Balloon), 0 (vaginal mi	soprostol)										
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	

Analysis 7.6. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 6 Cervix unfavourable/unchanged after 12 hours.






Analysis 7.7. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 7 Oxytocin augmentation.

Study or subgroup	Balloon	vaginal misoprostol	Risk Ratio	Weight	Risk Ratio	
	n/N	n/N	M-H, Random, 95% CI		M-H, Random, 95% CI	
Aduloju 2016	66/70	43/70	-	15.15%	1.53[1.26,1.86]	
Chavakula 2015	46/54	28/46		12.95%	1.4[1.08,1.81]	
Deo 2012	32/50	20/54	_ 	8.61%	1.73[1.15,2.59]	
Jozwiak 2014	46/56	32/64		12.38%	1.64[1.25,2.16]	
Kandil 2012	34/50	11/50		5.77%	3.09[1.77,5.39]	
Lemyre 2006	30/31	21/31		13.15%	1.43[1.11,1.84]	
Noor 2015	34/44	29/60	_ 	11.32%	1.6[1.18,2.17]	
Sheikher 2009	26/30	7/30		4.43%	3.71[1.91,7.21]	
Tabowei 2003	58/61	44/60	+	16.24%	1.3[1.1,1.53]	
Total (95% CI)	446	465	•	100%	1.62[1.38,1.9]	
Total events: 372 (Balloon), 235 (va	ginal misoprostol)					
Heterogeneity: Tau²=0.03; Chi²=21.	93, df=8(P=0.01); l ² =63.	.52%				
Test for overall effect: Z=5.95(P<0.0	001)					

Analysis 7.8. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 8 Uterine hyperstimulation without FHR changes.







Analysis 7.9. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 9 Uterine rupture.

Study or subgroup	Balloon	vaginal misoprostol			Ri	sk Ra	tio			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Aduloju 2016	0/70	0/70									Not estimable
Jozwiak 2014	0/56	0/64									Not estimable
Noor 2015	0/44	0/60									Not estimable
Total (95% CI)	170	194									Not estimable
Total events: 0 (Balloon), 0 (vaginal mi	soprostol)										
Heterogeneity: Not applicable											
Test for overall effect: Not applicable					1						
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	

Analysis 7.10. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 10 Epidural analgesia.



Analysis 7.11. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 11 Instrumental vaginal delivery.





Analysis 7.12. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 12 Meconium-stained liquor.

Study or subgroup	Balloon	vaginal misoprostol		R	isk Ratio	•			Weight	Risk Ratio
	n/N	n/N		М-Н,	Fixed, 95	5% CI				M-H, Fixed, 95% CI
Aduloju 2016	1/70	2/70	$\overline{+}$	+					2.17%	0.5[0.05,5.39]
Filho 2002	7/121	5/119			+		_		5.48%	1.38[0.45,4.22]
Kandil 2012	0/50	3/50	4						3.81%	0.14[0.01,2.7]
Oliveira 2010	11/80	14/80			+				15.22%	0.79[0.38,1.62]
Prager 2008	33/198	51/199		-	-				55.32%	0.65[0.44,0.96]
Roudsari 2011	3/60	5/50	_	+		_			5.93%	0.5[0.13,1.99]
Tabowei 2003	4/61	11/60	_	+					12.06%	0.36[0.12,1.06]
Total (95% CI)	640	628		<	>				100%	0.64[0.48,0.87]
Total events: 59 (Balloon), 91 (vaginal misoprostol)									
Heterogeneity: Tau ² =0; Chi ² =4.	.37, df=6(P=0.63); I ² =0%									
Test for overall effect: Z=2.88(F	P=0)									
		Favours balloon	0.1	0.2 0.5	1	2	5	¹⁰ Favo	ours misoprostol	


Analysis 7.13. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 13 Apgar score < 7 at 5 minutes.

Study or subgroup	Balloon	vaginal misoprostol	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Aduloju 2016	5/70	5/70		31.42%	1[0.3,3.3]
Chavakula 2015	1/54	0/46		3.39%	2.56[0.11,61.45]
Filho 2002	1/121	0/119		3.17%	2.95[0.12,71.72]
Jozwiak 2014	0/56	2/64		14.68%	0.23[0.01,4.65]
Oliveira 2010	3/80	3/80		18.85%	1[0.21,4.81]
Sheikher 2009	1/30	0/30		3.14%	3[0.13,70.83]
Tabowei 2003	3/61	4/60	-	25.35%	0.74[0.17,3.16]
Total (95% CI)	472	469		100%	1[0.5,1.97]
Total events: 14 (Balloon), 14 (vaginal misoprostol)				
Heterogeneity: Tau ² =0; Chi ² =2.	.33, df=6(P=0.89); I ² =0%				
Test for overall effect: Z=0.01(P	P=1)				
		Favours balloon	0.1 0.2 0.5 1 2 5 10	Favours misoprosto	l


Analysis 7.14. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 14 Neonatal intensive care unit admission.

Study or subgroup	Balloon	vaginal misoprostol			Ri	sk Ra	ntio			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Aduloju 2016	3/70	5/70				-				16.5%	0.6[0.15,2.41]
Chavakula 2015	4/54	1/46				+		+	→	3.56%	3.41[0.39,29.42]
Jozwiak 2014	2/56	1/64		_		+	+		→	3.08%	2.29[0.21,24.54]
Kandil 2012	0/50	0/50									Not estimable
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	





Analysis 7.15. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 15 Perinatal death.




Analysis 7.16. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 16 Maternal vomiting.


Study or subgroup	Balloon	vaginal misoprostol			Ris	sk Rati	o			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	5% CI				M-H, Fixed, 95% CI
Sheikher 2009	0/30	0/30									Not estimable
Total (95% CI)	30	30									Not estimable
Total events: 0 (Balloon), 0 (vaginal m	isoprostol)										
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	



Analysis 7.17. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 17 Postpartum haemorrhage.



Analysis 7.18. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 18 Maternal fever during labour.




Analysis 7.19. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 19 Chorioamnionitis.


Study or subgroup	Balloon	vaginal misoprostol			Ri	sk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	95% CI				M-H, Fixed, 95% CI
Chavakula 2015	1/54	0/46	_				•		→	15.24%	2.56[0.11,61.45]
Kandil 2012	3/50	3/50				+				84.76%	1[0.21,4.72]
Total (95% CI)	104	96						_		100%	1.24[0.31,4.88]
Total events: 4 (Balloon), 3 (va	ginal misoprostol)										
Heterogeneity: Tau ² =0; Chi ² =0	27, df=1(P=0.6); I ² =0%										
Test for overall effect: Z=0.31(F	P=0.76)										
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	




Analysis 7.20. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 20 Endometritis.



Analysis 7.21. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 21 Fetal distress.



Analysis 7.22. Comparison 7 Balloon (Foley or ATAD) versus low dose vaginal misoprostol: all women, Outcome 22 Umbilical artery pH <7.10.






Comparison 8. Balloon (Foley or ATAD versus low dose vaginal misoprostol: all primiparae

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Caesarean section	1	255	Risk Ratio (M-H, Fixed, 95% CI)	0.82 [0.59, 1.13]

Analysis 8.1. Comparison 8 Balloon (Foley or ATAD versus low dose vaginal misoprostol: all primiparae, Outcome 1 Caesarean section.



Comparison 9. Balloon (Foley or ATAD) versus low dose oral misoprostol: all women

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved within 24 hours	2	782	Risk Ratio (M-H, Fixed, 95% CI)	1.28 [1.13, 1.46]
2 Uterine hyperstimulation with FHR changes	2	2033	Risk Ratio (M-H, Fixed, 95% CI)	0.81 [0.48, 1.38]
3 Caesarean section	7	3178	Risk Ratio (M-H, Fixed, 95% CI)	1.17 [1.04, 1.32]
4 Serious perinatal morbidity/perinatal death	3	2627	Risk Ratio (M-H, Fixed, 95% CI)	1.11 [0.60, 2.06]
5 Serious maternal morbidity or death	3	2627	Risk Ratio (M-H, Fixed, 95% CI)	0.50 [0.05, 5.52]
6 Cervix unfavourable after 24 hours	4	994	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.61, 1.56]
7 Oxytocin augmentation	5	2847	Risk Ratio (M-H, Random, 95% CI)	1.28 [1.09, 1.49]
8 Uterine hyperstimulation without FHR changes	5	2838	Risk Ratio (M-H, Random, 95% CI)	0.50 [0.12, 2.07]



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
9 Uterine rupture	3	2627	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
10 Epidural	3	2635	Risk Ratio (M-H, Random, 95% CI)	1.08 [0.96, 1.22]
11 Instrumental vaginal delivery	3	2627	Risk Ratio (M-H, Fixed, 95% CI)	0.71 [0.55, 0.92]
12 Meconium-stained liquor	3	2627	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.44, 1.35]
13 Apgar score < 7 after 5 minutes	4	2693	Risk Ratio (M-H, Fixed, 95% CI)	0.71 [0.38, 1.32]
14 Neonatal intensive care unit admission	5	2873	Risk Ratio (M-H, Fixed, 95% CI)	0.82 [0.58, 1.17]
15 Neonatal encephalopathy	1	600	Risk Ratio (M-H, Fixed, 95% CI)	0.81 [0.32, 2.03]
16 Perinatal death	3	2627	Risk Ratio (M-H, Fixed, 95% CI)	1.28 [0.49, 3.30]
17 Maternal side effects (all)	2	662	Risk Ratio (M-H, Fixed, 95% CI)	0.61 [0.33, 1.13]
18 Maternal vomiting	2	662	Risk Ratio (M-H, Fixed, 95% CI)	0.73 [0.37, 1.46]
19 Maternal diarrhoea	1	602	Risk Ratio (M-H, Fixed, 95% CI)	0.29 [0.06, 1.37]
20 Postpartum haemorrhage	5	2966	Risk Ratio (M-H, Fixed, 95% CI)	1.03 [0.79, 1.34]
21 Maternal death	3	2627	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
22 Women not satisfied	1	602	Risk Ratio (M-H, Fixed, 95% CI)	1.70 [1.15, 2.50]
23 Maternal fever during labour	2	2033	Risk Ratio (M-H, Fixed, 95% CI)	0.98 [0.78, 1.24]
24 Antibiotics during labour	2 2033 Risk Ratio (M-H, Fixed, 95% CI)		1.22 [0.75, 2.00]	
25 Endometritis	1	188	Risk Ratio (M-H, Fixed, 95% CI)	0.56 [0.05, 6.03]
26 Fetal distress	5	2966	Risk Ratio (M-H, Fixed, 95%	0.82 [0.61, 1.09]



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
27 Umbilical artery pH < 7.10	2	1535	Risk Ratio (M-H, Fixed, 95% CI)	0.77 [0.53, 1.12]

Analysis 9.1. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 1 Vaginal delivery not achieved within 24 hours.

Study or subgroup	Balloon	Oral miso- prostol			Ri	sk Rati	io			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	5% CI				M-H, Fixed, 95% CI
Mundle 2017	159/300	130/302				-				69.68%	1.23[1.04,1.46]
Somirathne 2017	78/89	57/91				-	H			30.32%	1.4[1.17,1.67]
Total (95% CI)	389	393				•	•			100%	1.28[1.13,1.46]
Total events: 237 (Balloon), 18	7 (Oral misoprostol)										
Heterogeneity: Tau ² =0; Chi ² =1.	16, df=1(P=0.28); I ² =13.88%)									
Test for overall effect: Z=3.82(P	P=0)										
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	


Analysis 9.2. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 2 Uterine hyperstimulation with FHR changes.

Study or subgroup	Balloon	Oral miso- prostol			Ri	sk Rati	io			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	5% CI				M-H, Fixed, 95% CI
Kruit 2016	2/89	4/99			+					12.73%	0.56[0.1,2.96]
ten Eikelder 2016	22/921	26/924			-	-				87.27%	0.85[0.48,1.49]
Total (95% CI)	1010	1023			~					100%	0.81[0.48,1.38]
Total events: 24 (Balloon), 30 (Oral misoprostol)										
Heterogeneity: Tau ² =0; Chi ² =0	.22, df=1(P=0.64); I ² =0%										
Test for overall effect: Z=0.77(F	P=0.44)										
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	


Analysis 9.3. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 3 Caesarean section.

Study or subgroup	Balloon	Oral miso- prostol	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Goonewardene 2014	17/78	24/74		6.99%	0.67[0.39,1.15]
Kruit 2016	21/89	18/99		4.84%	1.3[0.74,2.27]
Mundle 2017	151/300	124/302	-	35.1%	1.23[1.03,1.46]
Saleem 2006	11/78	9/73	- 	2.64%	1.14[0.5,2.6]
		Favours balloon 0.	1 0.2 0.5 1 2 5	10 Favours misoprostol	






Analysis 9.4. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 4 Serious perinatal morbidity/perinatal death.



Analysis 9.5. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 5 Serious maternal morbidity or death.






Analysis 9.6. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 6 Cervix unfavourable after 24 hours.

Study or subgroup	Balloon	Oral miso- prostol			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		М-Н,	Random, 95%	6 CI			M-H, Random, 95% CI
Goonewardene 2014	14/78	20/74			-			37.55%	0.66[0.36,1.22]
Mundle 2017	0/300	0/302							Not estimable
Sheikher 2009	5/30	5/30			-			14.65%	1[0.32,3.1]
Somirathne 2017	27/89	21/91			-			47.79%	1.31[0.81,2.15]
Total (95% CI)	497	497			•			100%	0.98[0.61,1.56]
Total events: 46 (Balloon), 46 (Ora	al misoprostol)								
Heterogeneity: Tau ² =0.06; Chi ² =2.	.96, df=2(P=0.23); I ² =32.5	51%							
Test for overall effect: Z=0.1(P=0.9	92)								
		Favours balloon	0.01	0.1	1	10	100	Favours misoprostol	

Analysis 9.7. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 7 Oxytocin augmentation.



Analysis 9.8. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 8 Uterine hyperstimulation without FHR changes.

Study or subgroup	Balloon	Oral miso- prostol		1	Risk Ratio		Weight	Risk Ratio
	n/N	n/N		М-Н, Б	andom, 95% C	I		M-H, Random, 95% CI
Mundle 2017	1/300	2/302			•		19.22%	0.5[0.05,5.52]
Saleem 2006	0/78	5/73	\leftarrow	+			15.5%	0.09[0,1.51]
Sheikher 2009	0/30	1/30	-	•			13.71%	0.33[0.01,7.87]
Somirathne 2017	0/89	3/91	\leftarrow	•			15.02%	0.15[0.01,2.79]
ten Eikelder 2016	16/921	8/924			-		36.56%	2.01[0.86,4.67]
Total (95% CI)	1418	1420					100%	0.5[0.12,2.07]
Total events: 17 (Balloon), 19 (Oral misoprostol)							
Heterogeneity: Tau ² =1.26; Chi ²	² =8.12, df=4(P=0.09); l ² =50.7	5%						
		Favours balloon	0.01	0.1	1 1	0 100	Favours misoprostol	




Study or subgroup	Balloon	Oral miso- prostol			Risk Ratio	0		Weight	Risk Ratio
	n/N	n/N		М-Н, І	Random,	95% CI			M-H, Random, 95% CI
Test for overall effect: Z=0.96(P=0.34)			_						
		Favours halloon	0.01	0.1	1	10	100	Eavoure miconroctol	

Analysis 9.9. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 9 Uterine rupture.

Study or subgroup	Balloon	Oral miso- prostol			Ri	sk Rat	tio			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Mundle 2017	0/300	0/302									Not estimable
Somirathne 2017	0/89	0/91									Not estimable
ten Eikelder 2016	0/921	0/924									Not estimable
Total (95% CI)	1310	1317									Not estimable
Total events: 0 (Balloon), 0 (Oral misop	orostol)										
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	


Analysis 9.10. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 10 Epidural.




Analysis 9.11. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 11 Instrumental vaginal delivery.

Study or subgroup	Balloon	Oral miso- prostol			Risk Ratio					Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Mundle 2017	3/300	2/302		-			+		_	1.55%	1.51[0.25,8.97]
Somirathne 2017	0/89	1/91	+		-	-			_	1.16%	0.34[0.01,8.25]
ten Eikelder 2016	88/921	125/924			, -	-				97.29%	0.71[0.55,0.91]
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	





Analysis 9.12. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 12 Meconium-stained liquor.



Analysis 9.13. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 13 Apgar score < 7 after 5 minutes.


Study or subgroup	Balloon	Oral miso- prostol			Ri	sk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	5% CI				M-H, Fixed, 95% CI
Kruit 2016	0/89	0/99									Not estimable
Mundle 2017	1/298	6/302	←	•						24.9%	0.17[0.02,1.39]
Sheikher 2009	1/30	1/30	\leftarrow			-			→	4.18%	1[0.07,15.26]
ten Eikelder 2016	15/921	17/924					_			70.92%	0.89[0.44,1.76]
Total (95% CI)	1338	1355								100%	0.71[0.38,1.32]
Total events: 17 (Balloon), 24 (C	Oral misoprostol)										
Heterogeneity: Tau ² =0; Chi ² =2.2	23, df=2(P=0.33); I ² =10.29%					ĺ					
Test for overall effect: Z=1.08(P	=0.28)			1	1						
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	



Analysis 9.14. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 14 Neonatal intensive care unit admission.

Study or subgroup	Balloon	Oral miso- prostol		Risk Ratio		Weight	Risk Ratio
	n/N	n/N		M-H, Fixed, 95% CI			M-H, Fixed, 95% CI
Kruit 2016	7/89	9/99				13.06%	0.87[0.34,2.23]
Mundle 2017	19/298	28/302		-		42.62%	0.69[0.39,1.2]
Sheikher 2009	1/30	1/30	\leftarrow			1.53%	1[0.07,15.26]
Somirathne 2017	2/89	3/91		+	_	4.55%	0.68[0.12,3.98]
ten Eikelder 2016	24/921	25/924				38.25%	0.96[0.55,1.67]
Total (95% CI)	1427	1446		•		100%	0.82[0.58,1.17]
Total events: 53 (Balloon), 66 ((Oral misoprostol)						
Heterogeneity: Tau ² =0; Chi ² =0	.78, df=4(P=0.94); I ² =0%						
Test for overall effect: Z=1.1(P=	=0.27)						
		Favours balloon	0.1 0.2	0.5 1 2	5 10	Favours misoprostol	

Analysis 9.15. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 15 Neonatal encephalopathy.



Analysis 9.16. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 16 Perinatal death.


Study or subgroup	Balloon	Oral miso- prostol			Ri	sk Ra	tio			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Mundle 2017	5/300	6/302		_		-				80.02%	0.84[0.26,2.72]
Somirathne 2017	1/89	0/91	-			-	•		→	6.62%	3.07[0.13,74.29]
ten Eikelder 2016	3/921	1/924					•		→	13.36%	3.01[0.31,28.88]
Total (95% CI)	1310	1317			-					100%	1.28[0.49,3.3]
Total events: 9 (Balloon), 7 (Or	ral misoprostol)										
Heterogeneity: Tau ² =0; Chi ² =1	.33, df=2(P=0.51); I ² =0%										
Test for overall effect: Z=0.5(P	=0.62)										
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	



Analysis 9.17. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 17 Maternal side effects (all).

Study or subgroup	Balloon	Oral miso- prostol			Ri	sk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	95% CI				M-H, Fixed, 95% CI
Mundle 2017	15/300	24/302				+				94.1%	0.63[0.34,1.18]
Sheikher 2009	0/30	1/30	+		+				_	5.9%	0.33[0.01,7.87]
Total (95% CI)	330	332								100%	0.61[0.33,1.13]
Total events: 15 (Balloon), 25 (Oral misoprostol)										
Heterogeneity: Tau ² =0; Chi ² =0	.15, df=1(P=0.7); I ² =0%										
Test for overall effect: Z=1.57(F	P=0.12)										
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	

Analysis 9.18. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 18 Maternal vomiting.




Analysis 9.19. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 19 Maternal diarrhoea.

Study or subgroup	Balloon	Oral miso- prostol			Ri	sk Rati	o			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	5% CI				M-H, Fixed, 95% CI
Mundle 2017	2/300	7/302	+	-						100%	0.29[0.06,1.37]
Total (95% CI)	300	302								100%	0.29[0.06,1.37]
Total events: 2 (Balloon), 7 (Oral m	isoprostol)										
Heterogeneity: Not applicable											
Test for overall effect: Z=1.56(P=0.3	12)										
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	




Analysis 9.20. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 20 Postpartum haemorrhage.



Analysis 9.21. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 21 Maternal death.

Study or subgroup	Balloon	Oral miso- prostol			Ri	sk Rat	io:			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	95% CI				M-H, Fixed, 95% CI
Mundle 2017	0/300	0/302									Not estimable
Somirathne 2017	0/89	0/91									Not estimable
ten Eikelder 2016	0/921	0/924									Not estimable
Total (95% CI)	1310	1317									Not estimable
Total events: 0 (Balloon), 0 (Oral misop	rostol)										
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	

Analysis 9.22. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 22 Women not satisfied.







Analysis 9.23. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 23 Maternal fever during labour.

Study or subgroup	Balloon	Oral miso- prostol			Ri	isk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	95% CI				M-H, Fixed, 95% CI
Kruit 2016	2/89	2/99							_	1.54%	1.11[0.16,7.73]
ten Eikelder 2016	118/921	121/924				-				98.46%	0.98[0.77,1.24]
Total (95% CI)	1010	1023				•				100%	0.98[0.78,1.24]
Total events: 120 (Balloon), 12	3 (Oral misoprostol)										
Heterogeneity: Tau ² =0; Chi ² =0.	.02, df=1(P=0.9); I ² =0%										
Test for overall effect: Z=0.16(F	P=0.87)										
	-	Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	

Analysis 9.24. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 24 Antibiotics during labour.




Analysis 9.25. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 25 Endometritis.






Analysis 9.26. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 26 Fetal distress.



Analysis 9.27. Comparison 9 Balloon (Foley or ATAD) versus low dose oral misoprostol: all women, Outcome 27 Umbilical artery pH < 7.10.



Comparison 10. Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae


Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	2	573	Risk Ratio (M-H, Fixed, 95% CI)	1.19 [1.04, 1.37]
2 Uterine hyperstimulation with FHR changes	1	1206	Risk Ratio (M-H, Fixed, 95% CI)	0.81 [0.45, 1.46]
3 Caesarean section	3	1778	Risk Ratio (M-H, Fixed, 95% CI)	1.21 [1.06, 1.38]
4 Serious neonatal morbidity/perinatal death	2	1296	Risk Ratio (M-H, Fixed, 95% CI)	4.49 [0.77, 26.14]
5 Serious maternal morbidity or death	2	1296	Risk Ratio (M-H, Fixed, 95% CI)	0.51 [0.05, 5.63]



Analysis 10.1. Comparison 10 Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.

Study or subgroup	Balloon	Oral miso- prostol			Ri	sk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	5% CI				M-H, Fixed, 95% CI
Mundle 2017	142/247	117/236				1				79.27%	1.16[0.98,1.37]
Somirathne 2017	40/44	32/46				-	-			20.73%	1.31[1.06,1.62]
Total (95% CI)	291	282				•				100%	1.19[1.04,1.37]
Total events: 182 (Balloon), 14	9 (Oral misoprostol)										
Heterogeneity: Tau ² =0; Chi ² =0	.83, df=1(P=0.36); I ² =0%										
Test for overall effect: Z=2.45(F	P=0.01)										
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	

Analysis 10.2. Comparison 10 Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae, Outcome 2 Uterine hyperstimulation with FHR changes.



Analysis 10.3. Comparison 10 Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae, Outcome 3 Caesarean section.


Study or subgroup	Balloon	Oral miso- prostol			Ri	sk Ratio	•			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 95	5% CI				M-H, Fixed, 95% CI
Mundle 2017	138/246	112/236				-				43.88%	1.18[0.99,1.41]
Somirathne 2017	13/44	9/46			,	+				3.38%	1.51[0.72,3.17]
ten Eikelder 2016	164/596	139/610				-				52.74%	1.21[0.99,1.47]
Total (95% CI)	886	892				•				100%	1.21[1.06,1.38]
Total events: 315 (Balloon), 260	(Oral misoprostol)										
Heterogeneity: Tau ² =0; Chi ² =0.	4, df=2(P=0.82); I ² =0%										
Test for overall effect: Z=2.81(P	=0)										
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	



Analysis 10.4. Comparison 10 Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae, Outcome 4 Serious neonatal morbidity/perinatal death.

Study or subgroup	Balloon	Oral miso- prostol			Ri	isk Rati	0			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	5% CI				M-H, Fixed, 95% CI
Somirathne 2017	3/44	1/46					-		→	66.43%	3.14[0.34,29.03]
ten Eikelder 2016	3/596	0/610							-	33.57%	7.16[0.37,138.4]
Total (95% CI)	640	656								100%	4.49[0.77,26.14]
Total events: 6 (Balloon), 1 (Or	ral misoprostol)										
Heterogeneity: Tau ² =0; Chi ² =0	.2, df=1(P=0.66); I ² =0%										
Test for overall effect: Z=1.67(F	P=0.09)										
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	

Analysis 10.5. Comparison 10 Balloon (Foley or ATAD) versus low dose oral misoprostol: all primiparae, Outcome 5 Serious maternal morbidity or death.



Comparison 11. Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae


Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	2	209	Risk Ratio (M-H, Fixed, 95% CI)	1.55 [1.17, 2.06]
2 Uterine hyperstimulation with FHR changes	1	639	Risk Ratio (M-H, Fixed, 95% CI)	1.45 [0.24, 8.61]
3 Caesarean section	3	848	Risk Ratio (M-H, Fixed, 95% CI)	1.22 [0.79, 1.87]
4 Serious neonatal morbidity/perinatal death	2	729	Risk Ratio (M-H, Fixed, 95% CI)	0.98 [0.14, 6.86]
5 Serious maternal morbidity or death	2	729	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]



Analysis 11.1. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.

Study or subgroup	Balloon	Oral miso- prostol			Ri	sk Ra	tio			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Mundle 2017	17/53	13/66				+	-			31.66%	1.63[0.87,3.04]
Somirathne 2017	38/45	25/45				-	 			68.34%	1.52[1.14,2.03]
Total (95% CI)	98	111				•	•			100%	1.55[1.17,2.06]
Total events: 55 (Balloon), 38 (Oral misoprostol)										
Heterogeneity: Tau ² =0; Chi ² =0	.04, df=1(P=0.83); I ² =0%										
Test for overall effect: Z=3.07(F	P=0)										
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	

Analysis 11.2. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 2 Uterine hyperstimulation with FHR changes.




Analysis 11.3. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 3 Caesarean section.

Study or subgroup	Balloon	Oral miso- prostol		ı	Risk Ratio		Weight	Risk Ratio
	n/N	n/N		М-Н,	Fixed, 95% CI			M-H, Fixed, 95% CI
Mundle 2017	13/53	12/66			-		32.43%	1.35[0.67,2.71]
Somirathne 2017	5/45	6/45		_	-		18.2%	0.83[0.27,2.54]
ten Eikelder 2016	21/325	16/314			-		49.37%	1.27[0.67,2.38]
Total (95% CI)	423	425			•		100%	1.22[0.79,1.87]
Total events: 39 (Balloon), 34 ((Oral misoprostol)							
Heterogeneity: Tau ² =0; Chi ² =0	.55, df=2(P=0.76); I ² =0%							
Test for overall effect: Z=0.89(F	P=0.38)							
		Favours balloon	0.01	0.1	1 1	0 100	Favours misoprostol	



Analysis 11.4. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 4 Serious neonatal morbidity/perinatal death.



Analysis 11.5. Comparison 11 Balloon (Foley or ATAD) versus low dose oral misoprostol: all multiparae, Outcome 5 Serious maternal morbidity or death.

tudy or subgroup Balloon		Oral miso- prostol			Ri	sk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	5% CI				M-H, Fixed, 95% CI
Somirathne 2017	0/45	0/45									Not estimable
ten Eikelder 2016	0/325	0/314									Not estimable
Total (95% CI)	370	359									Not estimable
Total events: 0 (Balloon), 0 (Oral misop	orostol)										
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	


Comparison 12. Balloon (Foley or ATAD) versus oxytocin: all women

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Uterine hyperstimulation with FHR changes	1	200	Risk Ratio (M-H, Fixed, 95% CI)	0.2 [0.01, 4.11]
2 Caesarean section	8	781	Risk Ratio (M-H, Fixed, 95% CI)	0.68 [0.56, 0.83]
3 Serious neonatal morbidity/perinatal death	1	100	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Serious maternal morbidity or death	2	160	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Cervix unfavourable after 24 hours	1	100	Risk Ratio (M-H, Fixed, 95% CI)	0.56 [0.20, 1.54]
6 Uterine hyperstimulation without FHR changes	3	192	Risk Ratio (M-H, Fixed, 95% CI)	1.0 [0.23, 4.29]
7 Uterine rupture	1	100	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
8 Instrumental vaginal delivery	3	220	Risk Ratio (M-H, Fixed, 95% CI)	1.19 [0.55, 2.57]
9 Meconium-stained liquor	2	272	Risk Ratio (M-H, Fixed, 95% CI)	0.53 [0.23, 1.21]
10 Apgar score < 7 at 5 minutes	2	300	Risk Ratio (M-H, Fixed, 95% CI)	0.71 [0.14, 3.53]
11 Neonatal intensive care unit admission	3	372	Risk Ratio (M-H, Fixed, 95% CI)	0.8 [0.32, 1.98]
12 Perinatal death	1	100	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
13 Hemorrhagia postpartum	4	396	Risk Ratio (M-H, Fixed, 95% CI)	1.26 [0.51, 3.11]
14 Maternal fever during labour	1	60	Risk Ratio (M-H, Fixed, 95% CI)	0.2 [0.01, 4.00]
15 Fetal distress	3	332	Risk Ratio (M-H, Fixed, 95% CI)	0.43 [0.19, 0.98]

Analysis 12.1. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 1 Uterine hyperstimulation with FHR changes.



Analysis 12.2. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 2 Caesarean section.

Study or subgroup	Balloon	oxytocin	Risk Ratio	Weight	Risk Ratio	
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI	
Atad 1996	7/35	14/30		9.89%	0.43[0.2,0.92]	
El Khouly 2017	6/36	15/36		9.84%	0.4[0.18,0.91]	
Gelisen 2005	17/100	24/100		15.74%	0.71[0.41,1.24]	
Jagani 1982	1/10	3/10		1.97%	0.33[0.04,2.69]	
Joshi 2016	10/50	12/50		7.87%	0.83[0.4,1.75]	
Meetei 2015	10/30	12/30		7.87%	0.83[0.43,1.63]	
Orhue 1995	3/30	7/30	+ +	4.59%	0.43[0.12,1.5]	
Sarreau 2016	50/101	65/103	-	42.22%	0.78[0.61,1]	
Total (95% CI)	392	389	•	100%	0.68[0.56,0.83]	
Total events: 104 (Balloon), 15	52 (oxytocin)					
Heterogeneity: Tau ² =0; Chi ² =5	i.88, df=7(P=0.55); I ² =0%			1		
		Favours balloon	0.1 0.2 0.5 1 2	5 10 Favours oxytocin		




Study or subgroup	Balloon n/N	oxytocin n/N	Risk Ratio M-H, Fixed, 95% CI							Weight	Risk Ratio M-H, Fixed, 95% CI
Test for overall effect: Z=3.83(P=0)											
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours oxytocin	


Analysis 12.3. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 3 Serious neonatal morbidity/perinatal death.

Study or subgroup	Balloon	oxytocin		Risk Ratio					Weight	Risk Ratio	
	n/N	n/N			M-H, Fi	ixed, 9	5% CI				M-H, Fixed, 95% CI
Joshi 2016	0/50	0/50									Not estimable
Total (95% CI)	50	50									Not estimable
Total events: 0 (Balloon), 0 (oxytocin)											
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours oxytocin	

Analysis 12.4. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 4 Serious maternal morbidity or death.




Analysis 12.5. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 5 Cervix unfavourable after 24 hours.






Analysis 12.6. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 6 Uterine hyperstimulation without FHR changes.



Analysis 12.7. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 7 Uterine rupture.


Study or subgroup	Balloon	lloon oxytocin			Ri	sk Rat	tio		Weight	Risk Ratio	
	n/N	n/N	n/N			ixed,	95% CI				M-H, Fixed, 95% CI
Joshi 2016	0/50	0/50									Not estimable
Total (95% CI)	50	50									Not estimable
Total events: 0 (Balloon), 0 (oxytocin)											
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours oxytocin	

Analysis 12.8. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 8 Instrumental vaginal delivery.







Analysis 12.9. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 9 Meconium-stained liquor.



Analysis 12.10. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 10 Apgar score < 7 at 5 minutes.



Analysis 12.11. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 11 Neonatal intensive care unit admission.







Analysis 12.12. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 12 Perinatal death.

Study or subgroup	Balloon	oxytocin		Risk Ratio				Weight	Risk Ratio		
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Joshi 2016	0/50	0/50									Not estimable
Total (95% CI)	50	50									Not estimable
Total events: 0 (Balloon), 0 (oxytocin)						İ					
Heterogeneity: Not applicable											
Test for overall effect: Not applicable					1						
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours oxytocin	

Analysis 12.13. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 13 Hemorrhagia postpartum.




Analysis 12.14. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 14 Maternal fever during labour.



Analysis 12.15. Comparison 12 Balloon (Foley or ATAD) versus oxytocin: all women, Outcome 15 Fetal distress.

Study or subgroup	Balloon	oxytocin	Risk Ratio							Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
El Khouly 2017	1/36	2/36	+		+					11.43%	0.5[0.05,5.27]
Gelisen 2005	6/100	13/100		_	-	+				74.29%	0.46[0.18,1.17]
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours oxytocin	






Comparison 13. Balloon (Foley or ATAD) versus oxytocin: previous caesarean section

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Caesarean section	3	364	Risk Ratio (M-H, Fixed, 95% CI)	0.80 [0.64, 1.00]
2 Serious neonatal morbidity/perinatal death	1	100	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Serious maternal morbidity or death	1	100	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]


Analysis 13.1. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 1 Caesarean section.



Analysis 13.2. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 2 Serious neonatal morbidity/perinatal death.

Study or subgroup	Balloon	oxytocin		Ri	isk Rat	tio			Weight	Risk Ratio
	n/N	n/N		М-Н, F	ixed,	95% CI				M-H, Fixed, 95% CI
Joshi 2016	0/50	0/50								Not estimable
Total (95% CI)	50	50								Not estimable
		Favours balloon	0.1 0.2	0.5	1	2	5	10	Favours oxytocin	






Analysis 13.3. Comparison 13 Balloon (Foley or ATAD) versus oxytocin: previous caesarean section, Outcome 3 Serious maternal morbidity or death.

Study or subgroup	Balloon	oxytocin			Ris	sk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, Rai	ndom	, 95% CI				M-H, Random, 95% CI
Joshi 2016	0/50	0/50									Not estimable
Total (95% CI)	50	50									Not estimable
Total events: 0 (Balloon), 0 (oxytocin)											
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours oxytocin	

Comparison 14. Balloon (Foley or ATAD) versus oxytocin: all primiparae

Outcome or subgroup title	o title No. of No. of studies participants		Statistical method	Effect size
1 Caesarean section	1	60	Risk Ratio (M-H, Fixed, 95% CI)	0.43 [0.12, 1.50]
2 Serious maternal morbidity or death	1	60	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]

Analysis 14.1. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 1 Caesarean section.






Analysis 14.2. Comparison 14 Balloon (Foley or ATAD) versus oxytocin: all primiparae, Outcome 2 Serious maternal morbidity or death.

Study or subgroup	Balloon	oxytocin		Risk Ratio				Weight	Risk Ratio		
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Orhue 1995	0/30	0/30									Not estimable
Total (95% CI)	30	30									Not estimable
Total events: 0 (Balloon), 0 (oxytocin)						İ					
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
		Favours balloon	0.1	0.2	0.5	1	2	5	10	Favours oxytocin	

Comparison 15. Balloon (foley or ATAD) versus amniotomy: all women

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Caesarean section	1	20	Risk Ratio (M-H, Fixed, 95% CI)	0.25 [0.03, 1.86]

Analysis 15.1. Comparison 15 Balloon (foley or ATAD) versus amniotomy: all women, Outcome 1 Caesarean section.



Comparison 16. Single balloon (Foley) versus double balloon (ATAD/Cook): all women

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	3	608	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.75, 1.25]
2 Uterine hyperstimulation with FHR changes	1	217	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Caesarean section	5	862	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.71, 1.33]
4 Serious maternal morbidity or death	1	217	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
5 Oxytcocin augmentation	2	278	Risk Ratio (M-H, Fixed, 95% CI)	0.94 [0.82, 1.08]
6 Uterine hyperstimulation without FHR changes	1	217	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7 Uterine rupture	1	217	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
8 Epidural analgesia	3	608	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.83, 1.03]
9 Instrumental vaginal delivery	3	690	Risk Ratio (M-H, Fixed, 95% CI)	0.86 [0.61, 1.20]
10 Meconium-stained liquor	1	98	Risk Ratio (M-H, Fixed, 95% CI)	0.40 [0.15, 1.04]
11 Apgar score < 7 at 5 minutes	3	608	Risk Ratio (M-H, Fixed, 95% CI)	0.84 [0.25, 2.79]
12 Neonatal intensive care unit admission	2	391	Risk Ratio (M-H, Fixed, 95% CI)	1.67 [0.71, 3.93]
13 Other maternal side-effects: pain after insertion	1	74	Risk Ratio (M-H, Fixed, 95% CI)	0.67 [0.20, 2.17]
14 Postpartum haemorrhage	2	291	Risk Ratio (M-H, Fixed, 95% CI)	0.83 [0.27, 2.52]
15 Maternal fever during labour	3	584	Risk Ratio (M-H, Random, 95% CI)	0.61 [0.16, 2.34]
16 Antibiotics during labour	1	217	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.61, 1.56]
17 Chorioamnionitis	1	98	Risk Ratio (M-H, Fixed, 95% CI)	1.56 [0.47, 5.20]
18 Endometritis	1	217	Risk Ratio (M-H, Fixed, 95% CI)	1.95 [0.18, 21.14]
19 Fetal distress	4	682	Risk Ratio (M-H, Fixed, 95% CI)	0.98 [0.70, 1.36]
20 Umbilical artery pH < 7.10	1	217	Risk Ratio (M-H, Fixed, 95% CI)	0.42 [0.11, 1.57]




Analysis 16.1. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 1 Vaginal delivery not achieved in 24 hours.

Study or subgroup	Single balloon	Double balloon		Risk Ratio			Weight	Risk Ratio			
	n/N n/N M-H, Random, S					, 95% CI				M-H, Random, 95% CI	
Hoppe 2016	40/48	35/50				-	-			37.64%	1.19[0.95,1.49]
Pennell 2009	57/110	67/107			-	-				36.59%	0.83[0.66,1.04]
Salim 2011	40/145	45/148			-	+				25.77%	0.91[0.63,1.3]
Total (95% CI)	303	305				•				100%	0.97[0.75,1.25]
Total events: 137 (Single bal	loon), 147 (Double balloon)										
Heterogeneity: Tau ² =0.03; Ch	ni²=5.64, df=2(P=0.06); l²=64	.54%				İ					
Test for overall effect: Z=0.22	2(P=0.83)										
	Favo	ours single balloon	0.1	0.2	0.5	1	2	5	10	Favours double balloc	on

Analysis 16.2. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 2 Uterine hyperstimulation with FHR changes.

Study or subgroup	Single balloon	Double balloon		Risk Ratio			Weight	Risk Ratio			
	n/N	n/N	M-H, Fixed, 95% CI								M-H, Fixed, 95% CI
Pennell 2009	0/110	0/107									Not estimable
Total (95% CI)	110	107									Not estimable
Total events: 0 (Single balloon), 0	0 (Double balloon)										
Heterogeneity: Not applicable											
Test for overall effect: Not applic	able										
	Fav	ours single balloon	0.1	0.2	0.5	1	2	5	10	Favours double balloo	on

Analysis 16.3. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 3 Caesarean section.






Analysis 16.4. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 4 Serious maternal morbidity or death.

Study or subgroup	Single balloon	Double balloon	Risk Ratio				Weight	Risk Ratio			
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Pennell 2009	0/110	0/107									Not estimable
Total (95% CI)	110	107									Not estimable
Total events: 0 (Single balloor	n), 0 (Double balloon)										
Heterogeneity: Not applicable	2										
Test for overall effect: Not app	olicable										
	Favo	ours single balloon	0.1	0.2	0.5	1	2	5	10	Favours double balloo	n

Analysis 16.5. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 5 Oxytcocin augmentation.




Analysis 16.6. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 6 Uterine hyperstimulation without FHR changes.

Study or subgroup	Single balloon	Double balloon		Risk Ratio			Weight	Risk Ratio			
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Pennell 2009	0/110	0/107									Not estimable
Total (95% CI)	110	107									Not estimable
Total events: 0 (Single balloon), 0 (I	Double balloon)										
Heterogeneity: Not applicable											
Test for overall effect: Not applicab	le										
	Fav	ours single balloon	0.1	0.2	0.5	1	2	5	10	Favours double balloo	n


Analysis 16.7. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 7 Uterine rupture.

Study or subgroup	Single balloon	Double balloon			Ri	sk Ra	ntio			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Pennell 2009	0/110	0/107									Not estimable
	Favo	ours single balloon	0.1	0.2	0.5	1	2	5	10	Favours double balloon	1







Analysis 16.8. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 8 Epidural analgesia.




Analysis 16.9. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 9 Instrumental vaginal delivery.




Analysis 16.10. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 10 Meconium-stained liquor.









Analysis 16.11. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 11 Apgar score < 7 at 5 minutes.



Analysis 16.12. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 12 Neonatal intensive care unit admission.




Analysis 16.13. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 13 Other maternal side-effects: pain after insertion.






Study or subgroup	Single balloon	Double balloon n/N	Risk Ratio M-H, Fixed, 95% CI							Weight Risk Ratio M-H, Fixed, 95% CI
Test for overall effect: Z=0.67(P=0.5)										
	F	avours single balloon	0.1	0.2	0.5	1	2	5	10	Favours double balloon


Analysis 16.14. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 14 Postpartum haemorrhage.



Analysis 16.15. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 15 Maternal fever during labour.




Analysis 16.16. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 16 Antibiotics during labour.






Analysis 16.17. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 17 Chorioamnionitis.



Analysis 16.18. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 18 Endometritis.




Analysis 16.19. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 19 Fetal distress.

Study or subgroup	Single balloon	Double balloon			Ri	sk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	95% CI				M-H, Fixed, 95% CI
Ahmed 2016	7/37	4/37					+			6.7%	1.75[0.56,5.48]
Hoppe 2016	11/48	9/50			_	+				14.77%	1.27[0.58,2.8]
Pennell 2009	14/110	15/107				-	_			25.47%	0.91[0.46,1.79]
Salim 2011	26/145	32/148			-	-				53.06%	0.83[0.52,1.32]
Total (95% CI)	340	342				•				100%	0.98[0.7,1.36]
Total events: 58 (Single ballo	oon), 60 (Double balloon)										
Heterogeneity: Tau ² =0; Chi ² =	=1.96, df=3(P=0.58); I ² =0%										
Test for overall effect: Z=0.14	4(P=0.89)				1				1		
	Fav	ours single balloon	0.1	0.2	0.5	1	2	5	10	Favours double balloon	n




Analysis 16.20. Comparison 16 Single balloon (Foley) versus double balloon (ATAD/Cook): all women, Outcome 20 Umbilical artery pH < 7.10.



Comparison 17. Single balloon (Foley) versus double balloon (ATAD): all primiparae

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	1	50	Risk Ratio (M-H, Fixed, 95% CI)	1.14 [0.95, 1.38]
2 Caesarean section	4	374	Risk Ratio (M-H, Random, 95% CI)	1.30 [0.76, 2.22]


Analysis 17.1. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.



Analysis 17.2. Comparison 17 Single balloon (Foley) versus double balloon (ATAD): all primiparae, Outcome 2 Caesarean section.

Study or subgroup	Single balloon	Double balloon		Risk Ratio						Weight	Risk Ratio
	n/N	n/N			M-H, Ra	ndom	ı, 95% CI				M-H, Random, 95% CI
Ahmed 2016	11/37	8/37			-		•			21.54%	1.38[0.62,3.03]
Hoppe 2016	17/25	10/25				-	-			28.33%	1.7[0.98,2.95]
Salim 2011	12/77	20/78			-	+				25.54%	0.61[0.32,1.16]
Solt 2009	20/50	9/45				-	•	_		24.59%	2[1.02,3.93]
	Fav	ours single balloon	0.1	0.2	0.5	1	2	5	10	Favours double balloc	on







Comparison 18. Single balloon (Foley) versus double balloon (ATAD): all multiparae

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	1	48	Risk Ratio (M-H, Fixed, 95% CI)	1.24 [0.80, 1.93]
2 Caesarean section	2	186	Risk Ratio (M-H, Fixed, 95% CI)	0.74 [0.30, 1.84]

Analysis 18.1. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.



Analysis 18.2. Comparison 18 Single balloon (Foley) versus double balloon (ATAD): all multiparae, Outcome 2 Caesarean section.





Comparison 19. Laminaria tent versus vaginal prostaglandin E2: all women


Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Uterine hyperstimulation with FHR changes	3	188	Risk Ratio (M-H, Fixed, 95% CI)	0.11 [0.02, 0.60]
2 Caesarean section	5	263	Risk Ratio (M-H, Fixed, 95% CI)	0.91 [0.56, 1.48]
3 Serious perinatal morbidity/perinatal death	1	80	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Serious maternal morbidity or death	1	28	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Uterine hyperstimulation without fe- tal heart rate changes	3	180	Risk Ratio (M-H, Fixed, 95% CI)	0.22 [0.09, 0.49]
6 Epidural analgesia	1	80	Risk Ratio (M-H, Fixed, 95% CI)	0.91 [0.74, 1.13]
7 Instrumental vaginal delivery	1	80	Risk Ratio (M-H, Fixed, 95% CI)	0.71 [0.43, 1.17]
8 Meconium-stained liquor	1	80	Risk Ratio (M-H, Fixed, 95% CI)	0.14 [0.01, 2.68]
9 Apgar score < 7 at 5 minutes	2	160	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
10 Perinatal death	1	80	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
11 Maternal side effects: all	1	28	Risk Ratio (M-H, Fixed, 95% CI)	0.29 [0.01, 6.60]
12 Maternal nausea	1	28	Risk Ratio (M-H, Fixed, 95% CI)	0.29 [0.01, 6.60]
13 Fetal distress	3	188	Risk Ratio (M-H, Fixed, 95% CI)	0.62 [0.34, 1.15]

Analysis 19.1. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 1 Uterine hyperstimulation with FHR changes.

Study or subgroup	Laminaria	PGE2			Risk Rat	io		Weight	Risk Ratio
	n/N	n/N		М-Н	Fixed, 9	5% CI			M-H, Fixed, 95% CI
Bagratee 1990	0/40	5/40	+	-				42.75%	0.09[0.01,1.59]
Hay 1995	0/15	5/13	\leftarrow	1				45.6%	0.08[0,1.31]
Johnson 1985	0/40	1/40	•	+				11.66%	0.33[0.01,7.95]
Total (95% CI)	95	93			_			100%	0.11[0.02,0.6]
Total events: 0 (Laminaria), 11 (PGE	(2)								
Heterogeneity: Tau ² =0; Chi ² =0.53, d	lf=2(P=0.77); I ² =0%								
Test for overall effect: Z=2.57(P=0.0	1)			1		1			
		Favours laminaria	0.	.05 0.2	1	5 20)	Favours PGE2	



Analysis 19.2. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 2 Caesarean section.



Analysis 19.3. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 3 Serious perinatal morbidity/perinatal death.

Study or subgroup	Laminaria	Laminaria PGE2			Ri	sk Ra	tio			Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI								M-H, Fixed, 95% CI
Bagratee 1990	0/40	0/40									Not estimable
Total (95% CI)	40	40									Not estimable
Total events: 0 (Laminaria), 0 (PGE2)											
Heterogeneity: Not applicable											
Test for overall effect: Not applicable				1							
	F	avours laminaria	0.1	0.2	0.5	1	2	5	10	Favours PGE2	

Analysis 19.4. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 4 Serious maternal morbidity or death.


Study or subgroup	Laminaria	PGE2		Risk Ratio			Weight	Risk Ratio			
	n/N	n/N	n/N N			ixed, 9	95% CI				M-H, Fixed, 95% CI
Hay 1995	0/15	0/13									Not estimable
Total (95% CI)	15	13									Not estimable
Total events: 0 (Laminaria), 0 (PGE2)											
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
	F	avours laminaria	0.1	0.2	0.5	1	2	5	10	Favours PGE2	




Analysis 19.5. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 5 Uterine hyperstimulation without fetal heart rate changes.

Study or subgroup	Laminaria	PGE2			Risl	k Ratio			Weight	Risk Ratio M-H, Fixed, 95% CI
	n/N	n/N			M-H, Fix	ed, 95% CI				
Bagratee 1990	5/40	24/40	$\overline{+}$	1	_				94.12%	0.21[0.09,0.49]
Jeeva 1982	0/10	0/10				İ				Not estimable
Johnson 1985	0/40	1/40	+	+				_	5.88%	0.33[0.01,7.95]
Total (95% CI)	90	90	-	~	_				100%	0.22[0.09,0.49]
Total events: 5 (Laminaria), 25 (P	PGE2)					İ				
Heterogeneity: Tau ² =0; Chi ² =0.08	3, df=1(P=0.78); I ² =0%					İ				
Test for overall effect: Z=3.64(P=0	0)									
	F	avours laminaria	0.1	0.2	0.5	1 2	5	10	Favours PGE2	

Analysis 19.6. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia.




Analysis 19.7. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 7 Instrumental vaginal delivery.



Analysis 19.8. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 8 Meconium-stained liquor.

Study or subgroup	Laminaria	PGE2	Risk Ratio						Weight	Risk Ratio	
	n/N	n/N	M-H, Fixed, 95% CI							M-H, Fixed, 95% CI	
Johnson 1985	0/40	3/40	+	_						100%	0.14[0.01,2.68]
		Favours laminaria	0.1	0.2	0.5	1	2	5	10	Favours PGE2	






Analysis 19.9. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 9 Apgar score < 7 at 5 minutes.

Study or subgroup	Laminaria	PGE2			Ri	sk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Bagratee 1990	0/40	0/40									Not estimable
Johnson 1985	0/40	0/40									Not estimable
Total (95% CI)	80	80									Not estimable
Total events: 0 (Laminaria), 0 (PGE2)											
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
		Favours laminaria	0.1	0.2	0.5	1	2	5	10	Favours PGE2	

Analysis 19.10. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 10 Perinatal death.

Study or subgroup	Laminaria	PGE2		Risk Ratio				Weight	Risk Ratio		
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Bagratee 1990	0/40	0/40									Not estimable
Total (95% CI)	40	40									Not estimable
Total events: 0 (Laminaria), 0 (PGE2)											
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
		Favours laminaria	0.1	0.2	0.5	1	2	5	10	Favours PGE2	


Analysis 19.11. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 11 Maternal side effects: all.






Study or subgroup	Laminaria n/N	PGE2 n/N		Risk Ratio M-H, Fixed, 95% CI						Weight	Risk Ratio M-H, Fixed, 95% CI
Test for overall effect: Z=0.77(P=0.44)				1	1						
		Favours laminaria	0.1	0.2	0.5	1	2	5	10	Favours PGE2	

Analysis 19.12. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 12 Maternal nausea.



Analysis 19.13. Comparison 19 Laminaria tent versus vaginal prostaglandin E2: all women, Outcome 13 Fetal distress.




Comparison 20. Laminaria tent versus vaginal prostaglandin E2: all primiparae


Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Uterine hyperstimulation with FHR changes	1	80	Risk Ratio (M-H, Fixed, 95% CI)	0.33 [0.01, 7.95]
2 Caesarean section	2	90	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.24, 4.89]



Analysis 20.1. Comparison 20 Laminaria tent versus vaginal prostaglandin E2: all primiparae, Outcome 1 Uterine hyperstimulation with FHR changes.




Analysis 20.2. Comparison 20 Laminaria tent versus vaginal prostaglandin E2: all primiparae, Outcome 2 Caesarean section.



Comparison 21. Laminaria tent versus vaginal prostaglandin E2: all multiparae

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Caesarean section	1	10	Risk Ratio (M-H, Fixed, 95% CI)	0.5 [0.06, 3.91]

Analysis 21.1. Comparison 21 Laminaria tent versus vaginal prostaglandin E2: all multiparae, Outcome 1 Caesarean section.





Comparison 22. Laminaria tent versus intracervical prostaglandin E2: all women


Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Uterine hyperstimulation with FHR changes	2	350	Risk Ratio (M-H, Fixed, 95% CI)	0.17 [0.02, 1.42]
2 Caesarean section	5	920	Risk Ratio (M-H, Fixed, 95% CI)	1.16 [0.93, 1.45]
3 Serious neonatal morbidity/perinatal death	1	185	Risk Ratio (M-H, Fixed, 95% CI)	3.16 [0.13, 76.70]
4 Serious maternal morbidity or death	1	185	Risk Ratio (M-H, Fixed, 95% CI)	0.35 [0.01, 8.52]
5 Cervix unfavourable/unchanged after 12-24 hours	2	218	Risk Ratio (M-H, Random, 95% CI)	0.46 [0.11, 1.96]
6 Oxytocin augmentation	1	185	Risk Ratio (M-H, Fixed, 95% CI)	1.41 [1.21, 1.64]
7 Uterine hyperstimulation without FHR changes	2	601	Risk Ratio (M-H, Fixed, 95% CI)	0.17 [0.02, 1.36]
8 Uterine rupture	1	185	Risk Ratio (M-H, Fixed, 95% CI)	0.35 [0.01, 8.52]
9 Instrumental vaginal delivery	3	424	Risk Ratio (M-H, Fixed, 95% CI)	1.05 [0.65, 1.69]
10 Apgar score < 7 at 5 minutes	1	185	Risk Ratio (M-H, Fixed, 95% CI)	5.28 [0.63, 44.30]
11 Neonatal intensive care unit admission	2	259	Risk Ratio (M-H, Fixed, 95% CI)	1.58 [0.58, 4.33]
12 Perinatal death	1	185	Risk Ratio (M-H, Fixed, 95% CI)	3.16 [0.13, 76.70]
13 Maternal side effects	1	165	Risk Ratio (M-H, Fixed, 95% CI)	0.20 [0.01, 4.15]
14 Postpartum haemorrhage	2	239	Risk Ratio (M-H, Fixed, 95% CI)	1.14 [0.46, 2.81]
15 Chorioamnionitis	1	74	Risk Ratio (M-H, Fixed, 95% CI)	3.17 [0.35, 29.06]
16 Endometritis	2	490	Risk Ratio (M-H, Random, 95% CI)	0.30 [0.08, 1.09]
17 Fetal distress	2	128	Risk Ratio (M-H, Fixed, 95% CI)	0.44 [0.07, 2.90]




Analysis 22.1. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 1 Uterine hyperstimulation with FHR changes.

Study or subgroup	Laminaria	PGE2			Ri	sk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	95% CI				M-H, Fixed, 95% CI
Chua 1997	0/90	3/95	+							57.82%	0.15[0.01,2.88]
Roztocil 1998	0/82	2/83	+	-				_		42.18%	0.2[0.01,4.15]
Total (95% CI)	172	178								100%	0.17[0.02,1.42]
Total events: 0 (Laminaria), 5 (PGE2)											
Heterogeneity: Tau ² =0; Chi ² =0.02, df=	=1(P=0.89); I ² =0%										
Test for overall effect: Z=1.63(P=0.1)											
		Favours laminaria	0.1	0.2	0.5	1	2	5	10	Favours PGE2	

Analysis 22.2. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 2 Caesarean section.




Analysis 22.3. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 3 Serious neonatal morbidity/perinatal death.







Analysis 22.4. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 4 Serious maternal morbidity or death.



Analysis 22.5. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 5 Cervix unfavourable/unchanged after 12-24 hours.




Analysis 22.6. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 6 Oxytocin augmentation.




Analysis 22.7. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 7 Uterine hyperstimulation without FHR changes.

Study or subgroup	Laminaria	PGE2	Risk Ratio							Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Chua 1997	0/90	2/95	+	-						40.33%	0.21[0.01,4.34]
Krammer 1995a	0/214	3/202	-	-						59.67%	0.13[0.01,2.6]
		Favours laminaria	0.1	0.2	0.5	1	2	5	10	Favours PGE2	






Analysis 22.8. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 8 Uterine rupture.




Analysis 22.9. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 9 Instrumental vaginal delivery.




Analysis 22.10. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 10 Apgar score < 7 at 5 minutes.

Study or subgroup	Laminaria	PGE2	Risk Ratio						Weight	Risk Ratio	
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Chua 1997	5/90	1/95			-			+	→	100%	5.28[0.63,44.3]
Total (95% CI)	90	95			-					100%	5.28[0.63,44.3]
Total events: 5 (Laminaria), 1 (PGE2)											
		Favours laminaria	0.1	0.2	0.5	1	2	5	10	Favours PGE2	







Analysis 22.11. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 11 Neonatal intensive care unit admission.



Analysis 22.12. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 12 Perinatal death.



Analysis 22.13. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 13 Maternal side effects.







Analysis 22.14. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 14 Postpartum haemorrhage.

Study or subgroup	Laminaria	PGE2		Risk Ratio				Weight	Risk Ratio		
	n/N	n/N			M-H, F	ixed, 9	5% CI				M-H, Fixed, 95% CI
Roztocil 1998	9/82	8/83				-				100%	1.14[0.46,2.81]
Sanchez-Ramos 1992	0/36	0/38									Not estimable
Total (95% CI)	118	121			-		—			100%	1.14[0.46,2.81]
Total events: 9 (Laminaria), 8 (PGE2)											
Heterogeneity: Not applicable											
Test for overall effect: Z=0.28(P=0.78)											
	Fi	avours laminaria	0.1	0.2	0.5	1	2	5	10	Favours PGE2	

Analysis 22.15. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 15 Chorioamnionitis.



Analysis 22.16. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 16 Endometritis.






Analysis 22.17. Comparison 22 Laminaria tent versus intracervical prostaglandin E2: all women, Outcome 17 Fetal distress.

Study or subgroup	Laminaria	PGE2		Ri	sk Ra	tio			Weight	Risk Ratio
	n/N	n/N		M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Glagoleva 1999	0/27	1/27	+	-	_			_	43.53%	0.33[0.01,7.84]
Sanchez-Ramos 1992	1/36	2/38	+	•			_		56.47%	0.53[0.05,5.57]
Total (95% CI)	63	65							100%	0.44[0.07,2.9]
Total events: 1 (Laminaria), 3 (PGE2)										
Heterogeneity: Tau ² =0; Chi ² =0.05, df=	1(P=0.82); I ² =0%									
Test for overall effect: Z=0.85(P=0.4)										
		Favours laminaria	0.1	0.2 0.5	1	2	5	10	Favours PGE2	

Comparison 23. Laminaria tent versus intracervical prostaglandin E2: all primiparae

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Caesarean section	1	116	Risk Ratio (M-H, Fixed, 95% CI)	1.15 [0.62, 2.13]

Analysis 23.1. Comparison 23 Laminaria tent versus intracervical prostaglandin E2: all primiparae, Outcome 1 Caesarean section.



Comparison 24. Laminaria tent versus intracervical: prostaglandin E2 all multiparae

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Caesarean section	1	69	Risk Ratio (M-H, Fixed, 95% CI)	1.28 [0.45, 3.65]



Analysis 24.1. Comparison 24 Laminaria tent versus intracervical: prostaglandin E2 all multiparae, Outcome 1 Caesarean section.

Study or subgroup	Laminaria	PGE2			Ri	sk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	95% CI				M-H, Fixed, 95% CI
Chua 1997	7/36	5/33			_	+		_		100%	1.28[0.45,3.65]
Total (95% CI)	36	33						_		100%	1.28[0.45,3.65]
Total events: 7 (Laminaria), 5 (PGE2)											
Heterogeneity: Not applicable											
Test for overall effect: Z=0.47(P=0.64)											
		Favours laminaria	0.1	0.2	0.5	1	2	5	10	Favours PGE2	

Comparison 25. Laminaria tent versus oxytocin: all women

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Caesarean section	2	73	Risk Ratio (M-H, Fixed, 95% CI)	0.83 [0.36, 1.89]
2 Fetal distress	1	53	Risk Ratio (M-H, Fixed, 95% CI)	2.69 [0.11, 63.18]

Analysis 25.1. Comparison 25 Laminaria tent versus oxytocin: all women, Outcome 1 Caesarean section.

Study or subgroup	Laminaria	Oxytocin			Ris	sk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	95% CI				M-H, Fixed, 95% CI
Jagani 1982	3/10	3/10		-		-		_		32.12%	1[0.26,3.81]
Roberts 1986	5/28	6/25		_		+				67.88%	0.74[0.26,2.14]
Total (95% CI)	38	35					_			100%	0.83[0.36,1.89]
Total events: 8 (Laminaria), 9 (Oxy	ytocin)										
Heterogeneity: Tau ² =0; Chi ² =0.12,	, df=1(P=0.73); I ² =0%										
Test for overall effect: Z=0.45(P=0	.65)										
		Favours laminaria	0.1	0.2	0.5	1	2	5	10	Favours oxytocin	

Analysis 25.2. Comparison 25 Laminaria tent versus oxytocin: all women, Outcome 2 Fetal distress.

Study or subgroup	Laminaria	Oxytocin		Risk Ratio			Weight	Risk Ratio			
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Roberts 1986	1/28	0/25	_				+		→	100%	2.69[0.11,63.18]
Total (95% CI)	28	25	_							100%	2.69[0.11,63.18]
Total events: 1 (Laminaria), 0 (Oxytocin)										
Heterogeneity: Not applicable											
Test for overall effect: Z=0.61(P=0.54)											
		Favours laminaria	0.1	0.2	0.5	1	2	5	10	Favours oxytocin	



Comparison 26. Laminaria tent versus amniotomy: all women

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Caesarean section	1	20	Risk Ratio (M-H, Fixed, 95% CI)	0.75 [0.22, 2.52]


Analysis 26.1. Comparison 26 Laminaria tent versus amniotomy: all women, Outcome 1 Caesarean section.

Study or subgroup	Laminaria	Oxytocin			Ris	sk Ra	tio			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Jagani 1982	3/10	4/10								100%	0.75[0.22,2.52]
Total (95% CI)	10	10								100%	0.75[0.22,2.52]
Total events: 3 (Laminaria), 4 (Oxytocin)										
Heterogeneity: Not applicable											
Test for overall effect: Z=0.46(P=0.64)											
		Favours laminaria	0.1	0.2	0.5	1	2	5	10	Favours oxytocin	

Comparison 27. Laminaria tent versus other hygroscopic dilator: all women

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Caesarean section	1	41	Risk Ratio (M-H, Fixed, 95% CI)	1.70 [0.44, 6.66]

Analysis 27.1. Comparison 27 Laminaria tent versus other hygroscopic dilator: all women, Outcome 1 Caesarean section.





Comparison 28. EASI versus vaginal prostaglandin E2: all women

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	1	109	Risk Ratio (M-H, Fixed, 95% CI)	1.74 [1.21, 2.49]
2 Uterine hyperstimulation with FHR changes	2	221	Risk Ratio (M-H, Fixed, 95% CI)	0.23 [0.03, 2.07]
3 Caesarean section	2	221	Risk Ratio (M-H, Fixed, 95% CI)	1.35 [0.94, 1.96]
4 Oxytocin augmentation	1	109	Risk Ratio (M-H, Fixed, 95% CI)	12.71 [3.20, 50.57]
5 Uterine hyperstimula- tion without fetal heart rate changes	2	221	Risk Ratio (M-H, Fixed, 95% CI)	0.23 [0.03, 2.07]
6 Epidural analgesia	1	112	Risk Ratio (M-H, Fixed, 95% CI)	1.0 [0.97, 1.04]
7 Instrumental vaginal delivery	1	109	Risk Ratio (M-H, Fixed, 95% CI)	0.58 [0.30, 1.14]
8 Meconium-stained liquor	1	112	Risk Ratio (M-H, Fixed, 95% CI)	3.0 [0.12, 72.10]
9 Apgar score < 7 at 5 minutes	1	109	Risk Ratio (M-H, Fixed, 95% CI)	4.25 [0.21, 86.51]
10 Neonatal intensive care unit admission	1	112	Risk Ratio (M-H, Fixed, 95% CI)	1.5 [0.45, 5.03]
11 Woman not satisfied	1	109	Risk Ratio (M-H, Fixed, 95% CI)	0.56 [0.10, 3.25]
12 Fetal distress	1	112	Risk Ratio (M-H, Fixed, 95% CI)	1.2 [0.39, 3.71]

Analysis 28.1. Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.


Study or subgroup	EASI	PGE2			Ri	sk Ra	itio			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Lyndrup 1994	43/59	21/50				-	-			100%	1.74[1.21,2.49]
Total (95% CI)	59	50					•			100%	1.74[1.21,2.49]
Total events: 43 (EASI), 21 (PGE2)											
Heterogeneity: Not applicable											
Test for overall effect: Z=2.99(P=0)											
		Favours EASI	0.1	0.2	0.5	1	2	5	10	Favours PGE2	



Analysis 28.2. Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 2 Uterine hyperstimulation with FHR changes.

Study or subgroup	EASI	PGE2			Ri	sk Rat	tio			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Lyndrup 1994	0/59	1/50	$\overline{+}$	-					-	39.34%	0.28[0.01,6.8]
Rouben 1993	0/56	2/56	+	1				_		60.66%	0.2[0.01,4.07]
Total (95% CI)	115	106								100%	0.23[0.03,2.07]
Total events: 0 (EASI), 3 (PGE2)						ĺ					
Heterogeneity: Tau ² =0; Chi ² =0.02	, df=1(P=0.88); I ² =0%					İ					
Test for overall effect: Z=1.31(P=0	.19)										
		Favours EASI	0.1	0.2	0.5	1	2	5	10	Favours PGE2	

Analysis 28.3. Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 3 Caesarean section.




Analysis 28.4. Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 4 Oxytocin augmentation.

Study or subgroup	EASI	PGE2			Ri	sk Ra	tio			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Lyndrup 1994	30/59	2/50							→	100%	12.71[3.2,50.57]
Total (95% CI)	59	50								100%	12.71[3.2,50.57]
Total events: 30 (EASI), 2 (PGE2)											
Heterogeneity: Not applicable											
Test for overall effect: Z=3.61(P=0)											
		Favours EASI	0.1	0.2	0.5	1	2	5	10	Favours PGE2	


Analysis 28.5. Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 5 Uterine hyperstimulation without fetal heart rate changes.

Study or subgroup	EASI	PGE2			Ri	sk Ra	tio			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Lyndrup 1994	0/59	1/50	+	-	-				-	39.34%	0.28[0.01,6.8]
Rouben 1993	0/56	2/56	•	1		+		_		60.66%	0.2[0.01,4.07]
		Favours EASI	0.1	0.2	0.5	1	2	5	10	Favours PGE2	







Analysis 28.6. Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 6 Epidural analgesia.



Analysis 28.7. Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 7 Instrumental vaginal delivery.




Analysis 28.8. Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 8 Meconium-stained liquor.







Analysis 28.9. Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 9 Apgar score < 7 at 5 minutes.



Analysis 28.10. Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 10 Neonatal intensive care unit admission.




Analysis 28.11. Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 11 Woman not satisfied.



Analysis 28.12. Comparison 28 EASI versus vaginal prostaglandin E2: all women, Outcome 12 Fetal distress.

Study or subgroup	EASI	PGE2	E2			sk Ra	tio			Weight	Risk Ratio
	n/N	n/N			М-Н, F	ixed,	95% CI				M-H, Fixed, 95% CI
Rouben 1993	6/56	5/56				+		-		100%	1.2[0.39,3.71]
Total (95% CI)	56	56						-		100%	1.2[0.39,3.71]
Total events: 6 (EASI), 5 (PGE2)									1		
		Favours EASI	0.1	0.2	0.5	1	2	5	10	Favours PGE2	






Comparison 29. EASI versus intracervical prostaglandin E2: all women

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Caesarean section	2	155	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.10, 5.12]
2 Cervix unfavourable/unchanged after 12-24 hours	1	85	Risk Ratio (M-H, Fixed, 95% CI)	0.06 [0.00, 0.97]
3 Oxytocin augmentation	1	70	Risk Ratio (M-H, Fixed, 95% CI)	1.1 [0.54, 2.25]
4 Instrumental vaginal delivery	1	85	Risk Ratio (M-H, Fixed, 95% CI)	0.33 [0.04, 3.01]
5 Apgar score < 7 at 5 minutes	1	85	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
6 Endometritis	1	85	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7 Fetal distress	1	70	Risk Ratio (M-H, Fixed, 95% CI)	0.29 [0.06, 1.28]


Analysis 29.1. Comparison 29 EASI versus intracervical prostaglandin E2: all women, Outcome 1 Caesarean section.




Analysis 29.2. Comparison 29 EASI versus intracervical prostaglandin E2: all women, Outcome 2 Cervix unfavourable/unchanged after 12-24 hours.

Study or subgroup	EASI	PGE2		Risk Ratio						Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Hemlin 1998	0/43	8/42	+							100%	0.06[0,0.97]
		Favours EASI	0.1	0.2	0.5	1	2	5	10	Favours PGE2	






Analysis 29.3. Comparison 29 EASI versus intracervical prostaglandin E2: all women, Outcome 3 Oxytocin augmentation.



Analysis 29.4. Comparison 29 EASI versus intracervical prostaglandin E2: all women, Outcome 4 Instrumental vaginal delivery.



Analysis 29.5. Comparison 29 EASI versus intracervical prostaglandin E2: all women, Outcome 5 Apgar score < 7 at 5 minutes.


Study or subgroup	EASI	PGE2			Ri	sk Rat	tio			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Hemlin 1998	0/43	0/42									Not estimable
Total (95% CI)	43	42									Not estimable
Total events: 0 (EASI), 0 (PGE2)											
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
		Favours EASI	0.1	0.2	0.5	1	2	5	10	Favours PGE2	



Analysis 29.6. Comparison 29 EASI versus intracervical prostaglandin E2: all women, Outcome 6 Endometritis.

Study or subgroup	EASI	PGE2			Ri	sk Rat	tio			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Hemlin 1998	0/43	0/42									Not estimable
Total (95% CI)	43	42									Not estimable
Total events: 0 (EASI), 0 (PGE2)						İ					
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
		Favours EASI	0.1	0.2	0.5	1	2	5	10	Favours PGE2	


Analysis 29.7. Comparison 29 EASI versus intracervical prostaglandin E2: all women, Outcome 7 Fetal distress.



Comparison 30. EASI versus intracervical prostaglandin E2: all primiparae

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Caesarean section	1	70	Risk Ratio (M-H, Fixed, 95% CI)	0.25 [0.06, 1.09]

Analysis 30.1. Comparison 30 EASI versus intracervical prostaglandin E2: all primiparae, Outcome 1 Caesarean section.






Comparison 31. Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	1	39	Risk Ratio (M-H, Fixed, 95% CI)	0.84 [0.53, 1.33]
2 Uterine hyperstimulation with FHR changes	2	122	Risk Ratio (M-H, Fixed, 95% CI)	0.26 [0.01, 5.12]
3 Caesarean section	7	517	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.66, 1.40]
4 Cervix unfavourable/unchanged after 24 hours	1	122	Risk Ratio (M-H, Fixed, 95% CI)	0.52 [0.31, 0.85]
5 Oxytocin augmentation	1	44	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.64, 1.41]
6 Uterine hyperstimulation without FHR changes	3	239	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7 Epidural analgesia	1	39	Risk Ratio (M-H, Fixed, 95% CI)	0.98 [0.77, 1.24]
8 Instrumental vaginal delivery	2	78	Risk Ratio (M-H, Fixed, 95% CI)	0.56 [0.22, 1.45]
9 Meconium-stained liquor	1	120	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.33, 2.83]
10 Neonatal intensive care unit admission	1	44	Risk Ratio (M-H, Fixed, 95% CI)	0.26 [0.01, 5.12]
11 Postpartum haemorrhage	1	39	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
12 Chorioamnionitis	2	122	Risk Ratio (M-H, Fixed, 95% CI)	1.56 [0.45, 5.45]
13 Endometritis	3	237	Risk Ratio (M-H, Fixed, 95% CI)	1.07 [0.41, 2.78]
14 Fetal distress	2	140	Risk Ratio (M-H, Fixed, 95% CI)	2.28 [0.54, 9.69]


Analysis 31.1. Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.

Study or subgroup	Mechani- cal method	PGE2	Risk Ratio							We	ight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	95% CI					M-H, Fixed, 95% CI
Hibbard 1998	13/22	12/17				+			1		100%	0.84[0.53,1.33]
	Favours mech	anical method	0.1	0.2	0.5	1	2	5	10	PGE2		






Analysis 31.2. Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 2 Uterine hyperstimulation with FHR changes.



Analysis 31.3. Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 3 Caesarean section.






Analysis 31.4. Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 4 Cervix unfavourable/unchanged after 24 hours.

Study or subgroup	Mechani- cal method				Ri	sk Rat	tio		Weight			Ris	k Ratio
	n/N	n/N			M-H, F	ixed,	95% CI					M-H, Fi	xed, 95% CI
Allouche 1993	16/63	29/59			-	-					100%		0.52[0.31,0.85]
Total (95% CI)	63	59			•	-					100%	0	.52[0.31,0.85]
Total events: 16 (Mechanical metho	od), 29 (PGE2)												
Heterogeneity: Not applicable													
Test for overall effect: Z=2.61(P=0.0	1)			1	ı								
	Favours med	chanical method	0.1	0.2	0.5	1	2	5	10	PGE2			

Analysis 31.5. Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 5 Oxytocin augmentation.




Analysis 31.6. Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 6 Uterine hyperstimulation without FHR changes.


Study or subgroup	Mechani- cal method	PGE2	Risk Ratio							Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Allouche 1993	0/63	0/59									Not estimable
Hibbard 1998	0/22	0/17									Not estimable
Sullivan 1996	0/37	0/41									Not estimable
Total (95% CI)	122	117									Not estimable
Total events: 0 (Mechanical method), 0	(PGE2)										
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
	Favours med	thanical method	0.1	0.2	0.5	1	2	5	10	PGE2	




Analysis 31.7. Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 7 Epidural analgesia.



Analysis 31.8. Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 8 Instrumental vaginal delivery.




Analysis 31.9. Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 9 Meconium-stained liquor.







Analysis 31.10. Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 10 Neonatal intensive care unit admission.



Analysis 31.11. Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 11 Postpartum haemorrhage.




Analysis 31.12. Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 12 Chorioamnionitis.






Analysis 31.13. Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 13 Endometritis.



Analysis 31.14. Comparison 31 Any mechanical method and prostaglandin E2 versus prostaglandin E2 alone: all women, Outcome 14 Fetal distress.




Comparison 32. Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	1	127	Risk Ratio (M-H, Fixed, 95% CI)	0.32 [0.12, 0.82]
2 Caesarean section	1	127	Risk Ratio (M-H, Fixed, 95% CI)	1.09 [0.58, 2.04]
3 Serious neonatal morbidi- ty/perinatal death	1	127	Risk Ratio (M-H, Fixed, 95% CI)	0.19 [0.01, 3.90]
4 Cervix unfavourable/un- changed after 12-24 hours	1	127	Risk Ratio (M-H, Fixed, 95% CI)	0.41 [0.25, 0.67]
5 Oxytocin augmentation	1	127	Risk Ratio (M-H, Fixed, 95% CI)	1.21 [1.01, 1.46]
6 Uterine hyperstimulation without FHR changes	1	127	Risk Ratio (M-H, Fixed, 95% CI)	4.05 [1.44, 11.38]




Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
7 Instrumental vaginal delivery	1	127	Risk Ratio (M-H, Fixed, 95% CI)	1.26 [0.77, 2.04]
8 Meconium-stained liquor	1	127	Risk Ratio (M-H, Fixed, 95% CI)	0.56 [0.23, 1.32]
9 Apgar score < 7 at 5 minutes	1	127	Risk Ratio (M-H, Fixed, 95% CI)	1.91 [0.18, 20.51]
10 Neonatal intensive care unit admission	1	127	Risk Ratio (M-H, Fixed, 95% CI)	0.64 [0.31, 1.31]
11 Perinatal death	1	127	Risk Ratio (M-H, Fixed, 95% CI)	0.19 [0.01, 3.90]
12 Chorioamnionitis	1	127	Risk Ratio (M-H, Fixed, 95% CI)	1.91 [0.18, 20.51]
13 Endometritis	1	127	Risk Ratio (M-H, Fixed, 95% CI)	1.91 [0.36, 10.05]

Analysis 32.1. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.




Analysis 32.2. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 2 Caesarean section.







Analysis 32.3. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 3 Serious neonatal morbidity/perinatal death.



Analysis 32.4. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 4 Cervix unfavourable/unchanged after 12-24 hours.



Analysis 32.5. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 5 Oxytocin augmentation.







Analysis 32.6. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 6 Uterine hyperstimulation without FHR changes.

Study or subgroup	Mechani- cal method				Ri	sk Ra	tio		Weight	Risk Ratio	
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Perry 1998	17/65	4/62						1	→	100%	4.05[1.44,11.38]
Total (95% CI)	65	62							_	100%	4.05[1.44,11.38]
Total events: 17 (Mechanical method)), 4 (misoprostol)										
Heterogeneity: Not applicable											
Test for overall effect: Z=2.66(P=0.01)											
	Favours m	echanical method	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	

Analysis 32.7. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 7 Instrumental vaginal delivery.




Analysis 32.8. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 8 Meconium-stained liquor.







Analysis 32.9. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 9 Apgar score < 7 at 5 minutes.



Analysis 32.10. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 10 Neonatal intensive care unit admission.




Analysis 32.11. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 11 Perinatal death.






Analysis 32.12. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 12 Chorioamnionitis.




Analysis 32.13. Comparison 32 Any mechanical method and prostaglandin E2 versus low dose misoprostol alone: all women, Outcome 13 Endometritis.




Comparison 33. Any mechanical method and prostaglandin E2 versus oxytocin alone: all women

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Caesarean section	1	44	Risk Ratio (M-H, Fixed, 95% CI)	0.3 [0.04, 2.47]
2 Instrumental vaginal delivery	1	44	Risk Ratio (M-H, Fixed, 95% CI)	0.6 [0.12, 2.94]
3 Endometritis	1	44	Risk Ratio (M-H, Fixed, 95% CI)	3.57 [0.15, 83.14]


Analysis 33.1. Comparison 33 Any mechanical method and prostaglandin E2 versus oxytocin alone: all women, Outcome 1 Caesarean section.








Analysis 33.2. Comparison 33 Any mechanical method and prostaglandin E2 versus oxytocin alone: all women, Outcome 2 Instrumental vaginal delivery.



Analysis 33.3. Comparison 33 Any mechanical method and prostaglandin E2 versus oxytocin alone: all women, Outcome 3 Endometritis.



Comparison 34. Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	1	350	Risk Ratio (M-H, Fixed, 95% CI)	1.14 [0.89, 1.46]
2 Uterine hyperstimulation with FHR changes	1	327	Risk Ratio (M-H, Fixed, 95% CI)	0.75 [0.27, 2.13]



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
3 Caesarean section	1	350	Risk Ratio (M-H, Fixed, 95% CI)	0.85 [0.57, 1.25]
4 Serious neonatal morbidity/perinatal death	1	345	Risk Ratio (M-H, Fixed, 95% CI)	2.04 [0.19, 22.24]
5 Serious maternal morbidity or death	1	350	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
6 Oxytocin augmentation	1	350	Risk Ratio (M-H, Fixed, 95% CI)	0.54 [0.34, 0.86]
7 Uterine hyperstimulation without fetal heart rate changes	1	327	Risk Ratio (M-H, Fixed, 95% CI)	0.54 [0.22, 1.32]
8 Uterine rupture	1	350	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
9 Instrumental vaginal delivery	1	350	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.26, 3.98]
10 Meconium-stained liquor	1	339	Risk Ratio (M-H, Fixed, 95% CI)	1.15 [0.60, 2.23]
11 Apgar score < 7 at 5 minutes	1	346	Risk Ratio (M-H, Fixed, 95% CI)	0.68 [0.25, 1.88]
12 Neonatal intensive care unit admission	1	346	Risk Ratio (M-H, Fixed, 95% CI)	0.68 [0.12, 4.03]
13 Perinatal death	1	345	Risk Ratio (M-H, Fixed, 95% CI)	1.02 [0.06, 16.14]
14 Maternal side effects	1	314	Risk Ratio (M-H, Fixed, 95% CI)	1.16 [0.95, 1.43]
15 Maternal nausea	1	300	Risk Ratio (M-H, Fixed, 95% CI)	1.65 [0.98, 2.79]
16 Maternal diarrhoea	1	313	Risk Ratio (M-H, Fixed, 95% CI)	3.72 [1.53, 9.00]
17 Postpartum haemorrhage	1	348	Risk Ratio (M-H, Fixed, 95% CI)	0.98 [0.67, 1.41]
18 Serious maternal complications	1	350	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
19 Maternal fever during labour	1	347	Risk Ratio (M-H, Fixed, 95% CI)	1.53 [0.26, 9.02]


Analysis 34.1. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.

Study or subgroup	Mechani- cal method	PGE2		Risk Ratio					We	eight	Risk Ratio	
	n/N	n/N			M-H, Fi	ixed, 9	5% CI					M-H, Fixed, 95% CI
Matonhodze 2003	79/174	70/176				1					100%	1.14[0.89,1.46]
Total (95% CI)	174	176				•					100%	1.14[0.89,1.46]
Total events: 79 (Mechanical meth	nod), 70 (PGE2)											
Heterogeneity: Not applicable												
	Favours med	hanical method	0.1	0.2	0.5	1	2	5	10	PGE2		




Study or subgroup	Mechani- cal method	PGE2		Risk Ratio						Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Test for overall effect: Z=1.06(P=0.29)											
	Favours me	echanical method	0.1	0.2	0.5	1	2	5	10	PGE2	


Analysis 34.2. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 2 Uterine hyperstimulation with FHR changes.



Analysis 34.3. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 3 Caesarean section.



Analysis 34.4. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 4 Serious neonatal morbidity/perinatal death.







Analysis 34.5. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 5 Serious maternal morbidity or death.

Study or subgroup	Mechani- cal method	PGE2		Risk Ratio				Weight	Ris	k Ratio		
	n/N	n/N			M-H, F	ixed, 9	95% CI				M-H, Fi	xed, 95% CI
Matonhodze 2003	0/174	0/176										Not estimable
Total (95% CI)	174	176										Not estimable
Total events: 0 (Mechanical method),	0 (PGE2)											
Heterogeneity: Not applicable												
Test for overall effect: Not applicable												
	Favours med	hanical method	0.1	0.2	0.5	1	2	5	10	PGF2		

Analysis 34.6. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 6 Oxytocin augmentation.



Analysis 34.7. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 7 Uterine hyperstimulation without fetal heart rate changes.







Analysis 34.8. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 8 Uterine rupture.

Study or subgroup	Mechani- cal method	PGE2		Risk Ratio				Weight	ı	Risk Ratio		
	n/N	n/N			M-H, Fi	xed, 9	95% CI				М-Н,	Fixed, 95% CI
Matonhodze 2003	0/174	0/176										Not estimable
Total (95% CI)	174	176										Not estimable
Total events: 0 (Mechanical method), 0 (PGE2)											
Heterogeneity: Not applicable												
Test for overall effect: Not applicabl	e											
	Favours med	hanical method	0.1	0.2	0.5	1	2	5	10	PGE2		

Analysis 34.9. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 9 Instrumental vaginal delivery.




Analysis 34.10. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 10 Meconium-stained liquor.







Analysis 34.11. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 11 Apgar score < 7 at 5 minutes.



Analysis 34.12. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 12 Neonatal intensive care unit admission.




Analysis 34.13. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 13 Perinatal death.







Analysis 34.14. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 14 Maternal side effects.



Analysis 34.15. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 15 Maternal nausea.




Analysis 34.16. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 16 Maternal diarrhoea.







Analysis 34.17. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 17 Postpartum haemorrhage.



Analysis 34.18. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 18 Serious maternal complications.



Analysis 34.19. Comparison 34 Any mechanical method and low dose misoprostol versus prostaglandin E2 alone: all women, Outcome 19 Maternal fever during labour.






Comparison 35. Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	2	668	Risk Ratio (M-H, Random, 95% CI)	0.70 [0.25, 1.95]
2 Uterine hyperstimulation with FHR changes	4	707	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.20, 1.45]
3 Caesarean section	7	1422	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.66, 1.15]
4 Serious neonatal morbidity/perinatal death	2	487	Risk Ratio (M-H, Fixed, 95% CI)	1.25 [0.34, 4.55]
5 Serious maternal morbidity or death	2	490	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
6 Cervix unfavourable/unchanged after 12 hours	1	140	Risk Ratio (M-H, Fixed, 95% CI)	0.27 [0.08, 0.94]
7 Oxytocin augmentation	5	1051	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.70, 1.25]
8 Uterine hyperstimulation without FHR changes	4	982	Risk Ratio (M-H, Fixed, 95% CI)	0.53 [0.32, 0.90]
9 Uterine rupture	2	490	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
10 Epidural analgesia	3	443	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.91, 1.10]
11 Instrumental vaginal delivery	3	676	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.58, 1.51]
12 Meconium-stained liquor	6	1243	Risk Ratio (M-H, Random, 95% CI)	0.61 [0.35, 1.04]
13 Apgar score < 7 at 5 minutes	3	802	Risk Ratio (M-H, Random, 95% CI)	0.71 [0.37, 1.36]
14 Neonatal intensive care unit admission	6	1246	Risk Ratio (M-H, Fixed, 95% CI)	0.57 [0.36, 0.91]
15 Perinatal death	1	347	Risk Ratio (M-H, Fixed, 95% CI)	3.09 [0.13, 75.26]
16 Maternal side effects	1	300	Risk Ratio (M-H, Fixed, 95% CI)	1.06 [0.87, 1.30]
17 Maternal nausea	1	300	Risk Ratio (M-H, Fixed, 95% CI)	1.37 [0.84, 2.23]
18 Maternal diarrhoea	1	298	Risk Ratio (M-H, Fixed, 95% CI)	3.38 [1.40, 8.17]
19 Postpartum haemorrhage	2	466	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.65, 1.33]
20 Serious maternal complications	1	350	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
21 Chorioamnionitis	3	443	Risk Ratio (M-H, Fixed, 95% CI)	0.63 [0.28, 1.38]



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
22 Endometrits	2	435	Risk Ratio (M-H, Fixed, 95% CI)	0.41 [0.08, 2.08]
23 Fetal distress	4	784	Risk Ratio (M-H, Fixed, 95% CI)	0.78 [0.53, 1.14]

Analysis 35.1. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 1 Vaginal delivery not achieved in 24 hours.




Analysis 35.2. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 2 Uterine hyperstimulation with FHR changes.

Study or subgroup	Mechani- cal method	Misoprostol		Risk Ratio				Weight	Risk Ratio
	n/N	n/N		М-Н, Б	andom, 95%	CI			M-H, Random, 95% CI
Aduloju 2016	0/70	0/70							Not estimable
Carbone 2013	10/56	12/61			-			36.34%	0.91[0.43,1.93]
Lanka 2014	5/63	25/63		-	-			33.56%	0.2[0.08,0.49]
Matonhodze 2003	6/163	7/161		-	-			30.1%	0.85[0.29,2.46]
Total (95% CI)	352	355		•				100%	0.54[0.2,1.45]
Total events: 21 (Mechanical n	nethod), 44 (Misoprostol)								
Heterogeneity: Tau ² =0.57; Chi	² =7.4, df=2(P=0.02); I ² =72.9	3%							
Test for overall effect: Z=1.23(P=0.22)					1			
	Favours m	echanical method	0.01	0.1	1	10	100	Favours misoprostol	


Analysis 35.3. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 3 Caesarean section.

Study or subgroup	Mechani- cal method	Misoprostol		Risk Ratio				Weight	Risk Ratio
	n/N	n/N		М-Н,	Random, 9	5% CI			M-H, Random, 95% CI
Aduloju 2016	15/70	19/70	_		+			11.98%	0.79[0.44,1.42]
	Favours me	chanical method	0.01	0.1	1	10	100	Favours misoprostol	





Analysis 35.4. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 4 Serious neonatal morbidity/perinatal death.




Analysis 35.5. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 5 Serious maternal morbidity or death.


Study or subgroup	Mechani- cal method	Misoprostol		Risk Ratio				Weight	Risk Ratio		
	n/N	n/N			M-H, F	ixed, 9	95% CI				M-H, Fixed, 95% CI
Aduloju 2016	0/70	0/70									Not estimable
Matonhodze 2003	0/174	0/176									Not estimable
Total (95% CI)	244	246									Not estimable
Total events: 0 (Mechanical method),	0 (Misoprostol)										
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
	Favours m	echanical method	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	



Analysis 35.6. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 6 Cervix unfavourable/unchanged after 12 hours.



Analysis 35.7. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 7 Oxytocin augmentation.



Analysis 35.8. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 8 Uterine hyperstimulation without FHR changes.


Study or subgroup	Mechani- cal method	Misoprostol	Risk Ratio	Weight	Risk Ratio	
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI	
Aduloju 2016	0/70	0/70			Not estimable	
Al-Ibraheemi 2018	6/100	12/100		32.24%	0.5[0.2,1.28]	
Husain 2017	7/161	11/157		29.92%	0.62[0.25,1.56]	
Matonhodze 2003	7/163	14/161	-	37.84%	0.49[0.2,1.19]	
Total (95% CI)	494	488	•	100%	0.53[0.32,0.9]	
Total events: 20 (Mechanical r	method), 37 (Misoprostol)					
Heterogeneity: Tau ² =0; Chi ² =0	0.15, df=2(P=0.93); I ² =0%					
Test for overall effect: Z=2.34(P=0.02)					
	Favours m	echanical method 0.	1 0.2 0.5 1 2 5	10 Favours misoprostol		




Analysis 35.9. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 9 Uterine rupture.

Study or subgroup	Mechani- cal method	Misoprostol		Risk Ratio				Weight	Risk Ratio		
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Aduloju 2016	0/70	0/70									Not estimable
Matonhodze 2003	0/174	0/176									Not estimable
Total (95% CI)	244	246									Not estimable
Total events: 0 (Mechanical method), 0	0 (Misoprostol)										
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
	Favours m	echanical method	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	

Analysis 35.10. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 10 Epidural analgesia.




Analysis 35.11. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 11 Instrumental vaginal delivery.






Analysis 35.12. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 12 Meconium-stained liquor.




Analysis 35.13. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 13 Apgar score < 7 at 5 minutes.




Analysis 35.14. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 14 Neonatal intensive care unit admission.

Study or subgroup	Mechani- cal method	Misoprostol		Risk Ratio				Weight	Risk Ratio		
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Aduloju 2016	6/70	5/70				+		_		11.19%	1.2[0.38,3.75]
Al-Ibraheemi 2018	1/100	3/100	+		+					6.71%	0.33[0.04,3.15]
Carbone 2013	0/56	2/61	+	+		_				5.36%	0.22[0.01,4.44]
Husain 2017	11/161	26/157		_	-	-				58.9%	0.41[0.21,0.81]
Lanka 2014	5/63	5/63				+				11.19%	1[0.3,3.29]
Matonhodze 2003	2/171	3/174	_		+			_		6.65%	0.68[0.11,4.01]
Total (95% CI)	621	625			•	-				100%	0.57[0.36,0.91]
Total events: 25 (Mechanical I	method), 44 (Misoprostol)								1_		
	Favours me	echanical method	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	







Analysis 35.15. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 15 Perinatal death.



Analysis 35.16. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 16 Maternal side effects.




Analysis 35.17. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 17 Maternal nausea.






Analysis 35.18. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 18 Maternal diarrhoea.



Analysis 35.19. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 19 Postpartum haemorrhage.




Analysis 35.20. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 20 Serious maternal complications.


Study or subgroup	Mechani- cal method	Misoprostol		Risk Ratio			Weight	Risk Ratio			
	n/N	n/N			M-H, F	ixed, 9	5% CI				M-H, Fixed, 95% CI
Matonhodze 2003	0/174	0/176									Not estimable
Total (95% CI)	174	176									Not estimable
Total events: 0 (Mechanical method),	0 (Misoprostol)										
Heterogeneity: Not applicable											
Test for overall effect: Not applicable					ı						
	Favours me	echanical method	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	




Analysis 35.21. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 21 Chorioamnionitis.



Analysis 35.22. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 22 Endometrits.



Analysis 35.23. Comparison 35 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all women, Outcome 23 Fetal distress.







Comparison 36. Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	1	53	Risk Ratio (M-H, Fixed, 95% CI)	0.83 [0.23, 2.96]
2 Caesarean section	1	53	Risk Ratio (M-H, Fixed, 95% CI)	0.62 [0.15, 2.51]

Analysis 36.1. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.



Analysis 36.2. Comparison 36 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all primiparae, Outcome 2 Caesarean section.



Comparison 37. Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all multiparae

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	1	265	Risk Ratio (M-H, Fixed, 95% CI)	0.37 [0.21, 0.63]




Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
2 Caesarean section	1	265	Risk Ratio (M-H, Fixed, 95% CI)	0.35 [0.18, 0.68]

Analysis 37.1. Comparison 37 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all multiparae, Outcome 1 Vaginal delivery not achieved in 24 hours.

Study or subgroup	Mechani- cal method	Misoprostol		Risk Ratio				Weight	Risk Ratio		
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Husain 2017	15/132	41/133		_	-					100%	0.37[0.21,0.63]
Total (95% CI)	132	133		~	•					100%	0.37[0.21,0.63]
Total events: 15 (Mechanical metho	d), 41 (Misoprostol)										
Heterogeneity: Not applicable											
Test for overall effect: Z=3.62(P=0)											
	Favours me	echanical method	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	-

Analysis 37.2. Comparison 37 Any mechanical method and low dose misoprostol versus low dose misoprostol alone: all multiparae, Outcome 2 Caesarean section.




Comparison 38. Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre-specified)

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Uterine hyperstimulation with FHR changes	1	151	Risk Ratio (M-H, Fixed, 95% CI)	1.48 [0.55, 3.95]
2 Caesarean section	4	713	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.72, 1.20]
3 Serious maternal morbidity or death	1	200	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]




Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
4 Oxytocin augmentation	1	200	Risk Ratio (M-H, Fixed, 95% CI)	2.48 [1.95, 3.15]
5 Uterine hyperstimulation without FHR changes	1	151	Risk Ratio (M-H, Fixed, 95% CI)	2.19 [1.39, 3.46]
6 Instrumental vaginal delivery	1	41	Risk Ratio (M-H, Fixed, 95% CI)	0.35 [0.08, 1.58]
7 Meconium-stained liquor	1	151	Risk Ratio (M-H, Fixed, 95% CI)	1.13 [0.43, 2.95]
8 Apgar score < 7 at 5 minutes	1	151	Risk Ratio (M-H, Fixed, 95% CI)	2.96 [0.12, 71.55]
9 Neonatal intensive care unit admission	1	151	Risk Ratio (M-H, Fixed, 95% CI)	0.85 [0.30, 2.40]
10 Postpartum haemorrhage	1	151	Risk Ratio (M-H, Fixed, 95% CI)	0.14 [0.01, 2.68]
11 Endometritis	1	41	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
12 Fetal distress	3	498	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.61, 1.56]

Analysis 38.1. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre-specified), Outcome 1 Uterine hyperstimulation with FHR changes.







Analysis 38.2. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre-specified), Outcome 2 Caesarean section.



Analysis 38.3. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre-specified), Outcome 3 Serious maternal morbidity or death.



Analysis 38.4. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre-specified), Outcome 4 Oxytocin augmentation.







Analysis 38.5. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre-specified), Outcome 5 Uterine hyperstimulation without FHR changes.

Study or subgroup	Mechani- cal method	PGE2			Ris	sk Ra	tio			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Sharami 2005	40/76	18/75								100%	2.19[1.39,3.46]
Total (95% CI)	76	75					•			100%	2.19[1.39,3.46]
Total events: 40 (Mechanical m	nethod), 18 (PGE2)										
Heterogeneity: Not applicable											
Test for overall effect: Z=3.38(F	P=0)										
	Favours med	hanical method	0.1	0.2	0.5	1	2	5	10	Favours PGE2	

Analysis 38.6. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre-specified), Outcome 6 Instrumental vaginal delivery.




Analysis 38.7. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre-specified), Outcome 7 Meconium-stained liquor.







Analysis 38.8. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre-specified), Outcome 8 Apgar score < 7 at 5 minutes.



Analysis 38.9. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre-specified), Outcome 9 Neonatal intensive care unit admission.



Analysis 38.10. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre-specified), Outcome 10 Postpartum haemorrhage.






Analysis 38.11. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre-specified), Outcome 11 Endometritis.

Study or subgroup	Mechani- cal method	PGE2			Ris	sk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	95% CI				M-H, Fixed, 95% CI
Lyndrup 1989	0/22	0/19									Not estimable
Total (95% CI)	22	19									Not estimable
Total events: 0 (Mechanical metho	d), 0 (PGE2)										
Heterogeneity: Not applicable											
Test for overall effect: Not applicab	ole										
	Favours med	chanical method	0.1	0.2	0.5	1	2	5	10	Favours PGE2	

Analysis 38.12. Comparison 38 Any mechanical method and oxytocin versus prostaglandin E2 alone: all women (not pre-specified), Outcome 12 Fetal distress.



Comparison 39. Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not prespecified)

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	2	362	Risk Ratio (M-H, Fixed, 95% CI)	0.48 [0.37, 0.63]
2 Uterine hyperstimulation with FHR changes	3	1463	Risk Ratio (M-H, Fixed, 95% CI)	0.43 [0.17, 1.11]
3 Caesarean section	5	1779	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.80, 1.12]
4 Serious neonatal morbidity/perinatal death	2	1263	Risk Ratio (M-H, Fixed, 95% CI)	0.82 [0.18, 3.65]
5 Oxytocin augmentation	2	336	Risk Ratio (M-H, Random, 95% CI)	3.89 [0.70, 21.72]




Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
6 Uterine hyperstimulation without FHR changes	3	498	Risk Ratio (M-H, Fixed, 95% CI)	0.52 [0.30, 0.92]
7 Epidural analgesia	1	162	Risk Ratio (M-H, Fixed, 95% CI)	1.07 [0.90, 1.27]
8 Meconium-stained liquor	2	362	Risk Ratio (M-H, Fixed, 95% CI)	0.72 [0.43, 1.19]
9 Apgar score < 7 at 5 minutes	1	162	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.20, 4.58]
10 Neonatal intensive care unit admission	4	1599	Risk Ratio (M-H, Fixed, 95% CI)	0.66 [0.49, 0.90]
11 Perinatal death	2	1263	Risk Ratio (M-H, Fixed, 95% CI)	0.82 [0.18, 3.65]
12 Women not satisfied	1	866	Risk Ratio (M-H, Fixed, 95% CI)	1.68 [1.47, 1.93]
13 Maternal fever	2	298	Risk Ratio (M-H, Fixed, 95% CI)	0.13 [0.04, 0.50]
14 Chorioamnionitis	1	200	Risk Ratio (M-H, Fixed, 95% CI)	0.65 [0.32, 1.31]
15 Fetal distress	2	362	Risk Ratio (M-H, Fixed, 95% CI)	0.55 [0.25, 1.21]

Analysis 39.1. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre-specified), Outcome 1 Vaginal delivery not achieved in 24 hours.


Study or subgroup	Mechani- cal method	Misoprostol		Risk Ratio Weight				Risk Ratio			
	n/N	n/N			M-H, F	ixed,	95% CI				M-H, Fixed, 95% CI
Culver 2004	28/83	51/79			-					52.12%	0.52[0.37,0.74]
Mullin 2002	21/100	48/100		-	-					47.88%	0.44[0.28,0.67]
Total (95% CI)	183	179			•					100%	0.48[0.37,0.63]
Total events: 49 (Mechanical r	method), 99 (Misoprostol)										
Heterogeneity: Tau ² =0; Chi ² =0	0.41, df=1(P=0.52); I ² =0%										
Test for overall effect: Z=5.28(P<0.0001)										
	Favours m	echanical method	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	




Analysis 39.2. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre-specified), Outcome 2 Uterine hyperstimulation with FHR changes.



Analysis 39.3. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre-specified), Outcome 3 Caesarean section.



Analysis 39.4. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre-specified), Outcome 4 Serious neonatal morbidity/perinatal death.







Analysis 39.5. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre-specified), Outcome 5 Oxytocin augmentation.

Study or subgroup	Mechani- cal method	Misoprostol			Ri	sk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, Ra	ndom	, 95% CI				M-H, Random, 95% CI
Garba 2016	48/66	6/70							-	47.59%	8.48[3.89,18.5]
Mullin 2002	100/100	52/100								52.41%	1.91[1.59,2.31]
Total (95% CI)	166	170								100%	3.89[0.7,21.72]
Total events: 148 (Mechanical	method), 58 (Misoprostol)										
Heterogeneity: Tau ² =1.46; Chi	² =18.47, df=1(P<0.0001); I ² =	94.58%									
Test for overall effect: Z=1.55(F	P=0.12)										
	Favours m	echanical method	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	

Analysis 39.6. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre-specified), Outcome 6 Uterine hyperstimulation without FHR changes.



Analysis 39.7. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre-specified), Outcome 7 Epidural analgesia.






Analysis 39.8. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre-specified), Outcome 8 Meconium-stained liquor.

Study or subgroup	Mechani- cal method	Misoprostol			Risk Ratio			Weight	Risk Ratio
	n/N	n/N			M-H, Fixed, 95%	CI			M-H, Fixed, 95% CI
Culver 2004	11/83	15/79						50.61%	0.7[0.34,1.43]
Mullin 2002	11/100	15/100			-			49.39%	0.73[0.35,1.52]
Total (95% CI)	183	179						100%	0.72[0.43,1.19]
Total events: 22 (Mechanical r	method), 30 (Misoprostol)								
Heterogeneity: Tau ² =0; Chi ² =0	0.01, df=1(P=0.92); I ² =0%								
Test for overall effect: Z=1.29((P=0.2)			1					
	Favoure m	ochanical method	0.1	0.2	0.5 1 2	5	10	Favours misoprostol	

Analysis 39.9. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre-specified), Outcome 9 Apgar score < 7 at 5 minutes.




Analysis 39.10. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre-specified), Outcome 10 Neonatal intensive care unit admission.


Study or subgroup	Mechani- cal method	Misoprostol	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Culver 2004	16/83	19/79		21.33%	0.8[0.44,1.45]
Garba 2016	0/66	2/70	+	2.66%	0.21[0.01,4.33]
Gilson 2017	33/526	59/575		61.77%	0.61[0.41,0.92]
Mullin 2002	10/100	13/100		14.24%	0.77[0.35,1.67]
Total (95% CI)	775	824	•	100%	0.66[0.49,0.9]
Total events: 59 (Mechanical	method), 93 (Misoprostol)				
Heterogeneity: Tau ² =0; Chi ² =	1.24, df=3(P=0.74); I ² =0%				
Test for overall effect: Z=2.62	(P=0.01)				
	Favours m	echanical method	0.1 0.2 0.5 1 2 5	10 Favours misoprostol	




Analysis 39.11. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre-specified), Outcome 11 Perinatal death.



Analysis 39.12. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre-specified), Outcome 12 Women not satisfied.



Analysis 39.13. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre-specified), Outcome 13 Maternal fever.






Analysis 39.14. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre-specified), Outcome 14 Chorioamnionitis.

Study or subgroup	Mechani- cal method	Misoprostol			Ris	sk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	95% CI				M-H, Fixed, 95% CI
Mullin 2002	11/100	17/100			-	+				100%	0.65[0.32,1.31]
Total (95% CI)	100	100			—					100%	0.65[0.32,1.31]
Total events: 11 (Mechanical meth	hod), 17 (Misoprostol)										
Heterogeneity: Not applicable											
Test for overall effect: Z=1.21(P=0	.23)										
	Favours me	echanical method	0.1	0.2	0.5	1	2	5	10	Favours misoprostol	


Analysis 39.15. Comparison 39 Any mechanical method and oxytocin versus low dose misoprostol alone: all women (not pre-specified), Outcome 15 Fetal distress.



Comparison 40. Any mechanical method and oxytocin versus low dose misoprostol alone: all multiparae

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Caesarean section	1	136	Risk Ratio (M-H, Fixed, 95% CI)	0.45 [0.19, 1.11]

Analysis 40.1. Comparison 40 Any mechanical method and oxytocin versus low dose misoprostol alone: all multiparae, Outcome 1 Caesarean section.






Comparison 41. Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified)

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Vaginal delivery not achieved in 24 hours	2	321	Risk Ratio (M-H, Random, 95% CI)	0.71 [0.21, 2.40]
2 Caesarean section	6	718	Risk Ratio (M-H, Random, 95% CI)	0.68 [0.39, 1.20]
3 Serious neonatal morbidity/perinatal death	2	321	Risk Ratio (M-H, Fixed, 95% CI)	0.71 [0.12, 4.13]
4 Serious maternal morbidity or death	2	321	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Uterine hyperstimulation without FHR changes	2	199	Risk Ratio (M-H, Fixed, 95% CI)	0.85 [0.34, 2.09]
6 Uterine rupture	1	120	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7 Epidural analgesia	1	127	Risk Ratio (M-H, Fixed, 95% CI)	1.03 [0.98, 1.09]
8 Instrumental vaginal delivery	3	293	Risk Ratio (M-H, Fixed, 95% CI)	0.99 [0.48, 2.02]
9 Meconium-stained liquor	3	319	Risk Ratio (M-H, Fixed, 95% CI)	0.72 [0.32, 1.63]
10 Neonatal intensive care unit admission	3	400	Risk Ratio (M-H, Fixed, 95% CI)	0.98 [0.61, 1.58]
11 Postpartum haemorrhage	3	319	Risk Ratio (M-H, Fixed, 95% CI)	1.18 [0.44, 3.18]
12 Serious maternal complications	1	201	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
13 Antibiotics during labour	1	201	Risk Ratio (M-H, Fixed, 95% CI)	2.32 [0.82, 6.55]
14 Chorionamnionitis	2	328	Risk Ratio (M-H, Random, 95% CI)	4.34 [0.55, 34.01]
15 Endometritis	3	374	Risk Ratio (M-H, Fixed, 95% CI)	1.08 [0.16, 7.45]
16 Fetal distress	3	400	Risk Ratio (M-H, Fixed, 95% CI)	1.37 [0.68, 2.77]


Analysis 41.1. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified), Outcome 1 Vaginal delivery not achieved in 24 hours.

Study or subgroup	Mechani- cal method	Oxytocin			Ri	isk Ra	tio			Weight	Risk Ratio
	n/N	n/N			M-H, Ra	ndom	, 95% CI				M-H, Random, 95% CI
Mackeen 2018	32/93	28/108				+				49.54%	1.33[0.87,2.03]
Wu 2017	21/60	54/60			-					50.46%	0.39[0.27,0.55]
	Favours me	chanical method	0.1	0.2	0.5	1	2	5	10	Favours oxytocin	






Analysis 41.2. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified), Outcome 2 Caesarean section.



Analysis 41.3. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified), Outcome 3 Serious neonatal morbidity/perinatal death.






Analysis 41.4. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified), Outcome 4 Serious maternal morbidity or death.

Study or subgroup	Mechani- cal method	Oxytocin			Ri	sk Rat	tio			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	95% CI				M-H, Fixed, 95% CI
Mackeen 2018	0/93	0/108									Not estimable
Wu 2017	0/60	0/60									Not estimable
Total (95% CI)	153	168									Not estimable
Total events: 0 (Mechanical method), 0	O (Oxytocin)										
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
	Favours me	chanical method	0.1	0.2	0.5	1	2	5	10	Favours oxytocin	

Analysis 41.5. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified), Outcome 5 Uterine hyperstimulation without FHR changes.




Analysis 41.6. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified), Outcome 6 Uterine rupture.


Study or subgroup	Mechani- cal method	Oxytocin			Ri	sk Rati	0			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	5% CI				M-H, Fixed, 95% CI
Wu 2017	0/60	0/60									Not estimable
Total (95% CI)	60	60									Not estimable
Total events: 0 (Mechanical method), 0 (Oxytocin)										
Heterogeneity: Not applicable											
Test for overall effect: Not applicable	e										
	Favours me	chanical method	0.1	0.2	0.5	1	2	5	10	Favours oxytocin	



Analysis 41.7. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified), Outcome 7 Epidural analgesia.



Analysis 41.8. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified), Outcome 8 Instrumental vaginal delivery.




Analysis 41.9. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified), Outcome 9 Meconium-stained liquor.


Study or subgroup	Mechani- cal method	Oxytocin			Ri	sk Rat	io			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 9	95% CI				M-H, Fixed, 95% CI
Amorosa 2017	4/61	6/66		_		-				45.16%	0.72[0.21,2.43]
El Khouly 2017	1/36	2/36	+		-					15.67%	0.5[0.05,5.27]
Wu 2017	4/60	5/60				•				39.17%	0.8[0.23,2.83]
Total (95% CI)	157	162					-			100%	0.72[0.32,1.63]
Total events: 9 (Mechanical m	nethod), 13 (Oxytocin)										
Heterogeneity: Tau ² =0; Chi ² =	0.12, df=2(P=0.94); I ² =0%										
Test for overall effect: Z=0.79	(P=0.43)										
	Favours me	chanical method	0.1	0.2	0.5	1	2	5	10	Favours oxytocin	



Analysis 41.10. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified), Outcome 10 Neonatal intensive care unit admission.



Analysis 41.11. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified), Outcome 11 Postpartum haemorrhage.




Analysis 41.12. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified), Outcome 12 Serious maternal complications.


Study or subgroup	Mechani- cal method	Oxytocin			Ri	sk Ratio	•			Weight	Risk Ratio
	n/N	n/N			M-H, F	ixed, 95	% CI				M-H, Fixed, 95% CI
Mackeen 2018	0/93	0/108									Not estimable
Total (95% CI)	93	108									Not estimable
Total events: 0 (Mechanical method),	0 (Oxytocin)										
Heterogeneity: Not applicable											
Test for overall effect: Not applicable											
	Favours me	chanical method	0.1	0.2	0.5	1	2	5	10	Favours oxytocin	



Analysis 41.13. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified), Outcome 13 Antibiotics during labour.



Analysis 41.14. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified), Outcome 14 Chorionamnionitis.




Analysis 41.15. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified), Outcome 15 Endometritis.

Study or subgroup	Mechani- cal method	Oxytocin	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
Amorosa 2017	2/61	2/66		100%	1.08[0.16,7.45]
Lyndrup 1989	0/22	0/24			Not estimable
Mackeen 2018	0/93	0/108			Not estimable
Total (95% CI)	176	198		100%	1.08[0.16,7.45]
Total events: 2 (Mechanical m	nethod), 2 (Oxytocin)				
Heterogeneity: Tau ² =0; Chi ² =0	0, df=0(P<0.0001); I ² =100%				
Test for overall effect: Z=0.08((P=0.94)				
	Favours me	echanical method 0.1	1 0.2 0.5 1 2 5	10 Favours oxytocin	



Analysis 41.16. Comparison 41 Any mechanical method and oxytocin versus oxytocin alone: all women (not pre-specified), Outcome 16 Fetal distress.



APPENDICES

Appendix 1. ICTRP and ClinicalTrials.gov - search methods

ICTRP

Each line was run separately

foley AND induction

foley AND ripening

catheter AND induction

 $catheter\,AND\,ripening$

balloon AND induction

balloon AND ripening

laminaria AND induction

laminaria AND ripening

lamicel AND induction

lamicel AND ripening

extraamniotic AND induction

extraamniotic AND ripening

dilapan AND induction

dilapan AND ripening

ClinicalTrials.gov

Advanced search

Interventional studies | cervical ripening | catheter

Interventional studies | induction of labor | catheter

Interventional studies | cervical ripening | balloon



Interventional studies | induction of labor | balloon
Interventional studies | cervical ripening | foley
Interventional studies | induction of labor | foley
Interventional studies | cervical ripening | mechanical
Interventional studies | induction of labor | mechanical
Interventional studies | cervical ripening | laminaria
Interventional studies | induction of labor | laminaria
Interventional studies | cervical ripening | lamicel
Interventional studies | induction of labor | lamicel
Interventional studies | cervical ripening | dilapan
Interventional studies | induction of labor | dilapan
Interventional studies | cervical ripening | extraamniotic
Interventional studies | induction of labor | extraamniotic

WHAT'S NEW

Date	Event	Description
9 January 2018	New citation required and conclusions have changed	In this updated review, there is now evidence that mechanical induction of labour with a balloon probably is as effective as vaginal prostaglandin E2 (PGE2), but safer for the neonate. A balloon catheter may be slightly less effective as oral misoprostol, but It remains unclear if there is a difference in safety outcomes for the neonate. When compared to low-dose vaginal misoprostol, a balloon catheter may be less effective, but probably has a better safety profile.
9 January 2018	New search has been performed	Search updated. We included 60 new studies and excluded 74 new studies. Eighteen studies (previous included) are now excluded as they are no longer eligible. Also, 21 ongoing studies were identified (Ongoing studies) and two studies are awaiting further classification (Agboghoroma 2015; Mallah 2011). We updated the search on 19 March 2019 and added a further 38 trial reports to Studies awaiting classification for the next update. The references have been assessed but not incorporated into the review. Only seven of these trials are likely to contribute data for this review and are mainly small trials (Khatib 2019; Lim 2018; Osoti 2018; Souizi 2018; ten Eikelder 2017; Tulek 2018; Viteri 2019). We imputed the data for these trials and there is no change in results (not in direction or strength of the evidence). We will incorporate these trials fully at the next update.
		For this review, studies with high-dose misoprostol were excluded. Balloons, laminaria tents and extra-amniotic space infusion (EASI) were compared separately with other pharmacological methods and new comparisons were included. Comparisons with no intervention or placebo were excluded.



HISTORY

Protocol first published: Issue 2, 2000 Review first published: Issue 4, 2001

Date	Event	Description
30 September 2011	New citation required and conclusions have changed	New trials were added and the review was edited accordingly: the conclusion on primary outcome delivery before 24 hours has changed, partly due to change in statistical method (random-effects model, due to substantial heterogeneity). Also, some conclusions on secondary outcome measures have changed. We updated the search on 16 January 2012 and added the results to Studies awaiting classification for consideration in the next update.
30 April 2011	New search has been performed	Search updated. We have included 27 new studies and excluded 28 new studies. One trial (previously included) has now been reclassified as excluded (Abramovici 1999). Four new ongoing studies have also been identified (Hallak 2008a; Jozwiak 2009a; Lin 2006a; Manyonda 2007a).
18 September 2008	Amended	Converted to new review format.

CONTRIBUTIONS OF AUTHORS

For this update, M de Vaan, M ten Eikelder, KR Palmer and BW Mol performed data extraction. Risk of bias was assessed by M de Vaan, M ten Eikelder, KR Palmer and M Jozwiak. Marieke de Vaan and Marta Jozwiak entered the data and the review was drafted M de Vaan, which was finalised after feedback from M. ten Eikelder, M Jozwiak, KR Palmer, M Davies, K Bloemenkamp, BW Mol and M Boulvain. M. ten Eikelder, M. Jozwiak and BW Mol were not involved in data extraction nor in the 'Risk of bias' assessment of Jozwiak 2012; Jozwiak 2013; Jozwiak 2014; ten Eikelder 2016, due to their authorship.

DECLARATIONS OF INTEREST

Marieke de Vaan received a grant from The Netherlands Organisation for Scientific Research (NWO) (023.011.051).

Mieke ten Eikelder is co-author of three included trials (Jozwiak 2013; Jozwiak 2014; ten Eikelder 2016). She has not been involved in the 'Risk of bias' assessment and data extraction of these studies.

Marta Jozwiak is co-author of four included trials (Jozwiak 2012; Jozwiak 2013; Jozwiak 2014; ten Eikelder 2016). She has not been involved in 'Risk of bias' assessment and data extraction of these studies.

Kirsten Palmer: none known.

Miranda Davies-Tuck: none known.

Kitty Bloemenkamp is co-author of four included trials (Jozwiak 2012; Jozwiak 2013; Jozwiak 2014; ten Eikelder 2016). She has not been involved in 'Risk of bias' assessment and data extraction of these studies.

Ben Willem Mol is co-author of four included trials (Jozwiak 2012; Jozwiak 2013; Jozwiak 2014; ten Eikelder 2016). He has not been involved in 'Risk of bias' assessment and data extraction of these studies. Ben Willem Mol also reports receiving grants from NHMRC Australia, personal fees from ObsEva, grants and personal fees from Merck and Guerbet, outside the submitted work.

Michel Boulvain: none known.

SOURCES OF SUPPORT

Internal sources

• University of Geneva, Switzerland.



External sources

• Marieke de Vaan received a grant from The Netherlands Organisation for Scientific Research (NWO), Netherlands.

grant number: 023.011.051

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

Comparisons of a balloon catheter with concurrent oxytocin or prostaglandins versus prostaglandins or oxytocin alone were added. Also, comparisons of a single versus a double balloon and different forms of laminaria tents were added. The comparisons with placebo/no treatment were excluded. Regarding studies where a comparison was made with misoprostol, we chose only to include studies in which low-dose misoprostol was used. A number of non pre-specified outcomes relevant to the comparisons made in this review were added (maternal fever, antibiotics during labour, endometritis, chorioamnionitis. fetal distress, umbilical artery pH < 7.10).

For this update, we have also searched Clinical Trials.gov, the WHO International Clinical Trials Registry Platform (ICTRP).

INDEX TERMS

Medical Subject Headings (MeSH)

*Cervical Ripening; *Laminaria; *Oxytocics; Catheterization [*methods]; Cervix Uteri; Dinoprostone; Labor, Induced [*methods]; Misoprostol; Oxytocin; Pessaries; Polymers; Randomized Controlled Trials as Topic

MeSH check words

Female; Humans; Pregnancy